[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fNntIpTw79UmLRk5ThMtehVX8jIEjLR5BS5hDPrcCJ4o":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":88,"rows":95},"University Health Network, Toronto",[4],1405,false,356,96,358304,174,918,[14,17,20,23,26,29,31,34],{"name":15,"count":16},"Prostate Cancer",61,{"name":18,"count":19},"Breast Cancer",50,{"name":21,"count":22},"Lung Cancer",34,{"name":24,"count":25},"Cancer",32,{"name":27,"count":28},"Heart Failure",18,{"name":30,"count":28},"Head and Neck Cancer",{"name":32,"count":33},"Colorectal Cancer",17,{"name":35,"count":36},"Spinal Cord Injuries",16,[38,43,48,53,58,63,68,73,78,83],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT03112044","Lung Transplant HCV, Pilot Study","2020-01-02","Sofosbuvir-velpatasvir",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT04923659","Pharmacological Mechanisms of Low-intensity Focused Ultrasound for Motor Cortex Neuroplasticity","2022-07-10","Carbamazepine",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT04566887","Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma","2023-09-30","Acalabrutinib",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT04563338","An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)","2024-06-25","Atezolizumab",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT04084717","Study of Crizotinib for ROS1 and MET Activated Lung Cancer","2024-12","Crizotinib",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT03686202","Feasibility Study of MET-4: Evaluating Fecal Microbiome Effects in Immunotherapy Patients","2024-12-01","MET-4",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT02481635","A Study of Gemcitabine\u002FNab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer","2024-12-10","Gemcitabine",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT04261972","Cell-free DNA in Hereditary And High-Risk Malignancies 1","2024-12-31","Next generation sequencing",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT06526156","Hypobaric L5-S1 Study","2025-03-20","Bupivacaine",{"nctId":84,"briefTitle":85,"date":86,"intervention":87},"NCT03991832","Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors","2025-03-31","Olaparib",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,152,180,198,224,253,271,299,317,341,359,387,405,433,451,477,540,664,828,882,912,939,967,994,1012,1030,1056,1074,1098,1116,1141,1170,1196,1214,1242,1270,1288,1334,1473,1573,1634,1680,1746,1814,1846,1901,1928,1977,2034,2081,2107,2133,2159,2187,2222,2247,2281,2319,2341,2377,2406,2428,2452,2475,2493,2516,2534,2552,2576,2601,2626,2644,2662,2680,2698,2716,2734,2752,2770,2788,2814,2832,2850,2875,2899,2922,2940,2958,2983,3008,3032,3058,3083,3101,3125,3153,3171,3189,3216,3234,3252,3278,3296,3324,3342,3367,3385,3403,3421,3444,3494,3540,3566,3604,3634,3660,3682,3710,3728,3746,3764,3785,3811,3829,3853,3878,3896,3914,3941,3959,3985,4003,4026,4044,4062,4080,4102,4126,4170,4199,4250,4296,4328,4350,4373,4396,4430,4448,4466,4484,4502,4520,4538,4556,4580,4604,4625,4650,4672,4695,4718,4744,4762,4788,4806,4830,4856,4880,4898,4916,4948,4975,4993,5019,5040,5079,5114,5142,5183,5207,5231,5256,5280,5305,5330,5348,5372,5390,5408,5433,5451,5474,5497,5515,5541,5559,5583,5601,5624,5647,5672,5699,5717,5741,5766,5784,5809,5832,5855,5881,5899,5923,5948,5972,5990,6013,6031,6055,6073,6096,6120,6138,6161,6179,6197,6215,6237,6255,6281,6299,6324,6342,6363,6387,6411,6435,6457,6481,6507,6525,6549,6573,6591,6613,6637,6659,6682,6700,6725,6743,6767,6785,6803,6821,6878,6925,6961,7005,7039,7070,7107,7139,7172,7200,7224,7248,7273,7295,7319,7337,7363,7381,7403,7429,7447,7471,7496,7522,7540,7558,7580,7605,7631,7649,7671,7695,7718,7743,7767,7785,7809,7834,7856,7880,7898,7921,7946,7969,7993,8015,8039,8057,8075,8097,8119,8141,8159,8181,8199,8223,8246,8268,8329,8373,8423,8462,8499,8539,8573,8609,8652,8681,8711,8743,8765,8792,8816,8848,8877,8899,8933,8955,8986,9015,9040,9066,9097,9115,9137,9161,9185,9209,9234,9252,9274,9295,9317,9335,9353,9380,9404,9435,9453,9474,9492,9515,9539,9561,9579,9601,9624,9642,9660,9683,9705,9728,9750,9774,9792,9813,9831,9849,9871,9889,9911,9933,9951,9969,9992,10014,10032,10057,10075,10099,10117,10140,10161,10183,10201,10223,10245,10269,10287,10310,10328,10346,10368,10386,10408,10431,10449,10474,10492,10510,10534,10557,10581,10605,10628,10646,10664,10686,10709,10727,10750,10768,10786,10809,10834,10852,10870,10895,10913,10934,10952,10970,10995,11013,11035,11058,11076,11100,11122,11146,11171,11189,11213,11231,11254,11272,11290,11312,11330,11348,11370,11392,11413,11434,11452,11474,11492,11510,11528,11550,11574,11597,11618,11642,11660,11678,11696,11720,11743,11804,11845,11872,11897,11927,11958,11986,12012,12034,12057,12075,12098,12116,12141,12159,12177,12202,12220,12247,12271,12295,12316,12339,12357,12383,12406,12431,12449,12472,12497,12520,12543,12561,12584,12607,12630,12652,12670,12693,12716,12738,12759,12781,12802,12824,12850,12868,12890,12911,12933,12955,12977,13000,13018,13036,13054,13072,13090,13108,13129,13152,13176,13194,13218,13236,13263,13281,13299,13321,13343,13364,13387,13411,13429,13452,13475,13499,13521],{"intervention":97,"totalTrials":98,"cells":99},"Tranexamic acid",3,{"EARLY_PHASE1":100,"PHASE1":103,"PHASE2":105,"PHASE3":107,"PHASE4":120,"NA":150},{"trials":101,"activeCount":102},[],0,{"trials":104,"activeCount":102},[],{"trials":106,"activeCount":102},[],{"trials":108,"activeCount":102},[109],{"nctId":110,"briefTitle":111,"status":112,"phases":113,"completion":114,"start":115,"enrollment":116,"conditions":117,"interventions":119},"NCT00444470","Safety of Tranexamic Acid in Reducing Bleeding in Adults Undergoing Spinal Surgery","COMPLETED",[92],"2007-05","2003-02",151,[118],"Spine Surgery",[97],{"trials":121,"activeCount":149,"soonestReadout":127},[122,136],{"nctId":123,"briefTitle":124,"status":125,"phases":126,"primaryCompletion":127,"completion":127,"start":128,"enrollment":129,"conditions":130,"interventions":135},"NCT06452342","TRanEXamic Acid to Decrease Heavy Menstrual Bleeding in Individuals Anticoagulated for Venous Thromboembolism Pilot Study","NOT_YET_RECRUITING",[93],"2026-04","2024-06",20,[131,132,133,134],"Venous Thromboembolism","Venous Thromboses","Heavy Menstrual Bleeding","Anticoagulants and Bleeding Disorders",[97],{"nctId":137,"briefTitle":138,"status":112,"phases":139,"primaryCompletion":140,"completion":141,"start":142,"enrollment":143,"conditions":144,"interventions":147},"NCT00985920","Topical Tranexamic Acid for Total Knee Arthroplasty",[93],"2009-10","2009-11","2007-09",125,[145,146],"Surgical Blood Loss","Total Knee Arthroplasty",[148],"tranexamic acid",1,{"trials":151,"activeCount":102},[],{"intervention":153,"totalTrials":149,"cells":154},"Letermovir",{"EARLY_PHASE1":155,"PHASE1":157,"PHASE2":159,"PHASE3":161,"PHASE4":163,"NA":178},{"trials":156,"activeCount":102},[],{"trials":158,"activeCount":102},[],{"trials":160,"activeCount":102},[],{"trials":162,"activeCount":102},[],{"trials":164,"activeCount":149,"soonestReadout":170},[165],{"nctId":166,"briefTitle":167,"status":168,"phases":169,"primaryCompletion":170,"completion":170,"start":171,"enrollment":172,"conditions":173,"interventions":176},"NCT07235683","Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients","RECRUITING",[93],"2027-08","2025-12-24",40,[174,175],"CMV","Lung Transplant Recipient",[153,177],"Valganciclovir\u002FGanciclovir",{"trials":179,"activeCount":102},[],{"intervention":177,"totalTrials":149,"cells":181},{"EARLY_PHASE1":182,"PHASE1":184,"PHASE2":186,"PHASE3":188,"PHASE4":190,"NA":196},{"trials":183,"activeCount":102},[],{"trials":185,"activeCount":102},[],{"trials":187,"activeCount":102},[],{"trials":189,"activeCount":102},[],{"trials":191,"activeCount":149,"soonestReadout":170},[192],{"nctId":166,"briefTitle":167,"status":168,"phases":193,"primaryCompletion":170,"completion":170,"start":171,"enrollment":172,"conditions":194,"interventions":195},[93],[174,175],[153,177],{"trials":197,"activeCount":102},[],{"intervention":199,"totalTrials":149,"cells":200},"Topical TRanexamic Acid",{"EARLY_PHASE1":201,"PHASE1":203,"PHASE2":205,"PHASE3":207,"PHASE4":209,"NA":222},{"trials":202,"activeCount":102},[],{"trials":204,"activeCount":102},[],{"trials":206,"activeCount":102},[],{"trials":208,"activeCount":102},[],{"trials":210,"activeCount":149,"soonestReadout":215},[211],{"nctId":212,"briefTitle":213,"status":168,"phases":214,"primaryCompletion":215,"completion":216,"start":217,"enrollment":218,"conditions":219,"interventions":221},"NCT06384456","Topical TRanexamic Acid vs. Placebo on Acute Postoperative Pain Following DRF Fixation",[93],"2026-12","2027-12","2025-08-13",90,[220],"Distal Radius Fractures",[199],{"trials":223,"activeCount":102},[],{"intervention":225,"totalTrials":149,"cells":226},"Teclistamab",{"EARLY_PHASE1":227,"PHASE1":229,"PHASE2":231,"PHASE3":233,"PHASE4":235,"NA":251},{"trials":228,"activeCount":102},[],{"trials":230,"activeCount":102},[],{"trials":232,"activeCount":102},[],{"trials":234,"activeCount":102},[],{"trials":236,"activeCount":149,"soonestReadout":241},[237],{"nctId":238,"briefTitle":239,"status":168,"phases":240,"primaryCompletion":241,"completion":242,"start":243,"enrollment":244,"conditions":245,"interventions":249},"NCT06251076","Plan Development for Giving Teclistamab in the Outpatient Setting",[93],"2026-06-15","2026-10","2024-11-19",15,[246,247,248],"Multiple Myeloma","Relapsed Cancer","Refractory Cancer",[225,250],"Tocilizumab",{"trials":252,"activeCount":102},[],{"intervention":250,"totalTrials":149,"cells":254},{"EARLY_PHASE1":255,"PHASE1":257,"PHASE2":259,"PHASE3":261,"PHASE4":263,"NA":269},{"trials":256,"activeCount":102},[],{"trials":258,"activeCount":102},[],{"trials":260,"activeCount":102},[],{"trials":262,"activeCount":102},[],{"trials":264,"activeCount":149,"soonestReadout":241},[265],{"nctId":238,"briefTitle":239,"status":168,"phases":266,"primaryCompletion":241,"completion":242,"start":243,"enrollment":244,"conditions":267,"interventions":268},[93],[246,247,248],[225,250],{"trials":270,"activeCount":102},[],{"intervention":272,"totalTrials":149,"cells":273},"Intravenous (IV) acetaminophen + oral placebo",{"EARLY_PHASE1":274,"PHASE1":276,"PHASE2":278,"PHASE3":280,"PHASE4":282,"NA":297},{"trials":275,"activeCount":102},[],{"trials":277,"activeCount":102},[],{"trials":279,"activeCount":102},[],{"trials":281,"activeCount":102},[],{"trials":283,"activeCount":149,"soonestReadout":288},[284],{"nctId":285,"briefTitle":286,"status":168,"phases":287,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":292,"interventions":295},"NCT05425355","Intravenous vs Oral Acetaminophen in Postoperative Hip Fracture Adult Patients",[93],"2025-12-30","2026-06-30","2023-01-23",42,[293,294],"Hip-fracture","Surgery",[272,296],"Intravenous (IV) placebo plus oral acetaminophen",{"trials":298,"activeCount":102},[],{"intervention":296,"totalTrials":149,"cells":300},{"EARLY_PHASE1":301,"PHASE1":303,"PHASE2":305,"PHASE3":307,"PHASE4":309,"NA":315},{"trials":302,"activeCount":102},[],{"trials":304,"activeCount":102},[],{"trials":306,"activeCount":102},[],{"trials":308,"activeCount":102},[],{"trials":310,"activeCount":149,"soonestReadout":288},[311],{"nctId":285,"briefTitle":286,"status":168,"phases":312,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":313,"interventions":314},[93],[293,294],[272,296],{"trials":316,"activeCount":102},[],{"intervention":318,"totalTrials":149,"cells":319},"Entecavir",{"EARLY_PHASE1":320,"PHASE1":322,"PHASE2":324,"PHASE3":326,"PHASE4":328,"NA":339},{"trials":321,"activeCount":102},[],{"trials":323,"activeCount":102},[],{"trials":325,"activeCount":102},[],{"trials":327,"activeCount":102},[],{"trials":329,"activeCount":149,"soonestReadout":170},[330],{"nctId":331,"briefTitle":332,"status":168,"phases":333,"primaryCompletion":170,"completion":170,"start":334,"enrollment":129,"conditions":335,"interventions":337},"NCT07189377","Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors",[93],"2025-09-24",[336,175],"Hepatitis B Virus (HBV)",[318,338],"HBIG",{"trials":340,"activeCount":102},[],{"intervention":338,"totalTrials":149,"cells":342},{"EARLY_PHASE1":343,"PHASE1":345,"PHASE2":347,"PHASE3":349,"PHASE4":351,"NA":357},{"trials":344,"activeCount":102},[],{"trials":346,"activeCount":102},[],{"trials":348,"activeCount":102},[],{"trials":350,"activeCount":102},[],{"trials":352,"activeCount":149,"soonestReadout":170},[353],{"nctId":331,"briefTitle":332,"status":168,"phases":354,"primaryCompletion":170,"completion":170,"start":334,"enrollment":129,"conditions":355,"interventions":356},[93],[336,175],[318,338],{"trials":358,"activeCount":102},[],{"intervention":360,"totalTrials":149,"cells":361},"Prograf",{"EARLY_PHASE1":362,"PHASE1":364,"PHASE2":366,"PHASE3":368,"PHASE4":370,"NA":385},{"trials":363,"activeCount":102},[],{"trials":365,"activeCount":102},[],{"trials":367,"activeCount":102},[],{"trials":369,"activeCount":102},[],{"trials":371,"activeCount":149,"soonestReadout":377},[372],{"nctId":373,"briefTitle":374,"status":375,"phases":376,"primaryCompletion":377,"completion":378,"start":379,"enrollment":172,"conditions":380,"interventions":383},"NCT05655273","Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients","ENROLLING_BY_INVITATION",[93],"2025-04-30","2026-02-28","2024-01-01",[381,382],"Liver Transplant Rejection","Immune System Suppression",[360,384],"Envarsus",{"trials":386,"activeCount":102},[],{"intervention":384,"totalTrials":149,"cells":388},{"EARLY_PHASE1":389,"PHASE1":391,"PHASE2":393,"PHASE3":395,"PHASE4":397,"NA":403},{"trials":390,"activeCount":102},[],{"trials":392,"activeCount":102},[],{"trials":394,"activeCount":102},[],{"trials":396,"activeCount":102},[],{"trials":398,"activeCount":149,"soonestReadout":377},[399],{"nctId":373,"briefTitle":374,"status":375,"phases":400,"primaryCompletion":377,"completion":378,"start":379,"enrollment":172,"conditions":401,"interventions":402},[93],[381,382],[360,384],{"trials":404,"activeCount":102},[],{"intervention":406,"totalTrials":149,"cells":407},"Semaglutide Treatment",{"EARLY_PHASE1":408,"PHASE1":410,"PHASE2":412,"PHASE3":414,"PHASE4":416,"NA":431},{"trials":409,"activeCount":102},[],{"trials":411,"activeCount":102},[],{"trials":413,"activeCount":102},[],{"trials":415,"activeCount":102},[],{"trials":417,"activeCount":149,"soonestReadout":215},[418],{"nctId":419,"briefTitle":420,"status":375,"phases":421,"primaryCompletion":215,"completion":215,"start":422,"enrollment":423,"conditions":424,"interventions":429},"NCT05195944","Semaglutide vs Sitagliptin",[93],"2022-10-26",58,[425,426,427,428],"Liver Transplant; Complications","Diabetes Mellitus","NASH - Nonalcoholic Steatohepatitis","NAFLD",[406,430],"Sitagliptin 100mg",{"trials":432,"activeCount":102},[],{"intervention":430,"totalTrials":149,"cells":434},{"EARLY_PHASE1":435,"PHASE1":437,"PHASE2":439,"PHASE3":441,"PHASE4":443,"NA":449},{"trials":436,"activeCount":102},[],{"trials":438,"activeCount":102},[],{"trials":440,"activeCount":102},[],{"trials":442,"activeCount":102},[],{"trials":444,"activeCount":149,"soonestReadout":215},[445],{"nctId":419,"briefTitle":420,"status":375,"phases":446,"primaryCompletion":215,"completion":215,"start":422,"enrollment":423,"conditions":447,"interventions":448},[93],[425,426,427,428],[406,430],{"trials":450,"activeCount":102},[],{"intervention":452,"totalTrials":149,"cells":453},"5 mL of 0.25% bupivacaine with epinephrine",{"EARLY_PHASE1":454,"PHASE1":456,"PHASE2":458,"PHASE3":460,"PHASE4":462,"NA":475},{"trials":455,"activeCount":102},[],{"trials":457,"activeCount":102},[],{"trials":459,"activeCount":102},[],{"trials":461,"activeCount":102},[],{"trials":463,"activeCount":149,"soonestReadout":468},[464],{"nctId":465,"briefTitle":466,"status":125,"phases":467,"primaryCompletion":468,"completion":469,"start":470,"enrollment":471,"conditions":472,"interventions":474},"NCT07468604","Cervicothoracic Sympathetic Block Evaluation for Post COVID Condition",[93],"2027-04-01","2027-09-01","2026-04-01",78,[473],"Autonomic Dysfunction",[452],{"trials":476,"activeCount":102},[],{"intervention":478,"totalTrials":479,"cells":480},"Indocyanine Green",4,{"EARLY_PHASE1":481,"PHASE1":483,"PHASE2":485,"PHASE3":487,"PHASE4":489,"NA":517},{"trials":482,"activeCount":102},[],{"trials":484,"activeCount":102},[],{"trials":486,"activeCount":102},[],{"trials":488,"activeCount":102},[],{"trials":490,"activeCount":149,"soonestReadout":496},[491,504],{"nctId":492,"briefTitle":493,"status":494,"phases":495,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":499,"interventions":502},"NCT06002906","The Use of Indocyanine Green to Visualize Blood Flow to the Gastrojejunostomy During Bariatric Surgery.","ACTIVE_NOT_RECRUITING",[93],"2027-07-03","2023-01-25",300,[500,501],"Ulcer, Gastric","Obesity, Morbid",[503],"Indocyanine green",{"nctId":505,"briefTitle":506,"status":112,"phases":507,"primaryCompletion":508,"completion":509,"start":510,"enrollment":511,"conditions":512,"interventions":516},"NCT03969108","Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment",[93],"2019-11-12","2019-11-13","2019-08-06",10,[513,514,515],"Thyroid Cancer","Thyroid Goiter","Graves Disease",[478],{"trials":518,"activeCount":102},[519,528],{"nctId":520,"briefTitle":521,"status":112,"phases":522,"primaryCompletion":523,"completion":523,"start":524,"enrollment":149,"conditions":525,"interventions":527},"NCT02478138","Sentinel Lymph Node Mapping of Oral Cancer Using Near-Infrared Fluorescence Imaging",[94],"2024-01-08","2015-05",[526],"Head and Neck Neoplasms",[478],{"nctId":529,"briefTitle":530,"status":112,"phases":531,"primaryCompletion":532,"completion":533,"start":534,"enrollment":535,"conditions":536,"interventions":539},"NCT01886066","Accuracy of Sentinel Lymph Node Biopsy in Nodal Staging of High Risk Endometrial Cancer",[94],"2019-06-21","2021-09","2012-03",156,[537,538,478],"Endometrial Cancer","Sentinel Lymph Node",[478],{"intervention":72,"totalTrials":541,"cells":542},9,{"EARLY_PHASE1":543,"PHASE1":545,"PHASE2":559,"PHASE3":636,"PHASE4":660,"NA":662},{"trials":544,"activeCount":102},[],{"trials":546,"activeCount":102},[547],{"nctId":548,"briefTitle":549,"status":550,"phases":551,"primaryCompletion":552,"completion":552,"start":552,"enrollment":102,"conditions":553,"interventions":556},"NCT02105350","A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer","WITHDRAWN",[90],"2015-06",[554,555],"Biliary Tract Carcinoma","Gallbladder Carcinoma",[557,72,558],"MEK 162","Oxaliplatin",{"trials":560,"activeCount":98,"soonestReadout":71},[561,578,592,603,612,624],{"nctId":562,"briefTitle":563,"status":168,"phases":564,"primaryCompletion":565,"completion":566,"start":567,"enrollment":568,"conditions":569,"interventions":573},"NCT04966663","Using ctDNA to Determine Therapies for Lung Cancer",[91],"2026-08-01","2026-12-01","2022-03-28",66,[570,571,572],"Non Small Cell Lung Cancer","Complete Surgical Resection","Circulating Tumor DNA",[574,575,72,576,577],"Nivolumab","Pemetrexed","Cisplatin","Carboplatin",{"nctId":579,"briefTitle":580,"status":112,"phases":581,"primaryCompletion":582,"completion":582,"start":583,"enrollment":584,"conditions":585,"interventions":590},"NCT03520231","Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases",[91],"2020-12-01","2018-09-04",6,[586,587,588,589],"Urothelial Carcinoma","Kidney Cancer","Ureter Cancer","Bladder Cancer",[591,72,577,576],"Denosumab",{"nctId":593,"briefTitle":594,"status":494,"phases":595,"primaryCompletion":596,"completion":597,"start":598,"enrollment":599,"conditions":600,"interventions":601},"NCT02151084","A Study of Different Dosing Schedules of Selumetinib With Cisplatin\u002FGemcitabine (CIS\u002FGEM) Versus CIS\u002FGEM Alone in Biliary Cancer",[91],"2026-05","2026-09","2014-11",57,[554,555],[602,576,72],"Selumetinib",{"nctId":69,"briefTitle":70,"status":494,"phases":604,"primaryCompletion":71,"completion":605,"start":606,"enrollment":607,"conditions":608,"interventions":610},[90,91],"2026-01","2016-07",30,[609],"Pancreatic Cancer",[72,611],"Nab-paclitaxel",{"nctId":613,"briefTitle":614,"status":112,"phases":615,"primaryCompletion":616,"completion":617,"start":618,"enrollment":607,"conditions":619,"interventions":621},"NCT02750670","Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",[91],"2020-09-09","2021-02-09","2017-03-15",[620],"Lymphoma, Non-Hodgkin's",[622,72,623,576],"Obinutuzumab","Dexamethasone",{"nctId":625,"briefTitle":626,"status":112,"phases":627,"primaryCompletion":628,"completion":629,"start":630,"enrollment":129,"conditions":631,"interventions":633},"NCT00603915","A Study of Gemcitabine and Cisplatin\u002FCarboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer",[91],"2010-12","2011-04","2006-06",[632],"Nasopharyngeal Cancer",[72,634,635],"Carboplatin\u002FCisplatin","erlotinib",{"trials":637,"activeCount":659,"soonestReadout":215},[638,647],{"nctId":639,"briefTitle":640,"status":168,"phases":641,"primaryCompletion":215,"completion":216,"start":642,"enrollment":643,"conditions":644,"interventions":646},"NCT04574960","Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)",[92],"2021-02-08",14,[589,645],"Bladder Urothelial Carcinoma",[72,576,577],{"nctId":648,"briefTitle":649,"status":168,"phases":650,"primaryCompletion":651,"completion":651,"start":652,"enrollment":511,"conditions":653,"interventions":657},"NCT06783140","Study of NABPLAGEM vs. Nab-Paclitaxel\u002FGemcitabine in BRCA1\u002F2 or PALB2 Pancreatic Cancer",[91,92],"2031-06-02","2025-06-10",[654,655,656],"Pancreatic Cancer, Advanced or Metastatic","BRCA1\u002F2 Mutation","PALB2 Gene Mutation",[658,72,576],"Nab paclitaxel",2,{"trials":661,"activeCount":102},[],{"trials":663,"activeCount":102},[],{"intervention":576,"totalTrials":33,"cells":665},{"EARLY_PHASE1":666,"PHASE1":668,"PHASE2":704,"PHASE3":794,"PHASE4":814,"NA":816},{"trials":667,"activeCount":102},[],{"trials":669,"activeCount":102},[670,681,692],{"nctId":671,"briefTitle":672,"status":112,"phases":673,"primaryCompletion":674,"start":675,"enrollment":541,"conditions":676,"interventions":677},"NCT00052494","Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer",[90],"2009-02","2003-04",[21],[678,679,680],"cisplatin","imatinib mesylate","irinotecan hydrochloride",{"nctId":682,"briefTitle":683,"status":112,"phases":684,"primaryCompletion":685,"completion":524,"start":686,"enrollment":687,"conditions":688,"interventions":690},"NCT01737008","Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck",[90],"2015-02","2013-01",12,[689],"Squamous Cell Carcinoma of the Head and Neck",[691,576],"dacomitinib",{"nctId":693,"briefTitle":694,"status":112,"phases":695,"primaryCompletion":696,"completion":697,"start":698,"enrollment":541,"conditions":699,"interventions":702},"NCT02537223","Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer",[90],"2018-06-14","2020-02-20","2015-09",[700,701],"Squamous Cell Carcinoma of Head and Neck","Locoregionally Advanced",[703,576],"BYL719",{"trials":705,"activeCount":659,"soonestReadout":596},[706,710,714,724,738,748,752,764,776,780],{"nctId":562,"briefTitle":563,"status":168,"phases":707,"primaryCompletion":565,"completion":566,"start":567,"enrollment":568,"conditions":708,"interventions":709},[91],[570,571,572],[574,575,72,576,577],{"nctId":579,"briefTitle":580,"status":112,"phases":711,"primaryCompletion":582,"completion":582,"start":583,"enrollment":584,"conditions":712,"interventions":713},[91],[586,587,588,589],[591,72,577,576],{"nctId":715,"briefTitle":716,"status":112,"phases":717,"primaryCompletion":718,"completion":718,"start":719,"enrollment":720,"conditions":721,"interventions":722},"NCT00030576","Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer",[90,91],"2009-12","2001-11",51,[30],[678,723],"erlotinib hydrochloride",{"nctId":725,"briefTitle":726,"status":727,"phases":728,"primaryCompletion":729,"completion":729,"start":730,"enrollment":149,"conditions":731,"interventions":736},"NCT01083537","Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction","TERMINATED",[90,91],"2012-06","2010-02",[732,733,734,735],"Ovarian Cancer","Peritoneal Cancer","Fallopian Tube Cancer","Bowel Obstruction",[576,737],"Paclitaxel",{"nctId":739,"briefTitle":740,"status":727,"phases":741,"primaryCompletion":742,"completion":742,"start":743,"enrollment":584,"conditions":744,"interventions":747},"NCT00895648","Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma",[91],"2012-10","2009-01",[745,746],"Mesothelioma","Pleural Mesothelioma",[575,576],{"nctId":593,"briefTitle":594,"status":494,"phases":749,"primaryCompletion":596,"completion":597,"start":598,"enrollment":599,"conditions":750,"interventions":751},[91],[554,555],[602,576,72],{"nctId":753,"briefTitle":754,"status":112,"phases":755,"primaryCompletion":756,"completion":756,"start":757,"enrollment":758,"conditions":759,"interventions":761},"NCT00400114","Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer",[91],"2016-09-19","2006-09-25",36,[760],"Esophageal Cancer",[762,576,763],"Irinotecan","sunitinib",{"nctId":765,"briefTitle":766,"status":112,"phases":767,"primaryCompletion":768,"completion":769,"start":770,"enrollment":771,"conditions":772,"interventions":774},"NCT00510250","A Phase I\u002FII Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer",[90,91],"2010-09","2015-07","2007-06",13,[773],"Cancer of the Cervix",[775,576],"Sorafenib",{"nctId":613,"briefTitle":614,"status":112,"phases":777,"primaryCompletion":616,"completion":617,"start":618,"enrollment":607,"conditions":778,"interventions":779},[91],[620],[622,72,623,576],{"nctId":781,"briefTitle":782,"status":112,"phases":783,"primaryCompletion":784,"completion":784,"start":785,"enrollment":36,"conditions":786,"interventions":791},"NCT02394652","The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial",[91],"2021-01-12","2015-05-21",[787,788,789,790],"Uterine Cervical Neoplasms","Squamous Cell Carcinoma","Adenocarcinoma","Carcinoma, Adenosquamous",[792,576,793],"Metformin","FAZA",{"trials":795,"activeCount":659,"soonestReadout":215},[796,800,804],{"nctId":639,"briefTitle":640,"status":168,"phases":797,"primaryCompletion":215,"completion":216,"start":642,"enrollment":643,"conditions":798,"interventions":799},[92],[589,645],[72,576,577],{"nctId":648,"briefTitle":649,"status":168,"phases":801,"primaryCompletion":651,"completion":651,"start":652,"enrollment":511,"conditions":802,"interventions":803},[91,92],[654,655,656],[658,72,576],{"nctId":805,"briefTitle":806,"status":112,"phases":807,"primaryCompletion":808,"completion":808,"start":809,"enrollment":810,"conditions":811,"interventions":812},"NCT00160875","Pre-operative Chemo (CPT11, Cisplatin), Radiotherapy, Plus Surgery for Resectable Esophageal Cancer",[91,92],"2011-03","2009-04",54,[760],[813,576],"Irinotecan hydrochloride trihydrate",{"trials":815,"activeCount":102},[],{"trials":817,"activeCount":149,"soonestReadout":215},[818],{"nctId":819,"briefTitle":820,"status":168,"phases":821,"primaryCompletion":215,"completion":822,"start":823,"enrollment":824,"conditions":825,"interventions":827},"NCT04016389","FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery",[94],"2028-12","2020-02-11",31,[826],"Cervical Cancer",[576,577,737],{"intervention":577,"totalTrials":584,"cells":829},{"EARLY_PHASE1":830,"PHASE1":832,"PHASE2":858,"PHASE3":868,"PHASE4":874,"NA":876},{"trials":831,"activeCount":102},[],{"trials":833,"activeCount":149,"soonestReadout":848},[834,844],{"nctId":835,"briefTitle":836,"status":112,"phases":837,"primaryCompletion":838,"completion":838,"start":839,"enrollment":771,"conditions":840,"interventions":842},"NCT02185690","A Phase I\u002FIb Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung",[90],"2019-07-04","2017-03-07",[841],"Lungcancer",[843,575,577],"Binimetinib",{"nctId":845,"briefTitle":846,"status":494,"phases":847,"primaryCompletion":848,"completion":849,"start":850,"enrollment":584,"conditions":851,"interventions":856},"NCT06107868","Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer",[90],"2025-10-31","2026-01-30","2024-03-20",[852,853,854,855],"Recurrent Ovarian Cancer","Recurrent Uterine Cancer","Metastatic Cancer","Advanced Cancer",[857,577,737],"RP-6306",{"trials":859,"activeCount":149,"soonestReadout":565},[860,864],{"nctId":562,"briefTitle":563,"status":168,"phases":861,"primaryCompletion":565,"completion":566,"start":567,"enrollment":568,"conditions":862,"interventions":863},[91],[570,571,572],[574,575,72,576,577],{"nctId":579,"briefTitle":580,"status":112,"phases":865,"primaryCompletion":582,"completion":582,"start":583,"enrollment":584,"conditions":866,"interventions":867},[91],[586,587,588,589],[591,72,577,576],{"trials":869,"activeCount":149,"soonestReadout":215},[870],{"nctId":639,"briefTitle":640,"status":168,"phases":871,"primaryCompletion":215,"completion":216,"start":642,"enrollment":643,"conditions":872,"interventions":873},[92],[589,645],[72,576,577],{"trials":875,"activeCount":102},[],{"trials":877,"activeCount":149,"soonestReadout":215},[878],{"nctId":819,"briefTitle":820,"status":168,"phases":879,"primaryCompletion":215,"completion":822,"start":823,"enrollment":824,"conditions":880,"interventions":881},[94],[826],[576,577,737],{"intervention":67,"totalTrials":659,"cells":883},{"EARLY_PHASE1":884,"PHASE1":886,"PHASE2":888,"PHASE3":890,"PHASE4":899,"NA":901},{"trials":885,"activeCount":102},[],{"trials":887,"activeCount":102},[],{"trials":889,"activeCount":102},[],{"trials":891,"activeCount":149,"soonestReadout":66},[892],{"nctId":64,"briefTitle":65,"status":494,"phases":893,"primaryCompletion":66,"completion":566,"start":894,"enrollment":895,"conditions":896,"interventions":898},[91,92],"2018-11-30",65,[897],"All Solid Tumors",[67],{"trials":900,"activeCount":102},[],{"trials":902,"activeCount":149,"soonestReadout":605},[903],{"nctId":904,"briefTitle":905,"status":494,"phases":906,"primaryCompletion":605,"completion":907,"start":908,"enrollment":607,"conditions":909,"interventions":911},"NCT03838601","Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2",[94],"2026-03","2019-07-02",[910],"Head and Neck Squamous Cell Carcinoma",[67],{"intervention":913,"totalTrials":149,"cells":914},"H5N1 vaccine",{"EARLY_PHASE1":915,"PHASE1":917,"PHASE2":919,"PHASE3":921,"PHASE4":935,"NA":937},{"trials":916,"activeCount":102},[],{"trials":918,"activeCount":102},[],{"trials":920,"activeCount":102},[],{"trials":922,"activeCount":149,"soonestReadout":289},[923],{"nctId":924,"briefTitle":925,"status":168,"phases":926,"primaryCompletion":289,"completion":927,"start":928,"enrollment":929,"conditions":930,"interventions":934},"NCT07240558","Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)",[92],"2026-12-31","2025-11-03",120,[931,932,933],"Influenza (Pandemic)","Avian Influenza","Vaccination",[913],{"trials":936,"activeCount":102},[],{"trials":938,"activeCount":102},[],{"intervention":940,"totalTrials":149,"cells":941},"Modafinil 200mg",{"EARLY_PHASE1":942,"PHASE1":944,"PHASE2":946,"PHASE3":948,"PHASE4":963,"NA":965},{"trials":943,"activeCount":102},[],{"trials":945,"activeCount":102},[],{"trials":947,"activeCount":102},[],{"trials":949,"activeCount":149,"soonestReadout":954},[950],{"nctId":951,"briefTitle":952,"status":125,"phases":953,"primaryCompletion":954,"completion":954,"start":955,"enrollment":956,"conditions":957,"interventions":962},"NCT06354985","Modafinil and Exercise for Post Stroke Fatigue",[92],"2027-09","2025-09",212,[958,959,960,961],"Stroke","Fatigue","Modafinil","Exercise",[940],{"trials":964,"activeCount":102},[],{"trials":966,"activeCount":102},[],{"intervention":968,"totalTrials":149,"cells":969},"Semaglutide 3 MG [Rybelsus]",{"EARLY_PHASE1":970,"PHASE1":972,"PHASE2":974,"PHASE3":976,"PHASE4":990,"NA":992},{"trials":971,"activeCount":102},[],{"trials":973,"activeCount":102},[],{"trials":975,"activeCount":102},[],{"trials":977,"activeCount":149,"soonestReadout":982},[978],{"nctId":979,"briefTitle":980,"status":125,"phases":981,"primaryCompletion":982,"completion":982,"start":983,"enrollment":984,"conditions":985,"interventions":987},"NCT06913023","Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus",[91,92],"2027-11-30","2026-01-05",74,[986],"Kidney Transplant Recipient",[968,988,989],"Semaglutide 7 MG [Rybelsus]","Semaglutide 14 MG [Rybelsus]",{"trials":991,"activeCount":102},[],{"trials":993,"activeCount":102},[],{"intervention":988,"totalTrials":149,"cells":995},{"EARLY_PHASE1":996,"PHASE1":998,"PHASE2":1000,"PHASE3":1002,"PHASE4":1008,"NA":1010},{"trials":997,"activeCount":102},[],{"trials":999,"activeCount":102},[],{"trials":1001,"activeCount":102},[],{"trials":1003,"activeCount":149,"soonestReadout":982},[1004],{"nctId":979,"briefTitle":980,"status":125,"phases":1005,"primaryCompletion":982,"completion":982,"start":983,"enrollment":984,"conditions":1006,"interventions":1007},[91,92],[986],[968,988,989],{"trials":1009,"activeCount":102},[],{"trials":1011,"activeCount":102},[],{"intervention":989,"totalTrials":149,"cells":1013},{"EARLY_PHASE1":1014,"PHASE1":1016,"PHASE2":1018,"PHASE3":1020,"PHASE4":1026,"NA":1028},{"trials":1015,"activeCount":102},[],{"trials":1017,"activeCount":102},[],{"trials":1019,"activeCount":102},[],{"trials":1021,"activeCount":149,"soonestReadout":982},[1022],{"nctId":979,"briefTitle":980,"status":125,"phases":1023,"primaryCompletion":982,"completion":982,"start":983,"enrollment":984,"conditions":1024,"interventions":1025},[91,92],[986],[968,988,989],{"trials":1027,"activeCount":102},[],{"trials":1029,"activeCount":102},[],{"intervention":1031,"totalTrials":149,"cells":1032},"Adjuvant, non-live RSV vaccine",{"EARLY_PHASE1":1033,"PHASE1":1035,"PHASE2":1037,"PHASE3":1039,"PHASE4":1052,"NA":1054},{"trials":1034,"activeCount":102},[],{"trials":1036,"activeCount":102},[],{"trials":1038,"activeCount":102},[],{"trials":1040,"activeCount":149,"soonestReadout":597},[1041],{"nctId":1042,"briefTitle":1043,"status":494,"phases":1044,"primaryCompletion":597,"completion":597,"start":1045,"enrollment":1046,"conditions":1047,"interventions":1051},"NCT06593210","RSV Vaccine in Transplant Recipients",[92],"2024-10-01",100,[1048,1049,1050],"Vaccine Response Impaired","Respiratory Syncytial Virus Infections","Immune Suppression",[1031],{"trials":1053,"activeCount":102},[],{"trials":1055,"activeCount":102},[],{"intervention":658,"totalTrials":149,"cells":1057},{"EARLY_PHASE1":1058,"PHASE1":1060,"PHASE2":1062,"PHASE3":1064,"PHASE4":1070,"NA":1072},{"trials":1059,"activeCount":102},[],{"trials":1061,"activeCount":102},[],{"trials":1063,"activeCount":102},[],{"trials":1065,"activeCount":149,"soonestReadout":651},[1066],{"nctId":648,"briefTitle":649,"status":168,"phases":1067,"primaryCompletion":651,"completion":651,"start":652,"enrollment":511,"conditions":1068,"interventions":1069},[91,92],[654,655,656],[658,72,576],{"trials":1071,"activeCount":102},[],{"trials":1073,"activeCount":102},[],{"intervention":1075,"totalTrials":149,"cells":1076},"40 mg Methylprednisolone",{"EARLY_PHASE1":1077,"PHASE1":1079,"PHASE2":1081,"PHASE3":1083,"PHASE4":1094,"NA":1096},{"trials":1078,"activeCount":102},[],{"trials":1080,"activeCount":102},[],{"trials":1082,"activeCount":102},[],{"trials":1084,"activeCount":149,"soonestReadout":289},[1085],{"nctId":1086,"briefTitle":1087,"status":168,"phases":1088,"primaryCompletion":289,"completion":927,"start":1089,"enrollment":172,"conditions":1090,"interventions":1092},"NCT06848374","Dose Efficacy in Adhesive Capsulitis",[92],"2024-12-20",[1091],"Adhesive Capsulitis of the Shoulder",[1075,1093],"80 mg Methylprednisolone",{"trials":1095,"activeCount":102},[],{"trials":1097,"activeCount":102},[],{"intervention":1093,"totalTrials":149,"cells":1099},{"EARLY_PHASE1":1100,"PHASE1":1102,"PHASE2":1104,"PHASE3":1106,"PHASE4":1112,"NA":1114},{"trials":1101,"activeCount":102},[],{"trials":1103,"activeCount":102},[],{"trials":1105,"activeCount":102},[],{"trials":1107,"activeCount":149,"soonestReadout":289},[1108],{"nctId":1086,"briefTitle":1087,"status":168,"phases":1109,"primaryCompletion":289,"completion":927,"start":1089,"enrollment":172,"conditions":1110,"interventions":1111},[92],[1091],[1075,1093],{"trials":1113,"activeCount":102},[],{"trials":1115,"activeCount":102},[],{"intervention":1117,"totalTrials":149,"cells":1118},"efgartigimod",{"EARLY_PHASE1":1119,"PHASE1":1121,"PHASE2":1123,"PHASE3":1125,"PHASE4":1137,"NA":1139},{"trials":1120,"activeCount":102},[],{"trials":1122,"activeCount":102},[],{"trials":1124,"activeCount":102},[],{"trials":1126,"activeCount":149,"soonestReadout":1131},[1127],{"nctId":1128,"briefTitle":1129,"status":168,"phases":1130,"primaryCompletion":1131,"completion":1131,"start":1132,"enrollment":607,"conditions":1133,"interventions":1136},"NCT06587867","Seronegative Myasthenia Gravis - Efgartigimod IV",[92],"2025-05","2023-06-01",[1134,1135],"Efgartigimod","Generalized Myasthenia Gravis",[1117],{"trials":1138,"activeCount":102},[],{"trials":1140,"activeCount":102},[],{"intervention":1142,"totalTrials":149,"cells":1143},"Empagliflozin 25 MG",{"EARLY_PHASE1":1144,"PHASE1":1146,"PHASE2":1148,"PHASE3":1150,"PHASE4":1166,"NA":1168},{"trials":1145,"activeCount":102},[],{"trials":1147,"activeCount":102},[],{"trials":1149,"activeCount":102},[],{"trials":1151,"activeCount":149,"soonestReadout":1156},[1152],{"nctId":1153,"briefTitle":1154,"status":168,"phases":1155,"primaryCompletion":1156,"completion":1157,"start":1158,"enrollment":129,"conditions":1159,"interventions":1165},"NCT05715814","meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis",[92],"2027-05-01","2027-12-01","2024-09-01",[1160,1161,1162,1163,1164],"Peritoneal Dialysis Complication","End Stage Kidney Disease","Sodium-glucose Co-transporter-2 Inhibitors","Kidney Dysfunction","Residual Kidney Function",[1142],{"trials":1167,"activeCount":102},[],{"trials":1169,"activeCount":102},[],{"intervention":1171,"totalTrials":149,"cells":1172},"Bone Marrow Aspirate (BMA): Minimally manipulated autologous cellular preparation",{"EARLY_PHASE1":1173,"PHASE1":1175,"PHASE2":1177,"PHASE3":1179,"PHASE4":1192,"NA":1194},{"trials":1174,"activeCount":102},[],{"trials":1176,"activeCount":102},[],{"trials":1178,"activeCount":102},[],{"trials":1180,"activeCount":149,"soonestReadout":1185},[1181],{"nctId":1182,"briefTitle":1183,"status":168,"phases":1184,"primaryCompletion":1185,"completion":215,"start":1186,"enrollment":1187,"conditions":1188,"interventions":1190},"NCT05517434","Autologous BMA vs Saline and LAM + LP-PRP vs Saline Evaluations in Knee OA",[91,92],"2026-06","2025-01-01",148,[1189],"Osteoarthritis, Knee",[1171,1191],"Lipoaspirate Micronized + Leukocyte-Poor Platelet-Rich Plasma (LAM + LP-PRP): Minimally manipulated autologous cellular preparations",{"trials":1193,"activeCount":102},[],{"trials":1195,"activeCount":102},[],{"intervention":1191,"totalTrials":149,"cells":1197},{"EARLY_PHASE1":1198,"PHASE1":1200,"PHASE2":1202,"PHASE3":1204,"PHASE4":1210,"NA":1212},{"trials":1199,"activeCount":102},[],{"trials":1201,"activeCount":102},[],{"trials":1203,"activeCount":102},[],{"trials":1205,"activeCount":149,"soonestReadout":1185},[1206],{"nctId":1182,"briefTitle":1183,"status":168,"phases":1207,"primaryCompletion":1185,"completion":215,"start":1186,"enrollment":1187,"conditions":1208,"interventions":1209},[91,92],[1189],[1171,1191],{"trials":1211,"activeCount":102},[],{"trials":1213,"activeCount":102},[],{"intervention":1215,"totalTrials":149,"cells":1216},"Lidocaine 20mg\u002Fml",{"EARLY_PHASE1":1217,"PHASE1":1219,"PHASE2":1221,"PHASE3":1223,"PHASE4":1238,"NA":1240},{"trials":1218,"activeCount":102},[],{"trials":1220,"activeCount":102},[],{"trials":1222,"activeCount":102},[],{"trials":1224,"activeCount":149,"soonestReadout":1229},[1225],{"nctId":1226,"briefTitle":1227,"status":168,"phases":1228,"primaryCompletion":1229,"completion":1230,"start":1231,"enrollment":1232,"conditions":1233,"interventions":1237},"NCT04874038","Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN)",[92],"2026-03-01","2026-11-01","2021-09-22",1602,[1234,18,1235,1236],"Post-mastectomy Pain Syndrome","Pain, Postoperative","Pain, Chronic",[1215],{"trials":1239,"activeCount":102},[],{"trials":1241,"activeCount":102},[],{"intervention":1243,"totalTrials":149,"cells":1244},"Autologous Cold-Stored Platelets",{"EARLY_PHASE1":1245,"PHASE1":1247,"PHASE2":1249,"PHASE3":1251,"PHASE4":1266,"NA":1268},{"trials":1246,"activeCount":102},[],{"trials":1248,"activeCount":102},[],{"trials":1250,"activeCount":102},[],{"trials":1252,"activeCount":149,"soonestReadout":927},[1253],{"nctId":1254,"briefTitle":1255,"status":125,"phases":1256,"primaryCompletion":927,"completion":1257,"start":1258,"enrollment":1046,"conditions":1259,"interventions":1264},"NCT07064954","Autologous Cold-stored Apheresis Platelets",[91,92],"2027-04-30","2025-09-01",[1260,1261,1262,1263],"Bleeding","Platelets","Cardiopulmonary Bypass","Cardiac Surgery",[1243,1265],"Allogeneic Room Temperature-Stored Platelets",{"trials":1267,"activeCount":102},[],{"trials":1269,"activeCount":102},[],{"intervention":1265,"totalTrials":149,"cells":1271},{"EARLY_PHASE1":1272,"PHASE1":1274,"PHASE2":1276,"PHASE3":1278,"PHASE4":1284,"NA":1286},{"trials":1273,"activeCount":102},[],{"trials":1275,"activeCount":102},[],{"trials":1277,"activeCount":102},[],{"trials":1279,"activeCount":149,"soonestReadout":927},[1280],{"nctId":1254,"briefTitle":1255,"status":125,"phases":1281,"primaryCompletion":927,"completion":1257,"start":1258,"enrollment":1046,"conditions":1282,"interventions":1283},[91,92],[1260,1261,1262,1263],[1243,1265],{"trials":1285,"activeCount":102},[],{"trials":1287,"activeCount":102},[],{"intervention":1289,"totalTrials":98,"cells":1290},"Ketamine",{"EARLY_PHASE1":1291,"PHASE1":1293,"PHASE2":1295,"PHASE3":1297,"PHASE4":1320,"NA":1322},{"trials":1292,"activeCount":102},[],{"trials":1294,"activeCount":102},[],{"trials":1296,"activeCount":102},[],{"trials":1298,"activeCount":149,"soonestReadout":1313},[1299,1309],{"nctId":1300,"briefTitle":1301,"status":112,"phases":1302,"primaryCompletion":1303,"completion":1304,"start":1305,"enrollment":172,"conditions":1306,"interventions":1308},"NCT04646694","The Ketamine for Acute Postoperative Analgesia (KAPA) Trial",[92],"2023-03-31","2023-06-30","2020-11-17",[1307],"Postoperative Pain",[1289],{"nctId":1310,"briefTitle":1311,"status":168,"phases":1312,"primaryCompletion":1313,"completion":1314,"start":1315,"enrollment":1316,"conditions":1317,"interventions":1319},"NCT05306899","Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches",[92],"2026-02-01","2026-06-01","2022-06-01",56,[1318],"Chronic Daily Headache",[1289],{"trials":1321,"activeCount":102},[],{"trials":1323,"activeCount":102},[1324],{"nctId":1325,"briefTitle":1326,"status":112,"phases":1327,"primaryCompletion":1328,"completion":1329,"start":685,"enrollment":1330,"conditions":1331,"interventions":1333},"NCT02373449","Ketamine and fMRI for Neuropathic Pain",[94],"2019-12","2020-12",39,[1332],"Neuralgia",[1289],{"intervention":1335,"totalTrials":1336,"cells":1337},"Cyclophosphamide",11,{"EARLY_PHASE1":1338,"PHASE1":1340,"PHASE2":1413,"PHASE3":1467,"PHASE4":1469,"NA":1471},{"trials":1339,"activeCount":102},[],{"trials":1341,"activeCount":479,"soonestReadout":1360},[1342,1356,1370,1382,1396,1404],{"nctId":1343,"briefTitle":1344,"status":112,"phases":1345,"primaryCompletion":1346,"completion":1346,"start":1347,"enrollment":1348,"conditions":1349,"interventions":1352},"NCT03158935","The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial",[90],"2020-08-04","2017-07-07",8,[1350,1351],"Advanced Ovarian Cancer","Malignant Melanoma",[1335,1353,1354,1355],"Fludarabine","Tumor-Infiltrating Lymphocytes","Interleukin-2",{"nctId":1357,"briefTitle":1358,"status":168,"phases":1359,"primaryCompletion":1360,"completion":1361,"start":1362,"enrollment":1363,"conditions":1364,"interventions":1368},"NCT05963217","Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL\u002FSLL",[90],"2026-03-30","2026-05-30","2023-07-26",19,[1365,1366,1367],"Relapsed or Refractory CD19+ B-cell Lymphoma","Relapsed or Refractory Chronic Lymphocytic Leukemia","Relapsed or Refractory Small Lymphocytic Lymphoma",[1369,1335,1353],"TBI-2001",{"nctId":1371,"briefTitle":1372,"status":494,"phases":1373,"primaryCompletion":1185,"completion":1185,"start":1374,"enrollment":98,"conditions":1375,"interventions":1380},"NCT01883297","\"Re-Stimulated\" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[90],"2015-01",[1376,1377,1378,734,1379],"Recurrent","Platinum-resistant","High Grade Serous Ovarian Cancer","Primary Peritoneal Cancer",[1381,1355,1335],"Re-stimulated tumor-infiltrating lymphocytes",{"nctId":1383,"briefTitle":1384,"status":494,"phases":1385,"primaryCompletion":1386,"completion":1386,"start":1387,"enrollment":1388,"conditions":1389,"interventions":1394},"NCT02869217","Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors",[90],"2026-11","2016-09",22,[1390,1391,1392,760,732,21,589,1393],"NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients","Synovial Sarcoma","Melanoma","Liver Cancer",[1335,1395,1353],"TBI-1301",{"nctId":1397,"briefTitle":1398,"status":168,"phases":1399,"primaryCompletion":954,"completion":954,"start":1400,"enrollment":172,"conditions":1401,"interventions":1403},"NCT05950802","Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta",[90],"2023-07-14",[1402],"DLBCL - Diffuse Large B Cell Lymphoma",[1335],{"nctId":1405,"briefTitle":1406,"status":550,"phases":1407,"primaryCompletion":1386,"completion":1408,"start":1409,"enrollment":102,"conditions":1410,"interventions":1412},"NCT06003179","Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With Kymriah",[90],"2028-11","2024-04-05",[1411],"Lymphoma, Large B-Cell, Diffuse",[1335,1353],{"trials":1414,"activeCount":149,"soonestReadout":1428},[1415,1424,1437,1447,1455],{"nctId":1416,"briefTitle":1417,"status":112,"phases":1418,"primaryCompletion":1419,"completion":1419,"start":1420,"enrollment":541,"conditions":1421,"interventions":1422},"NCT02414945","TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients",[90,91],"2020-10","2015-05-15",[746],[1335,1353,1423,1355],"Autologous tumor infiltrating lymphocytes",{"nctId":1425,"briefTitle":1426,"status":494,"phases":1427,"primaryCompletion":1428,"completion":1429,"start":1430,"enrollment":1431,"conditions":1432,"interventions":1434},"NCT03029403","Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer",[91],"2025-12-12","2026-04-12","2018-02-12",47,[855,732,1433,734],"Primary Peritoneal Carcinoma",[1435,1436,1335],"Pembrolizumab","DPX-Survivac",{"nctId":1438,"briefTitle":1439,"status":112,"phases":1440,"primaryCompletion":1441,"completion":1441,"start":1442,"enrollment":687,"conditions":1443,"interventions":1445},"NCT01883323","Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma",[91],"2018-04","2013-06",[1444],"Metastatic, Stage III or Stage IV, Melanoma",[1335,1353,1354,1446],"Low-Dose Interleukin",{"nctId":1448,"briefTitle":1449,"status":112,"phases":1450,"primaryCompletion":685,"completion":685,"start":1451,"enrollment":1388,"conditions":1452,"interventions":1454},"NCT00605566","Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors",[91],"2008-01",[1453],"Neuroendocrine Tumors",[775,1335],{"nctId":1456,"briefTitle":1457,"status":112,"phases":1458,"primaryCompletion":1459,"completion":1460,"start":1461,"enrollment":607,"conditions":1462,"interventions":1464},"NCT05380713","......SMARTEST Trial......",[91],"2025-08-11","2025-12-20","2022-05-03",[1463],"Mesothelioma, Malignant",[1335,1465,1466],"Tremelimumab","Durvalumab",{"trials":1468,"activeCount":102},[],{"trials":1470,"activeCount":102},[],{"trials":1472,"activeCount":102},[],{"intervention":1466,"totalTrials":541,"cells":1474},{"EARLY_PHASE1":1475,"PHASE1":1477,"PHASE2":1491,"PHASE3":1567,"PHASE4":1569,"NA":1571},{"trials":1476,"activeCount":102},[],{"trials":1478,"activeCount":102},[1479],{"nctId":1480,"briefTitle":1481,"status":550,"phases":1482,"primaryCompletion":1483,"completion":1483,"start":1484,"enrollment":102,"conditions":1485,"interventions":1489},"NCT02993991","Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity",[90],"2017-12-21","2017-10-10",[1486,1487,1488],"Squamous Cell Carcinoma, Head And Neck","Squamous Cell Carcinoma Mouth","Resectable Squamous Cell Carcinoma of Oral Cavity",[1490,1466],"Mocetinostat",{"trials":1492,"activeCount":98,"soonestReadout":86},[1493,1503,1512,1522,1526,1535,1543,1555],{"nctId":1494,"briefTitle":1495,"status":727,"phases":1496,"primaryCompletion":1497,"completion":1497,"start":1498,"enrollment":511,"conditions":1499,"interventions":1502},"NCT06191250","--SuPERIOR Trial--",[91],"2024-12-30","2024-09-28",[1500,1501],"Non-Small Cell Lung Cancer (NSCLC)","Clinical Staging T2b-3 N0-1 M0",[1466],{"nctId":84,"briefTitle":85,"status":168,"phases":1504,"primaryCompletion":86,"completion":86,"start":1505,"enrollment":423,"conditions":1506,"interventions":1511},[91],"2019-12-31",[1507,1508,1509,1510],"Glioma","Cholangiocarcinoma","Solid Tumor","IDH Mutation",[87,1466],{"nctId":1513,"briefTitle":1514,"status":168,"phases":1515,"primaryCompletion":1516,"completion":1516,"start":1517,"enrollment":1388,"conditions":1518,"interventions":1520},"NCT06060405","Durvalumab and Oleclumab in Resectable PDAC",[91],"2026-10-30","2023-11-29",[1519],"Pancreatic Ductal Adenocarcinoma",[1466,1521],"Oleclumab",{"nctId":1456,"briefTitle":1457,"status":112,"phases":1523,"primaryCompletion":1459,"completion":1460,"start":1461,"enrollment":607,"conditions":1524,"interventions":1525},[91],[1463],[1335,1465,1466],{"nctId":1527,"briefTitle":1528,"status":550,"phases":1529,"primaryCompletion":1530,"completion":1530,"start":1531,"enrollment":102,"conditions":1532,"interventions":1534},"NCT04262388","A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation",[91],"2023-01","2021-01",[1519,1533,700],"Non-small Cell Lung Cancer",[1466,1521],{"nctId":1536,"briefTitle":1537,"status":550,"phases":1538,"primaryCompletion":1539,"completion":1539,"start":1531,"enrollment":102,"conditions":1540,"interventions":1542},"NCT04262375","A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION",[91],"2024-01",[570,1541],"Renal Cell Carcinoma",[1466,1521],{"nctId":1544,"briefTitle":1545,"status":494,"phases":1546,"primaryCompletion":1547,"completion":1547,"start":1548,"enrollment":218,"conditions":1549,"interventions":1553},"NCT03851614","Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors",[91],"2027-01-01","2019-04-08",[1550,1551,1552],"Mismatch Repair Proficient Colorectal Cancer","Pancreatic Adenocarcinoma","Leiomyosarcoma",[1466,87,1554],"Cediranib",{"nctId":1556,"briefTitle":1557,"status":112,"phases":1558,"primaryCompletion":1559,"completion":1346,"start":1387,"enrollment":1560,"conditions":1561,"interventions":1565},"NCT02811497","Study of Azacitidine and Durvalumab in Advanced Solid Tumors",[91],"2018-11-08",28,[1562,1563,1564],"Microsatellite Stable Colorectal Carcinoma","Platinum Resistant Epithelial Ovarian Cancer Type II","Estrogen Receptor Positive and HER2 Negative Breast Cancer",[1566,1466],"Azacitidine",{"trials":1568,"activeCount":102},[],{"trials":1570,"activeCount":102},[],{"trials":1572,"activeCount":102},[],{"intervention":574,"totalTrials":1574,"cells":1575},5,{"EARLY_PHASE1":1576,"PHASE1":1588,"PHASE2":1600,"PHASE3":1628,"PHASE4":1630,"NA":1632},{"trials":1577,"activeCount":102},[1578],{"nctId":1579,"briefTitle":1580,"status":112,"phases":1581,"primaryCompletion":1582,"completion":1582,"start":1583,"enrollment":511,"conditions":1584,"interventions":1586},"NCT03575598","Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study",[89],"2020-02-18","2018-08-30",[1486,1487,1585],"Squamous Cell Carcinoma of the Oral Cavity",[1587,574],"Sitravatinib",{"trials":1589,"activeCount":149,"soonestReadout":1594},[1590],{"nctId":1591,"briefTitle":1592,"status":168,"phases":1593,"primaryCompletion":1594,"completion":1594,"start":1595,"enrollment":687,"conditions":1596,"interventions":1598},"NCT06377111","A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma",[90],"2026-08","2024-06-24",[1597],"Melanoma (Skin)",[574,1599],"Ipilimumab",{"trials":1601,"activeCount":659,"soonestReadout":565},[1602,1606,1619],{"nctId":562,"briefTitle":563,"status":168,"phases":1603,"primaryCompletion":565,"completion":566,"start":567,"enrollment":568,"conditions":1604,"interventions":1605},[91],[570,571,572],[574,575,72,576,577],{"nctId":1607,"briefTitle":1608,"status":168,"phases":1609,"primaryCompletion":1610,"completion":1611,"start":1612,"enrollment":810,"conditions":1613,"interventions":1617},"NCT06319196","Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma",[91],"2027-02-15","2030-02-15","2026-02-27",[1614,1615,1616],"Cutaneous Melanoma","Melanoma Stage IV","Mucosal Melanoma",[1618,574],"Opdualag",{"nctId":1620,"briefTitle":1621,"status":727,"phases":1622,"primaryCompletion":1623,"completion":1623,"start":1624,"enrollment":1574,"conditions":1625,"interventions":1626},"NCT04966676","Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer",[91],"2025-02-19","2022-01-24",[570],[574,1599,1627],"Platinum-based Chemotherapy",{"trials":1629,"activeCount":102},[],{"trials":1631,"activeCount":102},[],{"trials":1633,"activeCount":102},[],{"intervention":1635,"totalTrials":98,"cells":1636},"Psilocybin",{"EARLY_PHASE1":1637,"PHASE1":1639,"PHASE2":1650,"PHASE3":1674,"PHASE4":1676,"NA":1678},{"trials":1638,"activeCount":102},[],{"trials":1640,"activeCount":149,"soonestReadout":1645},[1641],{"nctId":1642,"briefTitle":1643,"status":168,"phases":1644,"primaryCompletion":1645,"completion":1547,"start":1646,"enrollment":607,"conditions":1647,"interventions":1649},"NCT06506019","Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression",[90],"2026-09-01","2024-10-09",[1648],"Bipolar Depression",[1635],{"trials":1651,"activeCount":659,"soonestReadout":1665},[1652,1661],{"nctId":1653,"briefTitle":1654,"status":125,"phases":1655,"primaryCompletion":1656,"completion":1656,"start":1657,"enrollment":244,"conditions":1658,"interventions":1660},"NCT07048743","Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Caregivers of Patients With Advanced Cancer",[91],"2027-12-02","2025-07-02",[1659],"Caregiver Distress",[1635],{"nctId":1662,"briefTitle":1663,"status":494,"phases":1664,"primaryCompletion":1665,"completion":1665,"start":1666,"enrollment":244,"conditions":1667,"interventions":1673},"NCT06416085","Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer",[91],"2026-12-15","2024-06-06",[855,1668,1669,1670,1671,1672],"Stage IV Solid Tumor Cancer","Stage IV Sarcoma of Bone","Stage IV Lymphoma","Stage IV Melanoma","Endocrine Cancer",[1635],{"trials":1675,"activeCount":102},[],{"trials":1677,"activeCount":102},[],{"trials":1679,"activeCount":102},[],{"intervention":1435,"totalTrials":584,"cells":1681},{"EARLY_PHASE1":1682,"PHASE1":1684,"PHASE2":1694,"PHASE3":1731,"PHASE4":1733,"NA":1735},{"trials":1683,"activeCount":102},[],{"trials":1685,"activeCount":149,"soonestReadout":1594},[1686],{"nctId":1687,"briefTitle":1688,"status":168,"phases":1689,"primaryCompletion":1594,"completion":215,"start":1690,"enrollment":172,"conditions":1691,"interventions":1693},"NCT03991819","Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer",[90],"2019-09-20",[1692],"Non-small Cell Carcinoma",[843,1435],{"trials":1695,"activeCount":659,"soonestReadout":1428},[1696,1707,1716,1720],{"nctId":1697,"briefTitle":1698,"status":494,"phases":1699,"primaryCompletion":215,"completion":215,"start":1700,"enrollment":1046,"conditions":1701,"interventions":1706},"NCT02644369","Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors",[91],"2016-03-21",[1702,1703,1704,1351,1705],"Squamous Cell Cancer of Head and Neck","Triple Negative Breast Cancer","Epithelial Ovarian Cancer","Advanced Solid Tumors",[1435],{"nctId":1708,"briefTitle":1709,"status":727,"phases":1710,"primaryCompletion":1711,"completion":1711,"start":1712,"enrollment":28,"conditions":1713,"interventions":1715},"NCT03316872","Study of Pembrolizumab and Radiotherapy in Liver Cancer",[91],"2024-02-15","2018-02-15",[1714],"Hepatocellular Carcinoma",[1435],{"nctId":1425,"briefTitle":1426,"status":494,"phases":1717,"primaryCompletion":1428,"completion":1429,"start":1430,"enrollment":1431,"conditions":1718,"interventions":1719},[91],[855,732,1433,734],[1435,1436,1335],{"nctId":1721,"briefTitle":1722,"status":1723,"phases":1724,"primaryCompletion":1314,"completion":1314,"start":1725,"enrollment":1726,"conditions":1727,"interventions":1729},"NCT04510636","Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma","UNKNOWN",[91],"2021-12-20",37,[1728,247,248],"Classical Hodgkin Lymphoma",[1435,1730],"Bendamustine Hydrochloride",{"trials":1732,"activeCount":102},[],{"trials":1734,"activeCount":102},[],{"trials":1736,"activeCount":102},[1737],{"nctId":1738,"briefTitle":1739,"status":1723,"phases":1740,"primaryCompletion":1741,"completion":1741,"start":1742,"enrollment":149,"conditions":1743,"interventions":1745},"NCT05368207","Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient",[94],"2024-11-02","2021-12-06",[1744,732],"Small Cell Carcinoma, Hypercalcaemic Type",[1435],{"intervention":1747,"totalTrials":1574,"cells":1748},"Bevacizumab",{"EARLY_PHASE1":1749,"PHASE1":1751,"PHASE2":1753,"PHASE3":1808,"PHASE4":1810,"NA":1812},{"trials":1750,"activeCount":102},[],{"trials":1752,"activeCount":102},[],{"trials":1754,"activeCount":659,"soonestReadout":56},[1755,1763,1777,1789,1798],{"nctId":54,"briefTitle":55,"status":494,"phases":1756,"primaryCompletion":56,"completion":1757,"start":1758,"enrollment":758,"conditions":1759,"interventions":1762},[91],"2026-08-31","2021-06-04",[1714,1760,1761],"Non-small Cell Lung Cancer Metastatic","Liver Metastases",[57,1747],{"nctId":1764,"briefTitle":1765,"status":494,"phases":1766,"primaryCompletion":1767,"completion":1768,"start":1769,"enrollment":1770,"conditions":1771,"interventions":1773},"NCT05843188","Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer",[91],"2026-04-24","2026-10-24","2023-08-09",155,[1772],"Metastatic Colorectal Cancer",[1774,762,1775,1776,1747],"Hydroxychloroquine","Leucovorin","Fluorouracil",{"nctId":1778,"briefTitle":1779,"status":1723,"phases":1780,"primaryCompletion":1781,"completion":1781,"start":1782,"enrollment":172,"conditions":1783,"interventions":1786},"NCT05065021","Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor",[91],"2025-06-06","2023-02-23",[732,734,1379,1784,1785],"High Grade Serous Cancer","High Grade Endometrioid Cancer",[1787,1788,1747,737],"Niraparib","Dostarlimab",{"nctId":1790,"briefTitle":1791,"status":112,"phases":1792,"primaryCompletion":1793,"completion":1793,"start":1794,"enrollment":19,"conditions":1795,"interventions":1796},"NCT00483834","A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer",[91],"2011-07","2006-12",[32],[1747,762,1797],"Capecitabine",{"nctId":1799,"briefTitle":1800,"status":550,"phases":1801,"primaryCompletion":1802,"completion":1802,"start":1803,"enrollment":102,"conditions":1804,"interventions":1807},"NCT04510584","Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer",[91],"2023-02-22","2021-07-16",[1805,734,1379,1806],"Ovarian Endometrioid Tumor","TP53 Mutation",[57,1747],{"trials":1809,"activeCount":102},[],{"trials":1811,"activeCount":102},[],{"trials":1813,"activeCount":102},[],{"intervention":843,"totalTrials":98,"cells":1815},{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1828,"PHASE3":1840,"PHASE4":1842,"NA":1844},{"trials":1817,"activeCount":102},[],{"trials":1819,"activeCount":149,"soonestReadout":1594},[1820,1824],{"nctId":835,"briefTitle":836,"status":112,"phases":1821,"primaryCompletion":838,"completion":838,"start":839,"enrollment":771,"conditions":1822,"interventions":1823},[90],[841],[843,575,577],{"nctId":1687,"briefTitle":1688,"status":168,"phases":1825,"primaryCompletion":1594,"completion":215,"start":1690,"enrollment":172,"conditions":1826,"interventions":1827},[90],[1692],[843,1435],{"trials":1829,"activeCount":149,"soonestReadout":1834},[1830],{"nctId":1831,"briefTitle":1832,"status":494,"phases":1833,"primaryCompletion":1834,"completion":1834,"start":1835,"enrollment":1836,"conditions":1837,"interventions":1838},"NCT03839342","Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations",[91],"2025-12","2019-06-07",26,[1509],[843,1839],"Encorafenib",{"trials":1841,"activeCount":102},[],{"trials":1843,"activeCount":102},[],{"trials":1845,"activeCount":102},[],{"intervention":1847,"totalTrials":98,"cells":1848},"Doxorubicin",{"EARLY_PHASE1":1849,"PHASE1":1851,"PHASE2":1875,"PHASE3":1895,"PHASE4":1897,"NA":1899},{"trials":1850,"activeCount":102},[],{"trials":1852,"activeCount":149,"soonestReadout":1869},[1853,1865],{"nctId":1854,"briefTitle":1855,"status":112,"phases":1856,"primaryCompletion":1857,"completion":1858,"start":1859,"enrollment":1860,"conditions":1861,"interventions":1863},"NCT03042819","Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas",[90],"2019-11-30","2021-06-30","2017-05-16",25,[1862],"Soft Tissue Sarcoma",[1864,1847],"Selinexor",{"nctId":1866,"briefTitle":1867,"status":168,"phases":1868,"primaryCompletion":1869,"completion":1869,"start":1870,"enrollment":33,"conditions":1871,"interventions":1874},"NCT02811523","In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma",[90],"2030-09","2016-02",[1872,1862,1873],"Bone Sarcoma","Pulmonary Metastases",[1847],{"trials":1876,"activeCount":149,"soonestReadout":1881},[1877],{"nctId":1878,"briefTitle":1879,"status":125,"phases":1880,"primaryCompletion":1881,"completion":1881,"start":1882,"enrollment":1860,"conditions":1883,"interventions":1886},"NCT06813079","Using Tumor Models to Determine Treatments",[91],"2028-02-17","2025-02-17",[1884,855,1885],"Pancreatic Ductal Carcinoma","Epithelial Tumor",[1887,1888,1889,1890,1864,1891,1892,1847,1893,1894],"Cobimetinib","Ponatinib","Brigatinib","Colchicine","Abemaciclib","Neratinib","Etoposide","Ceritinib",{"trials":1896,"activeCount":102},[],{"trials":1898,"activeCount":102},[],{"trials":1900,"activeCount":102},[],{"intervention":1892,"totalTrials":659,"cells":1902},{"EARLY_PHASE1":1903,"PHASE1":1905,"PHASE2":1907,"PHASE3":1922,"PHASE4":1924,"NA":1926},{"trials":1904,"activeCount":102},[],{"trials":1906,"activeCount":102},[],{"trials":1908,"activeCount":659,"soonestReadout":1917},[1909,1913],{"nctId":1878,"briefTitle":1879,"status":125,"phases":1910,"primaryCompletion":1881,"completion":1881,"start":1882,"enrollment":1860,"conditions":1911,"interventions":1912},[91],[1884,855,1885],[1887,1888,1889,1890,1864,1891,1892,1847,1893,1894],{"nctId":1914,"briefTitle":1915,"status":168,"phases":1916,"primaryCompletion":1917,"completion":1917,"start":1918,"enrollment":244,"conditions":1919,"interventions":1921},"NCT05388149","Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease",[91],"2026-07","2022-12-06",[18,1920],"HER2-positive Breast Cancer",[1892],{"trials":1923,"activeCount":102},[],{"trials":1925,"activeCount":102},[],{"trials":1927,"activeCount":102},[],{"intervention":87,"totalTrials":1574,"cells":1929},{"EARLY_PHASE1":1930,"PHASE1":1932,"PHASE2":1934,"PHASE3":1962,"PHASE4":1964,"NA":1966},{"trials":1931,"activeCount":102},[],{"trials":1933,"activeCount":102},[],{"trials":1935,"activeCount":659,"soonestReadout":86},[1936,1940,1951,1958],{"nctId":84,"briefTitle":85,"status":168,"phases":1937,"primaryCompletion":86,"completion":86,"start":1505,"enrollment":423,"conditions":1938,"interventions":1939},[91],[1507,1508,1509,1510],[87,1466],{"nctId":1941,"briefTitle":1942,"status":1723,"phases":1943,"primaryCompletion":1944,"completion":1944,"start":1945,"enrollment":1946,"conditions":1947,"interventions":1950},"NCT02489006","A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer",[91],"2025-12-31","2016-07-19",71,[732,734,1948,1949],"Neoadjuvant Treatment","Debulking Surgical Procedures",[87,1627],{"nctId":1952,"briefTitle":1953,"status":112,"phases":1954,"primaryCompletion":1955,"completion":1955,"start":552,"enrollment":479,"conditions":1956,"interventions":1957},"NCT02340611","A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib",[91],"2018-06",[732],[87,1554],{"nctId":1544,"briefTitle":1545,"status":494,"phases":1959,"primaryCompletion":1547,"completion":1547,"start":1548,"enrollment":218,"conditions":1960,"interventions":1961},[91],[1550,1551,1552],[1466,87,1554],{"trials":1963,"activeCount":102},[],{"trials":1965,"activeCount":102},[],{"trials":1967,"activeCount":102},[1968],{"nctId":1969,"briefTitle":1970,"status":112,"phases":1971,"primaryCompletion":1972,"completion":1973,"start":1974,"enrollment":22,"conditions":1975,"interventions":1976},"NCT02681237","A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer",[94],"2022-01-10","2022-03-25","2016-04-29",[732],[1554,87],{"intervention":1978,"totalTrials":479,"cells":1979},"Pentoxifylline",{"EARLY_PHASE1":1980,"PHASE1":1982,"PHASE2":1984,"PHASE3":2016,"PHASE4":2030,"NA":2032},{"trials":1981,"activeCount":102},[],{"trials":1983,"activeCount":102},[],{"trials":1985,"activeCount":149,"soonestReadout":2000},[1986,1996,2007],{"nctId":1987,"briefTitle":1988,"status":727,"phases":1989,"start":1990,"enrollment":19,"conditions":1991,"interventions":1993},"NCT00188552","The Use of Pentoxifylline and Vitamin E in the Treatment of Late Radiation Related Injuries",[91],"2002-07",[1992],"Wounds and Injuries",[1994,1995],"pentoxifylline","α-Tocopherol",{"nctId":1997,"briefTitle":1998,"status":125,"phases":1999,"primaryCompletion":2000,"completion":2001,"start":1361,"enrollment":2002,"conditions":2003,"interventions":2006},"NCT06634056","Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation",[91],"2031-11-30","2032-11-30",150,[2004,2005],"Non-Small Cell Lung Cancer","Radiation Induced Lung Injury (RILI)",[1978],{"nctId":2008,"briefTitle":2009,"status":727,"phases":2010,"start":1990,"enrollment":2011,"conditions":2012,"interventions":2014},"NCT00188669","The Use of Pentoxifylline and Vitamin E in the Treatment of Chronic Breast Pain",[91],48,[2013],"Breast Neoplasms",[1994,2015],"alpha-Tocopherol",{"trials":2017,"activeCount":102},[2018],{"nctId":2019,"briefTitle":2020,"status":112,"phases":2021,"primaryCompletion":86,"completion":1944,"start":2022,"enrollment":2023,"conditions":2024,"interventions":2028},"NCT05513560","RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine",[91,92],"2023-05-31",460,[2025,2026,2027],"Long COVID","Post COVID Condition","Post Acute Sequelae of COVID-19",[2029,1978],"Ibudilast",{"trials":2031,"activeCount":102},[],{"trials":2033,"activeCount":102},[],{"intervention":2035,"totalTrials":98,"cells":2036},"Dapagliflozin 10 MG",{"EARLY_PHASE1":2037,"PHASE1":2039,"PHASE2":2041,"PHASE3":2063,"PHASE4":2077,"NA":2079},{"trials":2038,"activeCount":102},[],{"trials":2040,"activeCount":102},[],{"trials":2042,"activeCount":149,"soonestReadout":2056},[2043,2052],{"nctId":2044,"briefTitle":2045,"status":1723,"phases":2046,"primaryCompletion":2047,"completion":2047,"start":2048,"enrollment":19,"conditions":2049,"interventions":2051},"NCT04258371","DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk",[91],"2023-12","2020-02-10",[2050],"Cardiovascular Risk Factor",[2035],{"nctId":2053,"briefTitle":2054,"status":168,"phases":2055,"primaryCompletion":2056,"completion":2057,"start":2058,"enrollment":129,"conditions":2059,"interventions":2061},"NCT05938712","The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients",[91],"2027-10-01","2028-03-01","2023-10-24",[2060],"Kidney Transplant Recipients",[2035,2062],"Semaglutide, 1.0 mg\u002FmL",{"trials":2064,"activeCount":102},[2065],{"nctId":2066,"briefTitle":2067,"status":112,"phases":2068,"primaryCompletion":2069,"completion":2069,"start":2070,"enrollment":2071,"conditions":2072,"interventions":2075},"NCT04965935","Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients",[92],"2024-08-30","2021-07-15",52,[2060,2073,2074],"Post-transplant Diabetes Mellitus","Type 2 Diabetes",[2076],"Dapagliflozin 10 MG Oral",{"trials":2078,"activeCount":102},[],{"trials":2080,"activeCount":102},[],{"intervention":575,"totalTrials":98,"cells":2082},{"EARLY_PHASE1":2083,"PHASE1":2085,"PHASE2":2091,"PHASE3":2101,"PHASE4":2103,"NA":2105},{"trials":2084,"activeCount":102},[],{"trials":2086,"activeCount":102},[2087],{"nctId":835,"briefTitle":836,"status":112,"phases":2088,"primaryCompletion":838,"completion":838,"start":839,"enrollment":771,"conditions":2089,"interventions":2090},[90],[841],[843,575,577],{"trials":2092,"activeCount":149,"soonestReadout":565},[2093,2097],{"nctId":562,"briefTitle":563,"status":168,"phases":2094,"primaryCompletion":565,"completion":566,"start":567,"enrollment":568,"conditions":2095,"interventions":2096},[91],[570,571,572],[574,575,72,576,577],{"nctId":739,"briefTitle":740,"status":727,"phases":2098,"primaryCompletion":742,"completion":742,"start":743,"enrollment":584,"conditions":2099,"interventions":2100},[91],[745,746],[575,576],{"trials":2102,"activeCount":102},[],{"trials":2104,"activeCount":102},[],{"trials":2106,"activeCount":102},[],{"intervention":1521,"totalTrials":98,"cells":2108},{"EARLY_PHASE1":2109,"PHASE1":2111,"PHASE2":2113,"PHASE3":2127,"PHASE4":2129,"NA":2131},{"trials":2110,"activeCount":102},[],{"trials":2112,"activeCount":102},[],{"trials":2114,"activeCount":149,"soonestReadout":1516},[2115,2119,2123],{"nctId":1513,"briefTitle":1514,"status":168,"phases":2116,"primaryCompletion":1516,"completion":1516,"start":1517,"enrollment":1388,"conditions":2117,"interventions":2118},[91],[1519],[1466,1521],{"nctId":1527,"briefTitle":1528,"status":550,"phases":2120,"primaryCompletion":1530,"completion":1530,"start":1531,"enrollment":102,"conditions":2121,"interventions":2122},[91],[1519,1533,700],[1466,1521],{"nctId":1536,"briefTitle":1537,"status":550,"phases":2124,"primaryCompletion":1539,"completion":1539,"start":1531,"enrollment":102,"conditions":2125,"interventions":2126},[91],[570,1541],[1466,1521],{"trials":2128,"activeCount":102},[],{"trials":2130,"activeCount":102},[],{"trials":2132,"activeCount":102},[],{"intervention":762,"totalTrials":98,"cells":2134},{"EARLY_PHASE1":2135,"PHASE1":2137,"PHASE2":2139,"PHASE3":2153,"PHASE4":2155,"NA":2157},{"trials":2136,"activeCount":102},[],{"trials":2138,"activeCount":102},[],{"trials":2140,"activeCount":149,"soonestReadout":1767},[2141,2145,2149],{"nctId":753,"briefTitle":754,"status":112,"phases":2142,"primaryCompletion":756,"completion":756,"start":757,"enrollment":758,"conditions":2143,"interventions":2144},[91],[760],[762,576,763],{"nctId":1764,"briefTitle":1765,"status":494,"phases":2146,"primaryCompletion":1767,"completion":1768,"start":1769,"enrollment":1770,"conditions":2147,"interventions":2148},[91],[1772],[1774,762,1775,1776,1747],{"nctId":1790,"briefTitle":1791,"status":112,"phases":2150,"primaryCompletion":1793,"completion":1793,"start":1794,"enrollment":19,"conditions":2151,"interventions":2152},[91],[32],[1747,762,1797],{"trials":2154,"activeCount":102},[],{"trials":2156,"activeCount":102},[],{"trials":2158,"activeCount":102},[],{"intervention":1774,"totalTrials":659,"cells":2160},{"EARLY_PHASE1":2161,"PHASE1":2163,"PHASE2":2165,"PHASE3":2181,"PHASE4":2183,"NA":2185},{"trials":2162,"activeCount":102},[],{"trials":2164,"activeCount":102},[],{"trials":2166,"activeCount":149,"soonestReadout":1767},[2167,2177],{"nctId":2168,"briefTitle":2169,"status":112,"phases":2170,"primaryCompletion":2171,"completion":2171,"start":2172,"enrollment":771,"conditions":2173,"interventions":2175},"NCT03081702","A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer",[90,91],"2019-08-27","2017-07-25",[2174],"Platinum-resistant Epithelial Ovarian Cancer",[1774,2176],"Itraconazole",{"nctId":1764,"briefTitle":1765,"status":494,"phases":2178,"primaryCompletion":1767,"completion":1768,"start":1769,"enrollment":1770,"conditions":2179,"interventions":2180},[91],[1772],[1774,762,1775,1776,1747],{"trials":2182,"activeCount":102},[],{"trials":2184,"activeCount":102},[],{"trials":2186,"activeCount":102},[],{"intervention":2188,"totalTrials":659,"cells":2189},"Venetoclax",{"EARLY_PHASE1":2190,"PHASE1":2192,"PHASE2":2194,"PHASE3":2216,"PHASE4":2218,"NA":2220},{"trials":2191,"activeCount":102},[],{"trials":2193,"activeCount":102},[],{"trials":2195,"activeCount":149,"soonestReadout":927},[2196,2208],{"nctId":2197,"briefTitle":2198,"status":727,"phases":2199,"primaryCompletion":2200,"completion":2200,"start":2201,"enrollment":2202,"conditions":2203,"interventions":2206},"NCT04092179","Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers",[90,91],"2023-10-26","2020-11-05",27,[2204,247,248,2205],"Acute Myeloid Leukemia","IDH2 Gene Mutation",[2207,2188],"Enasidenib",{"nctId":2209,"briefTitle":2210,"status":168,"phases":2211,"primaryCompletion":927,"completion":927,"start":2212,"enrollment":172,"conditions":2213,"interventions":2215},"NCT05074355","Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms",[91],"2023-11-08",[2214],"Myeloproliferative Neoplasm",[1566,2188],{"trials":2217,"activeCount":102},[],{"trials":2219,"activeCount":102},[],{"trials":2221,"activeCount":102},[],{"intervention":1465,"totalTrials":659,"cells":2223},{"EARLY_PHASE1":2224,"PHASE1":2226,"PHASE2":2228,"PHASE3":2241,"PHASE4":2243,"NA":2245},{"trials":2225,"activeCount":102},[],{"trials":2227,"activeCount":102},[],{"trials":2229,"activeCount":149,"soonestReadout":2234},[2230,2237],{"nctId":2231,"briefTitle":2232,"status":168,"phases":2233,"primaryCompletion":2234,"completion":1386,"start":2200,"enrollment":1560,"conditions":2235,"interventions":2236},"NCT05440864","Durvalumab and Tremelimumab in Resectable HCC",[91],"2025-11",[1714],[1465],{"nctId":1456,"briefTitle":1457,"status":112,"phases":2238,"primaryCompletion":1459,"completion":1460,"start":1461,"enrollment":607,"conditions":2239,"interventions":2240},[91],[1463],[1335,1465,1466],{"trials":2242,"activeCount":102},[],{"trials":2244,"activeCount":102},[],{"trials":2246,"activeCount":102},[],{"intervention":2248,"totalTrials":659,"cells":2249},"Enzalutamide",{"EARLY_PHASE1":2250,"PHASE1":2252,"PHASE2":2254,"PHASE3":2275,"PHASE4":2277,"NA":2279},{"trials":2251,"activeCount":102},[],{"trials":2253,"activeCount":102},[],{"trials":2255,"activeCount":149,"soonestReadout":907},[2256,2265],{"nctId":2257,"briefTitle":2258,"status":168,"phases":2259,"primaryCompletion":907,"completion":907,"start":2260,"enrollment":2261,"conditions":2262,"interventions":2264},"NCT05404139","Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)",[91],"2023-05-24",132,[2263],"Metastatic Prostate Cancer",[2248],{"nctId":2266,"briefTitle":2267,"status":112,"phases":2268,"primaryCompletion":2269,"completion":2269,"start":2270,"enrollment":36,"conditions":2271,"interventions":2273},"NCT02429193","Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA",[91],"2019-09-01","2016-03",[2272],"Castration-resistant Prostate Cancer",[2274,2248],"Abiraterone + prednisone",{"trials":2276,"activeCount":102},[],{"trials":2278,"activeCount":102},[],{"trials":2280,"activeCount":102},[],{"intervention":2282,"totalTrials":659,"cells":2283},"Ketamine Hydrochloride",{"EARLY_PHASE1":2284,"PHASE1":2286,"PHASE2":2288,"PHASE3":2313,"PHASE4":2315,"NA":2317},{"trials":2285,"activeCount":102},[],{"trials":2287,"activeCount":102},[],{"trials":2289,"activeCount":149,"soonestReadout":907},[2290,2300],{"nctId":2291,"briefTitle":2292,"status":112,"phases":2293,"primaryCompletion":2294,"completion":2294,"start":2295,"enrollment":1388,"conditions":2296,"interventions":2299},"NCT03410446","Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care",[91],"2021-11-27","2018-07-16",[2297,24,2298],"Depression","Palliative Care",[2282],{"nctId":2301,"briefTitle":2302,"status":168,"phases":2303,"primaryCompletion":907,"completion":1185,"start":2304,"enrollment":2305,"conditions":2306,"interventions":2310},"NCT06480500","i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial",[91],"2024-01-02",110,[2307,2308,2309],"Major Depressive Disorder","Suicide","Treatment Resistant Depression",[2311,2312],"Ketamine hydrochloride","Midazolam Hydrochloride",{"trials":2314,"activeCount":102},[],{"trials":2316,"activeCount":102},[],{"trials":2318,"activeCount":102},[],{"intervention":57,"totalTrials":659,"cells":2320},{"EARLY_PHASE1":2321,"PHASE1":2323,"PHASE2":2325,"PHASE3":2335,"PHASE4":2337,"NA":2339},{"trials":2322,"activeCount":102},[],{"trials":2324,"activeCount":102},[],{"trials":2326,"activeCount":149,"soonestReadout":56},[2327,2331],{"nctId":54,"briefTitle":55,"status":494,"phases":2328,"primaryCompletion":56,"completion":1757,"start":1758,"enrollment":758,"conditions":2329,"interventions":2330},[91],[1714,1760,1761],[57,1747],{"nctId":1799,"briefTitle":1800,"status":550,"phases":2332,"primaryCompletion":1802,"completion":1802,"start":1803,"enrollment":102,"conditions":2333,"interventions":2334},[91],[1805,734,1379,1806],[57,1747],{"trials":2336,"activeCount":102},[],{"trials":2338,"activeCount":102},[],{"trials":2340,"activeCount":102},[],{"intervention":2342,"totalTrials":659,"cells":2343},"Degarelix",{"EARLY_PHASE1":2344,"PHASE1":2346,"PHASE2":2348,"PHASE3":2371,"PHASE4":2373,"NA":2375},{"trials":2345,"activeCount":102},[],{"trials":2347,"activeCount":102},[],{"trials":2349,"activeCount":149,"soonestReadout":822},[2350,2362],{"nctId":2351,"briefTitle":2352,"status":112,"phases":2353,"primaryCompletion":2354,"completion":2355,"start":2356,"enrollment":2357,"conditions":2358,"interventions":2359},"NCT01674270","Degarelix Neo-Adjuvant Radical Prostatectomy Trial",[91],"2014-12","2015-11","2012-08",35,[15],[2342,2360,2361],"Casodex","LHRH Agonist",{"nctId":2363,"briefTitle":2364,"status":125,"phases":2365,"primaryCompletion":822,"completion":822,"start":2366,"enrollment":2367,"conditions":2368,"interventions":2369},"NCT04176081","Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer",[91],"2024-07-02",208,[15],[2370,2342],"Darolutamide",{"trials":2372,"activeCount":102},[],{"trials":2374,"activeCount":102},[],{"trials":2376,"activeCount":102},[],{"intervention":1788,"totalTrials":659,"cells":2378},{"EARLY_PHASE1":2379,"PHASE1":2381,"PHASE2":2383,"PHASE3":2400,"PHASE4":2402,"NA":2404},{"trials":2380,"activeCount":102},[],{"trials":2382,"activeCount":102},[],{"trials":2384,"activeCount":149,"soonestReadout":2393},[2385,2389],{"nctId":1778,"briefTitle":1779,"status":1723,"phases":2386,"primaryCompletion":1781,"completion":1781,"start":1782,"enrollment":172,"conditions":2387,"interventions":2388},[91],[732,734,1379,1784,1785],[1787,1788,1747,737],{"nctId":2390,"briefTitle":2391,"status":168,"phases":2392,"primaryCompletion":2393,"completion":2394,"start":2395,"enrollment":607,"conditions":2396,"interventions":2398},"NCT07408063","A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent\u002FMetastatic (R\u002FM) Head and Neck Squamous Cell Carcinoma (HNSCC)",[91],"2030-06-30","2031-03-01","2026-04-27",[2397],"Recurrent\u002FMetastatic Head and Neck Squamous Cell Carcinoma",[2399,1788],"GSK5764227",{"trials":2401,"activeCount":102},[],{"trials":2403,"activeCount":102},[],{"trials":2405,"activeCount":102},[],{"intervention":1566,"totalTrials":659,"cells":2407},{"EARLY_PHASE1":2408,"PHASE1":2410,"PHASE2":2412,"PHASE3":2422,"PHASE4":2424,"NA":2426},{"trials":2409,"activeCount":102},[],{"trials":2411,"activeCount":102},[],{"trials":2413,"activeCount":149,"soonestReadout":927},[2414,2418],{"nctId":2209,"briefTitle":2210,"status":168,"phases":2415,"primaryCompletion":927,"completion":927,"start":2212,"enrollment":172,"conditions":2416,"interventions":2417},[91],[2214],[1566,2188],{"nctId":1556,"briefTitle":1557,"status":112,"phases":2419,"primaryCompletion":1559,"completion":1346,"start":1387,"enrollment":1560,"conditions":2420,"interventions":2421},[91],[1562,1563,1564],[1566,1466],{"trials":2423,"activeCount":102},[],{"trials":2425,"activeCount":102},[],{"trials":2427,"activeCount":102},[],{"intervention":2429,"totalTrials":149,"cells":2430},"Mitapivat",{"EARLY_PHASE1":2431,"PHASE1":2433,"PHASE2":2435,"PHASE3":2446,"PHASE4":2448,"NA":2450},{"trials":2432,"activeCount":102},[],{"trials":2434,"activeCount":102},[],{"trials":2436,"activeCount":149,"soonestReadout":289},[2437],{"nctId":2438,"briefTitle":2439,"status":168,"phases":2440,"primaryCompletion":289,"completion":2441,"start":2442,"enrollment":541,"conditions":2443,"interventions":2445},"NCT07055243","To Assess Safety of Mitapivat and Provide Proof of Concept of the Efficacy of the Drug in Patients With RBC Membranopathies or CDAII.",[91],"2027-06-30","2025-06-26",[2444],"Anemia",[2429],{"trials":2447,"activeCount":102},[],{"trials":2449,"activeCount":102},[],{"trials":2451,"activeCount":102},[],{"intervention":52,"totalTrials":149,"cells":2453},{"EARLY_PHASE1":2454,"PHASE1":2456,"PHASE2":2458,"PHASE3":2469,"PHASE4":2471,"NA":2473},{"trials":2455,"activeCount":102},[],{"trials":2457,"activeCount":102},[],{"trials":2459,"activeCount":149,"soonestReadout":51},[2460],{"nctId":49,"briefTitle":50,"status":168,"phases":2461,"primaryCompletion":51,"completion":2462,"start":2463,"enrollment":2464,"conditions":2465,"interventions":2467},[91],"2032-04-30","2021-03-01",105,[2466],"Mantle Cell Lymphoma",[52,2468],"R-CHOP chemotherapy",{"trials":2470,"activeCount":102},[],{"trials":2472,"activeCount":102},[],{"trials":2474,"activeCount":102},[],{"intervention":2468,"totalTrials":149,"cells":2476},{"EARLY_PHASE1":2477,"PHASE1":2479,"PHASE2":2481,"PHASE3":2487,"PHASE4":2489,"NA":2491},{"trials":2478,"activeCount":102},[],{"trials":2480,"activeCount":102},[],{"trials":2482,"activeCount":149,"soonestReadout":51},[2483],{"nctId":49,"briefTitle":50,"status":168,"phases":2484,"primaryCompletion":51,"completion":2462,"start":2463,"enrollment":2464,"conditions":2485,"interventions":2486},[91],[2466],[52,2468],{"trials":2488,"activeCount":102},[],{"trials":2490,"activeCount":102},[],{"trials":2492,"activeCount":102},[],{"intervention":2494,"totalTrials":149,"cells":2495},"Delayed Cold-Stored Buffy Coat Platelets",{"EARLY_PHASE1":2496,"PHASE1":2498,"PHASE2":2500,"PHASE3":2510,"PHASE4":2512,"NA":2514},{"trials":2497,"activeCount":102},[],{"trials":2499,"activeCount":102},[],{"trials":2501,"activeCount":149,"soonestReadout":1185},[2502],{"nctId":2503,"briefTitle":2504,"status":168,"phases":2505,"primaryCompletion":1185,"completion":215,"start":2506,"enrollment":2002,"conditions":2507,"interventions":2508},"NCT06147531","Delayed Cold-Stored Platelets -PLTS-1",[91],"2024-06-05",[1261,1260,1262,1263],[2494,2509],"Room Temperature Buffy Coat Platelets",{"trials":2511,"activeCount":102},[],{"trials":2513,"activeCount":102},[],{"trials":2515,"activeCount":102},[],{"intervention":2509,"totalTrials":149,"cells":2517},{"EARLY_PHASE1":2518,"PHASE1":2520,"PHASE2":2522,"PHASE3":2528,"PHASE4":2530,"NA":2532},{"trials":2519,"activeCount":102},[],{"trials":2521,"activeCount":102},[],{"trials":2523,"activeCount":149,"soonestReadout":1185},[2524],{"nctId":2503,"briefTitle":2504,"status":168,"phases":2525,"primaryCompletion":1185,"completion":215,"start":2506,"enrollment":2002,"conditions":2526,"interventions":2527},[91],[1261,1260,1262,1263],[2494,2509],{"trials":2529,"activeCount":102},[],{"trials":2531,"activeCount":102},[],{"trials":2533,"activeCount":102},[],{"intervention":1436,"totalTrials":149,"cells":2535},{"EARLY_PHASE1":2536,"PHASE1":2538,"PHASE2":2540,"PHASE3":2546,"PHASE4":2548,"NA":2550},{"trials":2537,"activeCount":102},[],{"trials":2539,"activeCount":102},[],{"trials":2541,"activeCount":149,"soonestReadout":1428},[2542],{"nctId":1425,"briefTitle":1426,"status":494,"phases":2543,"primaryCompletion":1428,"completion":1429,"start":1430,"enrollment":1431,"conditions":2544,"interventions":2545},[91],[855,732,1433,734],[1435,1436,1335],{"trials":2547,"activeCount":102},[],{"trials":2549,"activeCount":102},[],{"trials":2551,"activeCount":102},[],{"intervention":2553,"totalTrials":149,"cells":2554},"glofitamab",{"EARLY_PHASE1":2555,"PHASE1":2557,"PHASE2":2559,"PHASE3":2570,"PHASE4":2572,"NA":2574},{"trials":2556,"activeCount":102},[],{"trials":2558,"activeCount":102},[],{"trials":2560,"activeCount":149,"soonestReadout":2565},[2561],{"nctId":2562,"briefTitle":2563,"status":168,"phases":2564,"primaryCompletion":2565,"completion":2565,"start":2566,"enrollment":172,"conditions":2567,"interventions":2569},"NCT06050694","Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)",[91],"2027-11","2025-01-24",[2568],"Diffuse Large B Cell Lymphoma (DLBCL)",[2553],{"trials":2571,"activeCount":102},[],{"trials":2573,"activeCount":102},[],{"trials":2575,"activeCount":102},[],{"intervention":2577,"totalTrials":149,"cells":2578},"Monoferric Injectable Product",{"EARLY_PHASE1":2579,"PHASE1":2581,"PHASE2":2583,"PHASE3":2595,"PHASE4":2597,"NA":2599},{"trials":2580,"activeCount":102},[],{"trials":2582,"activeCount":102},[],{"trials":2584,"activeCount":149,"soonestReadout":215},[2585],{"nctId":2586,"briefTitle":2587,"status":168,"phases":2588,"primaryCompletion":215,"completion":2589,"start":2590,"enrollment":2591,"conditions":2592,"interventions":2594},"NCT06287619","Post-operative Intravenous Iron to Treat Iron-deficiency Anemia in Patients Undergoing Cardiac Surgery",[91],"2027-06","2025-04-03",60,[2593,1263],"Chronic Iron Deficiency Anaemia",[2577],{"trials":2596,"activeCount":102},[],{"trials":2598,"activeCount":102},[],{"trials":2600,"activeCount":102},[],{"intervention":2602,"totalTrials":149,"cells":2603},"Belimumab Auto-Injector [Benlysta]",{"EARLY_PHASE1":2604,"PHASE1":2606,"PHASE2":2608,"PHASE3":2620,"PHASE4":2622,"NA":2624},{"trials":2605,"activeCount":102},[],{"trials":2607,"activeCount":102},[],{"trials":2609,"activeCount":149,"soonestReadout":2614},[2610],{"nctId":2611,"briefTitle":2612,"status":168,"phases":2613,"primaryCompletion":2614,"completion":2615,"start":2616,"enrollment":2011,"conditions":2617,"interventions":2619},"NCT06381453","Belimumab in Autoimmune Hepatitis",[91],"2028-04-30","2029-04-30","2024-12-11",[2618],"Autoimmune Hepatitis",[2602],{"trials":2621,"activeCount":102},[],{"trials":2623,"activeCount":102},[],{"trials":2625,"activeCount":102},[],{"intervention":1618,"totalTrials":149,"cells":2627},{"EARLY_PHASE1":2628,"PHASE1":2630,"PHASE2":2632,"PHASE3":2638,"PHASE4":2640,"NA":2642},{"trials":2629,"activeCount":102},[],{"trials":2631,"activeCount":102},[],{"trials":2633,"activeCount":149,"soonestReadout":1610},[2634],{"nctId":1607,"briefTitle":1608,"status":168,"phases":2635,"primaryCompletion":1610,"completion":1611,"start":1612,"enrollment":810,"conditions":2636,"interventions":2637},[91],[1614,1615,1616],[1618,574],{"trials":2639,"activeCount":102},[],{"trials":2641,"activeCount":102},[],{"trials":2643,"activeCount":102},[],{"intervention":1887,"totalTrials":149,"cells":2645},{"EARLY_PHASE1":2646,"PHASE1":2648,"PHASE2":2650,"PHASE3":2656,"PHASE4":2658,"NA":2660},{"trials":2647,"activeCount":102},[],{"trials":2649,"activeCount":102},[],{"trials":2651,"activeCount":149,"soonestReadout":1881},[2652],{"nctId":1878,"briefTitle":1879,"status":125,"phases":2653,"primaryCompletion":1881,"completion":1881,"start":1882,"enrollment":1860,"conditions":2654,"interventions":2655},[91],[1884,855,1885],[1887,1888,1889,1890,1864,1891,1892,1847,1893,1894],{"trials":2657,"activeCount":102},[],{"trials":2659,"activeCount":102},[],{"trials":2661,"activeCount":102},[],{"intervention":1888,"totalTrials":149,"cells":2663},{"EARLY_PHASE1":2664,"PHASE1":2666,"PHASE2":2668,"PHASE3":2674,"PHASE4":2676,"NA":2678},{"trials":2665,"activeCount":102},[],{"trials":2667,"activeCount":102},[],{"trials":2669,"activeCount":149,"soonestReadout":1881},[2670],{"nctId":1878,"briefTitle":1879,"status":125,"phases":2671,"primaryCompletion":1881,"completion":1881,"start":1882,"enrollment":1860,"conditions":2672,"interventions":2673},[91],[1884,855,1885],[1887,1888,1889,1890,1864,1891,1892,1847,1893,1894],{"trials":2675,"activeCount":102},[],{"trials":2677,"activeCount":102},[],{"trials":2679,"activeCount":102},[],{"intervention":1889,"totalTrials":149,"cells":2681},{"EARLY_PHASE1":2682,"PHASE1":2684,"PHASE2":2686,"PHASE3":2692,"PHASE4":2694,"NA":2696},{"trials":2683,"activeCount":102},[],{"trials":2685,"activeCount":102},[],{"trials":2687,"activeCount":149,"soonestReadout":1881},[2688],{"nctId":1878,"briefTitle":1879,"status":125,"phases":2689,"primaryCompletion":1881,"completion":1881,"start":1882,"enrollment":1860,"conditions":2690,"interventions":2691},[91],[1884,855,1885],[1887,1888,1889,1890,1864,1891,1892,1847,1893,1894],{"trials":2693,"activeCount":102},[],{"trials":2695,"activeCount":102},[],{"trials":2697,"activeCount":102},[],{"intervention":1890,"totalTrials":149,"cells":2699},{"EARLY_PHASE1":2700,"PHASE1":2702,"PHASE2":2704,"PHASE3":2710,"PHASE4":2712,"NA":2714},{"trials":2701,"activeCount":102},[],{"trials":2703,"activeCount":102},[],{"trials":2705,"activeCount":149,"soonestReadout":1881},[2706],{"nctId":1878,"briefTitle":1879,"status":125,"phases":2707,"primaryCompletion":1881,"completion":1881,"start":1882,"enrollment":1860,"conditions":2708,"interventions":2709},[91],[1884,855,1885],[1887,1888,1889,1890,1864,1891,1892,1847,1893,1894],{"trials":2711,"activeCount":102},[],{"trials":2713,"activeCount":102},[],{"trials":2715,"activeCount":102},[],{"intervention":1891,"totalTrials":149,"cells":2717},{"EARLY_PHASE1":2718,"PHASE1":2720,"PHASE2":2722,"PHASE3":2728,"PHASE4":2730,"NA":2732},{"trials":2719,"activeCount":102},[],{"trials":2721,"activeCount":102},[],{"trials":2723,"activeCount":149,"soonestReadout":1881},[2724],{"nctId":1878,"briefTitle":1879,"status":125,"phases":2725,"primaryCompletion":1881,"completion":1881,"start":1882,"enrollment":1860,"conditions":2726,"interventions":2727},[91],[1884,855,1885],[1887,1888,1889,1890,1864,1891,1892,1847,1893,1894],{"trials":2729,"activeCount":102},[],{"trials":2731,"activeCount":102},[],{"trials":2733,"activeCount":102},[],{"intervention":1893,"totalTrials":149,"cells":2735},{"EARLY_PHASE1":2736,"PHASE1":2738,"PHASE2":2740,"PHASE3":2746,"PHASE4":2748,"NA":2750},{"trials":2737,"activeCount":102},[],{"trials":2739,"activeCount":102},[],{"trials":2741,"activeCount":149,"soonestReadout":1881},[2742],{"nctId":1878,"briefTitle":1879,"status":125,"phases":2743,"primaryCompletion":1881,"completion":1881,"start":1882,"enrollment":1860,"conditions":2744,"interventions":2745},[91],[1884,855,1885],[1887,1888,1889,1890,1864,1891,1892,1847,1893,1894],{"trials":2747,"activeCount":102},[],{"trials":2749,"activeCount":102},[],{"trials":2751,"activeCount":102},[],{"intervention":1894,"totalTrials":149,"cells":2753},{"EARLY_PHASE1":2754,"PHASE1":2756,"PHASE2":2758,"PHASE3":2764,"PHASE4":2766,"NA":2768},{"trials":2755,"activeCount":102},[],{"trials":2757,"activeCount":102},[],{"trials":2759,"activeCount":149,"soonestReadout":1881},[2760],{"nctId":1878,"briefTitle":1879,"status":125,"phases":2761,"primaryCompletion":1881,"completion":1881,"start":1882,"enrollment":1860,"conditions":2762,"interventions":2763},[91],[1884,855,1885],[1887,1888,1889,1890,1864,1891,1892,1847,1893,1894],{"trials":2765,"activeCount":102},[],{"trials":2767,"activeCount":102},[],{"trials":2769,"activeCount":102},[],{"intervention":602,"totalTrials":149,"cells":2771},{"EARLY_PHASE1":2772,"PHASE1":2774,"PHASE2":2776,"PHASE3":2782,"PHASE4":2784,"NA":2786},{"trials":2773,"activeCount":102},[],{"trials":2775,"activeCount":102},[],{"trials":2777,"activeCount":149,"soonestReadout":596},[2778],{"nctId":593,"briefTitle":594,"status":494,"phases":2779,"primaryCompletion":596,"completion":597,"start":598,"enrollment":599,"conditions":2780,"interventions":2781},[91],[554,555],[602,576,72],{"trials":2783,"activeCount":102},[],{"trials":2785,"activeCount":102},[],{"trials":2787,"activeCount":102},[],{"intervention":2789,"totalTrials":149,"cells":2790},"Tislelizumab",{"EARLY_PHASE1":2791,"PHASE1":2793,"PHASE2":2795,"PHASE3":2808,"PHASE4":2810,"NA":2812},{"trials":2792,"activeCount":102},[],{"trials":2794,"activeCount":102},[],{"trials":2796,"activeCount":149,"soonestReadout":127},[2797],{"nctId":2798,"briefTitle":2799,"status":168,"phases":2800,"primaryCompletion":127,"completion":216,"start":2801,"enrollment":2802,"conditions":2803,"interventions":2805},"NCT06167785","A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T",[91],"2025-06-04",76,[2804],"Large B-cell Lymphoma",[2789,2806,2807],"Zanubrutinib","Tislelizumab + Zanubrutinib",{"trials":2809,"activeCount":102},[],{"trials":2811,"activeCount":102},[],{"trials":2813,"activeCount":102},[],{"intervention":2806,"totalTrials":149,"cells":2815},{"EARLY_PHASE1":2816,"PHASE1":2818,"PHASE2":2820,"PHASE3":2826,"PHASE4":2828,"NA":2830},{"trials":2817,"activeCount":102},[],{"trials":2819,"activeCount":102},[],{"trials":2821,"activeCount":149,"soonestReadout":127},[2822],{"nctId":2798,"briefTitle":2799,"status":168,"phases":2823,"primaryCompletion":127,"completion":216,"start":2801,"enrollment":2802,"conditions":2824,"interventions":2825},[91],[2804],[2789,2806,2807],{"trials":2827,"activeCount":102},[],{"trials":2829,"activeCount":102},[],{"trials":2831,"activeCount":102},[],{"intervention":2807,"totalTrials":149,"cells":2833},{"EARLY_PHASE1":2834,"PHASE1":2836,"PHASE2":2838,"PHASE3":2844,"PHASE4":2846,"NA":2848},{"trials":2835,"activeCount":102},[],{"trials":2837,"activeCount":102},[],{"trials":2839,"activeCount":149,"soonestReadout":127},[2840],{"nctId":2798,"briefTitle":2799,"status":168,"phases":2841,"primaryCompletion":127,"completion":216,"start":2801,"enrollment":2802,"conditions":2842,"interventions":2843},[91],[2804],[2789,2806,2807],{"trials":2845,"activeCount":102},[],{"trials":2847,"activeCount":102},[],{"trials":2849,"activeCount":102},[],{"intervention":2851,"totalTrials":149,"cells":2852},"Evofosfamide",{"EARLY_PHASE1":2853,"PHASE1":2855,"PHASE2":2857,"PHASE3":2869,"PHASE4":2871,"NA":2873},{"trials":2854,"activeCount":102},[],{"trials":2856,"activeCount":102},[],{"trials":2858,"activeCount":149,"soonestReadout":2863},[2859],{"nctId":2860,"briefTitle":2861,"status":125,"phases":2862,"primaryCompletion":2863,"completion":2864,"start":2865,"enrollment":2357,"conditions":2866,"interventions":2868},"NCT06836726","Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer",[91],"2028-05-27","2030-05-27","2026-05-27",[2867],"Castration Resistant Prostate Cancer",[2851],{"trials":2870,"activeCount":102},[],{"trials":2872,"activeCount":102},[],{"trials":2874,"activeCount":102},[],{"intervention":2876,"totalTrials":149,"cells":2877},"VIR-3434",{"EARLY_PHASE1":2878,"PHASE1":2880,"PHASE2":2882,"PHASE3":2893,"PHASE4":2895,"NA":2897},{"trials":2879,"activeCount":102},[],{"trials":2881,"activeCount":102},[],{"trials":2883,"activeCount":149,"soonestReadout":2888},[2884],{"nctId":2885,"briefTitle":2886,"status":168,"phases":2887,"primaryCompletion":2888,"completion":2888,"start":2889,"enrollment":244,"conditions":2890,"interventions":2892},"NCT06216470","Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection [VISION]",[91],"2029-12","2024-03-13",[2891],"Hepatitis B, Chronic",[2876],{"trials":2894,"activeCount":102},[],{"trials":2896,"activeCount":102},[],{"trials":2898,"activeCount":102},[],{"intervention":2900,"totalTrials":149,"cells":2901},"Avelumab",{"EARLY_PHASE1":2902,"PHASE1":2904,"PHASE2":2906,"PHASE3":2916,"PHASE4":2918,"NA":2920},{"trials":2903,"activeCount":102},[],{"trials":2905,"activeCount":102},[],{"trials":2907,"activeCount":149,"soonestReadout":927},[2908],{"nctId":2909,"briefTitle":2910,"status":494,"phases":2911,"primaryCompletion":927,"completion":927,"start":2912,"enrollment":1860,"conditions":2913,"interventions":2915},"NCT03391479","A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy",[91],"2018-08-15",[2914,855,854],"Penile Cancer",[2900],{"trials":2917,"activeCount":102},[],{"trials":2919,"activeCount":102},[],{"trials":2921,"activeCount":102},[],{"intervention":1775,"totalTrials":149,"cells":2923},{"EARLY_PHASE1":2924,"PHASE1":2926,"PHASE2":2928,"PHASE3":2934,"PHASE4":2936,"NA":2938},{"trials":2925,"activeCount":102},[],{"trials":2927,"activeCount":102},[],{"trials":2929,"activeCount":149,"soonestReadout":1767},[2930],{"nctId":1764,"briefTitle":1765,"status":494,"phases":2931,"primaryCompletion":1767,"completion":1768,"start":1769,"enrollment":1770,"conditions":2932,"interventions":2933},[91],[1772],[1774,762,1775,1776,1747],{"trials":2935,"activeCount":102},[],{"trials":2937,"activeCount":102},[],{"trials":2939,"activeCount":102},[],{"intervention":1776,"totalTrials":149,"cells":2941},{"EARLY_PHASE1":2942,"PHASE1":2944,"PHASE2":2946,"PHASE3":2952,"PHASE4":2954,"NA":2956},{"trials":2943,"activeCount":102},[],{"trials":2945,"activeCount":102},[],{"trials":2947,"activeCount":149,"soonestReadout":1767},[2948],{"nctId":1764,"briefTitle":1765,"status":494,"phases":2949,"primaryCompletion":1767,"completion":1768,"start":1769,"enrollment":1770,"conditions":2950,"interventions":2951},[91],[1772],[1774,762,1775,1776,1747],{"trials":2953,"activeCount":102},[],{"trials":2955,"activeCount":102},[],{"trials":2957,"activeCount":102},[],{"intervention":2959,"totalTrials":149,"cells":2960},"Gemcitabine\u002FCisplatin\u002FNab-Paclitaxel and Rilvegostomig",{"EARLY_PHASE1":2961,"PHASE1":2963,"PHASE2":2965,"PHASE3":2977,"PHASE4":2979,"NA":2981},{"trials":2962,"activeCount":102},[],{"trials":2964,"activeCount":102},[],{"trials":2966,"activeCount":149,"soonestReadout":2971},[2967],{"nctId":2968,"briefTitle":2969,"status":125,"phases":2970,"primaryCompletion":2971,"completion":2972,"start":2973,"enrollment":172,"conditions":2974,"interventions":2976},"NCT06569225","Gemcitabine\u002FCisplatin\u002FNab-Paclitaxel and Rilvegostomig in Resectable iCCA",[91],"2027-12-31","2028-12-31","2024-12-15",[2975],"Cholangiocarcinoma Resectable",[2959],{"trials":2978,"activeCount":102},[],{"trials":2980,"activeCount":102},[],{"trials":2982,"activeCount":102},[],{"intervention":2984,"totalTrials":149,"cells":2985},"AZD2936",{"EARLY_PHASE1":2986,"PHASE1":2988,"PHASE2":2990,"PHASE3":3002,"PHASE4":3004,"NA":3006},{"trials":2987,"activeCount":102},[],{"trials":2989,"activeCount":102},[],{"trials":2991,"activeCount":149,"soonestReadout":954},[2992],{"nctId":2993,"briefTitle":2994,"status":168,"phases":2995,"primaryCompletion":954,"completion":2996,"start":2997,"enrollment":2998,"conditions":2999,"interventions":3001},"NCT05414032","Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC",[91],"2028-07","2023-07-12",102,[3000],"Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)",[2984],{"trials":3003,"activeCount":102},[],{"trials":3005,"activeCount":102},[],{"trials":3007,"activeCount":102},[],{"intervention":3009,"totalTrials":149,"cells":3010},"ABSK043 single agent",{"EARLY_PHASE1":3011,"PHASE1":3013,"PHASE2":3015,"PHASE3":3026,"PHASE4":3028,"NA":3030},{"trials":3012,"activeCount":102},[],{"trials":3014,"activeCount":102},[],{"trials":3016,"activeCount":149,"soonestReadout":3021},[3017],{"nctId":3018,"briefTitle":3019,"status":168,"phases":3020,"primaryCompletion":3021,"completion":3021,"start":3022,"enrollment":129,"conditions":3023,"interventions":3025},"NCT07014137","A Trial of ABSK043, an Oral PD-L1 Inhibitor, in Patients With Angiogenic Sarcomas",[91],"2026-03-02","2025-09-09",[3024],"Sarcoma",[3009],{"trials":3027,"activeCount":102},[],{"trials":3029,"activeCount":102},[],{"trials":3031,"activeCount":102},[],{"intervention":3033,"totalTrials":149,"cells":3034},"Tarlatamab",{"EARLY_PHASE1":3035,"PHASE1":3037,"PHASE2":3039,"PHASE3":3052,"PHASE4":3054,"NA":3056},{"trials":3036,"activeCount":102},[],{"trials":3038,"activeCount":102},[],{"trials":3040,"activeCount":149,"soonestReadout":3045},[3041],{"nctId":3042,"briefTitle":3043,"status":168,"phases":3044,"primaryCompletion":3045,"completion":3045,"start":3046,"enrollment":3047,"conditions":3048,"interventions":3051},"NCT06776250","Study of How Safe and Effective Tarlatamab is in Brain Cancers",[91],"2028-03-03","2025-08-18",44,[3049,3050],"Astrocytic Tumor","Oligodendroglial Tumor",[3033],{"trials":3053,"activeCount":102},[],{"trials":3055,"activeCount":102},[],{"trials":3057,"activeCount":102},[],{"intervention":3059,"totalTrials":149,"cells":3060},"Vitamin C",{"EARLY_PHASE1":3061,"PHASE1":3063,"PHASE2":3065,"PHASE3":3077,"PHASE4":3079,"NA":3081},{"trials":3062,"activeCount":102},[],{"trials":3064,"activeCount":102},[],{"trials":3066,"activeCount":149,"soonestReadout":1944},[3067],{"nctId":3068,"briefTitle":3069,"status":168,"phases":3070,"primaryCompletion":1944,"completion":927,"start":3071,"enrollment":498,"conditions":3072,"interventions":3076},"NCT06123715","Perioperative Vitamin C to Reduce Persistent Pain After Total Knee Arthroplasty",[91],"2024-04-16",[3073,3074,3075],"Chronic Pain","Knee Pain Chronic","Post Operative Pain",[3059],{"trials":3078,"activeCount":102},[],{"trials":3080,"activeCount":102},[],{"trials":3082,"activeCount":102},[],{"intervention":611,"totalTrials":149,"cells":3084},{"EARLY_PHASE1":3085,"PHASE1":3087,"PHASE2":3089,"PHASE3":3095,"PHASE4":3097,"NA":3099},{"trials":3086,"activeCount":102},[],{"trials":3088,"activeCount":102},[],{"trials":3090,"activeCount":149,"soonestReadout":71},[3091],{"nctId":69,"briefTitle":70,"status":494,"phases":3092,"primaryCompletion":71,"completion":605,"start":606,"enrollment":607,"conditions":3093,"interventions":3094},[90,91],[609],[72,611],{"trials":3096,"activeCount":102},[],{"trials":3098,"activeCount":102},[],{"trials":3100,"activeCount":102},[],{"intervention":3102,"totalTrials":149,"cells":3103},"Cabozantinib",{"EARLY_PHASE1":3104,"PHASE1":3106,"PHASE2":3108,"PHASE3":3119,"PHASE4":3121,"NA":3123},{"trials":3105,"activeCount":102},[],{"trials":3107,"activeCount":102},[],{"trials":3109,"activeCount":149,"soonestReadout":1314},[3110],{"nctId":3111,"briefTitle":3112,"status":168,"phases":3113,"primaryCompletion":1314,"completion":289,"start":3114,"enrollment":129,"conditions":3115,"interventions":3118},"NCT04204850","Cabozantinib to Treat Recurrent Liver Cancer Post Transplant",[91],"2020-08-07",[1714,3116,3117],"Recurrent Cancer","Liver Transplant",[3102],{"trials":3120,"activeCount":102},[],{"trials":3122,"activeCount":102},[],{"trials":3124,"activeCount":102},[],{"intervention":3126,"totalTrials":149,"cells":3127},"Atezolizumab & Bevacizumab",{"EARLY_PHASE1":3128,"PHASE1":3130,"PHASE2":3132,"PHASE3":3147,"PHASE4":3149,"NA":3151},{"trials":3129,"activeCount":102},[],{"trials":3131,"activeCount":102},[],{"trials":3133,"activeCount":149,"soonestReadout":3138},[3134],{"nctId":3135,"briefTitle":3136,"status":168,"phases":3137,"primaryCompletion":3138,"completion":3139,"start":61,"enrollment":2011,"conditions":3140,"interventions":3145},"NCT06725121","Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant",[90,91],"2031-06","2034-06",[3141,3142,3143,3144],"Hepatocellular Carcinoma (HCC)","Macrovascular Invasion","Liver Transplant Surgery","Downstaging",[3126,3146],"Yttrium-90",{"trials":3148,"activeCount":102},[],{"trials":3150,"activeCount":102},[],{"trials":3152,"activeCount":102},[],{"intervention":3146,"totalTrials":149,"cells":3154},{"EARLY_PHASE1":3155,"PHASE1":3157,"PHASE2":3159,"PHASE3":3165,"PHASE4":3167,"NA":3169},{"trials":3156,"activeCount":102},[],{"trials":3158,"activeCount":102},[],{"trials":3160,"activeCount":149,"soonestReadout":3138},[3161],{"nctId":3135,"briefTitle":3136,"status":168,"phases":3162,"primaryCompletion":3138,"completion":3139,"start":61,"enrollment":2011,"conditions":3163,"interventions":3164},[90,91],[3141,3142,3143,3144],[3126,3146],{"trials":3166,"activeCount":102},[],{"trials":3168,"activeCount":102},[],{"trials":3170,"activeCount":102},[],{"intervention":1839,"totalTrials":149,"cells":3172},{"EARLY_PHASE1":3173,"PHASE1":3175,"PHASE2":3177,"PHASE3":3183,"PHASE4":3185,"NA":3187},{"trials":3174,"activeCount":102},[],{"trials":3176,"activeCount":102},[],{"trials":3178,"activeCount":149,"soonestReadout":1834},[3179],{"nctId":1831,"briefTitle":1832,"status":494,"phases":3180,"primaryCompletion":1834,"completion":1834,"start":1835,"enrollment":1836,"conditions":3181,"interventions":3182},[91],[1509],[843,1839],{"trials":3184,"activeCount":102},[],{"trials":3186,"activeCount":102},[],{"trials":3188,"activeCount":102},[],{"intervention":3190,"totalTrials":149,"cells":3191},"No high risk mutation",{"EARLY_PHASE1":3192,"PHASE1":3194,"PHASE2":3196,"PHASE3":3210,"PHASE4":3212,"NA":3214},{"trials":3193,"activeCount":102},[],{"trials":3195,"activeCount":102},[],{"trials":3197,"activeCount":149,"soonestReadout":3202},[3198],{"nctId":3199,"briefTitle":3200,"status":125,"phases":3201,"primaryCompletion":3202,"completion":3203,"start":3204,"enrollment":3205,"conditions":3206,"interventions":3208},"NCT07538401","ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE)",[91],"2028-04-25","2029-04-25","2026-04-25",45,[3207],"Chronic Myeloid Leukemia (CML) in",[3190,3209],"High Risk Mutation",{"trials":3211,"activeCount":102},[],{"trials":3213,"activeCount":102},[],{"trials":3215,"activeCount":102},[],{"intervention":3209,"totalTrials":149,"cells":3217},{"EARLY_PHASE1":3218,"PHASE1":3220,"PHASE2":3222,"PHASE3":3228,"PHASE4":3230,"NA":3232},{"trials":3219,"activeCount":102},[],{"trials":3221,"activeCount":102},[],{"trials":3223,"activeCount":149,"soonestReadout":3202},[3224],{"nctId":3199,"briefTitle":3200,"status":125,"phases":3225,"primaryCompletion":3202,"completion":3203,"start":3204,"enrollment":3205,"conditions":3226,"interventions":3227},[91],[3207],[3190,3209],{"trials":3229,"activeCount":102},[],{"trials":3231,"activeCount":102},[],{"trials":3233,"activeCount":102},[],{"intervention":2062,"totalTrials":149,"cells":3235},{"EARLY_PHASE1":3236,"PHASE1":3238,"PHASE2":3240,"PHASE3":3246,"PHASE4":3248,"NA":3250},{"trials":3237,"activeCount":102},[],{"trials":3239,"activeCount":102},[],{"trials":3241,"activeCount":149,"soonestReadout":2056},[3242],{"nctId":2053,"briefTitle":2054,"status":168,"phases":3243,"primaryCompletion":2056,"completion":2057,"start":2058,"enrollment":129,"conditions":3244,"interventions":3245},[91],[2060],[2035,2062],{"trials":3247,"activeCount":102},[],{"trials":3249,"activeCount":102},[],{"trials":3251,"activeCount":102},[],{"intervention":3253,"totalTrials":149,"cells":3254},"Mounjaro",{"EARLY_PHASE1":3255,"PHASE1":3257,"PHASE2":3259,"PHASE3":3272,"PHASE4":3274,"NA":3276},{"trials":3256,"activeCount":102},[],{"trials":3258,"activeCount":102},[],{"trials":3260,"activeCount":149,"soonestReadout":3265},[3261],{"nctId":3262,"briefTitle":3263,"status":125,"phases":3264,"primaryCompletion":3265,"completion":3266,"start":3267,"enrollment":1946,"conditions":3268,"interventions":3270},"NCT06073184","Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium",[91],"2027-02","2032-02","2025-08",[537,3269],"Atypical Hyperplasia",[3253,3271],"Mirena",{"trials":3273,"activeCount":102},[],{"trials":3275,"activeCount":102},[],{"trials":3277,"activeCount":102},[],{"intervention":3271,"totalTrials":149,"cells":3279},{"EARLY_PHASE1":3280,"PHASE1":3282,"PHASE2":3284,"PHASE3":3290,"PHASE4":3292,"NA":3294},{"trials":3281,"activeCount":102},[],{"trials":3283,"activeCount":102},[],{"trials":3285,"activeCount":149,"soonestReadout":3265},[3286],{"nctId":3262,"briefTitle":3263,"status":125,"phases":3287,"primaryCompletion":3265,"completion":3266,"start":3267,"enrollment":1946,"conditions":3288,"interventions":3289},[91],[537,3269],[3253,3271],{"trials":3291,"activeCount":102},[],{"trials":3293,"activeCount":102},[],{"trials":3295,"activeCount":102},[],{"intervention":3297,"totalTrials":149,"cells":3298},"Single Psychedelic Dose Psilocybin",{"EARLY_PHASE1":3299,"PHASE1":3301,"PHASE2":3303,"PHASE3":3318,"PHASE4":3320,"NA":3322},{"trials":3300,"activeCount":102},[],{"trials":3302,"activeCount":102},[],{"trials":3304,"activeCount":149,"soonestReadout":3309},[3305],{"nctId":3306,"briefTitle":3307,"status":168,"phases":3308,"primaryCompletion":3309,"completion":3310,"start":3311,"enrollment":3312,"conditions":3313,"interventions":3316},"NCT06341426","Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin",[91],"2028-02-01","2028-08-01","2024-02-05",92,[2307,2297,3314,3315],"Treatment-Resistant Depression","Mood Disorders",[3297,3317],"Two Psychedelic Doses Psilocybin",{"trials":3319,"activeCount":102},[],{"trials":3321,"activeCount":102},[],{"trials":3323,"activeCount":102},[],{"intervention":3317,"totalTrials":149,"cells":3325},{"EARLY_PHASE1":3326,"PHASE1":3328,"PHASE2":3330,"PHASE3":3336,"PHASE4":3338,"NA":3340},{"trials":3327,"activeCount":102},[],{"trials":3329,"activeCount":102},[],{"trials":3331,"activeCount":149,"soonestReadout":3309},[3332],{"nctId":3306,"briefTitle":3307,"status":168,"phases":3333,"primaryCompletion":3309,"completion":3310,"start":3311,"enrollment":3312,"conditions":3334,"interventions":3335},[91],[2307,2297,3314,3315],[3297,3317],{"trials":3337,"activeCount":102},[],{"trials":3339,"activeCount":102},[],{"trials":3341,"activeCount":102},[],{"intervention":62,"totalTrials":149,"cells":3343},{"EARLY_PHASE1":3344,"PHASE1":3346,"PHASE2":3348,"PHASE3":3361,"PHASE4":3363,"NA":3365},{"trials":3345,"activeCount":102},[],{"trials":3347,"activeCount":102},[],{"trials":3349,"activeCount":149,"soonestReadout":61},[3350],{"nctId":59,"briefTitle":60,"status":168,"phases":3351,"primaryCompletion":61,"completion":3352,"start":3353,"enrollment":19,"conditions":3354,"interventions":3360},[91],"2025-06","2019-12-03",[3355,3356,3357,3358,3359],"Non-squamous Non-small-cell Lung Cancer","Stage IV Non-small Cell Lung Cancer","ROS1 Gene Rearrangement","MET Activating Mutation","MET Amplification",[62],{"trials":3362,"activeCount":102},[],{"trials":3364,"activeCount":102},[],{"trials":3366,"activeCount":102},[],{"intervention":2370,"totalTrials":149,"cells":3368},{"EARLY_PHASE1":3369,"PHASE1":3371,"PHASE2":3373,"PHASE3":3379,"PHASE4":3381,"NA":3383},{"trials":3370,"activeCount":102},[],{"trials":3372,"activeCount":102},[],{"trials":3374,"activeCount":149,"soonestReadout":822},[3375],{"nctId":2363,"briefTitle":2364,"status":125,"phases":3376,"primaryCompletion":822,"completion":822,"start":2366,"enrollment":2367,"conditions":3377,"interventions":3378},[91],[15],[2370,2342],{"trials":3380,"activeCount":102},[],{"trials":3382,"activeCount":102},[],{"trials":3384,"activeCount":102},[],{"intervention":2312,"totalTrials":149,"cells":3386},{"EARLY_PHASE1":3387,"PHASE1":3389,"PHASE2":3391,"PHASE3":3397,"PHASE4":3399,"NA":3401},{"trials":3388,"activeCount":102},[],{"trials":3390,"activeCount":102},[],{"trials":3392,"activeCount":149,"soonestReadout":907},[3393],{"nctId":2301,"briefTitle":2302,"status":168,"phases":3394,"primaryCompletion":907,"completion":1185,"start":2304,"enrollment":2305,"conditions":3395,"interventions":3396},[91],[2307,2308,2309],[2311,2312],{"trials":3398,"activeCount":102},[],{"trials":3400,"activeCount":102},[],{"trials":3402,"activeCount":102},[],{"intervention":2399,"totalTrials":149,"cells":3404},{"EARLY_PHASE1":3405,"PHASE1":3407,"PHASE2":3409,"PHASE3":3415,"PHASE4":3417,"NA":3419},{"trials":3406,"activeCount":102},[],{"trials":3408,"activeCount":102},[],{"trials":3410,"activeCount":149,"soonestReadout":2393},[3411],{"nctId":2390,"briefTitle":2391,"status":168,"phases":3412,"primaryCompletion":2393,"completion":2394,"start":2395,"enrollment":607,"conditions":3413,"interventions":3414},[91],[2397],[2399,1788],{"trials":3416,"activeCount":102},[],{"trials":3418,"activeCount":102},[],{"trials":3420,"activeCount":102},[],{"intervention":3422,"totalTrials":149,"cells":3423},"Tamoxifen",{"EARLY_PHASE1":3424,"PHASE1":3426,"PHASE2":3428,"PHASE3":3438,"PHASE4":3440,"NA":3442},{"trials":3425,"activeCount":102},[],{"trials":3427,"activeCount":102},[],{"trials":3429,"activeCount":149,"soonestReadout":3434},[3430],{"nctId":3431,"briefTitle":3432,"status":125,"phases":3433,"primaryCompletion":3434,"completion":3434,"start":127,"enrollment":9,"conditions":3435,"interventions":3437},"NCT07535905","Clinical Trial to Observe the Effects of Tamoxifen on Testosterone Recovery in Medically Castrated Prostate Cancer Patients",[91],"2030-10",[3436,15],"Hypogonadism",[3422],{"trials":3439,"activeCount":102},[],{"trials":3441,"activeCount":102},[],{"trials":3443,"activeCount":102},[],{"intervention":1864,"totalTrials":479,"cells":3445},{"EARLY_PHASE1":3446,"PHASE1":3448,"PHASE2":3464,"PHASE3":3470,"PHASE4":3472,"NA":3474},{"trials":3447,"activeCount":102},[],{"trials":3449,"activeCount":102},[3450,3460],{"nctId":3451,"briefTitle":3452,"status":112,"phases":3453,"primaryCompletion":3454,"completion":3454,"start":3455,"enrollment":1316,"conditions":3456,"interventions":3459},"NCT04811196","A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients",[90],"2025-05-15","2021-03-29",[1862,3457,1552,3458],"Malignant Peripheral Nerve Sheath Tumor (MPNST)","Endometrial Stromal Sarcoma",[1864],{"nctId":1854,"briefTitle":1855,"status":112,"phases":3461,"primaryCompletion":1857,"completion":1858,"start":1859,"enrollment":1860,"conditions":3462,"interventions":3463},[90],[1862],[1864,1847],{"trials":3465,"activeCount":149,"soonestReadout":1881},[3466],{"nctId":1878,"briefTitle":1879,"status":125,"phases":3467,"primaryCompletion":1881,"completion":1881,"start":1882,"enrollment":1860,"conditions":3468,"interventions":3469},[91],[1884,855,1885],[1887,1888,1889,1890,1864,1891,1892,1847,1893,1894],{"trials":3471,"activeCount":102},[],{"trials":3473,"activeCount":102},[],{"trials":3475,"activeCount":102},[3476],{"nctId":3477,"briefTitle":3478,"status":112,"phases":3479,"primaryCompletion":3480,"completion":3480,"start":3481,"enrollment":3482,"conditions":3483,"interventions":3487},"NCT02069730","A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes",[94],"2023-06","2014-06",114,[3484,3485,3486,1376],"Salivary Gland Cancer","Metastatic","Advanced",[1864,3488,3489,3490,3491,3492,3493],"EGFR or HER2 Inhibitor","FGFR Inhibitor","C-KIT Inhibitor","Anti-androgen","NOTCH Inhibitor","MEK or PI3K Inhibitor",{"intervention":3495,"totalTrials":98,"cells":3496},"Decidual Stromal Cells",{"EARLY_PHASE1":3497,"PHASE1":3499,"PHASE2":3501,"PHASE3":3524,"PHASE4":3526,"NA":3528},{"trials":3498,"activeCount":102},[],{"trials":3500,"activeCount":102},[],{"trials":3502,"activeCount":149,"soonestReadout":3519},[3503,3515],{"nctId":3504,"briefTitle":3505,"status":112,"phases":3506,"primaryCompletion":3507,"completion":3507,"start":3508,"enrollment":149,"conditions":3509,"interventions":3513},"NCT04926194","Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome\u002FMyeloproliferative Neoplasm",[91],"2021-06-09","2021-03-11",[3510,3511,3512],"Myelodysplastic\u002FMyeloproliferative Neoplasm","Steroid Refractory GVHD","Allogeneic Hematopoietic Cell Transplant",[3514],"Decidual stromal cells",{"nctId":3516,"briefTitle":3517,"status":494,"phases":3518,"primaryCompletion":3519,"completion":3519,"start":3520,"enrollment":19,"conditions":3521,"interventions":3523},"NCT05132166","A Randomized Phase II Study to Compare the Potential Long-Lasting Positive Effect of Decidual Stromal Cells to the Best Available Treatment in Graft Versus Host Disease",[91],"2026-04-26","2021-12-22",[3522],"Graft Vs Host Disease",[3495],{"trials":3525,"activeCount":102},[],{"trials":3527,"activeCount":102},[],{"trials":3529,"activeCount":102},[3530],{"nctId":3531,"briefTitle":3532,"status":112,"phases":3533,"primaryCompletion":3534,"completion":3534,"start":3535,"enrollment":1363,"conditions":3536,"interventions":3539},"NCT04451291","Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure",[94],"2023-11-07","2020-09-25",[3537,3538],"COVID-19","Acute Respiratory Distress Syndrome",[3495],{"intervention":1554,"totalTrials":98,"cells":3541},{"EARLY_PHASE1":3542,"PHASE1":3544,"PHASE2":3546,"PHASE3":3556,"PHASE4":3558,"NA":3560},{"trials":3543,"activeCount":102},[],{"trials":3545,"activeCount":102},[],{"trials":3547,"activeCount":149,"soonestReadout":1547},[3548,3552],{"nctId":1952,"briefTitle":1953,"status":112,"phases":3549,"primaryCompletion":1955,"completion":1955,"start":552,"enrollment":479,"conditions":3550,"interventions":3551},[91],[732],[87,1554],{"nctId":1544,"briefTitle":1545,"status":494,"phases":3553,"primaryCompletion":1547,"completion":1547,"start":1548,"enrollment":218,"conditions":3554,"interventions":3555},[91],[1550,1551,1552],[1466,87,1554],{"trials":3557,"activeCount":102},[],{"trials":3559,"activeCount":102},[],{"trials":3561,"activeCount":102},[3562],{"nctId":1969,"briefTitle":1970,"status":112,"phases":3563,"primaryCompletion":1972,"completion":1973,"start":1974,"enrollment":22,"conditions":3564,"interventions":3565},[94],[732],[1554,87],{"intervention":1353,"totalTrials":584,"cells":3567},{"EARLY_PHASE1":3568,"PHASE1":3570,"PHASE2":3588,"PHASE3":3598,"PHASE4":3600,"NA":3602},{"trials":3569,"activeCount":102},[],{"trials":3571,"activeCount":659,"soonestReadout":1360},[3572,3576,3580,3584],{"nctId":1343,"briefTitle":1344,"status":112,"phases":3573,"primaryCompletion":1346,"completion":1346,"start":1347,"enrollment":1348,"conditions":3574,"interventions":3575},[90],[1350,1351],[1335,1353,1354,1355],{"nctId":1357,"briefTitle":1358,"status":168,"phases":3577,"primaryCompletion":1360,"completion":1361,"start":1362,"enrollment":1363,"conditions":3578,"interventions":3579},[90],[1365,1366,1367],[1369,1335,1353],{"nctId":1383,"briefTitle":1384,"status":494,"phases":3581,"primaryCompletion":1386,"completion":1386,"start":1387,"enrollment":1388,"conditions":3582,"interventions":3583},[90],[1390,1391,1392,760,732,21,589,1393],[1335,1395,1353],{"nctId":1405,"briefTitle":1406,"status":550,"phases":3585,"primaryCompletion":1386,"completion":1408,"start":1409,"enrollment":102,"conditions":3586,"interventions":3587},[90],[1411],[1335,1353],{"trials":3589,"activeCount":102},[3590,3594],{"nctId":1416,"briefTitle":1417,"status":112,"phases":3591,"primaryCompletion":1419,"completion":1419,"start":1420,"enrollment":541,"conditions":3592,"interventions":3593},[90,91],[746],[1335,1353,1423,1355],{"nctId":1438,"briefTitle":1439,"status":112,"phases":3595,"primaryCompletion":1441,"completion":1441,"start":1442,"enrollment":687,"conditions":3596,"interventions":3597},[91],[1444],[1335,1353,1354,1446],{"trials":3599,"activeCount":102},[],{"trials":3601,"activeCount":102},[],{"trials":3603,"activeCount":102},[],{"intervention":737,"totalTrials":479,"cells":3605},{"EARLY_PHASE1":3606,"PHASE1":3608,"PHASE2":3614,"PHASE3":3624,"PHASE4":3626,"NA":3628},{"trials":3607,"activeCount":102},[],{"trials":3609,"activeCount":149,"soonestReadout":848},[3610],{"nctId":845,"briefTitle":846,"status":494,"phases":3611,"primaryCompletion":848,"completion":849,"start":850,"enrollment":584,"conditions":3612,"interventions":3613},[90],[852,853,854,855],[857,577,737],{"trials":3615,"activeCount":102},[3616,3620],{"nctId":725,"briefTitle":726,"status":727,"phases":3617,"primaryCompletion":729,"completion":729,"start":730,"enrollment":149,"conditions":3618,"interventions":3619},[90,91],[732,733,734,735],[576,737],{"nctId":1778,"briefTitle":1779,"status":1723,"phases":3621,"primaryCompletion":1781,"completion":1781,"start":1782,"enrollment":172,"conditions":3622,"interventions":3623},[91],[732,734,1379,1784,1785],[1787,1788,1747,737],{"trials":3625,"activeCount":102},[],{"trials":3627,"activeCount":102},[],{"trials":3629,"activeCount":149,"soonestReadout":215},[3630],{"nctId":819,"briefTitle":820,"status":168,"phases":3631,"primaryCompletion":215,"completion":822,"start":823,"enrollment":824,"conditions":3632,"interventions":3633},[94],[826],[576,577,737],{"intervention":1355,"totalTrials":98,"cells":3635},{"EARLY_PHASE1":3636,"PHASE1":3638,"PHASE2":3648,"PHASE3":3654,"PHASE4":3656,"NA":3658},{"trials":3637,"activeCount":102},[],{"trials":3639,"activeCount":149,"soonestReadout":1185},[3640,3644],{"nctId":1343,"briefTitle":1344,"status":112,"phases":3641,"primaryCompletion":1346,"completion":1346,"start":1347,"enrollment":1348,"conditions":3642,"interventions":3643},[90],[1350,1351],[1335,1353,1354,1355],{"nctId":1371,"briefTitle":1372,"status":494,"phases":3645,"primaryCompletion":1185,"completion":1185,"start":1374,"enrollment":98,"conditions":3646,"interventions":3647},[90],[1376,1377,1378,734,1379],[1381,1355,1335],{"trials":3649,"activeCount":102},[3650],{"nctId":1416,"briefTitle":1417,"status":112,"phases":3651,"primaryCompletion":1419,"completion":1419,"start":1420,"enrollment":541,"conditions":3652,"interventions":3653},[90,91],[746],[1335,1353,1423,1355],{"trials":3655,"activeCount":102},[],{"trials":3657,"activeCount":102},[],{"trials":3659,"activeCount":102},[],{"intervention":1599,"totalTrials":659,"cells":3661},{"EARLY_PHASE1":3662,"PHASE1":3664,"PHASE2":3670,"PHASE3":3676,"PHASE4":3678,"NA":3680},{"trials":3663,"activeCount":102},[],{"trials":3665,"activeCount":149,"soonestReadout":1594},[3666],{"nctId":1591,"briefTitle":1592,"status":168,"phases":3667,"primaryCompletion":1594,"completion":1594,"start":1595,"enrollment":687,"conditions":3668,"interventions":3669},[90],[1597],[574,1599],{"trials":3671,"activeCount":102},[3672],{"nctId":1620,"briefTitle":1621,"status":727,"phases":3673,"primaryCompletion":1623,"completion":1623,"start":1624,"enrollment":1574,"conditions":3674,"interventions":3675},[91],[570],[574,1599,1627],{"trials":3677,"activeCount":102},[],{"trials":3679,"activeCount":102},[],{"trials":3681,"activeCount":102},[],{"intervention":558,"totalTrials":659,"cells":3683},{"EARLY_PHASE1":3684,"PHASE1":3686,"PHASE2":3702,"PHASE3":3704,"PHASE4":3706,"NA":3708},{"trials":3685,"activeCount":102},[],{"trials":3687,"activeCount":149,"soonestReadout":565},[3688,3698],{"nctId":3689,"briefTitle":3690,"status":168,"phases":3691,"primaryCompletion":565,"completion":3692,"start":3693,"enrollment":511,"conditions":3694,"interventions":3697},"NCT05611034","In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung",[90],"2032-01-01","2023-02-06",[3695,3696,32],"Lung Metastases","Colorectal Cancer Metastatic",[558],{"nctId":548,"briefTitle":549,"status":550,"phases":3699,"primaryCompletion":552,"completion":552,"start":552,"enrollment":102,"conditions":3700,"interventions":3701},[90],[554,555],[557,72,558],{"trials":3703,"activeCount":102},[],{"trials":3705,"activeCount":102},[],{"trials":3707,"activeCount":102},[],{"trials":3709,"activeCount":102},[],{"intervention":1369,"totalTrials":149,"cells":3711},{"EARLY_PHASE1":3712,"PHASE1":3714,"PHASE2":3720,"PHASE3":3722,"PHASE4":3724,"NA":3726},{"trials":3713,"activeCount":102},[],{"trials":3715,"activeCount":149,"soonestReadout":1360},[3716],{"nctId":1357,"briefTitle":1358,"status":168,"phases":3717,"primaryCompletion":1360,"completion":1361,"start":1362,"enrollment":1363,"conditions":3718,"interventions":3719},[90],[1365,1366,1367],[1369,1335,1353],{"trials":3721,"activeCount":102},[],{"trials":3723,"activeCount":102},[],{"trials":3725,"activeCount":102},[],{"trials":3727,"activeCount":102},[],{"intervention":857,"totalTrials":149,"cells":3729},{"EARLY_PHASE1":3730,"PHASE1":3732,"PHASE2":3738,"PHASE3":3740,"PHASE4":3742,"NA":3744},{"trials":3731,"activeCount":102},[],{"trials":3733,"activeCount":149,"soonestReadout":848},[3734],{"nctId":845,"briefTitle":846,"status":494,"phases":3735,"primaryCompletion":848,"completion":849,"start":850,"enrollment":584,"conditions":3736,"interventions":3737},[90],[852,853,854,855],[857,577,737],{"trials":3739,"activeCount":102},[],{"trials":3741,"activeCount":102},[],{"trials":3743,"activeCount":102},[],{"trials":3745,"activeCount":102},[],{"intervention":1381,"totalTrials":149,"cells":3747},{"EARLY_PHASE1":3748,"PHASE1":3750,"PHASE2":3756,"PHASE3":3758,"PHASE4":3760,"NA":3762},{"trials":3749,"activeCount":102},[],{"trials":3751,"activeCount":149,"soonestReadout":1185},[3752],{"nctId":1371,"briefTitle":1372,"status":494,"phases":3753,"primaryCompletion":1185,"completion":1185,"start":1374,"enrollment":98,"conditions":3754,"interventions":3755},[90],[1376,1377,1378,734,1379],[1381,1355,1335],{"trials":3757,"activeCount":102},[],{"trials":3759,"activeCount":102},[],{"trials":3761,"activeCount":102},[],{"trials":3763,"activeCount":102},[],{"intervention":3765,"totalTrials":149,"cells":3766},"IL-12",{"EARLY_PHASE1":3767,"PHASE1":3769,"PHASE2":3777,"PHASE3":3779,"PHASE4":3781,"NA":3783},{"trials":3768,"activeCount":102},[],{"trials":3770,"activeCount":149,"soonestReadout":1594},[3771],{"nctId":3772,"briefTitle":3773,"status":494,"phases":3774,"primaryCompletion":1594,"completion":1594,"start":698,"enrollment":541,"conditions":3775,"interventions":3776},"NCT02483312","A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)",[90],[2204],[3765],{"trials":3778,"activeCount":102},[],{"trials":3780,"activeCount":102},[],{"trials":3782,"activeCount":102},[],{"trials":3784,"activeCount":102},[],{"intervention":3786,"totalTrials":149,"cells":3787},"BOLD-100",{"EARLY_PHASE1":3788,"PHASE1":3790,"PHASE2":3803,"PHASE3":3805,"PHASE4":3807,"NA":3809},{"trials":3789,"activeCount":102},[],{"trials":3791,"activeCount":149,"soonestReadout":3796},[3792],{"nctId":3793,"briefTitle":3794,"status":125,"phases":3795,"primaryCompletion":3796,"completion":3796,"start":1360,"enrollment":25,"conditions":3797,"interventions":3801},"NCT07027423","BOLD-100 Plus Doxorubicin in Advanced Soft Tissue Sarcomas",[90],"2027-01-29",[3798,3024,3799,3800],"Sarcoma, Soft-tissue","Sarcoma,Soft Tissue","Sarcomas",[3786,3802,3786,3802],"Doxorubicin 75 mg\u002Fm^2",{"trials":3804,"activeCount":102},[],{"trials":3806,"activeCount":102},[],{"trials":3808,"activeCount":102},[],{"trials":3810,"activeCount":102},[],{"intervention":3802,"totalTrials":149,"cells":3812},{"EARLY_PHASE1":3813,"PHASE1":3815,"PHASE2":3821,"PHASE3":3823,"PHASE4":3825,"NA":3827},{"trials":3814,"activeCount":102},[],{"trials":3816,"activeCount":149,"soonestReadout":3796},[3817],{"nctId":3793,"briefTitle":3794,"status":125,"phases":3818,"primaryCompletion":3796,"completion":3796,"start":1360,"enrollment":25,"conditions":3819,"interventions":3820},[90],[3798,3024,3799,3800],[3786,3802,3786,3802],{"trials":3822,"activeCount":102},[],{"trials":3824,"activeCount":102},[],{"trials":3826,"activeCount":102},[],{"trials":3828,"activeCount":102},[],{"intervention":3830,"totalTrials":149,"cells":3831},"Liposomal Curcumin",{"EARLY_PHASE1":3832,"PHASE1":3834,"PHASE2":3845,"PHASE3":3847,"PHASE4":3849,"NA":3851},{"trials":3833,"activeCount":102},[],{"trials":3835,"activeCount":149,"soonestReadout":3840},[3836],{"nctId":3837,"briefTitle":3838,"status":125,"phases":3839,"primaryCompletion":3840,"completion":3840,"start":3021,"enrollment":129,"conditions":3841,"interventions":3844},"NCT07456605","Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma",[90],"2028-03-02",[3842,3843],"Multiple Myeloma Refractory","Multiple Myeloma in Relapse",[3830],{"trials":3846,"activeCount":102},[],{"trials":3848,"activeCount":102},[],{"trials":3850,"activeCount":102},[],{"trials":3852,"activeCount":102},[],{"intervention":3854,"totalTrials":149,"cells":3855},"CFI-402257",{"EARLY_PHASE1":3856,"PHASE1":3858,"PHASE2":3870,"PHASE3":3872,"PHASE4":3874,"NA":3876},{"trials":3857,"activeCount":102},[],{"trials":3859,"activeCount":149,"soonestReadout":3864},[3860],{"nctId":3861,"briefTitle":3862,"status":494,"phases":3863,"primaryCompletion":3864,"completion":3864,"start":3865,"enrollment":2071,"conditions":3866,"interventions":3868},"NCT02792465","A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors",[90],"2027-05","2016-11-11",[3867,18],"Advanced Solid Cancers",[3854,3869],"Fulvestrant",{"trials":3871,"activeCount":102},[],{"trials":3873,"activeCount":102},[],{"trials":3875,"activeCount":102},[],{"trials":3877,"activeCount":102},[],{"intervention":3869,"totalTrials":149,"cells":3879},{"EARLY_PHASE1":3880,"PHASE1":3882,"PHASE2":3888,"PHASE3":3890,"PHASE4":3892,"NA":3894},{"trials":3881,"activeCount":102},[],{"trials":3883,"activeCount":149,"soonestReadout":3864},[3884],{"nctId":3861,"briefTitle":3862,"status":494,"phases":3885,"primaryCompletion":3864,"completion":3864,"start":3865,"enrollment":2071,"conditions":3886,"interventions":3887},[90],[3867,18],[3854,3869],{"trials":3889,"activeCount":102},[],{"trials":3891,"activeCount":102},[],{"trials":3893,"activeCount":102},[],{"trials":3895,"activeCount":102},[],{"intervention":1395,"totalTrials":149,"cells":3897},{"EARLY_PHASE1":3898,"PHASE1":3900,"PHASE2":3906,"PHASE3":3908,"PHASE4":3910,"NA":3912},{"trials":3899,"activeCount":102},[],{"trials":3901,"activeCount":149,"soonestReadout":1386},[3902],{"nctId":1383,"briefTitle":1384,"status":494,"phases":3903,"primaryCompletion":1386,"completion":1386,"start":1387,"enrollment":1388,"conditions":3904,"interventions":3905},[90],[1390,1391,1392,760,732,21,589,1393],[1335,1395,1353],{"trials":3907,"activeCount":102},[],{"trials":3909,"activeCount":102},[],{"trials":3911,"activeCount":102},[],{"trials":3913,"activeCount":102},[],{"intervention":3915,"totalTrials":149,"cells":3916},"PORPHYSOMES",{"EARLY_PHASE1":3917,"PHASE1":3919,"PHASE2":3933,"PHASE3":3935,"PHASE4":3937,"NA":3939},{"trials":3918,"activeCount":102},[],{"trials":3920,"activeCount":149,"soonestReadout":3925},[3921],{"nctId":3922,"briefTitle":3923,"status":168,"phases":3924,"primaryCompletion":3925,"completion":3926,"start":3927,"enrollment":3928,"conditions":3929,"interventions":3931},"NCT06977126","Study to Assess the Safety and Effects of Porphysome Nanoparticles for Imaging in Gynaecological Cancers",[90],"2026-11-18","2027-11-19","2025-11-18",24,[3930],"Gynecological Cancers",[3915,3932],"64Cu-PORPHYSOMES",{"trials":3934,"activeCount":102},[],{"trials":3936,"activeCount":102},[],{"trials":3938,"activeCount":102},[],{"trials":3940,"activeCount":102},[],{"intervention":3932,"totalTrials":149,"cells":3942},{"EARLY_PHASE1":3943,"PHASE1":3945,"PHASE2":3951,"PHASE3":3953,"PHASE4":3955,"NA":3957},{"trials":3944,"activeCount":102},[],{"trials":3946,"activeCount":149,"soonestReadout":3925},[3947],{"nctId":3922,"briefTitle":3923,"status":168,"phases":3948,"primaryCompletion":3925,"completion":3926,"start":3927,"enrollment":3928,"conditions":3949,"interventions":3950},[90],[3930],[3915,3932],{"trials":3952,"activeCount":102},[],{"trials":3954,"activeCount":102},[],{"trials":3956,"activeCount":102},[],{"trials":3958,"activeCount":102},[],{"intervention":3960,"totalTrials":149,"cells":3961},"Ketoconazole",{"EARLY_PHASE1":3962,"PHASE1":3975,"PHASE2":3977,"PHASE3":3979,"PHASE4":3981,"NA":3983},{"trials":3963,"activeCount":149,"soonestReadout":3352},[3964],{"nctId":3965,"briefTitle":3966,"status":125,"phases":3967,"primaryCompletion":3352,"completion":2589,"start":3968,"enrollment":607,"conditions":3969,"interventions":3973},"NCT03763396","Azoles Targeting Recurrent High Grade Gliomas",[89],"2024-06-01",[3970,3971,3972],"Brain Tumor, Recurrent","Cancer, Advanced","Glioma of Brain",[3960,3974],"Posaconazole",{"trials":3976,"activeCount":102},[],{"trials":3978,"activeCount":102},[],{"trials":3980,"activeCount":102},[],{"trials":3982,"activeCount":102},[],{"trials":3984,"activeCount":102},[],{"intervention":3974,"totalTrials":149,"cells":3986},{"EARLY_PHASE1":3987,"PHASE1":3993,"PHASE2":3995,"PHASE3":3997,"PHASE4":3999,"NA":4001},{"trials":3988,"activeCount":149,"soonestReadout":3352},[3989],{"nctId":3965,"briefTitle":3966,"status":125,"phases":3990,"primaryCompletion":3352,"completion":2589,"start":3968,"enrollment":607,"conditions":3991,"interventions":3992},[89],[3970,3971,3972],[3960,3974],{"trials":3994,"activeCount":102},[],{"trials":3996,"activeCount":102},[],{"trials":3998,"activeCount":102},[],{"trials":4000,"activeCount":102},[],{"trials":4002,"activeCount":102},[],{"intervention":47,"totalTrials":149,"cells":4004},{"EARLY_PHASE1":4005,"PHASE1":4016,"PHASE2":4018,"PHASE3":4020,"PHASE4":4022,"NA":4024},{"trials":4006,"activeCount":149,"soonestReadout":46},[4007],{"nctId":44,"briefTitle":45,"status":494,"phases":4008,"primaryCompletion":46,"completion":596,"start":4009,"enrollment":129,"conditions":4010,"interventions":4012},[89],"2021-05-25",[4011],"Low Intensity Focussed Ultrasound",[47,4013,4014,4015],"Lorazepam","Dextromethorphan","Nimodipine",{"trials":4017,"activeCount":102},[],{"trials":4019,"activeCount":102},[],{"trials":4021,"activeCount":102},[],{"trials":4023,"activeCount":102},[],{"trials":4025,"activeCount":102},[],{"intervention":4013,"totalTrials":149,"cells":4027},{"EARLY_PHASE1":4028,"PHASE1":4034,"PHASE2":4036,"PHASE3":4038,"PHASE4":4040,"NA":4042},{"trials":4029,"activeCount":149,"soonestReadout":46},[4030],{"nctId":44,"briefTitle":45,"status":494,"phases":4031,"primaryCompletion":46,"completion":596,"start":4009,"enrollment":129,"conditions":4032,"interventions":4033},[89],[4011],[47,4013,4014,4015],{"trials":4035,"activeCount":102},[],{"trials":4037,"activeCount":102},[],{"trials":4039,"activeCount":102},[],{"trials":4041,"activeCount":102},[],{"trials":4043,"activeCount":102},[],{"intervention":4014,"totalTrials":149,"cells":4045},{"EARLY_PHASE1":4046,"PHASE1":4052,"PHASE2":4054,"PHASE3":4056,"PHASE4":4058,"NA":4060},{"trials":4047,"activeCount":149,"soonestReadout":46},[4048],{"nctId":44,"briefTitle":45,"status":494,"phases":4049,"primaryCompletion":46,"completion":596,"start":4009,"enrollment":129,"conditions":4050,"interventions":4051},[89],[4011],[47,4013,4014,4015],{"trials":4053,"activeCount":102},[],{"trials":4055,"activeCount":102},[],{"trials":4057,"activeCount":102},[],{"trials":4059,"activeCount":102},[],{"trials":4061,"activeCount":102},[],{"intervention":4015,"totalTrials":149,"cells":4063},{"EARLY_PHASE1":4064,"PHASE1":4070,"PHASE2":4072,"PHASE3":4074,"PHASE4":4076,"NA":4078},{"trials":4065,"activeCount":149,"soonestReadout":46},[4066],{"nctId":44,"briefTitle":45,"status":494,"phases":4067,"primaryCompletion":46,"completion":596,"start":4009,"enrollment":129,"conditions":4068,"interventions":4069},[89],[4011],[47,4013,4014,4015],{"trials":4071,"activeCount":102},[],{"trials":4073,"activeCount":102},[],{"trials":4075,"activeCount":102},[],{"trials":4077,"activeCount":102},[],{"trials":4079,"activeCount":102},[],{"intervention":42,"totalTrials":149,"cells":4081},{"EARLY_PHASE1":4082,"PHASE1":4092,"PHASE2":4094,"PHASE3":4096,"PHASE4":4098,"NA":4100},{"trials":4083,"activeCount":149,"soonestReadout":41},[4084],{"nctId":39,"briefTitle":40,"status":494,"phases":4085,"primaryCompletion":41,"completion":4086,"start":4087,"enrollment":1836,"conditions":4088,"interventions":4091},[89],"2027-05-31","2017-09-19",[4089,4090],"Lung Transplant Infection","Hepatitis C",[42],{"trials":4093,"activeCount":102},[],{"trials":4095,"activeCount":102},[],{"trials":4097,"activeCount":102},[],{"trials":4099,"activeCount":102},[],{"trials":4101,"activeCount":102},[],{"intervention":4103,"totalTrials":149,"cells":4104},"SYN002",{"EARLY_PHASE1":4105,"PHASE1":4116,"PHASE2":4118,"PHASE3":4120,"PHASE4":4122,"NA":4124},{"trials":4106,"activeCount":149,"soonestReadout":4111},[4107],{"nctId":4108,"briefTitle":4109,"status":125,"phases":4110,"primaryCompletion":4111,"completion":2971,"start":4112,"enrollment":687,"conditions":4113,"interventions":4115},"NCT07488481","Renal Ex Vivo SYN002 Perfusion to Eliminate CMV Transmission",[89],"2027-03-16","2026-03-16",[4114,986],"Cytomegalovirus (CMV) Infection",[4103],{"trials":4117,"activeCount":102},[],{"trials":4119,"activeCount":102},[],{"trials":4121,"activeCount":102},[],{"trials":4123,"activeCount":102},[],{"trials":4125,"activeCount":102},[],{"intervention":4127,"totalTrials":98,"cells":4128},"Pimonidazole",{"EARLY_PHASE1":4129,"PHASE1":4131,"PHASE2":4133,"PHASE3":4146,"PHASE4":4148,"NA":4150},{"trials":4130,"activeCount":102},[],{"trials":4132,"activeCount":102},[],{"trials":4134,"activeCount":102},[4135],{"nctId":4136,"briefTitle":4137,"status":112,"phases":4138,"primaryCompletion":4139,"completion":4140,"start":4141,"enrollment":4142,"conditions":4143,"interventions":4144},"NCT01992042","Novel Window of Opportunity Trial to Evaluate the Impact of Statins to Oppose Prostate Cancer",[91],"2016-10","2016-12","2014-02",33,[15],[4145,4127],"Fluvastatin",{"trials":4147,"activeCount":102},[],{"trials":4149,"activeCount":102},[],{"trials":4151,"activeCount":659,"soonestReadout":4156},[4152,4160],{"nctId":4153,"briefTitle":4154,"status":494,"phases":4155,"primaryCompletion":4156,"completion":4156,"start":4157,"enrollment":1330,"conditions":4158,"interventions":4159},"NCT02095249","Prostate Hypoxia - TIC",[94],"2028-01","2014-09",[15],[4127],{"nctId":4161,"briefTitle":4162,"status":494,"phases":4163,"primaryCompletion":4164,"completion":4164,"start":4165,"enrollment":4166,"conditions":4167,"interventions":4168},"NCT03418818","FAZA PET\u002FMRI Sarcoma",[94],"2028-10","2018-03-27",70,[3024],[4169,4127],"18F-FAZA",{"intervention":4169,"totalTrials":659,"cells":4171},{"EARLY_PHASE1":4172,"PHASE1":4174,"PHASE2":4176,"PHASE3":4178,"PHASE4":4180,"NA":4182},{"trials":4173,"activeCount":102},[],{"trials":4175,"activeCount":102},[],{"trials":4177,"activeCount":102},[],{"trials":4179,"activeCount":102},[],{"trials":4181,"activeCount":102},[],{"trials":4183,"activeCount":659,"soonestReadout":4188},[4184,4195],{"nctId":4185,"briefTitle":4186,"status":494,"phases":4187,"primaryCompletion":4188,"completion":4188,"start":4189,"enrollment":129,"conditions":4190,"interventions":4194},"NCT04395469","FAZA PET\u002FMRI Pancreas",[94],"2027-03","2021-05-18",[4191,4192,4193],"Pancreatic Adenocarcinoma Non-resectable","Locally Advanced Pancreatic Adenocarcinoma","Unresectable Pancreatic Cancer",[4169],{"nctId":4161,"briefTitle":4162,"status":494,"phases":4196,"primaryCompletion":4164,"completion":4164,"start":4165,"enrollment":4166,"conditions":4197,"interventions":4198},[94],[3024],[4169,4127],{"intervention":4200,"totalTrials":98,"cells":4201},"Ruxolitinib",{"EARLY_PHASE1":4202,"PHASE1":4204,"PHASE2":4206,"PHASE3":4222,"PHASE4":4224,"NA":4226},{"trials":4203,"activeCount":102},[],{"trials":4205,"activeCount":102},[],{"trials":4207,"activeCount":102},[4208],{"nctId":4209,"briefTitle":4210,"status":112,"phases":4211,"primaryCompletion":4212,"completion":4212,"start":4213,"enrollment":479,"conditions":4214,"interventions":4220},"NCT01914484","Phase I\u002FII Study of Nilotinib\u002FRuxolitinb Therapy for TKI Resistant Ph-Leukemia",[90,91],"2018-12-31","2013-08-01",[4215,4216,4217,4218,4219],"Chronic Phase Chronic Myeloid Leukemia","Accelerated Phase Chronic Myeloid Leukemia","Blastic Phase Chronic Myeloid Leukemia","Philadelphia Positive Acute Lymphoblastic Leukemia","Resistant to Tyrosine Kinase Inhibitor Therapy",[4221,4200],"Nilotinib",{"trials":4223,"activeCount":102},[],{"trials":4225,"activeCount":102},[],{"trials":4227,"activeCount":149,"soonestReadout":927},[4228,4240],{"nctId":4229,"briefTitle":4230,"status":494,"phases":4231,"primaryCompletion":927,"completion":927,"start":4232,"enrollment":218,"conditions":4233,"interventions":4237},"NCT04217356","Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis",[],"2020-08-05",[4234,4235,4236],"Myelofibrosis","High-Risk Cancer","Bone Marrow Cancer",[4238,4200,4239],"Hematopoietic stem cell transplant","Hydroxyurea",{"nctId":4241,"briefTitle":4242,"status":727,"phases":4243,"primaryCompletion":4244,"completion":4245,"start":4246,"enrollment":98,"conditions":4247,"interventions":4249},"NCT04331665","Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia",[94],"2021-01-05","2021-03-24","2020-05-21",[3537,4248],"Pneumonia",[4200],{"intervention":82,"totalTrials":98,"cells":4251},{"EARLY_PHASE1":4252,"PHASE1":4254,"PHASE2":4256,"PHASE3":4258,"PHASE4":4272,"NA":4286},{"trials":4253,"activeCount":102},[],{"trials":4255,"activeCount":102},[],{"trials":4257,"activeCount":102},[],{"trials":4259,"activeCount":102},[4260],{"nctId":4261,"briefTitle":4262,"status":112,"phases":4263,"primaryCompletion":4264,"completion":4265,"start":4266,"enrollment":98,"conditions":4267,"interventions":4269},"NCT03009500","Randomized Controlled Trial of Efficacy and Safety of Local Anesthetics and Steroids for Chronic Peripheral Post-traumatic Neuropathic Pain",[92],"2018-03","2019-06","2017-01",[1332,4268],"Peripheral Neuropathic Pain",[82,4270,4271],"Depo-Medrol Injectable Product","Lidocaine",{"trials":4273,"activeCount":102},[4274],{"nctId":4275,"briefTitle":4276,"status":112,"phases":4277,"primaryCompletion":4141,"completion":4141,"start":1793,"enrollment":4278,"conditions":4279,"interventions":4284},"NCT01398982","TAP Block in DIEP or Free MS-TRAM Donor Site: A RCT",[93],93,[4280,4281,4282,4283],"Transversus Abdominis Plane (TAP) Block Catheter","DIEP or Free MS-TRAM Breast Reconstruction","Local Pain Management","Abdominal\u002F Donor Site",[82,4285],"Isotonic saline",{"trials":4287,"activeCount":149,"soonestReadout":81},[4288],{"nctId":79,"briefTitle":80,"status":494,"phases":4289,"primaryCompletion":81,"completion":1944,"start":4290,"enrollment":4291,"conditions":4292,"interventions":4295},[],"2024-07-22",55,[4293,4294],"Anesthesia","Anesthesia, Local",[82],{"intervention":4297,"totalTrials":659,"cells":4298},"Molecular Profiling",{"EARLY_PHASE1":4299,"PHASE1":4301,"PHASE2":4303,"PHASE3":4305,"PHASE4":4307,"NA":4309},{"trials":4300,"activeCount":102},[],{"trials":4302,"activeCount":102},[],{"trials":4304,"activeCount":102},[],{"trials":4306,"activeCount":102},[],{"trials":4308,"activeCount":102},[],{"trials":4310,"activeCount":149,"soonestReadout":2565},[4311,4320],{"nctId":4312,"briefTitle":4313,"status":112,"phases":4314,"primaryCompletion":3267,"completion":3267,"start":4315,"enrollment":4316,"conditions":4317,"interventions":4319},"NCT02750657","Study of Changes and Characteristics of Genes in Patients With Pancreatic Cancer for Better Treatment Selection",[],"2015-12",332,[4318],"Carcinoma, Pancreatic Ductal",[4297],{"nctId":4321,"briefTitle":4322,"status":168,"phases":4323,"primaryCompletion":2565,"completion":2565,"start":4324,"enrollment":929,"conditions":4325,"interventions":4327},"NCT04219137","Molecular Characteristics of Gastroesophageal Adenocarcinoma (MOCHA): A Prospective Feasibility Study",[],"2019-11-14",[4326],"Esophagogastric Adenocarcinoma",[4297],{"intervention":4329,"totalTrials":149,"cells":4330},"18-F FDG",{"EARLY_PHASE1":4331,"PHASE1":4333,"PHASE2":4335,"PHASE3":4337,"PHASE4":4339,"NA":4341},{"trials":4332,"activeCount":102},[],{"trials":4334,"activeCount":102},[],{"trials":4336,"activeCount":102},[],{"trials":4338,"activeCount":102},[],{"trials":4340,"activeCount":102},[],{"trials":4342,"activeCount":149,"soonestReadout":1408},[4343],{"nctId":4344,"briefTitle":4345,"status":168,"phases":4346,"primaryCompletion":1408,"completion":1408,"start":4347,"enrollment":129,"conditions":4348,"interventions":4349},"NCT02678884","Head and Neck Squamous Cell Carcinoma (HNSCC)PET-CT Pilot Study",[94],"2014-10",[910],[4329],{"intervention":4351,"totalTrials":149,"cells":4352},"F18-FDG",{"EARLY_PHASE1":4353,"PHASE1":4355,"PHASE2":4357,"PHASE3":4359,"PHASE4":4361,"NA":4363},{"trials":4354,"activeCount":102},[],{"trials":4356,"activeCount":102},[],{"trials":4358,"activeCount":102},[],{"trials":4360,"activeCount":102},[],{"trials":4362,"activeCount":102},[],{"trials":4364,"activeCount":149,"soonestReadout":4369},[4365],{"nctId":4366,"briefTitle":4367,"status":494,"phases":4368,"primaryCompletion":4369,"completion":4369,"start":4370,"enrollment":172,"conditions":4371,"interventions":4372},"NCT04804371","Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors",[94],"2027-02-22","2021-03-04",[1453],[4351],{"intervention":4374,"totalTrials":149,"cells":4375},"Lutetium-177 Octreotate",{"EARLY_PHASE1":4376,"PHASE1":4378,"PHASE2":4380,"PHASE3":4382,"PHASE4":4384,"NA":4386},{"trials":4377,"activeCount":102},[],{"trials":4379,"activeCount":102},[],{"trials":4381,"activeCount":102},[],{"trials":4383,"activeCount":102},[],{"trials":4385,"activeCount":102},[],{"trials":4387,"activeCount":149,"soonestReadout":1185},[4388],{"nctId":4389,"briefTitle":4390,"status":494,"phases":4391,"primaryCompletion":1185,"completion":1185,"start":4392,"enrollment":4393,"conditions":4394,"interventions":4395},"NCT02743741","Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors",[94],"2016-07-15",195,[1453],[4374],{"intervention":4397,"totalTrials":149,"cells":4398},"Early Cohort corticosteroid dose",{"EARLY_PHASE1":4399,"PHASE1":4401,"PHASE2":4403,"PHASE3":4405,"PHASE4":4407,"NA":4409},{"trials":4400,"activeCount":102},[],{"trials":4402,"activeCount":102},[],{"trials":4404,"activeCount":102},[],{"trials":4406,"activeCount":102},[],{"trials":4408,"activeCount":102},[],{"trials":4410,"activeCount":149,"soonestReadout":4415},[4411],{"nctId":4412,"briefTitle":4413,"status":168,"phases":4414,"primaryCompletion":4415,"completion":4415,"start":4416,"enrollment":4417,"conditions":4418,"interventions":4422},"NCT05440851","Platform of Randomized Adaptive Clinical Trials in Critical Illness",[94],"2027-03-31","2023-04-30",6250,[4419,4420,4421],"Respiratory Insufficiency","Extracorporeal Membrane Oxygenation Complication","Mechanical Ventilation Pressure High",[4397,4423,4424,4425,4426,4427,4428,4429],"Extended Cohort corticosteroid dose","Usual care without routine corticosteroids","Usual care without extending corticosteroids","Usual care with fludrocortisone","Usual care without fludrocortisone","Drug 4 mL:","Drug 40 mg:",{"intervention":4423,"totalTrials":149,"cells":4431},{"EARLY_PHASE1":4432,"PHASE1":4434,"PHASE2":4436,"PHASE3":4438,"PHASE4":4440,"NA":4442},{"trials":4433,"activeCount":102},[],{"trials":4435,"activeCount":102},[],{"trials":4437,"activeCount":102},[],{"trials":4439,"activeCount":102},[],{"trials":4441,"activeCount":102},[],{"trials":4443,"activeCount":149,"soonestReadout":4415},[4444],{"nctId":4412,"briefTitle":4413,"status":168,"phases":4445,"primaryCompletion":4415,"completion":4415,"start":4416,"enrollment":4417,"conditions":4446,"interventions":4447},[94],[4419,4420,4421],[4397,4423,4424,4425,4426,4427,4428,4429],{"intervention":4424,"totalTrials":149,"cells":4449},{"EARLY_PHASE1":4450,"PHASE1":4452,"PHASE2":4454,"PHASE3":4456,"PHASE4":4458,"NA":4460},{"trials":4451,"activeCount":102},[],{"trials":4453,"activeCount":102},[],{"trials":4455,"activeCount":102},[],{"trials":4457,"activeCount":102},[],{"trials":4459,"activeCount":102},[],{"trials":4461,"activeCount":149,"soonestReadout":4415},[4462],{"nctId":4412,"briefTitle":4413,"status":168,"phases":4463,"primaryCompletion":4415,"completion":4415,"start":4416,"enrollment":4417,"conditions":4464,"interventions":4465},[94],[4419,4420,4421],[4397,4423,4424,4425,4426,4427,4428,4429],{"intervention":4425,"totalTrials":149,"cells":4467},{"EARLY_PHASE1":4468,"PHASE1":4470,"PHASE2":4472,"PHASE3":4474,"PHASE4":4476,"NA":4478},{"trials":4469,"activeCount":102},[],{"trials":4471,"activeCount":102},[],{"trials":4473,"activeCount":102},[],{"trials":4475,"activeCount":102},[],{"trials":4477,"activeCount":102},[],{"trials":4479,"activeCount":149,"soonestReadout":4415},[4480],{"nctId":4412,"briefTitle":4413,"status":168,"phases":4481,"primaryCompletion":4415,"completion":4415,"start":4416,"enrollment":4417,"conditions":4482,"interventions":4483},[94],[4419,4420,4421],[4397,4423,4424,4425,4426,4427,4428,4429],{"intervention":4426,"totalTrials":149,"cells":4485},{"EARLY_PHASE1":4486,"PHASE1":4488,"PHASE2":4490,"PHASE3":4492,"PHASE4":4494,"NA":4496},{"trials":4487,"activeCount":102},[],{"trials":4489,"activeCount":102},[],{"trials":4491,"activeCount":102},[],{"trials":4493,"activeCount":102},[],{"trials":4495,"activeCount":102},[],{"trials":4497,"activeCount":149,"soonestReadout":4415},[4498],{"nctId":4412,"briefTitle":4413,"status":168,"phases":4499,"primaryCompletion":4415,"completion":4415,"start":4416,"enrollment":4417,"conditions":4500,"interventions":4501},[94],[4419,4420,4421],[4397,4423,4424,4425,4426,4427,4428,4429],{"intervention":4427,"totalTrials":149,"cells":4503},{"EARLY_PHASE1":4504,"PHASE1":4506,"PHASE2":4508,"PHASE3":4510,"PHASE4":4512,"NA":4514},{"trials":4505,"activeCount":102},[],{"trials":4507,"activeCount":102},[],{"trials":4509,"activeCount":102},[],{"trials":4511,"activeCount":102},[],{"trials":4513,"activeCount":102},[],{"trials":4515,"activeCount":149,"soonestReadout":4415},[4516],{"nctId":4412,"briefTitle":4413,"status":168,"phases":4517,"primaryCompletion":4415,"completion":4415,"start":4416,"enrollment":4417,"conditions":4518,"interventions":4519},[94],[4419,4420,4421],[4397,4423,4424,4425,4426,4427,4428,4429],{"intervention":4428,"totalTrials":149,"cells":4521},{"EARLY_PHASE1":4522,"PHASE1":4524,"PHASE2":4526,"PHASE3":4528,"PHASE4":4530,"NA":4532},{"trials":4523,"activeCount":102},[],{"trials":4525,"activeCount":102},[],{"trials":4527,"activeCount":102},[],{"trials":4529,"activeCount":102},[],{"trials":4531,"activeCount":102},[],{"trials":4533,"activeCount":149,"soonestReadout":4415},[4534],{"nctId":4412,"briefTitle":4413,"status":168,"phases":4535,"primaryCompletion":4415,"completion":4415,"start":4416,"enrollment":4417,"conditions":4536,"interventions":4537},[94],[4419,4420,4421],[4397,4423,4424,4425,4426,4427,4428,4429],{"intervention":4429,"totalTrials":149,"cells":4539},{"EARLY_PHASE1":4540,"PHASE1":4542,"PHASE2":4544,"PHASE3":4546,"PHASE4":4548,"NA":4550},{"trials":4541,"activeCount":102},[],{"trials":4543,"activeCount":102},[],{"trials":4545,"activeCount":102},[],{"trials":4547,"activeCount":102},[],{"trials":4549,"activeCount":102},[],{"trials":4551,"activeCount":149,"soonestReadout":4415},[4552],{"nctId":4412,"briefTitle":4413,"status":168,"phases":4553,"primaryCompletion":4415,"completion":4415,"start":4416,"enrollment":4417,"conditions":4554,"interventions":4555},[94],[4419,4420,4421],[4397,4423,4424,4425,4426,4427,4428,4429],{"intervention":4557,"totalTrials":149,"cells":4558},"Modified Folforinox",{"EARLY_PHASE1":4559,"PHASE1":4561,"PHASE2":4563,"PHASE3":4565,"PHASE4":4567,"NA":4569},{"trials":4560,"activeCount":102},[],{"trials":4562,"activeCount":102},[],{"trials":4564,"activeCount":102},[],{"trials":4566,"activeCount":102},[],{"trials":4568,"activeCount":102},[],{"trials":4570,"activeCount":149,"soonestReadout":1185},[4571],{"nctId":4572,"briefTitle":4573,"status":494,"phases":4574,"primaryCompletion":1185,"completion":215,"start":4575,"enrollment":4576,"conditions":4577,"interventions":4579},"NCT04472910","GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma",[94],"2020-08-21",84,[4578],"Resectable Pancreatic Cancer",[4557],{"intervention":4581,"totalTrials":149,"cells":4582},"Forteo",{"EARLY_PHASE1":4583,"PHASE1":4585,"PHASE2":4587,"PHASE3":4589,"PHASE4":4591,"NA":4593},{"trials":4584,"activeCount":102},[],{"trials":4586,"activeCount":102},[],{"trials":4588,"activeCount":102},[],{"trials":4590,"activeCount":102},[],{"trials":4592,"activeCount":102},[],{"trials":4594,"activeCount":149,"soonestReadout":4599},[4595],{"nctId":4596,"briefTitle":4597,"status":494,"phases":4598,"primaryCompletion":4599,"completion":4156,"start":4600,"enrollment":2591,"conditions":4601,"interventions":4603},"NCT01155245","Teriparatide (PTH) and Bone Strength in Postmenopausal Women",[],"2027-01","2008-06",[4602],"Osteoporosis",[4581],{"intervention":77,"totalTrials":149,"cells":4605},{"EARLY_PHASE1":4606,"PHASE1":4608,"PHASE2":4610,"PHASE3":4612,"PHASE4":4614,"NA":4616},{"trials":4607,"activeCount":102},[],{"trials":4609,"activeCount":102},[],{"trials":4611,"activeCount":102},[],{"trials":4613,"activeCount":102},[],{"trials":4615,"activeCount":102},[],{"trials":4617,"activeCount":149,"soonestReadout":76},[4618],{"nctId":74,"briefTitle":75,"status":494,"phases":4619,"primaryCompletion":76,"completion":927,"start":4620,"enrollment":4621,"conditions":4622,"interventions":4624},[],"2018-07-01",1416,[4623],"Hereditary Cancer Syndrome",[77],{"intervention":4626,"totalTrials":149,"cells":4627},"Fecal Microbial Transplant Enema",{"EARLY_PHASE1":4628,"PHASE1":4630,"PHASE2":4632,"PHASE3":4634,"PHASE4":4636,"NA":4638},{"trials":4629,"activeCount":102},[],{"trials":4631,"activeCount":102},[],{"trials":4633,"activeCount":102},[],{"trials":4635,"activeCount":102},[],{"trials":4637,"activeCount":102},[],{"trials":4639,"activeCount":149,"soonestReadout":4644},[4640],{"nctId":4641,"briefTitle":4642,"status":125,"phases":4643,"primaryCompletion":4644,"completion":4645,"start":4646,"enrollment":129,"conditions":4647,"interventions":4649},"NCT07509450","Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cell Transplant: A Pilot Study",[94],"2029-04-15","2029-04-29","2026-04-15",[4648],"Lymphoma Receiving CAR-T Therapy",[4626,4626],{"intervention":4651,"totalTrials":149,"cells":4652},"Teriparatide",{"EARLY_PHASE1":4653,"PHASE1":4655,"PHASE2":4657,"PHASE3":4659,"PHASE4":4661,"NA":4663},{"trials":4654,"activeCount":102},[],{"trials":4656,"activeCount":102},[],{"trials":4658,"activeCount":102},[],{"trials":4660,"activeCount":102},[],{"trials":4662,"activeCount":102},[],{"trials":4664,"activeCount":149,"soonestReadout":4599},[4665],{"nctId":4666,"briefTitle":4667,"status":494,"phases":4668,"primaryCompletion":4599,"completion":4156,"start":4669,"enrollment":1046,"conditions":4670,"interventions":4671},"NCT01155232","Effects of Teriparatide (PTH) on Bone in Men and Women With Osteoporosis",[],"2004-11",[4602],[4651],{"intervention":4673,"totalTrials":149,"cells":4674},"[68Ga]Ga-PentixaFor",{"EARLY_PHASE1":4675,"PHASE1":4677,"PHASE2":4679,"PHASE3":4681,"PHASE4":4683,"NA":4685},{"trials":4676,"activeCount":102},[],{"trials":4678,"activeCount":102},[],{"trials":4680,"activeCount":102},[],{"trials":4682,"activeCount":102},[],{"trials":4684,"activeCount":102},[],{"trials":4686,"activeCount":149,"soonestReadout":4691},[4687],{"nctId":4688,"briefTitle":4689,"status":168,"phases":4690,"primaryCompletion":4691,"completion":4691,"start":4692,"enrollment":607,"conditions":4693,"interventions":4694},"NCT06871176","PET\u002FMR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM)",[94],"2028-03-04","2025-04-22",[246],[4673],{"intervention":4696,"totalTrials":149,"cells":4697},"PET\u002FMR with 18F-FDG",{"EARLY_PHASE1":4698,"PHASE1":4700,"PHASE2":4702,"PHASE3":4704,"PHASE4":4706,"NA":4708},{"trials":4699,"activeCount":102},[],{"trials":4701,"activeCount":102},[],{"trials":4703,"activeCount":102},[],{"trials":4705,"activeCount":102},[],{"trials":4707,"activeCount":102},[],{"trials":4709,"activeCount":149,"soonestReadout":1314},[4710],{"nctId":4711,"briefTitle":4712,"status":168,"phases":4713,"primaryCompletion":1314,"completion":1314,"start":4714,"enrollment":172,"conditions":4715,"interventions":4717},"NCT04901884","PET\u002FMR Pre- and Post Radiotherapy for Cardiopulmonary Dysfunction Evaluation",[94],"2021-06-01",[4716],"Pulmonary Hypertension",[4696],{"intervention":4719,"totalTrials":149,"cells":4720},"CBD",{"EARLY_PHASE1":4721,"PHASE1":4723,"PHASE2":4725,"PHASE3":4727,"PHASE4":4729,"NA":4731},{"trials":4722,"activeCount":102},[],{"trials":4724,"activeCount":102},[],{"trials":4726,"activeCount":102},[],{"trials":4728,"activeCount":102},[],{"trials":4730,"activeCount":102},[],{"trials":4732,"activeCount":149,"soonestReadout":927},[4733],{"nctId":4734,"briefTitle":4735,"status":168,"phases":4736,"primaryCompletion":927,"completion":4737,"start":4738,"enrollment":1046,"conditions":4739,"interventions":4742},"NCT06878417","Cannabinoids for Osteoarthritis Pain Effectiveness Trial",[94],"2027-02-28","2026-01-29",[4740,4741],"Osteoarthritis of Knee","Osteoarthritis Hip",[4719,4743],"THC",{"intervention":4743,"totalTrials":149,"cells":4745},{"EARLY_PHASE1":4746,"PHASE1":4748,"PHASE2":4750,"PHASE3":4752,"PHASE4":4754,"NA":4756},{"trials":4747,"activeCount":102},[],{"trials":4749,"activeCount":102},[],{"trials":4751,"activeCount":102},[],{"trials":4753,"activeCount":102},[],{"trials":4755,"activeCount":102},[],{"trials":4757,"activeCount":149,"soonestReadout":927},[4758],{"nctId":4734,"briefTitle":4735,"status":168,"phases":4759,"primaryCompletion":927,"completion":4737,"start":4738,"enrollment":1046,"conditions":4760,"interventions":4761},[94],[4740,4741],[4719,4743],{"intervention":4763,"totalTrials":149,"cells":4764},"Erector Spinae (ESP) Block with Lidocaine\u002FBupivacaine",{"EARLY_PHASE1":4765,"PHASE1":4767,"PHASE2":4769,"PHASE3":4771,"PHASE4":4773,"NA":4775},{"trials":4766,"activeCount":102},[],{"trials":4768,"activeCount":102},[],{"trials":4770,"activeCount":102},[],{"trials":4772,"activeCount":102},[],{"trials":4774,"activeCount":102},[],{"trials":4776,"activeCount":149,"soonestReadout":4781},[4777],{"nctId":4778,"briefTitle":4779,"status":168,"phases":4780,"primaryCompletion":4781,"completion":288,"start":4782,"enrollment":2071,"conditions":4783,"interventions":4786},"NCT04646707","Effect of Erector Spinae (ESP) Block on Opioid Reduction and Enhanced Recovery After Posterior Cervical Spine Surgery",[94],"2025-12-17","2020-02-17",[4784,4785],"Postoperative","Pain",[4763,4787],"Erector Spinae (ESP) Block with placebo",{"intervention":4787,"totalTrials":149,"cells":4789},{"EARLY_PHASE1":4790,"PHASE1":4792,"PHASE2":4794,"PHASE3":4796,"PHASE4":4798,"NA":4800},{"trials":4791,"activeCount":102},[],{"trials":4793,"activeCount":102},[],{"trials":4795,"activeCount":102},[],{"trials":4797,"activeCount":102},[],{"trials":4799,"activeCount":102},[],{"trials":4801,"activeCount":149,"soonestReadout":4781},[4802],{"nctId":4778,"briefTitle":4779,"status":168,"phases":4803,"primaryCompletion":4781,"completion":288,"start":4782,"enrollment":2071,"conditions":4804,"interventions":4805},[94],[4784,4785],[4763,4787],{"intervention":4807,"totalTrials":149,"cells":4808},"Standardized Prescription",{"EARLY_PHASE1":4809,"PHASE1":4811,"PHASE2":4813,"PHASE3":4815,"PHASE4":4817,"NA":4819},{"trials":4810,"activeCount":102},[],{"trials":4812,"activeCount":102},[],{"trials":4814,"activeCount":102},[],{"trials":4816,"activeCount":102},[],{"trials":4818,"activeCount":102},[],{"trials":4820,"activeCount":149,"soonestReadout":215},[4821],{"nctId":4822,"briefTitle":4823,"status":168,"phases":4824,"primaryCompletion":215,"completion":927,"start":4825,"enrollment":4826,"conditions":4827,"interventions":4829},"NCT04044820","Opioid Use Post-Discharge After Ambulatory Distal Arm Surgery",[94],"2019-03-04",292,[4828],"Opioid Use",[4807],{"intervention":4831,"totalTrials":149,"cells":4832},"TruGraf liver gene expression",{"EARLY_PHASE1":4833,"PHASE1":4835,"PHASE2":4837,"PHASE3":4839,"PHASE4":4841,"NA":4843},{"trials":4834,"activeCount":102},[],{"trials":4836,"activeCount":102},[],{"trials":4838,"activeCount":102},[],{"trials":4840,"activeCount":102},[],{"trials":4842,"activeCount":102},[],{"trials":4844,"activeCount":149,"soonestReadout":4849},[4845],{"nctId":4846,"briefTitle":4847,"status":168,"phases":4848,"primaryCompletion":4849,"completion":4850,"start":4851,"enrollment":4852,"conditions":4853,"interventions":4855},"NCT06557564","Diagnosis of Graft Pathology by TruGraf",[],"2027-07-20","2027-12-30","2024-07-20",471,[4854],"Acute Graft Rejection",[4831],{"intervention":4857,"totalTrials":149,"cells":4858},"Liquid Biopsy",{"EARLY_PHASE1":4859,"PHASE1":4861,"PHASE2":4863,"PHASE3":4865,"PHASE4":4867,"NA":4869},{"trials":4860,"activeCount":102},[],{"trials":4862,"activeCount":102},[],{"trials":4864,"activeCount":102},[],{"trials":4866,"activeCount":102},[],{"trials":4868,"activeCount":102},[],{"trials":4870,"activeCount":149,"soonestReadout":4875},[4871],{"nctId":4872,"briefTitle":4873,"status":168,"phases":4874,"primaryCompletion":4875,"completion":4876,"start":4877,"enrollment":1046,"conditions":4878,"interventions":4879},"NCT06268405","Positron Emission Mammography and Liquid Biopsy in Women With High-risk Breast Screenings",[94],"2026-07-31","2027-07-31","2023-09-21",[18],[4857],{"intervention":4238,"totalTrials":149,"cells":4881},{"EARLY_PHASE1":4882,"PHASE1":4884,"PHASE2":4886,"PHASE3":4888,"PHASE4":4890,"NA":4892},{"trials":4883,"activeCount":102},[],{"trials":4885,"activeCount":102},[],{"trials":4887,"activeCount":102},[],{"trials":4889,"activeCount":102},[],{"trials":4891,"activeCount":102},[],{"trials":4893,"activeCount":149,"soonestReadout":927},[4894],{"nctId":4229,"briefTitle":4230,"status":494,"phases":4895,"primaryCompletion":927,"completion":927,"start":4232,"enrollment":218,"conditions":4896,"interventions":4897},[],[4234,4235,4236],[4238,4200,4239],{"intervention":4239,"totalTrials":149,"cells":4899},{"EARLY_PHASE1":4900,"PHASE1":4902,"PHASE2":4904,"PHASE3":4906,"PHASE4":4908,"NA":4910},{"trials":4901,"activeCount":102},[],{"trials":4903,"activeCount":102},[],{"trials":4905,"activeCount":102},[],{"trials":4907,"activeCount":102},[],{"trials":4909,"activeCount":102},[],{"trials":4911,"activeCount":149,"soonestReadout":927},[4912],{"nctId":4229,"briefTitle":4230,"status":494,"phases":4913,"primaryCompletion":927,"completion":927,"start":4232,"enrollment":218,"conditions":4914,"interventions":4915},[],[4234,4235,4236],[4238,4200,4239],{"intervention":4917,"totalTrials":149,"cells":4918},"Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents.",{"EARLY_PHASE1":4919,"PHASE1":4921,"PHASE2":4923,"PHASE3":4925,"PHASE4":4927,"NA":4929},{"trials":4920,"activeCount":102},[],{"trials":4922,"activeCount":102},[],{"trials":4924,"activeCount":102},[],{"trials":4926,"activeCount":102},[],{"trials":4928,"activeCount":102},[],{"trials":4930,"activeCount":149,"soonestReadout":2888},[4931],{"nctId":4932,"briefTitle":4933,"status":168,"phases":4934,"primaryCompletion":2888,"completion":2888,"start":4935,"enrollment":4936,"conditions":4937,"interventions":4947},"NCT04151342","CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)",[],"2020-01-17",5500,[24,4938,4939,4940,4941,4942,4943,4944,4945,4946],"Malignancies Multiple","Malignant Solid Tumor","Cancer, Therapy-Related","Molecular Sequence Variation","Genetic Alteration","Gene Fusion","Receptor Tyrosine Kinase Gene Mutation","RTK Family Gene Mutation","Ras (Kras or Nras) Gene Mutation",[4917],{"intervention":4949,"totalTrials":149,"cells":4950},"Propofol group",{"EARLY_PHASE1":4951,"PHASE1":4953,"PHASE2":4955,"PHASE3":4957,"PHASE4":4959,"NA":4961},{"trials":4952,"activeCount":102},[],{"trials":4954,"activeCount":102},[],{"trials":4956,"activeCount":102},[],{"trials":4958,"activeCount":102},[],{"trials":4960,"activeCount":102},[],{"trials":4962,"activeCount":149,"soonestReadout":4967},[4963],{"nctId":4964,"briefTitle":4965,"status":168,"phases":4966,"primaryCompletion":4967,"completion":4968,"start":4969,"enrollment":172,"conditions":4970,"interventions":4973},"NCT04962672","Anesthesia Induced Brain Cancer Survival (ABC Survival): A Feasibility Study",[94],"2025-07-01","2025-09-30","2022-01-01",[4293,4971,4972],"Brain Cancer","Survival",[4949,4974],"Sevoflurane group",{"intervention":4974,"totalTrials":149,"cells":4976},{"EARLY_PHASE1":4977,"PHASE1":4979,"PHASE2":4981,"PHASE3":4983,"PHASE4":4985,"NA":4987},{"trials":4978,"activeCount":102},[],{"trials":4980,"activeCount":102},[],{"trials":4982,"activeCount":102},[],{"trials":4984,"activeCount":102},[],{"trials":4986,"activeCount":102},[],{"trials":4988,"activeCount":149,"soonestReadout":4967},[4989],{"nctId":4964,"briefTitle":4965,"status":168,"phases":4990,"primaryCompletion":4967,"completion":4968,"start":4969,"enrollment":172,"conditions":4991,"interventions":4992},[94],[4293,4971,4972],[4949,4974],{"intervention":4994,"totalTrials":149,"cells":4995},"Cisatracurium",{"EARLY_PHASE1":4996,"PHASE1":4998,"PHASE2":5000,"PHASE3":5002,"PHASE4":5004,"NA":5006},{"trials":4997,"activeCount":102},[],{"trials":4999,"activeCount":102},[],{"trials":5001,"activeCount":102},[],{"trials":5003,"activeCount":102},[],{"trials":5005,"activeCount":102},[],{"trials":5007,"activeCount":149,"soonestReadout":566},[5008],{"nctId":5009,"briefTitle":5010,"status":168,"phases":5011,"primaryCompletion":566,"completion":5012,"start":5013,"enrollment":5014,"conditions":5015,"interventions":5018},"NCT04524585","Partial Neuromuscular Blockade in Acute Hypoxemic Respiratory Failure",[94],"2027-03-01","2020-10-01",23,[4419,5016,5017],"Neuromuscular Blockade","Mechanical Ventilation",[4994],{"intervention":5020,"totalTrials":149,"cells":5021},"18-F-FAZA",{"EARLY_PHASE1":5022,"PHASE1":5024,"PHASE2":5026,"PHASE3":5028,"PHASE4":5030,"NA":5032},{"trials":5023,"activeCount":102},[],{"trials":5025,"activeCount":102},[],{"trials":5027,"activeCount":102},[],{"trials":5029,"activeCount":102},[],{"trials":5031,"activeCount":102},[],{"trials":5033,"activeCount":149,"soonestReadout":2589},[5034],{"nctId":5035,"briefTitle":5036,"status":494,"phases":5037,"primaryCompletion":2589,"completion":2589,"start":2354,"enrollment":758,"conditions":5038,"interventions":5039},"NCT02701699","18F-Fluoroazomycin Arabinoside (18F-FAZA) in Lung Cancer",[94],[21],[5020],{"intervention":5041,"totalTrials":659,"cells":5042},"Standard of Care",{"EARLY_PHASE1":5043,"PHASE1":5045,"PHASE2":5047,"PHASE3":5049,"PHASE4":5051,"NA":5077},{"trials":5044,"activeCount":102},[],{"trials":5046,"activeCount":102},[],{"trials":5048,"activeCount":102},[],{"trials":5050,"activeCount":102},[],{"trials":5052,"activeCount":102},[5053,5065],{"nctId":5054,"briefTitle":5055,"status":112,"phases":5056,"primaryCompletion":5057,"completion":5058,"start":5059,"enrollment":607,"conditions":5060,"interventions":5063},"NCT03731169","CYP2C19 Genotype-Specific Dosing Plus TDM on Reaching Therapeutic Voriconazole Blood Levels",[93],"2019-08-31","2020-08-28","2018-01-10",[5061,5062],"Aspergillosis Invasive","Fungal Infection",[5064,5041],"Voriconazole genotype-specific dosing",{"nctId":5066,"briefTitle":5067,"status":112,"phases":5068,"primaryCompletion":5069,"completion":5070,"start":5071,"enrollment":471,"conditions":5072,"interventions":5074},"NCT03954379","IPACK Study in Total Knee Arthroplasty Patients",[93],"2020-12-02","2021-03-31","2019-10-24",[5073],"Knee Replacement Arthroplasty",[5041,5075,5076],"IPACK and multi-modal analgesic regimen","IV Dexamethasone 8mg at the end of surgery as standard of care",{"trials":5078,"activeCount":102},[],{"intervention":5080,"totalTrials":659,"cells":5081},"glucagon",{"EARLY_PHASE1":5082,"PHASE1":5084,"PHASE2":5086,"PHASE3":5088,"PHASE4":5101,"NA":5112},{"trials":5083,"activeCount":102},[],{"trials":5085,"activeCount":102},[],{"trials":5087,"activeCount":102},[],{"trials":5089,"activeCount":102},[5090],{"nctId":5091,"briefTitle":5092,"status":1723,"phases":5093,"primaryCompletion":5094,"completion":5095,"start":5096,"enrollment":129,"conditions":5097,"interventions":5099},"NCT03650582","Intranasal Glucagon and Energy Balance",[91,92],"2018-09-30","2018-10-30","2017-06-06",[5098],"Obesity",[5100],"Glucagon",{"trials":5102,"activeCount":102},[5103],{"nctId":5104,"briefTitle":5105,"status":112,"phases":5106,"primaryCompletion":5107,"completion":5107,"start":5108,"enrollment":541,"conditions":5109,"interventions":5111},"NCT01155206","Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon",[93],"2010-01","2009-06",[5110],"Diabetes",[5080],{"trials":5113,"activeCount":102},[],{"intervention":4271,"totalTrials":659,"cells":5115},{"EARLY_PHASE1":5116,"PHASE1":5118,"PHASE2":5120,"PHASE3":5122,"PHASE4":5128,"NA":5140},{"trials":5117,"activeCount":102},[],{"trials":5119,"activeCount":102},[],{"trials":5121,"activeCount":102},[],{"trials":5123,"activeCount":102},[5124],{"nctId":4261,"briefTitle":4262,"status":112,"phases":5125,"primaryCompletion":4264,"completion":4265,"start":4266,"enrollment":98,"conditions":5126,"interventions":5127},[92],[1332,4268],[82,4270,4271],{"trials":5129,"activeCount":102},[5130],{"nctId":5131,"briefTitle":5132,"status":1723,"phases":5133,"primaryCompletion":5134,"completion":5134,"start":1374,"enrollment":810,"conditions":5135,"interventions":5138},"NCT02324166","Cefazolin-Lidocaine Combination Solution to Reduce Antibiotic Pain",[93],"2016-01",[5136,5137],"Vitreoretinal Surgery","Endophthalmitis",[5139,4271],"Cefazolin",{"trials":5141,"activeCount":102},[],{"intervention":5143,"totalTrials":659,"cells":5144},"Frozen Plasma",{"EARLY_PHASE1":5145,"PHASE1":5147,"PHASE2":5149,"PHASE3":5163,"PHASE4":5165,"NA":5181},{"trials":5146,"activeCount":102},[],{"trials":5148,"activeCount":102},[],{"trials":5150,"activeCount":102},[5151],{"nctId":5152,"briefTitle":5153,"status":1723,"phases":5154,"primaryCompletion":5155,"completion":5156,"start":5157,"enrollment":5158,"conditions":5159,"interventions":5161},"NCT04114643","Factor Replacement in Surgery",[91],"2020-07-21","2020-12-31","2019-09-24",103,[5160],"Bleeding in Cardiac Surgery",[5162,5143],"Prothrombin Complex Concentrate",{"trials":5164,"activeCount":102},[],{"trials":5166,"activeCount":102},[5167],{"nctId":5168,"briefTitle":5169,"status":1723,"phases":5170,"primaryCompletion":5171,"completion":5172,"start":5173,"enrollment":5174,"conditions":5175,"interventions":5179},"NCT04534751","Factor In the Initial Resuscitation of Severe Trauma 2 Patients",[93],"2023-12-31","2024-01-30","2021-04-01",350,[5176,5177,5178],"Traumatic Hemorrhage","Coagulopathy","Massive Hemorrhage",[5180,5143],"Fibrinogen + PCC",{"trials":5182,"activeCount":102},[],{"intervention":5184,"totalTrials":149,"cells":5185},"Carnitine",{"EARLY_PHASE1":5186,"PHASE1":5188,"PHASE2":5190,"PHASE3":5192,"PHASE4":5194,"NA":5205},{"trials":5187,"activeCount":102},[],{"trials":5189,"activeCount":102},[],{"trials":5191,"activeCount":102},[],{"trials":5193,"activeCount":102},[],{"trials":5195,"activeCount":102},[5196],{"nctId":5197,"briefTitle":5198,"status":1723,"phases":5199,"primaryCompletion":5200,"completion":4140,"start":5201,"enrollment":607,"conditions":5202,"interventions":5204},"NCT01904396","Identification of Carnitine-Responsive Cardiomyopathy",[93],"2016-08","2013-08",[5203],"Carnitine Deficiency",[5184],{"trials":5206,"activeCount":102},[],{"intervention":5208,"totalTrials":149,"cells":5209},"mRNA-1273 vaccine",{"EARLY_PHASE1":5210,"PHASE1":5212,"PHASE2":5214,"PHASE3":5216,"PHASE4":5218,"NA":5229},{"trials":5211,"activeCount":102},[],{"trials":5213,"activeCount":102},[],{"trials":5215,"activeCount":102},[],{"trials":5217,"activeCount":102},[],{"trials":5219,"activeCount":102},[5220],{"nctId":5221,"briefTitle":5222,"status":112,"phases":5223,"primaryCompletion":5224,"completion":5225,"start":4009,"enrollment":929,"conditions":5226,"interventions":5228},"NCT04885907","Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients",[93],"2021-07-30","2021-08-30",[1048,1050,5227],"Covid19",[5208],{"trials":5230,"activeCount":102},[],{"intervention":5232,"totalTrials":149,"cells":5233},"DOR\u002F3TC\u002FTDF",{"EARLY_PHASE1":5234,"PHASE1":5236,"PHASE2":5238,"PHASE3":5240,"PHASE4":5242,"NA":5254},{"trials":5235,"activeCount":102},[],{"trials":5237,"activeCount":102},[],{"trials":5239,"activeCount":102},[],{"trials":5241,"activeCount":102},[],{"trials":5243,"activeCount":102},[5244],{"nctId":5245,"briefTitle":5246,"status":727,"phases":5247,"primaryCompletion":5248,"completion":5248,"start":5249,"enrollment":479,"conditions":5250,"interventions":5253},"NCT04665375","Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine\u002FLamivudine\u002FTenofovir DF?",[93],"2024-03-31","2021-04-26",[5251,5252],"Hiv","Weight Gain",[5232],{"trials":5255,"activeCount":102},[],{"intervention":5257,"totalTrials":149,"cells":5258},"Tenofovir Alafenamide",{"EARLY_PHASE1":5259,"PHASE1":5261,"PHASE2":5263,"PHASE3":5265,"PHASE4":5267,"NA":5278},{"trials":5260,"activeCount":102},[],{"trials":5262,"activeCount":102},[],{"trials":5264,"activeCount":102},[],{"trials":5266,"activeCount":102},[],{"trials":5268,"activeCount":102},[5269],{"nctId":5270,"briefTitle":5271,"status":1723,"phases":5272,"primaryCompletion":5273,"completion":5274,"start":5275,"enrollment":244,"conditions":5276,"interventions":5277},"NCT04070079","Tenofovir Alafenamide With Fine Needle Aspiration Biopsy in Chronic Hepatitis B:",[93],"2022-08-30","2022-12-31","2019-01-29",[2891],[5257],{"trials":5279,"activeCount":102},[],{"intervention":5281,"totalTrials":149,"cells":5282},"Febuxostat",{"EARLY_PHASE1":5283,"PHASE1":5285,"PHASE2":5287,"PHASE3":5289,"PHASE4":5291,"NA":5303},{"trials":5284,"activeCount":102},[],{"trials":5286,"activeCount":102},[],{"trials":5288,"activeCount":102},[],{"trials":5290,"activeCount":102},[],{"trials":5292,"activeCount":102},[5293],{"nctId":5294,"briefTitle":5295,"status":112,"phases":5296,"primaryCompletion":5297,"completion":5297,"start":5298,"enrollment":5299,"conditions":5300,"interventions":5302},"NCT02344602","The Effect of Uric Acid Lowering in Type 1 Diabetes",[93],"2015-09-22","2012-12-18",73,[5301],"Type 1 Diabetes Mellitus",[5281],{"trials":5304,"activeCount":102},[],{"intervention":5306,"totalTrials":149,"cells":5307},"The polysaccharide vaccine used is Pneumovax",{"EARLY_PHASE1":5308,"PHASE1":5310,"PHASE2":5312,"PHASE3":5314,"PHASE4":5316,"NA":5328},{"trials":5309,"activeCount":102},[],{"trials":5311,"activeCount":102},[],{"trials":5313,"activeCount":102},[],{"trials":5315,"activeCount":102},[],{"trials":5317,"activeCount":102},[5318],{"nctId":5319,"briefTitle":5320,"status":112,"phases":5321,"primaryCompletion":5322,"completion":5322,"start":5323,"enrollment":4166,"conditions":5324,"interventions":5326},"NCT00143780","Pneumonia Vaccine in Bone Marrow Transplant Recipients: Usefulness of Donor Vaccination",[93],"2006-07","2002-05",[5325],"Bone Marrow Transplant",[5306,5327],"The conjugate vaccine used is Prevnar",{"trials":5329,"activeCount":102},[],{"intervention":5327,"totalTrials":149,"cells":5331},{"EARLY_PHASE1":5332,"PHASE1":5334,"PHASE2":5336,"PHASE3":5338,"PHASE4":5340,"NA":5346},{"trials":5333,"activeCount":102},[],{"trials":5335,"activeCount":102},[],{"trials":5337,"activeCount":102},[],{"trials":5339,"activeCount":102},[],{"trials":5341,"activeCount":102},[5342],{"nctId":5319,"briefTitle":5320,"status":112,"phases":5343,"primaryCompletion":5322,"completion":5322,"start":5323,"enrollment":4166,"conditions":5344,"interventions":5345},[93],[5325],[5306,5327],{"trials":5347,"activeCount":102},[],{"intervention":5349,"totalTrials":149,"cells":5350},"Extended Release Opioid Formulation, Shortened Intervals",{"EARLY_PHASE1":5351,"PHASE1":5353,"PHASE2":5355,"PHASE3":5357,"PHASE4":5359,"NA":5370},{"trials":5352,"activeCount":102},[],{"trials":5354,"activeCount":102},[],{"trials":5356,"activeCount":102},[],{"trials":5358,"activeCount":102},[],{"trials":5360,"activeCount":102},[5361],{"nctId":5362,"briefTitle":5363,"status":550,"phases":5364,"primaryCompletion":5365,"completion":5365,"start":5366,"enrollment":102,"conditions":5367,"interventions":5368},"NCT04132011","Dosing Intervals of Opioid Medication for Chronic Pain",[93],"2020-03-08","2019-05-01",[3073],[5349,5369],"Extended Release Opioid Formulation, Standard intervals",{"trials":5371,"activeCount":102},[],{"intervention":5369,"totalTrials":149,"cells":5373},{"EARLY_PHASE1":5374,"PHASE1":5376,"PHASE2":5378,"PHASE3":5380,"PHASE4":5382,"NA":5388},{"trials":5375,"activeCount":102},[],{"trials":5377,"activeCount":102},[],{"trials":5379,"activeCount":102},[],{"trials":5381,"activeCount":102},[],{"trials":5383,"activeCount":102},[5384],{"nctId":5362,"briefTitle":5363,"status":550,"phases":5385,"primaryCompletion":5365,"completion":5365,"start":5366,"enrollment":102,"conditions":5386,"interventions":5387},[93],[3073],[5349,5369],{"trials":5389,"activeCount":102},[],{"intervention":5064,"totalTrials":149,"cells":5391},{"EARLY_PHASE1":5392,"PHASE1":5394,"PHASE2":5396,"PHASE3":5398,"PHASE4":5400,"NA":5406},{"trials":5393,"activeCount":102},[],{"trials":5395,"activeCount":102},[],{"trials":5397,"activeCount":102},[],{"trials":5399,"activeCount":102},[],{"trials":5401,"activeCount":102},[5402],{"nctId":5054,"briefTitle":5055,"status":112,"phases":5403,"primaryCompletion":5057,"completion":5058,"start":5059,"enrollment":607,"conditions":5404,"interventions":5405},[93],[5061,5062],[5064,5041],{"trials":5407,"activeCount":102},[],{"intervention":5409,"totalTrials":149,"cells":5410},"FLUAD® influenza vaccine",{"EARLY_PHASE1":5411,"PHASE1":5413,"PHASE2":5415,"PHASE3":5417,"PHASE4":5419,"NA":5431},{"trials":5412,"activeCount":102},[],{"trials":5414,"activeCount":102},[],{"trials":5416,"activeCount":102},[],{"trials":5418,"activeCount":102},[],{"trials":5420,"activeCount":102},[5421],{"nctId":5422,"briefTitle":5423,"status":112,"phases":5424,"primaryCompletion":1870,"completion":5200,"start":5425,"enrollment":5299,"conditions":5426,"interventions":5429},"NCT02560909","Adjuvanted Influenza Vaccine in Stem Cell Transplant",[93],"2015-10",[5427,5428],"Transplantation","Influenza Vaccines",[5409,5430],"FLUVIRAL®",{"trials":5432,"activeCount":102},[],{"intervention":5430,"totalTrials":149,"cells":5434},{"EARLY_PHASE1":5435,"PHASE1":5437,"PHASE2":5439,"PHASE3":5441,"PHASE4":5443,"NA":5449},{"trials":5436,"activeCount":102},[],{"trials":5438,"activeCount":102},[],{"trials":5440,"activeCount":102},[],{"trials":5442,"activeCount":102},[],{"trials":5444,"activeCount":102},[5445],{"nctId":5422,"briefTitle":5423,"status":112,"phases":5446,"primaryCompletion":1870,"completion":5200,"start":5425,"enrollment":5299,"conditions":5447,"interventions":5448},[93],[5427,5428],[5409,5430],{"trials":5450,"activeCount":102},[],{"intervention":5452,"totalTrials":149,"cells":5453},"sodium phenylbutyrate",{"EARLY_PHASE1":5454,"PHASE1":5456,"PHASE2":5458,"PHASE3":5460,"PHASE4":5462,"NA":5472},{"trials":5455,"activeCount":102},[],{"trials":5457,"activeCount":102},[],{"trials":5459,"activeCount":102},[],{"trials":5461,"activeCount":102},[],{"trials":5463,"activeCount":102},[5464],{"nctId":5465,"briefTitle":5466,"status":112,"phases":5467,"primaryCompletion":718,"completion":5468,"start":142,"enrollment":511,"conditions":5469,"interventions":5471},"NCT00533559","Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl",[93],"2010-03",[5110,5470],"Insulin Resistance",[5452],{"trials":5473,"activeCount":102},[],{"intervention":5475,"totalTrials":149,"cells":5476},"Fluoxetine+Olanzapine",{"EARLY_PHASE1":5477,"PHASE1":5479,"PHASE2":5481,"PHASE3":5483,"PHASE4":5485,"NA":5495},{"trials":5478,"activeCount":102},[],{"trials":5480,"activeCount":102},[],{"trials":5482,"activeCount":102},[],{"trials":5484,"activeCount":102},[],{"trials":5486,"activeCount":102},[5487],{"nctId":5488,"briefTitle":5489,"status":112,"phases":5490,"primaryCompletion":5108,"completion":5108,"start":5491,"enrollment":291,"conditions":5492,"interventions":5493},"NCT00188942","A Neuroimaging Investigation of Brain Activity in Major Depressive Disorder and Bipolar Disorder",[93],"2005-02",[2307],[5475,5494],"Olanzapine",{"trials":5496,"activeCount":102},[],{"intervention":5494,"totalTrials":149,"cells":5498},{"EARLY_PHASE1":5499,"PHASE1":5501,"PHASE2":5503,"PHASE3":5505,"PHASE4":5507,"NA":5513},{"trials":5500,"activeCount":102},[],{"trials":5502,"activeCount":102},[],{"trials":5504,"activeCount":102},[],{"trials":5506,"activeCount":102},[],{"trials":5508,"activeCount":102},[5509],{"nctId":5488,"briefTitle":5489,"status":112,"phases":5510,"primaryCompletion":5108,"completion":5108,"start":5491,"enrollment":291,"conditions":5511,"interventions":5512},[93],[2307],[5475,5494],{"trials":5514,"activeCount":102},[],{"intervention":5516,"totalTrials":149,"cells":5517},"tenofovir-alafenamide-emtricitabine",{"EARLY_PHASE1":5518,"PHASE1":5520,"PHASE2":5522,"PHASE3":5524,"PHASE4":5526,"NA":5539},{"trials":5519,"activeCount":102},[],{"trials":5521,"activeCount":102},[],{"trials":5523,"activeCount":102},[],{"trials":5525,"activeCount":102},[],{"trials":5527,"activeCount":102},[5528],{"nctId":5529,"briefTitle":5530,"status":112,"phases":5531,"primaryCompletion":5532,"completion":5532,"start":5533,"enrollment":22,"conditions":5534,"interventions":5537},"NCT02815566","Bone Health in Aging HIV Infected Women",[93],"2021-02-25","2017-09-12",[4602,5535,5536],"HIV","Menopause",[5516,5538],"tenofovir-emtricitabine",{"trials":5540,"activeCount":102},[],{"intervention":5538,"totalTrials":149,"cells":5542},{"EARLY_PHASE1":5543,"PHASE1":5545,"PHASE2":5547,"PHASE3":5549,"PHASE4":5551,"NA":5557},{"trials":5544,"activeCount":102},[],{"trials":5546,"activeCount":102},[],{"trials":5548,"activeCount":102},[],{"trials":5550,"activeCount":102},[],{"trials":5552,"activeCount":102},[5553],{"nctId":5529,"briefTitle":5530,"status":112,"phases":5554,"primaryCompletion":5532,"completion":5532,"start":5533,"enrollment":22,"conditions":5555,"interventions":5556},[93],[4602,5535,5536],[5516,5538],{"trials":5558,"activeCount":102},[],{"intervention":5560,"totalTrials":149,"cells":5561},"Continue NA treatment",{"EARLY_PHASE1":5562,"PHASE1":5564,"PHASE2":5566,"PHASE3":5568,"PHASE4":5570,"NA":5581},{"trials":5563,"activeCount":102},[],{"trials":5565,"activeCount":102},[],{"trials":5567,"activeCount":102},[],{"trials":5569,"activeCount":102},[],{"trials":5571,"activeCount":102},[5572],{"nctId":5573,"briefTitle":5574,"status":1723,"phases":5575,"primaryCompletion":5134,"completion":2270,"start":5576,"enrollment":568,"conditions":5577,"interventions":5579},"NCT01911156","Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues",[93],"2013-07",[5578],"Chronic Hepatitis B",[5560,5580],"Discontinue NA Treatment",{"trials":5582,"activeCount":102},[],{"intervention":5580,"totalTrials":149,"cells":5584},{"EARLY_PHASE1":5585,"PHASE1":5587,"PHASE2":5589,"PHASE3":5591,"PHASE4":5593,"NA":5599},{"trials":5586,"activeCount":102},[],{"trials":5588,"activeCount":102},[],{"trials":5590,"activeCount":102},[],{"trials":5592,"activeCount":102},[],{"trials":5594,"activeCount":102},[5595],{"nctId":5573,"briefTitle":5574,"status":1723,"phases":5596,"primaryCompletion":5134,"completion":2270,"start":5576,"enrollment":568,"conditions":5597,"interventions":5598},[93],[5578],[5560,5580],{"trials":5600,"activeCount":102},[],{"intervention":5602,"totalTrials":149,"cells":5603},"Thymoglobulin",{"EARLY_PHASE1":5604,"PHASE1":5606,"PHASE2":5608,"PHASE3":5610,"PHASE4":5612,"NA":5622},{"trials":5605,"activeCount":102},[],{"trials":5607,"activeCount":102},[],{"trials":5609,"activeCount":102},[],{"trials":5611,"activeCount":102},[],{"trials":5613,"activeCount":102},[5614],{"nctId":5615,"briefTitle":5616,"status":1723,"phases":5617,"primaryCompletion":674,"completion":5108,"start":5618,"enrollment":607,"conditions":5619,"interventions":5621},"NCT00706680","Thymoglobulin in Calcineurin Inhibitor and Steroid Minimization Protocol",[93],"2008-02",[5110,5620],"Graft Rejection",[5602],{"trials":5623,"activeCount":102},[],{"intervention":5625,"totalTrials":149,"cells":5626},"Dexamethasone plus Radium-223",{"EARLY_PHASE1":5627,"PHASE1":5629,"PHASE2":5631,"PHASE3":5633,"PHASE4":5635,"NA":5645},{"trials":5628,"activeCount":102},[],{"trials":5630,"activeCount":102},[],{"trials":5632,"activeCount":102},[],{"trials":5634,"activeCount":102},[],{"trials":5636,"activeCount":102},[5637],{"nctId":5638,"briefTitle":5639,"status":1723,"phases":5640,"primaryCompletion":51,"completion":5641,"start":5642,"enrollment":3928,"conditions":5643,"interventions":5644},"NCT03432949","Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC",[93],"2024-07-30","2018-02-23",[2263],[5625],{"trials":5646,"activeCount":102},[],{"intervention":5648,"totalTrials":149,"cells":5649},"Sugammadex Injection [Bridion]",{"EARLY_PHASE1":5650,"PHASE1":5652,"PHASE2":5654,"PHASE3":5656,"PHASE4":5658,"NA":5670},{"trials":5651,"activeCount":102},[],{"trials":5653,"activeCount":102},[],{"trials":5655,"activeCount":102},[],{"trials":5657,"activeCount":102},[],{"trials":5659,"activeCount":102},[5660],{"nctId":5661,"briefTitle":5662,"status":112,"phases":5663,"primaryCompletion":5664,"completion":5665,"start":5666,"enrollment":172,"conditions":5667,"interventions":5669},"NCT03087513","A Randomized Controlled Crossover Study Comparing Sugammadex and Placebo",[93],"2019-12-30","2020-04-30","2018-02-05",[5668],"Posterior Cervical Decompression and Fusion",[5648],{"trials":5671,"activeCount":102},[],{"intervention":5673,"totalTrials":149,"cells":5674},"Esmolol",{"EARLY_PHASE1":5675,"PHASE1":5677,"PHASE2":5679,"PHASE3":5681,"PHASE4":5683,"NA":5697},{"trials":5676,"activeCount":102},[],{"trials":5678,"activeCount":102},[],{"trials":5680,"activeCount":102},[],{"trials":5682,"activeCount":102},[],{"trials":5684,"activeCount":102},[5685],{"nctId":5686,"briefTitle":5687,"status":727,"phases":5688,"primaryCompletion":629,"completion":5689,"start":629,"enrollment":129,"conditions":5690,"interventions":5695},"NCT01404767","Tight Hemodynamic Control in Patients Who Are Chronically on Metoprolol",[93],"2013-12",[5691,5692,5693,5694],"Vascular Disease","Hypertension","Angina","Cardiac Disease",[5673,5696],"Metoprolol",{"trials":5698,"activeCount":102},[],{"intervention":5696,"totalTrials":149,"cells":5700},{"EARLY_PHASE1":5701,"PHASE1":5703,"PHASE2":5705,"PHASE3":5707,"PHASE4":5709,"NA":5715},{"trials":5702,"activeCount":102},[],{"trials":5704,"activeCount":102},[],{"trials":5706,"activeCount":102},[],{"trials":5708,"activeCount":102},[],{"trials":5710,"activeCount":102},[5711],{"nctId":5686,"briefTitle":5687,"status":727,"phases":5712,"primaryCompletion":629,"completion":5689,"start":629,"enrollment":129,"conditions":5713,"interventions":5714},[93],[5691,5692,5693,5694],[5673,5696],{"trials":5716,"activeCount":102},[],{"intervention":5718,"totalTrials":149,"cells":5719},"Venlafaxine and Lamotrigine",{"EARLY_PHASE1":5720,"PHASE1":5722,"PHASE2":5724,"PHASE3":5726,"PHASE4":5728,"NA":5739},{"trials":5721,"activeCount":102},[],{"trials":5723,"activeCount":102},[],{"trials":5725,"activeCount":102},[],{"trials":5727,"activeCount":102},[],{"trials":5729,"activeCount":102},[5730],{"nctId":5731,"briefTitle":5732,"status":112,"phases":5733,"completion":5734,"start":5735,"enrollment":172,"conditions":5736,"interventions":5738},"NCT00188643","Venlafaxine Versus Lamotrigine in the Treatment of Bipolar I\u002FII Depression",[93],"2007-01","2002-01",[5737],"Bipolar Disorder",[5718],{"trials":5740,"activeCount":102},[],{"intervention":5742,"totalTrials":149,"cells":5743},"Sugammadex Sodium",{"EARLY_PHASE1":5744,"PHASE1":5746,"PHASE2":5748,"PHASE3":5750,"PHASE4":5752,"NA":5764},{"trials":5745,"activeCount":102},[],{"trials":5747,"activeCount":102},[],{"trials":5749,"activeCount":102},[],{"trials":5751,"activeCount":102},[],{"trials":5753,"activeCount":102},[5754],{"nctId":5755,"briefTitle":5756,"status":112,"phases":5757,"primaryCompletion":5758,"completion":5758,"start":5759,"enrollment":929,"conditions":5760,"interventions":5762},"NCT03679611","Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery and Complications",[93],"2021-10-26","2019-01-14",[5761],"Obstructive Sleep Apnea",[5742,5763],"Neostigmine",{"trials":5765,"activeCount":102},[],{"intervention":5763,"totalTrials":149,"cells":5767},{"EARLY_PHASE1":5768,"PHASE1":5770,"PHASE2":5772,"PHASE3":5774,"PHASE4":5776,"NA":5782},{"trials":5769,"activeCount":102},[],{"trials":5771,"activeCount":102},[],{"trials":5773,"activeCount":102},[],{"trials":5775,"activeCount":102},[],{"trials":5777,"activeCount":102},[5778],{"nctId":5755,"briefTitle":5756,"status":112,"phases":5779,"primaryCompletion":5758,"completion":5758,"start":5759,"enrollment":929,"conditions":5780,"interventions":5781},[93],[5761],[5742,5763],{"trials":5783,"activeCount":102},[],{"intervention":5785,"totalTrials":149,"cells":5786},"APO-clonidine",{"EARLY_PHASE1":5787,"PHASE1":5789,"PHASE2":5791,"PHASE3":5793,"PHASE4":5795,"NA":5807},{"trials":5788,"activeCount":102},[],{"trials":5790,"activeCount":102},[],{"trials":5792,"activeCount":102},[],{"trials":5794,"activeCount":102},[],{"trials":5796,"activeCount":102},[5797],{"nctId":5798,"briefTitle":5799,"status":1723,"phases":5800,"completion":5801,"start":5802,"enrollment":25,"conditions":5803,"interventions":5806},"NCT00152750","Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHD",[93],"2008-10","2006-09",[5804,5805],"Tourette's Syndrome","Attention Deficit Hyperactivity Disorder",[5785],{"trials":5808,"activeCount":102},[],{"intervention":5810,"totalTrials":149,"cells":5811},"Sitaglitpin",{"EARLY_PHASE1":5812,"PHASE1":5814,"PHASE2":5816,"PHASE3":5818,"PHASE4":5820,"NA":5830},{"trials":5813,"activeCount":102},[],{"trials":5815,"activeCount":102},[],{"trials":5817,"activeCount":102},[],{"trials":5819,"activeCount":102},[],{"trials":5821,"activeCount":102},[5822],{"nctId":5823,"briefTitle":5824,"status":112,"phases":5825,"primaryCompletion":5826,"completion":4266,"start":5827,"enrollment":758,"conditions":5828,"interventions":5829},"NCT02406443","The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion",[93],"2016-06","2015-03",[2074],[5810],{"trials":5831,"activeCount":102},[],{"intervention":5833,"totalTrials":149,"cells":5834},"Albuterol",{"EARLY_PHASE1":5835,"PHASE1":5837,"PHASE2":5839,"PHASE3":5841,"PHASE4":5843,"NA":5853},{"trials":5836,"activeCount":102},[],{"trials":5838,"activeCount":102},[],{"trials":5840,"activeCount":102},[],{"trials":5842,"activeCount":102},[],{"trials":5844,"activeCount":102},[5845],{"nctId":5846,"briefTitle":5847,"status":1723,"phases":5848,"start":5849,"enrollment":511,"conditions":5850,"interventions":5852},"NCT00385359","A Pilot Efficacy Study of Inhaled Albuterol Delivered With Akita Breath Control",[93],"2006-10",[5851],"Asthma",[5833],{"trials":5854,"activeCount":102},[],{"intervention":5856,"totalTrials":149,"cells":5857},"Suprascapular & axillary blocks",{"EARLY_PHASE1":5858,"PHASE1":5860,"PHASE2":5862,"PHASE3":5864,"PHASE4":5866,"NA":5879},{"trials":5859,"activeCount":102},[],{"trials":5861,"activeCount":102},[],{"trials":5863,"activeCount":102},[],{"trials":5865,"activeCount":102},[],{"trials":5867,"activeCount":102},[5868],{"nctId":5869,"briefTitle":5870,"status":112,"phases":5871,"primaryCompletion":5872,"completion":5872,"start":5873,"enrollment":5874,"conditions":5875,"interventions":5877},"NCT02517437","Suprascapular and Axillary Blocks Versus Interscalene Block for Shoulder Surgery",[93],"2018-01","2015-08",130,[5876],"Shoulder Pain",[5856,5878],"Interscalene block",{"trials":5880,"activeCount":102},[],{"intervention":5878,"totalTrials":149,"cells":5882},{"EARLY_PHASE1":5883,"PHASE1":5885,"PHASE2":5887,"PHASE3":5889,"PHASE4":5891,"NA":5897},{"trials":5884,"activeCount":102},[],{"trials":5886,"activeCount":102},[],{"trials":5888,"activeCount":102},[],{"trials":5890,"activeCount":102},[],{"trials":5892,"activeCount":102},[5893],{"nctId":5869,"briefTitle":5870,"status":112,"phases":5894,"primaryCompletion":5872,"completion":5872,"start":5873,"enrollment":5874,"conditions":5895,"interventions":5896},[93],[5876],[5856,5878],{"trials":5898,"activeCount":102},[],{"intervention":5900,"totalTrials":149,"cells":5901},"alpha lipoic acid",{"EARLY_PHASE1":5902,"PHASE1":5904,"PHASE2":5906,"PHASE3":5908,"PHASE4":5910,"NA":5921},{"trials":5903,"activeCount":102},[],{"trials":5905,"activeCount":102},[],{"trials":5907,"activeCount":102},[],{"trials":5909,"activeCount":102},[],{"trials":5911,"activeCount":102},[5912],{"nctId":5913,"briefTitle":5914,"status":112,"phases":5915,"primaryCompletion":5916,"completion":5917,"start":730,"enrollment":244,"conditions":5918,"interventions":5920},"NCT01056497","The Effect of A-lipoic Acid (ALA) on Fatty Acid-induced Impairment of Glucose-stimulated Insulin Secretion",[93],"2011-01","2011-06",[2074,5919],"Prediabetes",[5900],{"trials":5922,"activeCount":102},[],{"intervention":5924,"totalTrials":149,"cells":5925},"N-acetylcysteine, intralipid, heparin",{"EARLY_PHASE1":5926,"PHASE1":5928,"PHASE2":5930,"PHASE3":5932,"PHASE4":5934,"NA":5946},{"trials":5927,"activeCount":102},[],{"trials":5929,"activeCount":102},[],{"trials":5931,"activeCount":102},[],{"trials":5933,"activeCount":102},[],{"trials":5935,"activeCount":102},[5936],{"nctId":5937,"briefTitle":5938,"status":112,"phases":5939,"primaryCompletion":5940,"completion":1451,"start":5941,"enrollment":244,"conditions":5942,"interventions":5945},"NCT00188773","Mechanism of Fatty Acid-Induced Impairment of Glucose-Stimulated Insulin Secretion",[93],"2007-08","2004-01",[5943,5944],"Insulin Resistance Syndrome X","Pancreatic Beta Cell Function",[5924],{"trials":5947,"activeCount":102},[],{"intervention":5949,"totalTrials":149,"cells":5950},"Fluticasone propionate inhaler",{"EARLY_PHASE1":5951,"PHASE1":5953,"PHASE2":5955,"PHASE3":5957,"PHASE4":5959,"NA":5970},{"trials":5952,"activeCount":102},[],{"trials":5954,"activeCount":102},[],{"trials":5956,"activeCount":102},[],{"trials":5958,"activeCount":102},[],{"trials":5960,"activeCount":102},[5961],{"nctId":5962,"briefTitle":5963,"status":112,"phases":5964,"primaryCompletion":685,"completion":685,"start":4157,"enrollment":1388,"conditions":5965,"interventions":5968},"NCT02338362","Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma",[93],[5966,5967],"Ocular Hypertension","Glaucoma, Open-Angle",[5949,5969],"Saline placebo inhaler",{"trials":5971,"activeCount":102},[],{"intervention":5969,"totalTrials":149,"cells":5973},{"EARLY_PHASE1":5974,"PHASE1":5976,"PHASE2":5978,"PHASE3":5980,"PHASE4":5982,"NA":5988},{"trials":5975,"activeCount":102},[],{"trials":5977,"activeCount":102},[],{"trials":5979,"activeCount":102},[],{"trials":5981,"activeCount":102},[],{"trials":5983,"activeCount":102},[5984],{"nctId":5962,"briefTitle":5963,"status":112,"phases":5985,"primaryCompletion":685,"completion":685,"start":4157,"enrollment":1388,"conditions":5986,"interventions":5987},[93],[5966,5967],[5949,5969],{"trials":5989,"activeCount":102},[],{"intervention":5991,"totalTrials":149,"cells":5992},"Lidocaine per-embolization",{"EARLY_PHASE1":5993,"PHASE1":5995,"PHASE2":5997,"PHASE3":5999,"PHASE4":6001,"NA":6011},{"trials":5994,"activeCount":102},[],{"trials":5996,"activeCount":102},[],{"trials":5998,"activeCount":102},[],{"trials":6000,"activeCount":102},[],{"trials":6002,"activeCount":102},[6003],{"nctId":6004,"briefTitle":6005,"status":112,"phases":6006,"primaryCompletion":2270,"completion":2270,"start":598,"enrollment":2591,"conditions":6007,"interventions":6009},"NCT02293447","Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization",[93],[6008],"Uterine Leiomyomas",[5991,6010],"Lidocaine post-embolization",{"trials":6012,"activeCount":102},[],{"intervention":6010,"totalTrials":149,"cells":6014},{"EARLY_PHASE1":6015,"PHASE1":6017,"PHASE2":6019,"PHASE3":6021,"PHASE4":6023,"NA":6029},{"trials":6016,"activeCount":102},[],{"trials":6018,"activeCount":102},[],{"trials":6020,"activeCount":102},[],{"trials":6022,"activeCount":102},[],{"trials":6024,"activeCount":102},[6025],{"nctId":6004,"briefTitle":6005,"status":112,"phases":6026,"primaryCompletion":2270,"completion":2270,"start":598,"enrollment":2591,"conditions":6027,"interventions":6028},[93],[6008],[5991,6010],{"trials":6030,"activeCount":102},[],{"intervention":6032,"totalTrials":149,"cells":6033},"The polysaccharide vaccine Pneumovax",{"EARLY_PHASE1":6034,"PHASE1":6036,"PHASE2":6038,"PHASE3":6040,"PHASE4":6042,"NA":6053},{"trials":6035,"activeCount":102},[],{"trials":6037,"activeCount":102},[],{"trials":6039,"activeCount":102},[],{"trials":6041,"activeCount":102},[],{"trials":6043,"activeCount":102},[6044],{"nctId":6045,"briefTitle":6046,"status":1723,"phases":6047,"completion":743,"start":6048,"enrollment":5874,"conditions":6049,"interventions":6051},"NCT00152802","Pneumonia Vaccine in Liver Transplant Recipients: a Booster Strategy Using a Conjugate Vaccine",[93],"2005-01",[6050],"Transplant",[6032,6052],"The conjugate vaccine used will be Prevnar",{"trials":6054,"activeCount":102},[],{"intervention":6052,"totalTrials":149,"cells":6056},{"EARLY_PHASE1":6057,"PHASE1":6059,"PHASE2":6061,"PHASE3":6063,"PHASE4":6065,"NA":6071},{"trials":6058,"activeCount":102},[],{"trials":6060,"activeCount":102},[],{"trials":6062,"activeCount":102},[],{"trials":6064,"activeCount":102},[],{"trials":6066,"activeCount":102},[6067],{"nctId":6045,"briefTitle":6046,"status":1723,"phases":6068,"completion":743,"start":6048,"enrollment":5874,"conditions":6069,"interventions":6070},[93],[6050],[6032,6052],{"trials":6072,"activeCount":102},[],{"intervention":6074,"totalTrials":149,"cells":6075},"Dapagliflozin",{"EARLY_PHASE1":6076,"PHASE1":6078,"PHASE2":6080,"PHASE3":6082,"PHASE4":6084,"NA":6094},{"trials":6077,"activeCount":102},[],{"trials":6079,"activeCount":102},[],{"trials":6081,"activeCount":102},[],{"trials":6083,"activeCount":102},[],{"trials":6085,"activeCount":102},[6086],{"nctId":6087,"briefTitle":6088,"status":112,"phases":6089,"primaryCompletion":6090,"completion":6090,"start":698,"enrollment":511,"conditions":6091,"interventions":6093},"NCT02585804","Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects",[93],"2017-04-24",[6092],"Focal Segmental Glomerulosclerosis",[6074],{"trials":6095,"activeCount":102},[],{"intervention":6097,"totalTrials":149,"cells":6098},"Oxycodone",{"EARLY_PHASE1":6099,"PHASE1":6101,"PHASE2":6103,"PHASE3":6105,"PHASE4":6107,"NA":6118},{"trials":6100,"activeCount":102},[],{"trials":6102,"activeCount":102},[],{"trials":6104,"activeCount":102},[],{"trials":6106,"activeCount":102},[],{"trials":6108,"activeCount":102},[6109],{"nctId":6110,"briefTitle":6111,"status":112,"phases":6112,"primaryCompletion":5134,"completion":5134,"start":2356,"enrollment":6113,"conditions":6114,"interventions":6116},"NCT02295124","Nausea in Patients Receiving Hydromorphone vs Oxycodone After Total Hip Replacement Surgery",[93],200,[6115],"Nausea",[6097,6117],"Hydromorphone",{"trials":6119,"activeCount":102},[],{"intervention":6117,"totalTrials":149,"cells":6121},{"EARLY_PHASE1":6122,"PHASE1":6124,"PHASE2":6126,"PHASE3":6128,"PHASE4":6130,"NA":6136},{"trials":6123,"activeCount":102},[],{"trials":6125,"activeCount":102},[],{"trials":6127,"activeCount":102},[],{"trials":6129,"activeCount":102},[],{"trials":6131,"activeCount":102},[6132],{"nctId":6110,"briefTitle":6111,"status":112,"phases":6133,"primaryCompletion":5134,"completion":5134,"start":2356,"enrollment":6113,"conditions":6134,"interventions":6135},[93],[6115],[6097,6117],{"trials":6137,"activeCount":102},[],{"intervention":6139,"totalTrials":149,"cells":6140},"CI 0.2% ropivacaine",{"EARLY_PHASE1":6141,"PHASE1":6143,"PHASE2":6145,"PHASE3":6147,"PHASE4":6149,"NA":6159},{"trials":6142,"activeCount":102},[],{"trials":6144,"activeCount":102},[],{"trials":6146,"activeCount":102},[],{"trials":6148,"activeCount":102},[],{"trials":6150,"activeCount":102},[6151],{"nctId":6152,"briefTitle":6153,"status":1723,"phases":6154,"primaryCompletion":6155,"completion":1955,"start":4347,"enrollment":2591,"conditions":6156,"interventions":6157},"NCT02707874","PIB Versus CI Through a Popliteal Sciatic Nerve Catheter for Analgesia Following Major Ankle Surgery",[93],"2017-12",[1235],[6139,6158],"PIB 0.2% ropivacaine",{"trials":6160,"activeCount":102},[],{"intervention":6158,"totalTrials":149,"cells":6162},{"EARLY_PHASE1":6163,"PHASE1":6165,"PHASE2":6167,"PHASE3":6169,"PHASE4":6171,"NA":6177},{"trials":6164,"activeCount":102},[],{"trials":6166,"activeCount":102},[],{"trials":6168,"activeCount":102},[],{"trials":6170,"activeCount":102},[],{"trials":6172,"activeCount":102},[6173],{"nctId":6152,"briefTitle":6153,"status":1723,"phases":6174,"primaryCompletion":6155,"completion":1955,"start":4347,"enrollment":2591,"conditions":6175,"interventions":6176},[93],[1235],[6139,6158],{"trials":6178,"activeCount":102},[],{"intervention":5075,"totalTrials":149,"cells":6180},{"EARLY_PHASE1":6181,"PHASE1":6183,"PHASE2":6185,"PHASE3":6187,"PHASE4":6189,"NA":6195},{"trials":6182,"activeCount":102},[],{"trials":6184,"activeCount":102},[],{"trials":6186,"activeCount":102},[],{"trials":6188,"activeCount":102},[],{"trials":6190,"activeCount":102},[6191],{"nctId":5066,"briefTitle":5067,"status":112,"phases":6192,"primaryCompletion":5069,"completion":5070,"start":5071,"enrollment":471,"conditions":6193,"interventions":6194},[93],[5073],[5041,5075,5076],{"trials":6196,"activeCount":102},[],{"intervention":5076,"totalTrials":149,"cells":6198},{"EARLY_PHASE1":6199,"PHASE1":6201,"PHASE2":6203,"PHASE3":6205,"PHASE4":6207,"NA":6213},{"trials":6200,"activeCount":102},[],{"trials":6202,"activeCount":102},[],{"trials":6204,"activeCount":102},[],{"trials":6206,"activeCount":102},[],{"trials":6208,"activeCount":102},[6209],{"nctId":5066,"briefTitle":5067,"status":112,"phases":6210,"primaryCompletion":5069,"completion":5070,"start":5071,"enrollment":471,"conditions":6211,"interventions":6212},[93],[5073],[5041,5075,5076],{"trials":6214,"activeCount":102},[],{"intervention":6216,"totalTrials":149,"cells":6217},"Sevoflurane or Propofol",{"EARLY_PHASE1":6218,"PHASE1":6220,"PHASE2":6222,"PHASE3":6224,"PHASE4":6226,"NA":6235},{"trials":6219,"activeCount":102},[],{"trials":6221,"activeCount":102},[],{"trials":6223,"activeCount":102},[],{"trials":6225,"activeCount":102},[],{"trials":6227,"activeCount":102},[6228],{"nctId":6229,"briefTitle":6230,"status":112,"phases":6231,"completion":5618,"start":5849,"conditions":6232,"interventions":6234},"NCT00336401","Peri-Operative And Long-Term Cardioprotective Properties Of Sevoflurane In High Risk Patients Undergoing Non-Cardiac Surgery",[93],[6233],"Non Cardiac Surgery",[6216],{"trials":6236,"activeCount":102},[],{"intervention":5139,"totalTrials":149,"cells":6238},{"EARLY_PHASE1":6239,"PHASE1":6241,"PHASE2":6243,"PHASE3":6245,"PHASE4":6247,"NA":6253},{"trials":6240,"activeCount":102},[],{"trials":6242,"activeCount":102},[],{"trials":6244,"activeCount":102},[],{"trials":6246,"activeCount":102},[],{"trials":6248,"activeCount":102},[6249],{"nctId":5131,"briefTitle":5132,"status":1723,"phases":6250,"primaryCompletion":5134,"completion":5134,"start":1374,"enrollment":810,"conditions":6251,"interventions":6252},[93],[5136,5137],[5139,4271],{"trials":6254,"activeCount":102},[],{"intervention":6256,"totalTrials":149,"cells":6257},"Pre and post-CPB Drug: Dobutamine Hydrochloride",{"EARLY_PHASE1":6258,"PHASE1":6260,"PHASE2":6262,"PHASE3":6264,"PHASE4":6266,"NA":6279},{"trials":6259,"activeCount":102},[],{"trials":6261,"activeCount":102},[],{"trials":6263,"activeCount":102},[],{"trials":6265,"activeCount":102},[],{"trials":6267,"activeCount":102},[6268],{"nctId":6269,"briefTitle":6270,"status":1723,"phases":6271,"primaryCompletion":6272,"completion":6273,"start":6274,"enrollment":2591,"conditions":6275,"interventions":6277},"NCT05025644","Quantitative Assessment of Hypertrophic Obstructive Cardiomyopathy With Intraoperative Three-dimensional Transesophageal Echocardiography Under Provocative Dobutamine Stress Test",[93],"2024-08","2024-11","2023-03",[6276],"Hypertrophic Obstructive Cardiomyopathy",[6256,6278],"Post-CPB Drug: Dobutamine Hydrochloride",{"trials":6280,"activeCount":102},[],{"intervention":6278,"totalTrials":149,"cells":6282},{"EARLY_PHASE1":6283,"PHASE1":6285,"PHASE2":6287,"PHASE3":6289,"PHASE4":6291,"NA":6297},{"trials":6284,"activeCount":102},[],{"trials":6286,"activeCount":102},[],{"trials":6288,"activeCount":102},[],{"trials":6290,"activeCount":102},[],{"trials":6292,"activeCount":102},[6293],{"nctId":6269,"briefTitle":6270,"status":1723,"phases":6294,"primaryCompletion":6272,"completion":6273,"start":6274,"enrollment":2591,"conditions":6295,"interventions":6296},[93],[6276],[6256,6278],{"trials":6298,"activeCount":102},[],{"intervention":6300,"totalTrials":149,"cells":6301},"Inhaled Epoprostenol and phenylephrine",{"EARLY_PHASE1":6302,"PHASE1":6304,"PHASE2":6306,"PHASE3":6308,"PHASE4":6310,"NA":6322},{"trials":6303,"activeCount":102},[],{"trials":6305,"activeCount":102},[],{"trials":6307,"activeCount":102},[],{"trials":6309,"activeCount":102},[],{"trials":6311,"activeCount":102},[6312],{"nctId":6313,"briefTitle":6314,"status":112,"phases":6315,"primaryCompletion":6316,"completion":4212,"start":2270,"enrollment":1348,"conditions":6317,"interventions":6319},"NCT02748265","Nebulized Epoprostenol (FLOLAN) and Phenylephrine on One Lung Ventilation (OLV)",[93],"2017-07-30",[6318],"Oxygenation During One Lung Ventilation",[6300,6320,6321],"Sevoflurane","Propofol",{"trials":6323,"activeCount":102},[],{"intervention":6320,"totalTrials":149,"cells":6325},{"EARLY_PHASE1":6326,"PHASE1":6328,"PHASE2":6330,"PHASE3":6332,"PHASE4":6334,"NA":6340},{"trials":6327,"activeCount":102},[],{"trials":6329,"activeCount":102},[],{"trials":6331,"activeCount":102},[],{"trials":6333,"activeCount":102},[],{"trials":6335,"activeCount":102},[6336],{"nctId":6313,"briefTitle":6314,"status":112,"phases":6337,"primaryCompletion":6316,"completion":4212,"start":2270,"enrollment":1348,"conditions":6338,"interventions":6339},[93],[6318],[6300,6320,6321],{"trials":6341,"activeCount":102},[],{"intervention":6343,"totalTrials":149,"cells":6344},"Norepinephrine intra-arteriel\u002Fhepatic",{"EARLY_PHASE1":6345,"PHASE1":6347,"PHASE2":6349,"PHASE3":6351,"PHASE4":6353,"NA":6361},{"trials":6346,"activeCount":102},[],{"trials":6348,"activeCount":102},[],{"trials":6350,"activeCount":102},[],{"trials":6352,"activeCount":102},[],{"trials":6354,"activeCount":102},[6355],{"nctId":6356,"briefTitle":6357,"status":112,"phases":6358,"primaryCompletion":582,"completion":582,"start":5134,"enrollment":511,"conditions":6359,"interventions":6360},"NCT02472249","Pharmacological Manipulation of Intrahepatic Arterial Blood Flow in HCC",[93],[1714],[6343],{"trials":6362,"activeCount":102},[],{"intervention":6364,"totalTrials":149,"cells":6365},"varenicline",{"EARLY_PHASE1":6366,"PHASE1":6368,"PHASE2":6370,"PHASE3":6372,"PHASE4":6374,"NA":6385},{"trials":6367,"activeCount":102},[],{"trials":6369,"activeCount":102},[],{"trials":6371,"activeCount":102},[],{"trials":6373,"activeCount":102},[],{"trials":6375,"activeCount":102},[6376],{"nctId":6377,"briefTitle":6378,"status":1723,"phases":6379,"primaryCompletion":6380,"completion":5917,"start":4600,"enrollment":6381,"conditions":6382,"interventions":6384},"NCT00937508","Smoking Cessation Program in the Preadmission Clinic",[93],"2010-07",290,[6383],"Smoking",[6364],{"trials":6386,"activeCount":102},[],{"intervention":6388,"totalTrials":149,"cells":6389},"IVIG",{"EARLY_PHASE1":6390,"PHASE1":6392,"PHASE2":6394,"PHASE3":6396,"PHASE4":6398,"NA":6409},{"trials":6391,"activeCount":102},[],{"trials":6393,"activeCount":102},[],{"trials":6395,"activeCount":102},[],{"trials":6397,"activeCount":102},[],{"trials":6399,"activeCount":102},[6400],{"nctId":6401,"briefTitle":6402,"status":112,"phases":6403,"primaryCompletion":6380,"completion":6380,"start":6404,"enrollment":6405,"conditions":6406,"interventions":6408},"NCT01179893","Intravenous Immunoglobulin and Plasma Exchange in Myasthenia Gravis",[93],"2007-03",87,[6407],"Myasthenia Gravid",[6388],{"trials":6410,"activeCount":102},[],{"intervention":6412,"totalTrials":149,"cells":6413},"Autologous platelet rich plasma eye drops",{"EARLY_PHASE1":6414,"PHASE1":6416,"PHASE2":6418,"PHASE3":6420,"PHASE4":6422,"NA":6433},{"trials":6415,"activeCount":102},[],{"trials":6417,"activeCount":102},[],{"trials":6419,"activeCount":102},[],{"trials":6421,"activeCount":102},[],{"trials":6423,"activeCount":102},[6424],{"nctId":6425,"briefTitle":6426,"status":1723,"phases":6427,"primaryCompletion":6428,"completion":1530,"start":1531,"enrollment":1046,"conditions":6429,"interventions":6432},"NCT04608084","Platelet Rich Plasma Eye Drops for Treatment of Ocular Surface Disease",[93],"2022-01",[6430,6431],"Ocular Surface Disease","Dry Eye Syndromes",[6412],{"trials":6434,"activeCount":102},[],{"intervention":6436,"totalTrials":149,"cells":6437},"Local Anesthetic Injection above the serratus anterior",{"EARLY_PHASE1":6438,"PHASE1":6440,"PHASE2":6442,"PHASE3":6444,"PHASE4":6446,"NA":6455},{"trials":6439,"activeCount":102},[],{"trials":6441,"activeCount":102},[],{"trials":6443,"activeCount":102},[],{"trials":6445,"activeCount":102},[],{"trials":6447,"activeCount":102},[6448],{"nctId":6449,"briefTitle":6450,"status":1723,"phases":6451,"primaryCompletion":4140,"completion":4140,"start":1387,"enrollment":172,"conditions":6452,"interventions":6454},"NCT02893384","Local Anesthetic for Total Mastectomy Surgery",[93],[6453],"Breast Pain",[6436],{"trials":6456,"activeCount":102},[],{"intervention":6458,"totalTrials":149,"cells":6459},"brimonidine tartrate 0.2%",{"EARLY_PHASE1":6460,"PHASE1":6462,"PHASE2":6464,"PHASE3":6466,"PHASE4":6468,"NA":6479},{"trials":6461,"activeCount":102},[],{"trials":6463,"activeCount":102},[],{"trials":6465,"activeCount":102},[],{"trials":6467,"activeCount":102},[],{"trials":6469,"activeCount":102},[6470],{"nctId":6471,"briefTitle":6472,"status":112,"phases":6473,"primaryCompletion":6474,"completion":6475,"start":6476,"enrollment":1836,"conditions":6477,"interventions":6478},"NCT02818816","Preoperative Brimonidine on IOP of Patients Undergoing RALP",[93],"2017-01-24","2017-08-07","2016-02-29",[15],[6458],{"trials":6480,"activeCount":102},[],{"intervention":6482,"totalTrials":149,"cells":6483},"Tapered doses of TNFi",{"EARLY_PHASE1":6484,"PHASE1":6486,"PHASE2":6488,"PHASE3":6490,"PHASE4":6492,"NA":6505},{"trials":6485,"activeCount":102},[],{"trials":6487,"activeCount":102},[],{"trials":6489,"activeCount":102},[],{"trials":6491,"activeCount":102},[],{"trials":6493,"activeCount":102},[6494],{"nctId":6495,"briefTitle":6496,"status":1723,"phases":6497,"primaryCompletion":6498,"completion":6499,"start":6500,"enrollment":244,"conditions":6501,"interventions":6503},"NCT05115903","Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis",[93],"2024-07-01","2024-08-01","2021-12-01",[6502],"Axial Spondyloarthritis",[6482,6504],"Standard dose of TNFi",{"trials":6506,"activeCount":102},[],{"intervention":6504,"totalTrials":149,"cells":6508},{"EARLY_PHASE1":6509,"PHASE1":6511,"PHASE2":6513,"PHASE3":6515,"PHASE4":6517,"NA":6523},{"trials":6510,"activeCount":102},[],{"trials":6512,"activeCount":102},[],{"trials":6514,"activeCount":102},[],{"trials":6516,"activeCount":102},[],{"trials":6518,"activeCount":102},[6519],{"nctId":6495,"briefTitle":6496,"status":1723,"phases":6520,"primaryCompletion":6498,"completion":6499,"start":6500,"enrollment":244,"conditions":6521,"interventions":6522},[93],[6502],[6482,6504],{"trials":6524,"activeCount":102},[],{"intervention":6526,"totalTrials":149,"cells":6527},"Trivalent Inactivated Influenza Vaccine",{"EARLY_PHASE1":6528,"PHASE1":6530,"PHASE2":6532,"PHASE3":6534,"PHASE4":6536,"NA":6547},{"trials":6529,"activeCount":102},[],{"trials":6531,"activeCount":102},[],{"trials":6533,"activeCount":102},[],{"trials":6535,"activeCount":102},[],{"trials":6537,"activeCount":102},[6538],{"nctId":6539,"briefTitle":6540,"status":112,"phases":6541,"primaryCompletion":6542,"completion":6543,"start":5849,"enrollment":19,"conditions":6544,"interventions":6546},"NCT00402805","Improving the Humoral Response to Influenza Vaccine in Lung Transplant Recipients by an Intradermal Strategy",[93],"2007-02","2007-07",[6545,5428],"Lung Transplantation",[6526],{"trials":6548,"activeCount":102},[],{"intervention":6550,"totalTrials":149,"cells":6551},"MMF",{"EARLY_PHASE1":6552,"PHASE1":6554,"PHASE2":6556,"PHASE3":6558,"PHASE4":6560,"NA":6571},{"trials":6553,"activeCount":102},[],{"trials":6555,"activeCount":102},[],{"trials":6557,"activeCount":102},[],{"trials":6559,"activeCount":102},[],{"trials":6561,"activeCount":102},[6562],{"nctId":6563,"briefTitle":6564,"status":1723,"phases":6565,"primaryCompletion":718,"completion":718,"start":1451,"enrollment":6566,"conditions":6567,"interventions":6569},"NCT00611494","Gastrointestinal Tolerability of MMF vs EC-MPS in Maintenance Transplant Patients Treated With Calcineurin Inhibitors",[93],400,[6568],"Organ Transplantation",[6550,6570],"EC-MPS",{"trials":6572,"activeCount":102},[],{"intervention":6570,"totalTrials":149,"cells":6574},{"EARLY_PHASE1":6575,"PHASE1":6577,"PHASE2":6579,"PHASE3":6581,"PHASE4":6583,"NA":6589},{"trials":6576,"activeCount":102},[],{"trials":6578,"activeCount":102},[],{"trials":6580,"activeCount":102},[],{"trials":6582,"activeCount":102},[],{"trials":6584,"activeCount":102},[6585],{"nctId":6563,"briefTitle":6564,"status":1723,"phases":6586,"primaryCompletion":718,"completion":718,"start":1451,"enrollment":6566,"conditions":6587,"interventions":6588},[93],[6568],[6550,6570],{"trials":6590,"activeCount":102},[],{"intervention":6592,"totalTrials":149,"cells":6593},"Sertraline",{"EARLY_PHASE1":6594,"PHASE1":6596,"PHASE2":6598,"PHASE3":6600,"PHASE4":6602,"NA":6611},{"trials":6595,"activeCount":102},[],{"trials":6597,"activeCount":102},[],{"trials":6599,"activeCount":102},[],{"trials":6601,"activeCount":102},[],{"trials":6603,"activeCount":102},[6604],{"nctId":6605,"briefTitle":6606,"status":112,"phases":6607,"primaryCompletion":606,"completion":606,"start":6608,"enrollment":1860,"conditions":6609,"interventions":6610},"NCT02228005","The Effect of a Selective Serotonin Reuptake Inhibitor on Gait, Balance, and Bone Metabolism in Older Adults",[93],"2014-07",[2297],[6592],{"trials":6612,"activeCount":102},[],{"intervention":6614,"totalTrials":149,"cells":6615},"clonidine hydrochloride",{"EARLY_PHASE1":6616,"PHASE1":6618,"PHASE2":6620,"PHASE3":6622,"PHASE4":6624,"NA":6635},{"trials":6617,"activeCount":102},[],{"trials":6619,"activeCount":102},[],{"trials":6621,"activeCount":102},[],{"trials":6623,"activeCount":102},[],{"trials":6625,"activeCount":102},[6626],{"nctId":6627,"briefTitle":6628,"status":1723,"phases":6629,"primaryCompletion":6630,"completion":718,"start":630,"enrollment":6631,"conditions":6632,"interventions":6634},"NCT00335582","EPIC (Evaluating Perioperative Ischemia Reduction by Clonidine)",[93],"2009-08",165,[6633],"Heart Disease",[6614],{"trials":6636,"activeCount":102},[],{"intervention":6638,"totalTrials":149,"cells":6639},"Botulinum Toxin",{"EARLY_PHASE1":6640,"PHASE1":6642,"PHASE2":6644,"PHASE3":6646,"PHASE4":6648,"NA":6657},{"trials":6641,"activeCount":102},[],{"trials":6643,"activeCount":102},[],{"trials":6645,"activeCount":102},[],{"trials":6647,"activeCount":102},[],{"trials":6649,"activeCount":102},[6650],{"nctId":6651,"briefTitle":6652,"status":1723,"phases":6653,"primaryCompletion":769,"completion":698,"start":6608,"enrollment":643,"conditions":6654,"interventions":6656},"NCT02472210","The Use of Botox in Advanced Parkinson's Patients Experiencing Pain",[93],[6655],"Parkinson's Disease",[6638],{"trials":6658,"activeCount":102},[],{"intervention":6660,"totalTrials":149,"cells":6661},"quinipril",{"EARLY_PHASE1":6662,"PHASE1":6664,"PHASE2":6666,"PHASE3":6668,"PHASE4":6670,"NA":6680},{"trials":6663,"activeCount":102},[],{"trials":6665,"activeCount":102},[],{"trials":6667,"activeCount":102},[],{"trials":6669,"activeCount":102},[],{"trials":6671,"activeCount":102},[6672],{"nctId":6673,"briefTitle":6674,"status":1723,"phases":6675,"start":6676,"enrollment":19,"conditions":6677,"interventions":6679},"NCT00188188","Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease",[93],"2002-03",[6678],"Systemic Lupus Erythematosus",[6660],{"trials":6681,"activeCount":102},[],{"intervention":4285,"totalTrials":149,"cells":6683},{"EARLY_PHASE1":6684,"PHASE1":6686,"PHASE2":6688,"PHASE3":6690,"PHASE4":6692,"NA":6698},{"trials":6685,"activeCount":102},[],{"trials":6687,"activeCount":102},[],{"trials":6689,"activeCount":102},[],{"trials":6691,"activeCount":102},[],{"trials":6693,"activeCount":102},[6694],{"nctId":4275,"briefTitle":4276,"status":112,"phases":6695,"primaryCompletion":4141,"completion":4141,"start":1793,"enrollment":4278,"conditions":6696,"interventions":6697},[93],[4280,4281,4282,4283],[82,4285],{"trials":6699,"activeCount":102},[],{"intervention":6701,"totalTrials":149,"cells":6702},"Mupirocin ointment",{"EARLY_PHASE1":6703,"PHASE1":6705,"PHASE2":6707,"PHASE3":6709,"PHASE4":6711,"NA":6723},{"trials":6704,"activeCount":102},[],{"trials":6706,"activeCount":102},[],{"trials":6708,"activeCount":102},[],{"trials":6710,"activeCount":102},[],{"trials":6712,"activeCount":102},[6713],{"nctId":6714,"briefTitle":6715,"status":112,"phases":6716,"primaryCompletion":5108,"completion":6717,"start":6718,"enrollment":6113,"conditions":6719,"interventions":6721},"NCT00400595","Use of Ointments in Prevention of Catheter Related Infections in PD",[93],"2010-06","2006-02",[6720],"End Stage Renal Disease",[6701,6722],"Polysporin Triple",{"trials":6724,"activeCount":102},[],{"intervention":6722,"totalTrials":149,"cells":6726},{"EARLY_PHASE1":6727,"PHASE1":6729,"PHASE2":6731,"PHASE3":6733,"PHASE4":6735,"NA":6741},{"trials":6728,"activeCount":102},[],{"trials":6730,"activeCount":102},[],{"trials":6732,"activeCount":102},[],{"trials":6734,"activeCount":102},[],{"trials":6736,"activeCount":102},[6737],{"nctId":6714,"briefTitle":6715,"status":112,"phases":6738,"primaryCompletion":5108,"completion":6717,"start":6718,"enrollment":6113,"conditions":6739,"interventions":6740},[93],[6720],[6701,6722],{"trials":6742,"activeCount":102},[],{"intervention":6744,"totalTrials":149,"cells":6745},"Adductor Canal Block",{"EARLY_PHASE1":6746,"PHASE1":6748,"PHASE2":6750,"PHASE3":6752,"PHASE4":6754,"NA":6765},{"trials":6747,"activeCount":102},[],{"trials":6749,"activeCount":102},[],{"trials":6751,"activeCount":102},[],{"trials":6753,"activeCount":102},[],{"trials":6755,"activeCount":102},[6756],{"nctId":6757,"briefTitle":6758,"status":112,"phases":6759,"primaryCompletion":4140,"completion":4140,"start":6760,"enrollment":6113,"conditions":6761,"interventions":6762},"NCT02411149","Adductor Canal Block and Recovery After Total Knee Replacement Surgery",[93],"2014-04",[146],[6744,6763,6764],"Adductor Canal Block with Morphine","Local Infiltration",{"trials":6766,"activeCount":102},[],{"intervention":6763,"totalTrials":149,"cells":6768},{"EARLY_PHASE1":6769,"PHASE1":6771,"PHASE2":6773,"PHASE3":6775,"PHASE4":6777,"NA":6783},{"trials":6770,"activeCount":102},[],{"trials":6772,"activeCount":102},[],{"trials":6774,"activeCount":102},[],{"trials":6776,"activeCount":102},[],{"trials":6778,"activeCount":102},[6779],{"nctId":6757,"briefTitle":6758,"status":112,"phases":6780,"primaryCompletion":4140,"completion":4140,"start":6760,"enrollment":6113,"conditions":6781,"interventions":6782},[93],[146],[6744,6763,6764],{"trials":6784,"activeCount":102},[],{"intervention":6764,"totalTrials":149,"cells":6786},{"EARLY_PHASE1":6787,"PHASE1":6789,"PHASE2":6791,"PHASE3":6793,"PHASE4":6795,"NA":6801},{"trials":6788,"activeCount":102},[],{"trials":6790,"activeCount":102},[],{"trials":6792,"activeCount":102},[],{"trials":6794,"activeCount":102},[],{"trials":6796,"activeCount":102},[6797],{"nctId":6757,"briefTitle":6758,"status":112,"phases":6798,"primaryCompletion":4140,"completion":4140,"start":6760,"enrollment":6113,"conditions":6799,"interventions":6800},[93],[146],[6744,6763,6764],{"trials":6802,"activeCount":102},[],{"intervention":5180,"totalTrials":149,"cells":6804},{"EARLY_PHASE1":6805,"PHASE1":6807,"PHASE2":6809,"PHASE3":6811,"PHASE4":6813,"NA":6819},{"trials":6806,"activeCount":102},[],{"trials":6808,"activeCount":102},[],{"trials":6810,"activeCount":102},[],{"trials":6812,"activeCount":102},[],{"trials":6814,"activeCount":102},[6815],{"nctId":5168,"briefTitle":5169,"status":1723,"phases":6816,"primaryCompletion":5171,"completion":5172,"start":5173,"enrollment":5174,"conditions":6817,"interventions":6818},[93],[5176,5177,5178],[5180,5143],{"trials":6820,"activeCount":102},[],{"intervention":792,"totalTrials":584,"cells":6822},{"EARLY_PHASE1":6823,"PHASE1":6825,"PHASE2":6827,"PHASE3":6863,"PHASE4":6874,"NA":6876},{"trials":6824,"activeCount":102},[],{"trials":6826,"activeCount":102},[],{"trials":6828,"activeCount":102},[6829,6838,6847,6853,6857],{"nctId":6830,"briefTitle":6831,"status":550,"phases":6832,"primaryCompletion":6833,"completion":6834,"start":6833,"enrollment":102,"conditions":6835,"interventions":6836},"NCT02497638","LIpitor and biGuanide to Androgen Delay Trial",[91],"2021-12","2022-12",[15],[792,6837],"Atorvastatin",{"nctId":6839,"briefTitle":6840,"status":112,"phases":6841,"primaryCompletion":6842,"completion":6843,"start":6844,"enrollment":1560,"conditions":6845,"interventions":6846},"NCT03086733","Phase II Lung Metcore - Preoperative Metformin for Lung Cancer",[91],"2020-07","2020-08","2016-12-05",[570,21],[792],{"nctId":6848,"briefTitle":6849,"status":550,"phases":6850,"primaryCompletion":4347,"completion":4347,"start":686,"enrollment":102,"conditions":6851,"interventions":6852},"NCT01733836","Prostate Cancer Active Surveillance Metformin Trial",[91],[15],[792],{"nctId":781,"briefTitle":782,"status":112,"phases":6854,"primaryCompletion":784,"completion":784,"start":785,"enrollment":36,"conditions":6855,"interventions":6856},[91],[787,788,789,790],[792,576,793],{"nctId":6858,"briefTitle":6859,"status":727,"phases":6860,"primaryCompletion":808,"completion":729,"start":5108,"enrollment":3928,"conditions":6861,"interventions":6862},"NCT00881725","A Study of Pre-operative Metformin in Prostate Cancer",[91],[15],[792],{"trials":6864,"activeCount":102},[6865],{"nctId":6866,"briefTitle":6867,"status":1723,"phases":6868,"primaryCompletion":6869,"completion":6272,"start":6870,"enrollment":6871,"conditions":6872,"interventions":6873},"NCT01864096","The Metformin Active Surveillance Trial (MAST) Study",[92],"2024-02-16","2013-10",408,[15],[792],{"trials":6875,"activeCount":102},[],{"trials":6877,"activeCount":102},[],{"intervention":6879,"totalTrials":479,"cells":6880},"Escitalopram",{"EARLY_PHASE1":6881,"PHASE1":6883,"PHASE2":6885,"PHASE3":6893,"PHASE4":6921,"NA":6923},{"trials":6882,"activeCount":102},[],{"trials":6884,"activeCount":102},[],{"trials":6886,"activeCount":102},[6887],{"nctId":6888,"briefTitle":6889,"status":727,"phases":6890,"primaryCompletion":4266,"completion":4266,"start":5827,"enrollment":1860,"conditions":6891,"interventions":6892},"NCT02407821","The Routine Use of SSRI's at the Initiation of End-stage Renal Disease Treatment (RoSIE)",[91],[6720],[6879],{"trials":6894,"activeCount":102},[6895,6905,6913],{"nctId":6896,"briefTitle":6897,"status":112,"phases":6898,"primaryCompletion":4266,"completion":4266,"start":6899,"enrollment":6900,"conditions":6901,"interventions":6902},"NCT01655706","Canadian Biomarker Integration Network for Depression Study",[92],"2012-04-23",211,[2307],[6903,6904],"escitalopram","aripiprazole",{"nctId":6906,"briefTitle":6907,"status":112,"phases":6908,"start":6909,"enrollment":2591,"conditions":6910,"interventions":6911},"NCT00296933","Memory Functioning and Antidepressant Treatment",[92],"2005-12",[2297,2307],[6879,6912],"Bupropion XL",{"nctId":6914,"briefTitle":6915,"status":112,"phases":6916,"primaryCompletion":5274,"completion":5274,"start":6917,"enrollment":149,"conditions":6918,"interventions":6919},"NCT04162522","Canadian Biomarker Integration Network for Depression (CAN-BIND) - Validation Study",[92],"2019-12-23",[2307],[6879,6920],"Brexpiprazole",{"trials":6922,"activeCount":102},[],{"trials":6924,"activeCount":102},[],{"intervention":1787,"totalTrials":98,"cells":6926},{"EARLY_PHASE1":6927,"PHASE1":6929,"PHASE2":6931,"PHASE3":6945,"PHASE4":6957,"NA":6959},{"trials":6928,"activeCount":102},[],{"trials":6930,"activeCount":102},[],{"trials":6932,"activeCount":102},[6933,6941],{"nctId":6934,"briefTitle":6935,"status":1723,"phases":6936,"primaryCompletion":4244,"completion":1834,"start":6937,"enrollment":720,"conditions":6938,"interventions":6939},"NCT03016338","Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer",[91],"2017-11-06",[537],[1787,6940],"TSR-042",{"nctId":1778,"briefTitle":1779,"status":1723,"phases":6942,"primaryCompletion":1781,"completion":1781,"start":1782,"enrollment":172,"conditions":6943,"interventions":6944},[91],[732,734,1379,1784,1785],[1787,1788,1747,737],{"trials":6946,"activeCount":102},[6947],{"nctId":6948,"briefTitle":6949,"status":727,"phases":6950,"primaryCompletion":6951,"completion":6951,"start":1305,"enrollment":1336,"conditions":6952,"interventions":6956},"NCT04159155","A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer",[91,92],"2025-05-26",[6953,6954,6955],"Endometrial Carcinoma","P53 Mutation","Serous Carcinoma",[1787],{"trials":6958,"activeCount":102},[],{"trials":6960,"activeCount":102},[],{"intervention":6962,"totalTrials":98,"cells":6963},"Intranasal insulin",{"EARLY_PHASE1":6964,"PHASE1":6966,"PHASE2":6977,"PHASE3":6989,"PHASE4":7001,"NA":7003},{"trials":6965,"activeCount":102},[],{"trials":6967,"activeCount":102},[6968],{"nctId":6969,"briefTitle":6970,"status":112,"phases":6971,"primaryCompletion":6608,"completion":6608,"start":6972,"enrollment":1348,"conditions":6973,"interventions":6975},"NCT02131948","Regulation of Endogenous Glucose Production by Brain Insulin Action",[90],"2013-11",[6974],"Insulin Resistance, Diabetes",[6962,6976],"Intranasal placebo",{"trials":6978,"activeCount":102},[6979],{"nctId":6980,"briefTitle":6981,"status":112,"phases":6982,"primaryCompletion":6983,"completion":6984,"start":6985,"enrollment":6986,"conditions":6987,"interventions":6988},"NCT03383822","Regulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance",[90,91],"2017-07-31","2017-12-01","2015-09-08",7,[5470],[6962,6976],{"trials":6990,"activeCount":102},[6991],{"nctId":6992,"briefTitle":6993,"status":112,"phases":6994,"primaryCompletion":6995,"completion":6995,"start":6996,"enrollment":2591,"conditions":6997,"interventions":6998},"NCT00314314","The Effect of Intranasal Insulin on Neurocognitive Function in Euthymic Patients With Bipolar Disorder",[92],"2009-03","2006-05",[5737],[6999,7000],"Intranasal Insulin","Diluent",{"trials":7002,"activeCount":102},[],{"trials":7004,"activeCount":102},[],{"intervention":7006,"totalTrials":659,"cells":7007},"Valacyclovir",{"EARLY_PHASE1":7008,"PHASE1":7010,"PHASE2":7012,"PHASE3":7014,"PHASE4":7035,"NA":7037},{"trials":7009,"activeCount":102},[],{"trials":7011,"activeCount":102},[],{"trials":7013,"activeCount":102},[],{"trials":7015,"activeCount":102},[7016,7024],{"nctId":7017,"briefTitle":7018,"status":112,"phases":7019,"primaryCompletion":5201,"completion":5201,"start":768,"enrollment":2591,"conditions":7020,"interventions":7023},"NCT01176409","Can Valacyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2?",[92],[7021,7022],"Human Immunodeficiency Virus","Herpes Simplex",[7006],{"nctId":7025,"briefTitle":7026,"status":112,"phases":7027,"primaryCompletion":5873,"completion":5873,"start":5468,"enrollment":7028,"conditions":7029,"interventions":7033},"NCT00860977","Can Valacyclovir Delay the Need for Initiation of Human Immunodeficiency Virus (HIV) Treatment in HIV-infected Individuals?",[92],202,[7030,7031,7032],"HIV Infection","Herpes Simplex Type II","HIV Infections",[7034],"valacyclovir",{"trials":7036,"activeCount":102},[],{"trials":7038,"activeCount":102},[],{"intervention":7040,"totalTrials":659,"cells":7041},"Teduglutide",{"EARLY_PHASE1":7042,"PHASE1":7044,"PHASE2":7046,"PHASE3":7048,"PHASE4":7066,"NA":7068},{"trials":7043,"activeCount":102},[],{"trials":7045,"activeCount":102},[],{"trials":7047,"activeCount":102},[],{"trials":7049,"activeCount":102},[7050,7059],{"nctId":7051,"briefTitle":7052,"status":112,"phases":7053,"primaryCompletion":4714,"completion":6500,"start":7054,"enrollment":7055,"conditions":7056,"interventions":7058},"NCT03442972","Glucagon-like Peptide-2 Mediated Secretion of Stored Enteral Lipids",[91,92],"2019-01-17",21,[7057],"Hyperlipidemias",[7040],{"nctId":7060,"briefTitle":7061,"status":112,"phases":7062,"primaryCompletion":4714,"completion":6500,"start":7063,"enrollment":511,"conditions":7064,"interventions":7065},"NCT03422666","Plasma Lipoprotein Response to Glucagon-like Peptide-2",[91,92],"2018-09-21",[7057],[7040],{"trials":7067,"activeCount":102},[],{"trials":7069,"activeCount":102},[],{"intervention":7071,"totalTrials":659,"cells":7072},"Peginterferon Lambda-1A",{"EARLY_PHASE1":7073,"PHASE1":7075,"PHASE2":7077,"PHASE3":7091,"PHASE4":7103,"NA":7105},{"trials":7074,"activeCount":102},[],{"trials":7076,"activeCount":102},[],{"trials":7078,"activeCount":102},[7079],{"nctId":7080,"briefTitle":7081,"status":112,"phases":7082,"primaryCompletion":7083,"completion":7084,"start":7085,"enrollment":7086,"conditions":7087,"interventions":7090},"NCT04354259","Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19",[91],"2022-08-19","2022-12-08","2020-05-13",157,[7088,7089],"Sars-CoV2","Covid-19",[7071],{"trials":7092,"activeCount":102},[7093],{"nctId":7094,"briefTitle":7095,"status":1723,"phases":7096,"primaryCompletion":7097,"completion":7098,"start":7099,"enrollment":7100,"conditions":7101,"interventions":7102},"NCT04967430","TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19",[92],"2022-03-21","2022-06-30","2021-08-27",763,[7088,5227],[7071],{"trials":7104,"activeCount":102},[],{"trials":7106,"activeCount":102},[],{"intervention":7108,"totalTrials":659,"cells":7109},"Sildenafil",{"EARLY_PHASE1":7110,"PHASE1":7112,"PHASE2":7114,"PHASE3":7126,"PHASE4":7135,"NA":7137},{"trials":7111,"activeCount":102},[],{"trials":7113,"activeCount":102},[],{"trials":7115,"activeCount":102},[7116],{"nctId":7117,"briefTitle":7118,"status":727,"phases":7119,"primaryCompletion":7120,"completion":7121,"start":7122,"enrollment":687,"conditions":7123,"interventions":7125},"NCT01517854","Revatio Portal-Pulmonary Arterial Hypertension Trial",[91],"2017-10-30","2019-05-14","2012-11-14",[7124],"Portopulmonary Hypertension",[7108],{"trials":7127,"activeCount":102},[7128],{"nctId":7129,"briefTitle":7130,"status":550,"phases":7131,"conditions":7132,"interventions":7134},"NCT00780728","Study Evaluating the Addition of Sildenafil to Bosentan Therapy in Pulmonary Arterial Hypertension",[92],[7133],"Hypertension, Pulmonary",[7108],{"trials":7136,"activeCount":102},[],{"trials":7138,"activeCount":102},[],{"intervention":7140,"totalTrials":659,"cells":7141},"Liraglutide",{"EARLY_PHASE1":7142,"PHASE1":7144,"PHASE2":7146,"PHASE3":7158,"PHASE4":7168,"NA":7170},{"trials":7143,"activeCount":102},[],{"trials":7145,"activeCount":102},[],{"trials":7147,"activeCount":102},[7148],{"nctId":7149,"briefTitle":7150,"status":550,"phases":7151,"primaryCompletion":4139,"completion":4139,"start":524,"enrollment":102,"conditions":7152,"interventions":7156},"NCT02472717","Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study",[91],[7153,7154,7155,2074],"Psoriatic Arthritis","Psoriasis","Impaired Glucose Tolerance",[7157],"liraglutide",{"trials":7159,"activeCount":102},[7160],{"nctId":7161,"briefTitle":7162,"status":112,"phases":7163,"primaryCompletion":7164,"completion":7165,"start":524,"enrollment":7055,"conditions":7166,"interventions":7167},"NCT02423824","Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists",[92],"2016-04","2016-05",[5737,2307],[7140],{"trials":7169,"activeCount":102},[],{"trials":7171,"activeCount":102},[],{"intervention":7000,"totalTrials":659,"cells":7173},{"EARLY_PHASE1":7174,"PHASE1":7176,"PHASE2":7178,"PHASE3":7190,"PHASE4":7196,"NA":7198},{"trials":7175,"activeCount":102},[],{"trials":7177,"activeCount":102},[],{"trials":7179,"activeCount":102},[7180],{"nctId":7181,"briefTitle":7182,"status":1723,"phases":7183,"primaryCompletion":7184,"completion":7184,"start":7185,"enrollment":2002,"conditions":7186,"interventions":7188},"NCT03915613","Brain Insulin Resistance in Mood Disorders",[90,91],"2024-10-05","2021-10-06",[2307,5737,7187,6999],"Anhedonia",[7189,7000],"Humulin R",{"trials":7191,"activeCount":102},[7192],{"nctId":6992,"briefTitle":6993,"status":112,"phases":7193,"primaryCompletion":6995,"completion":6995,"start":6996,"enrollment":2591,"conditions":7194,"interventions":7195},[92],[5737],[6999,7000],{"trials":7197,"activeCount":102},[],{"trials":7199,"activeCount":102},[],{"intervention":7201,"totalTrials":149,"cells":7202},"donepezil hcl",{"EARLY_PHASE1":7203,"PHASE1":7205,"PHASE2":7207,"PHASE3":7209,"PHASE4":7220,"NA":7222},{"trials":7204,"activeCount":102},[],{"trials":7206,"activeCount":102},[],{"trials":7208,"activeCount":102},[],{"trials":7210,"activeCount":102},[7211],{"nctId":7212,"briefTitle":7213,"status":112,"phases":7214,"completion":7215,"start":7216,"conditions":7217,"interventions":7219},"NCT00188812","Safety of Donepezil in Patients With Dementia Associated With Cerebrovascular Disease",[92],"2005-08","2004-05",[7218],"Dementia Associated With Cerebrovascular Disease",[7201],{"trials":7221,"activeCount":102},[],{"trials":7223,"activeCount":102},[],{"intervention":7225,"totalTrials":149,"cells":7226},"Meloxicam",{"EARLY_PHASE1":7227,"PHASE1":7229,"PHASE2":7231,"PHASE3":7233,"PHASE4":7244,"NA":7246},{"trials":7228,"activeCount":102},[],{"trials":7230,"activeCount":102},[],{"trials":7232,"activeCount":102},[],{"trials":7234,"activeCount":102},[7235],{"nctId":7236,"briefTitle":7237,"status":112,"phases":7238,"primaryCompletion":7239,"completion":7239,"start":7240,"enrollment":1046,"conditions":7241,"interventions":7243},"NCT00152919","Mobicox: Study of Meloxicam to Reduce Prostate Swelling in Permanent Seed Prostate Brachytherapy",[92],"2009-05","2004-02",[7242],"Prostatic Neoplasms",[7225],{"trials":7245,"activeCount":102},[],{"trials":7247,"activeCount":102},[],{"intervention":7249,"totalTrials":149,"cells":7250},"LIA Combination Mixture",{"EARLY_PHASE1":7251,"PHASE1":7253,"PHASE2":7255,"PHASE3":7257,"PHASE4":7269,"NA":7271},{"trials":7252,"activeCount":102},[],{"trials":7254,"activeCount":102},[],{"trials":7256,"activeCount":102},[],{"trials":7258,"activeCount":102},[7259],{"nctId":7260,"briefTitle":7261,"status":1723,"phases":7262,"primaryCompletion":7263,"completion":7263,"start":7164,"enrollment":7264,"conditions":7265,"interventions":7268},"NCT02760043","Dexamethasone in Total Knee and Total Hip Arthroplasty",[91,92],"2018-10",314,[146,7266,7267],"Total Hip Arthroplasty","Osteoarthritis",[623,7249],{"trials":7270,"activeCount":102},[],{"trials":7272,"activeCount":102},[],{"intervention":7274,"totalTrials":149,"cells":7275},"TED + glucose",{"EARLY_PHASE1":7276,"PHASE1":7278,"PHASE2":7280,"PHASE3":7282,"PHASE4":7291,"NA":7293},{"trials":7277,"activeCount":102},[],{"trials":7279,"activeCount":102},[],{"trials":7281,"activeCount":102},[],{"trials":7283,"activeCount":102},[7284],{"nctId":7285,"briefTitle":7286,"status":1723,"phases":7287,"primaryCompletion":6500,"completion":7288,"start":5366,"enrollment":244,"conditions":7289,"interventions":7290},"NCT03860688","Effects of Oral Glucose and Teduglutide on Plasma Lipoproteins",[91,92],"2022-05",[7057],[7274],{"trials":7292,"activeCount":102},[],{"trials":7294,"activeCount":102},[],{"intervention":7296,"totalTrials":149,"cells":7297},"Minocycline",{"EARLY_PHASE1":7298,"PHASE1":7300,"PHASE2":7302,"PHASE3":7304,"PHASE4":7315,"NA":7317},{"trials":7299,"activeCount":102},[],{"trials":7301,"activeCount":102},[],{"trials":7303,"activeCount":102},[],{"trials":7305,"activeCount":102},[7306],{"nctId":7307,"briefTitle":7308,"status":112,"phases":7309,"primaryCompletion":4141,"completion":2354,"start":1793,"enrollment":7310,"conditions":7311,"interventions":7314},"NCT01403662","Evaluating the Efficacy of Adjunctive Minocycline for the Treatment of Bipolar Depression",[92],29,[5737,1648,7312,7313],"Bipolar I Depression","Bipolar II Depression",[7296],{"trials":7316,"activeCount":102},[],{"trials":7318,"activeCount":102},[],{"intervention":6904,"totalTrials":149,"cells":7320},{"EARLY_PHASE1":7321,"PHASE1":7323,"PHASE2":7325,"PHASE3":7327,"PHASE4":7333,"NA":7335},{"trials":7322,"activeCount":102},[],{"trials":7324,"activeCount":102},[],{"trials":7326,"activeCount":102},[],{"trials":7328,"activeCount":102},[7329],{"nctId":6896,"briefTitle":6897,"status":112,"phases":7330,"primaryCompletion":4266,"completion":4266,"start":6899,"enrollment":6900,"conditions":7331,"interventions":7332},[92],[2307],[6903,6904],{"trials":7334,"activeCount":102},[],{"trials":7336,"activeCount":102},[],{"intervention":7338,"totalTrials":149,"cells":7339},"Olanzapine 10 milligram",{"EARLY_PHASE1":7340,"PHASE1":7342,"PHASE2":7344,"PHASE3":7346,"PHASE4":7359,"NA":7361},{"trials":7341,"activeCount":102},[],{"trials":7343,"activeCount":102},[],{"trials":7345,"activeCount":102},[],{"trials":7347,"activeCount":102},[7348],{"nctId":7349,"briefTitle":7350,"status":1723,"phases":7351,"primaryCompletion":7352,"completion":7353,"start":7354,"enrollment":244,"conditions":7355,"interventions":7357},"NCT04181385","Acute Olanzapine and Lipid Response",[91,92],"2020-01-01","2020-06-01","2019-01-01",[7356],"Healthy",[7338,7358],"Bromocriptine 5 milligram",{"trials":7360,"activeCount":102},[],{"trials":7362,"activeCount":102},[],{"intervention":7358,"totalTrials":149,"cells":7364},{"EARLY_PHASE1":7365,"PHASE1":7367,"PHASE2":7369,"PHASE3":7371,"PHASE4":7377,"NA":7379},{"trials":7366,"activeCount":102},[],{"trials":7368,"activeCount":102},[],{"trials":7370,"activeCount":102},[],{"trials":7372,"activeCount":102},[7373],{"nctId":7349,"briefTitle":7350,"status":1723,"phases":7374,"primaryCompletion":7352,"completion":7353,"start":7354,"enrollment":244,"conditions":7375,"interventions":7376},[91,92],[7356],[7338,7358],{"trials":7378,"activeCount":102},[],{"trials":7380,"activeCount":102},[],{"intervention":7382,"totalTrials":149,"cells":7383},"GLP-2",{"EARLY_PHASE1":7384,"PHASE1":7386,"PHASE2":7388,"PHASE3":7390,"PHASE4":7399,"NA":7401},{"trials":7385,"activeCount":102},[],{"trials":7387,"activeCount":102},[],{"trials":7389,"activeCount":102},[],{"trials":7391,"activeCount":102},[7392],{"nctId":7393,"briefTitle":7394,"status":112,"phases":7395,"primaryCompletion":3481,"completion":3481,"start":534,"enrollment":687,"conditions":7396,"interventions":7398},"NCT01958775","Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like Peptide 2",[92],[7397],"Dyslipidemia",[7382],{"trials":7400,"activeCount":102},[],{"trials":7402,"activeCount":102},[],{"intervention":7404,"totalTrials":149,"cells":7405},"Octafibrin",{"EARLY_PHASE1":7406,"PHASE1":7408,"PHASE2":7410,"PHASE3":7412,"PHASE4":7425,"NA":7427},{"trials":7407,"activeCount":102},[],{"trials":7409,"activeCount":102},[],{"trials":7411,"activeCount":102},[],{"trials":7413,"activeCount":102},[7414],{"nctId":7415,"briefTitle":7416,"status":112,"phases":7417,"primaryCompletion":894,"completion":7418,"start":7419,"enrollment":7420,"conditions":7421,"interventions":7423},"NCT03037424","FIBrinogen REplenishment in Surgery",[92],"2019-03-27","2017-02-22",827,[7422],"Deficiency; Fibrinogen, Acquired",[7404,7424],"Cryoprecipitate",{"trials":7426,"activeCount":102},[],{"trials":7428,"activeCount":102},[],{"intervention":7424,"totalTrials":149,"cells":7430},{"EARLY_PHASE1":7431,"PHASE1":7433,"PHASE2":7435,"PHASE3":7437,"PHASE4":7443,"NA":7445},{"trials":7432,"activeCount":102},[],{"trials":7434,"activeCount":102},[],{"trials":7436,"activeCount":102},[],{"trials":7438,"activeCount":102},[7439],{"nctId":7415,"briefTitle":7416,"status":112,"phases":7440,"primaryCompletion":894,"completion":7418,"start":7419,"enrollment":7420,"conditions":7441,"interventions":7442},[92],[7422],[7404,7424],{"trials":7444,"activeCount":102},[],{"trials":7446,"activeCount":102},[],{"intervention":7448,"totalTrials":149,"cells":7449},"Methotrexate and folic acid",{"EARLY_PHASE1":7450,"PHASE1":7452,"PHASE2":7454,"PHASE3":7456,"PHASE4":7467,"NA":7469},{"trials":7451,"activeCount":102},[],{"trials":7453,"activeCount":102},[],{"trials":7455,"activeCount":102},[],{"trials":7457,"activeCount":102},[7458],{"nctId":7459,"briefTitle":7460,"status":112,"phases":7461,"completion":7462,"start":7463,"enrollment":7464,"conditions":7465,"interventions":7466},"NCT00470522","Study of Methotrexate in Lupus Erythematosus",[92],"2001-12","1995-06",86,[6678],[7448],{"trials":7468,"activeCount":102},[],{"trials":7470,"activeCount":102},[],{"intervention":7472,"totalTrials":149,"cells":7473},"VPM1002",{"EARLY_PHASE1":7474,"PHASE1":7476,"PHASE2":7478,"PHASE3":7480,"PHASE4":7492,"NA":7494},{"trials":7475,"activeCount":102},[],{"trials":7477,"activeCount":102},[],{"trials":7479,"activeCount":102},[],{"trials":7481,"activeCount":102},[7482],{"nctId":7483,"briefTitle":7484,"status":112,"phases":7485,"primaryCompletion":7486,"completion":7486,"start":7487,"enrollment":7488,"conditions":7489,"interventions":7491},"NCT04439045","Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity",[92],"2021-09-09","2020-06-24",122,[7490],"SARS-CoV-2 Infection",[7472],{"trials":7493,"activeCount":102},[],{"trials":7495,"activeCount":102},[],{"intervention":7497,"totalTrials":149,"cells":7498},"Vancomycin",{"EARLY_PHASE1":7499,"PHASE1":7501,"PHASE2":7503,"PHASE3":7505,"PHASE4":7518,"NA":7520},{"trials":7500,"activeCount":102},[],{"trials":7502,"activeCount":102},[],{"trials":7504,"activeCount":102},[],{"trials":7506,"activeCount":102},[7507],{"nctId":7508,"briefTitle":7509,"status":727,"phases":7510,"primaryCompletion":4347,"completion":4347,"start":7511,"enrollment":7512,"conditions":7513,"interventions":7516},"NCT01226992","Oral Vancomycin Followed by Fecal Transplant Versus Tapering Oral Vancomycin",[91,92],"2010-10",81,[7514,7515],"Recurrent Clostridium Difficile Infection","Laboratory Confirmed Clostridium Difficile Infection",[7497,7517],"Fecal Transplant",{"trials":7519,"activeCount":102},[],{"trials":7521,"activeCount":102},[],{"intervention":7517,"totalTrials":149,"cells":7523},{"EARLY_PHASE1":7524,"PHASE1":7526,"PHASE2":7528,"PHASE3":7530,"PHASE4":7536,"NA":7538},{"trials":7525,"activeCount":102},[],{"trials":7527,"activeCount":102},[],{"trials":7529,"activeCount":102},[],{"trials":7531,"activeCount":102},[7532],{"nctId":7508,"briefTitle":7509,"status":727,"phases":7533,"primaryCompletion":4347,"completion":4347,"start":7511,"enrollment":7512,"conditions":7534,"interventions":7535},[91,92],[7514,7515],[7497,7517],{"trials":7537,"activeCount":102},[],{"trials":7539,"activeCount":102},[],{"intervention":2029,"totalTrials":149,"cells":7541},{"EARLY_PHASE1":7542,"PHASE1":7544,"PHASE2":7546,"PHASE3":7548,"PHASE4":7554,"NA":7556},{"trials":7543,"activeCount":102},[],{"trials":7545,"activeCount":102},[],{"trials":7547,"activeCount":102},[],{"trials":7549,"activeCount":102},[7550],{"nctId":2019,"briefTitle":2020,"status":112,"phases":7551,"primaryCompletion":86,"completion":1944,"start":2022,"enrollment":2023,"conditions":7552,"interventions":7553},[91,92],[2025,2026,2027],[2029,1978],{"trials":7555,"activeCount":102},[],{"trials":7557,"activeCount":102},[],{"intervention":7559,"totalTrials":149,"cells":7560},"Peginterferon alfa-2b",{"EARLY_PHASE1":7561,"PHASE1":7563,"PHASE2":7565,"PHASE3":7567,"PHASE4":7576,"NA":7578},{"trials":7562,"activeCount":102},[],{"trials":7564,"activeCount":102},[],{"trials":7566,"activeCount":102},[],{"trials":7568,"activeCount":102},[7569],{"nctId":7570,"briefTitle":7571,"status":727,"phases":7572,"primaryCompletion":5917,"completion":5917,"start":730,"enrollment":659,"conditions":7573,"interventions":7575},"NCT01095445","EXtended Therapy in Hepatitis C Genotype 3 Infected Patients",[92],[7574],"Chronic Hepatitis C",[7559],{"trials":7577,"activeCount":102},[],{"trials":7579,"activeCount":102},[],{"intervention":7581,"totalTrials":149,"cells":7582},"Fenfluramine",{"EARLY_PHASE1":7583,"PHASE1":7585,"PHASE2":7587,"PHASE3":7589,"PHASE4":7601,"NA":7603},{"trials":7584,"activeCount":102},[],{"trials":7586,"activeCount":102},[],{"trials":7588,"activeCount":102},[],{"trials":7590,"activeCount":102},[7591],{"nctId":7592,"briefTitle":7593,"status":727,"phases":7594,"primaryCompletion":7595,"completion":7595,"start":7596,"enrollment":6986,"conditions":7597,"interventions":7600},"NCT05560282","Fenfluramine for Adult Dravet Patients",[92],"2025-05-13","2023-01-11",[7598,7599],"Dravet Syndrome","Dravet Syndrome, Intractable",[7581],{"trials":7602,"activeCount":102},[],{"trials":7604,"activeCount":102},[],{"intervention":7606,"totalTrials":149,"cells":7607},"Fluzone High-dose Influenza Vaccine",{"EARLY_PHASE1":7608,"PHASE1":7610,"PHASE2":7612,"PHASE3":7614,"PHASE4":7627,"NA":7629},{"trials":7609,"activeCount":102},[],{"trials":7611,"activeCount":102},[],{"trials":7613,"activeCount":102},[],{"trials":7615,"activeCount":102},[7616],{"nctId":7617,"briefTitle":7618,"status":112,"phases":7619,"primaryCompletion":7620,"completion":6842,"start":4139,"enrollment":7621,"conditions":7622,"interventions":7625},"NCT03139565","High Dose vs. Standard Influenza Vaccine in Adult SOT",[92],"2017-06",172,[7623,7624],"Influenza","Immunosuppression",[7606,7626],"Standard 2016-2017 Flu vaccine",{"trials":7628,"activeCount":102},[],{"trials":7630,"activeCount":102},[],{"intervention":7626,"totalTrials":149,"cells":7632},{"EARLY_PHASE1":7633,"PHASE1":7635,"PHASE2":7637,"PHASE3":7639,"PHASE4":7645,"NA":7647},{"trials":7634,"activeCount":102},[],{"trials":7636,"activeCount":102},[],{"trials":7638,"activeCount":102},[],{"trials":7640,"activeCount":102},[7641],{"nctId":7617,"briefTitle":7618,"status":112,"phases":7642,"primaryCompletion":7620,"completion":6842,"start":4139,"enrollment":7621,"conditions":7643,"interventions":7644},[92],[7623,7624],[7606,7626],{"trials":7646,"activeCount":102},[],{"trials":7648,"activeCount":102},[],{"intervention":7650,"totalTrials":149,"cells":7651},"Tacrolimus",{"EARLY_PHASE1":7652,"PHASE1":7654,"PHASE2":7656,"PHASE3":7658,"PHASE4":7667,"NA":7669},{"trials":7653,"activeCount":102},[],{"trials":7655,"activeCount":102},[],{"trials":7657,"activeCount":102},[],{"trials":7659,"activeCount":102},[7660],{"nctId":7661,"briefTitle":7662,"status":112,"phases":7663,"primaryCompletion":4141,"completion":4141,"start":1442,"enrollment":771,"conditions":7664,"interventions":7666},"NCT01797341","Prograf-Advagraf Cross Over Conversion Study",[92],[7665],"Kidney-Pancreas Transplantation",[7650,7650],{"trials":7668,"activeCount":102},[],{"trials":7670,"activeCount":102},[],{"intervention":7672,"totalTrials":149,"cells":7673},"recombinant subunit Herpes zoster vaccine",{"EARLY_PHASE1":7674,"PHASE1":7676,"PHASE2":7678,"PHASE3":7680,"PHASE4":7691,"NA":7693},{"trials":7675,"activeCount":102},[],{"trials":7677,"activeCount":102},[],{"trials":7679,"activeCount":102},[],{"trials":7681,"activeCount":102},[7682],{"nctId":7683,"briefTitle":7684,"status":112,"phases":7685,"primaryCompletion":7686,"completion":7686,"start":7687,"enrollment":5014,"conditions":7688,"interventions":7690},"NCT03685682","Recombinant Subunit Herpes Zoster Vaccine in VZV-Seronegative Organ Transplant Recipients",[92],"2019-09-05","2018-05-25",[7689],"Varicella Zoster Vaccine",[7672],{"trials":7692,"activeCount":102},[],{"trials":7694,"activeCount":102},[],{"intervention":7696,"totalTrials":149,"cells":7697},"AS03-adjuvanted H1N1 pandemic influenza vaccine",{"EARLY_PHASE1":7698,"PHASE1":7700,"PHASE2":7702,"PHASE3":7704,"PHASE4":7714,"NA":7716},{"trials":7699,"activeCount":102},[],{"trials":7701,"activeCount":102},[],{"trials":7703,"activeCount":102},[],{"trials":7705,"activeCount":102},[7706],{"nctId":7707,"briefTitle":7708,"status":112,"phases":7709,"primaryCompletion":5468,"completion":6717,"start":141,"enrollment":291,"conditions":7710,"interventions":7713},"NCT01016548","Evaluation of Influenza H1N1 Vaccine in Adults With Lymphoid Malignancies on Chemotherapy",[92],[7711,246,7712],"Lymphoma","Influenza A Virus, H1N1 Subtype",[7696],{"trials":7715,"activeCount":102},[],{"trials":7717,"activeCount":102},[],{"intervention":7719,"totalTrials":149,"cells":7720},"Tenofovir disoproxil",{"EARLY_PHASE1":7721,"PHASE1":7723,"PHASE2":7725,"PHASE3":7727,"PHASE4":7739,"NA":7741},{"trials":7722,"activeCount":102},[],{"trials":7724,"activeCount":102},[],{"trials":7726,"activeCount":102},[],{"trials":7728,"activeCount":102},[7729],{"nctId":7730,"briefTitle":7731,"status":1723,"phases":7732,"primaryCompletion":7733,"completion":7733,"start":524,"enrollment":7734,"conditions":7735,"interventions":7738},"NCT02186574","Tenofovir to Prevent HBV Reactivation",[92],"2021-02",184,[7736,7711,7737],"Hepatitis B","Non-Hodgkin",[7719],{"trials":7740,"activeCount":102},[],{"trials":7742,"activeCount":102},[],{"intervention":7744,"totalTrials":149,"cells":7745},"IV dexamethasone",{"EARLY_PHASE1":7746,"PHASE1":7748,"PHASE2":7750,"PHASE3":7752,"PHASE4":7763,"NA":7765},{"trials":7747,"activeCount":102},[],{"trials":7749,"activeCount":102},[],{"trials":7751,"activeCount":102},[],{"trials":7753,"activeCount":102},[7754],{"nctId":7755,"briefTitle":7756,"status":112,"phases":7757,"primaryCompletion":7758,"completion":7758,"start":7759,"enrollment":28,"conditions":7760,"interventions":7762},"NCT02864602","IV Dexamethasone for Prolongation of Peripheral Nerve Block",[92],"2018-02-20","2016-11-12",[7761],"Anesthesia, Conduction",[7744],{"trials":7764,"activeCount":102},[],{"trials":7766,"activeCount":102},[],{"intervention":6912,"totalTrials":149,"cells":7768},{"EARLY_PHASE1":7769,"PHASE1":7771,"PHASE2":7773,"PHASE3":7775,"PHASE4":7781,"NA":7783},{"trials":7770,"activeCount":102},[],{"trials":7772,"activeCount":102},[],{"trials":7774,"activeCount":102},[],{"trials":7776,"activeCount":102},[7777],{"nctId":6906,"briefTitle":6907,"status":112,"phases":7778,"start":6909,"enrollment":2591,"conditions":7779,"interventions":7780},[92],[2297,2307],[6879,6912],{"trials":7782,"activeCount":102},[],{"trials":7784,"activeCount":102},[],{"intervention":7786,"totalTrials":149,"cells":7787},"Tissue Plasminogen Activator",{"EARLY_PHASE1":7788,"PHASE1":7790,"PHASE2":7792,"PHASE3":7794,"PHASE4":7805,"NA":7807},{"trials":7789,"activeCount":102},[],{"trials":7791,"activeCount":102},[],{"trials":7793,"activeCount":102},[],{"trials":7795,"activeCount":102},[7796],{"nctId":7797,"briefTitle":7798,"status":727,"phases":7799,"primaryCompletion":7800,"completion":6972,"start":7801,"enrollment":2357,"conditions":7802,"interventions":7804},"NCT00417768","Safety and Effectiveness of tPA in Intra-abdominal Abscesses",[91,92],"2012-07","2005-07",[7803],"Abscess",[7786],{"trials":7806,"activeCount":102},[],{"trials":7808,"activeCount":102},[],{"intervention":7810,"totalTrials":149,"cells":7811},"basiliximab",{"EARLY_PHASE1":7812,"PHASE1":7814,"PHASE2":7816,"PHASE3":7818,"PHASE4":7830,"NA":7832},{"trials":7813,"activeCount":102},[],{"trials":7815,"activeCount":102},[],{"trials":7817,"activeCount":102},[],{"trials":7819,"activeCount":102},[7820],{"nctId":7821,"briefTitle":7822,"status":112,"phases":7823,"primaryCompletion":7824,"completion":7824,"start":7216,"enrollment":1388,"conditions":7825,"interventions":7829},"NCT00188825","Study Comparing Simulect Plus Standard Immunosuppression to Standard Immunosuppression Alone for the Prevention of Acute Rejection and Bronchiolitis Obliterans in Lung Transplant",[92],"2007-10",[7826,7827,7828],"COPD","Emphysema","Alpha-1 Antitrypsan Deficiency",[7810],{"trials":7831,"activeCount":102},[],{"trials":7833,"activeCount":102},[],{"intervention":7835,"totalTrials":149,"cells":7836},"Teriparatide 20 mcg",{"EARLY_PHASE1":7837,"PHASE1":7839,"PHASE2":7841,"PHASE3":7843,"PHASE4":7852,"NA":7854},{"trials":7838,"activeCount":102},[],{"trials":7840,"activeCount":102},[],{"trials":7842,"activeCount":102},[],{"trials":7844,"activeCount":102},[7845],{"nctId":7846,"briefTitle":7847,"status":112,"phases":7848,"primaryCompletion":6833,"completion":6834,"start":5576,"enrollment":22,"conditions":7849,"interventions":7851},"NCT01896011","Effect of Teriparatide on Fracture Healing in Patients With Incomplete Atypical Femur Fractures",[92],[7850],"Non Displaced Atypical Femoral Fractures",[7835],{"trials":7853,"activeCount":102},[],{"trials":7855,"activeCount":102},[],{"intervention":7857,"totalTrials":149,"cells":7858},"N-acetylcysteine",{"EARLY_PHASE1":7859,"PHASE1":7861,"PHASE2":7863,"PHASE3":7865,"PHASE4":7876,"NA":7878},{"trials":7860,"activeCount":102},[],{"trials":7862,"activeCount":102},[],{"trials":7864,"activeCount":102},[],{"trials":7866,"activeCount":102},[7867],{"nctId":7868,"briefTitle":7869,"status":112,"phases":7870,"primaryCompletion":6542,"completion":6543,"start":7871,"enrollment":7872,"conditions":7873,"interventions":7875},"NCT00188630","N-Acetylcysteine for Preventing Renal Injury After Cardiac Surgery",[92],"2003-07",176,[6633,7874],"Acute Renal Failure",[7857],{"trials":7877,"activeCount":102},[],{"trials":7879,"activeCount":102},[],{"intervention":6920,"totalTrials":149,"cells":7881},{"EARLY_PHASE1":7882,"PHASE1":7884,"PHASE2":7886,"PHASE3":7888,"PHASE4":7894,"NA":7896},{"trials":7883,"activeCount":102},[],{"trials":7885,"activeCount":102},[],{"trials":7887,"activeCount":102},[],{"trials":7889,"activeCount":102},[7890],{"nctId":6914,"briefTitle":6915,"status":112,"phases":7891,"primaryCompletion":5274,"completion":5274,"start":6917,"enrollment":149,"conditions":7892,"interventions":7893},[92],[2307],[6879,6920],{"trials":7895,"activeCount":102},[],{"trials":7897,"activeCount":102},[],{"intervention":7899,"totalTrials":149,"cells":7900},"Tenofovir disoproxil fumarate",{"EARLY_PHASE1":7901,"PHASE1":7903,"PHASE2":7905,"PHASE3":7907,"PHASE4":7917,"NA":7919},{"trials":7902,"activeCount":102},[],{"trials":7904,"activeCount":102},[],{"trials":7906,"activeCount":102},[],{"trials":7908,"activeCount":102},[7909],{"nctId":7910,"briefTitle":7911,"status":112,"phases":7912,"primaryCompletion":7913,"completion":7913,"start":7914,"enrollment":19,"conditions":7915,"interventions":7916},"NCT02600117","Use of TDF in Patients With Inactive Chronic Hepatitis B Infection",[92],"2023-02-28","2016-01-26",[2891],[7899],{"trials":7918,"activeCount":102},[],{"trials":7920,"activeCount":102},[],{"intervention":7922,"totalTrials":149,"cells":7923},"Insulin",{"EARLY_PHASE1":7924,"PHASE1":7926,"PHASE2":7928,"PHASE3":7930,"PHASE4":7942,"NA":7944},{"trials":7925,"activeCount":102},[],{"trials":7927,"activeCount":102},[],{"trials":7929,"activeCount":102},[],{"trials":7931,"activeCount":102},[7932],{"nctId":7933,"briefTitle":7934,"status":112,"phases":7935,"primaryCompletion":7936,"completion":7937,"start":7938,"enrollment":541,"conditions":7939,"interventions":7941},"NCT03141827","The Effect of Intranasal Insulin on Hepatic and Intestinal Triglyceride-rich Lipoprotein Production",[91,92],"2017-02-15","2017-04-26","2016-04-14",[7940],"Hyperlipidemia",[7922],{"trials":7943,"activeCount":102},[],{"trials":7945,"activeCount":102},[],{"intervention":7947,"totalTrials":149,"cells":7948},"Finasteride",{"EARLY_PHASE1":7949,"PHASE1":7951,"PHASE2":7953,"PHASE3":7955,"PHASE4":7965,"NA":7967},{"trials":7950,"activeCount":102},[],{"trials":7952,"activeCount":102},[],{"trials":7954,"activeCount":102},[],{"trials":7956,"activeCount":102},[7957],{"nctId":7958,"briefTitle":7959,"status":112,"phases":7960,"primaryCompletion":7961,"completion":7961,"start":5618,"enrollment":1363,"conditions":7962,"interventions":7964},"NCT00542243","A Trial of PROSCAR (Finasteride) Versus Placebo in Men With an Initial Negative Prostate Biopsy",[92],"2012-12",[7963],"Enlarged Prostate",[7947],{"trials":7966,"activeCount":102},[],{"trials":7968,"activeCount":102},[],{"intervention":7970,"totalTrials":149,"cells":7971},"Rivaroxaban 10 MG",{"EARLY_PHASE1":7972,"PHASE1":7974,"PHASE2":7976,"PHASE3":7978,"PHASE4":7989,"NA":7991},{"trials":7973,"activeCount":102},[],{"trials":7975,"activeCount":102},[],{"trials":7977,"activeCount":102},[],{"trials":7979,"activeCount":102},[7980],{"nctId":7981,"briefTitle":7982,"status":727,"phases":7983,"primaryCompletion":1045,"completion":1045,"start":7984,"enrollment":479,"conditions":7985,"interventions":7988},"NCT05033314","THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS)",[92],"2022-06-07",[7986,7987,131],"Sickle Cell Disease","Central Venous Catheter Thrombosis",[7970],{"trials":7990,"activeCount":102},[],{"trials":7992,"activeCount":102},[],{"intervention":7994,"totalTrials":149,"cells":7995},"peg interferon plus ribavirin",{"EARLY_PHASE1":7996,"PHASE1":7998,"PHASE2":8000,"PHASE3":8002,"PHASE4":8011,"NA":8013},{"trials":7997,"activeCount":102},[],{"trials":7999,"activeCount":102},[],{"trials":8001,"activeCount":102},[],{"trials":8003,"activeCount":102},[8004],{"nctId":8005,"briefTitle":8006,"status":727,"phases":8007,"completion":8008,"start":7801,"enrollment":1046,"conditions":8009,"interventions":8010},"NCT00296972","Tolerability of Peginterferon Plus Ribavirin for Chronic Hepatitis C and HIV for Patients Receiving Antiretroviral Medication vs Not Receiving Antiretroviral Medication",[92],"2007-04",[7574,7032],[7994],{"trials":8012,"activeCount":102},[],{"trials":8014,"activeCount":102},[],{"intervention":8016,"totalTrials":149,"cells":8017},"Teduglutide + Normal Saline",{"EARLY_PHASE1":8018,"PHASE1":8020,"PHASE2":8022,"PHASE3":8024,"PHASE4":8035,"NA":8037},{"trials":8019,"activeCount":102},[],{"trials":8021,"activeCount":102},[],{"trials":8023,"activeCount":102},[],{"trials":8025,"activeCount":102},[8026],{"nctId":8027,"briefTitle":8028,"status":112,"phases":8029,"primaryCompletion":8030,"completion":8030,"start":8031,"enrollment":511,"conditions":8032,"interventions":8033},"NCT03534661","L-NMMA on GLP-2 Mediated Intestinal Lipoprotein Release",[91,92],"2019-03-20","2017-09-27",[7057],[8016,8034],"Teduglutide + L-NMMA",{"trials":8036,"activeCount":102},[],{"trials":8038,"activeCount":102},[],{"intervention":8034,"totalTrials":149,"cells":8040},{"EARLY_PHASE1":8041,"PHASE1":8043,"PHASE2":8045,"PHASE3":8047,"PHASE4":8053,"NA":8055},{"trials":8042,"activeCount":102},[],{"trials":8044,"activeCount":102},[],{"trials":8046,"activeCount":102},[],{"trials":8048,"activeCount":102},[8049],{"nctId":8027,"briefTitle":8028,"status":112,"phases":8050,"primaryCompletion":8030,"completion":8030,"start":8031,"enrollment":511,"conditions":8051,"interventions":8052},[91,92],[7057],[8016,8034],{"trials":8054,"activeCount":102},[],{"trials":8056,"activeCount":102},[],{"intervention":4270,"totalTrials":149,"cells":8058},{"EARLY_PHASE1":8059,"PHASE1":8061,"PHASE2":8063,"PHASE3":8065,"PHASE4":8071,"NA":8073},{"trials":8060,"activeCount":102},[],{"trials":8062,"activeCount":102},[],{"trials":8064,"activeCount":102},[],{"trials":8066,"activeCount":102},[8067],{"nctId":4261,"briefTitle":4262,"status":112,"phases":8068,"primaryCompletion":4264,"completion":4265,"start":4266,"enrollment":98,"conditions":8069,"interventions":8070},[92],[1332,4268],[82,4270,4271],{"trials":8072,"activeCount":102},[],{"trials":8074,"activeCount":102},[],{"intervention":8076,"totalTrials":149,"cells":8077},"dexamethasone intravitreal implant",{"EARLY_PHASE1":8078,"PHASE1":8080,"PHASE2":8082,"PHASE3":8084,"PHASE4":8093,"NA":8095},{"trials":8079,"activeCount":102},[],{"trials":8081,"activeCount":102},[],{"trials":8083,"activeCount":102},[],{"trials":8085,"activeCount":102},[8086],{"nctId":8087,"briefTitle":8088,"status":112,"phases":8089,"primaryCompletion":698,"completion":698,"start":7961,"enrollment":3928,"conditions":8090,"interventions":8092},"NCT01748487","The Effect of Intravitreal Ozurdex on DME After Cataract Surgery",[92],[8091],"Diabetic Macular Edema",[8076],{"trials":8094,"activeCount":102},[],{"trials":8096,"activeCount":102},[],{"intervention":8098,"totalTrials":149,"cells":8099},"Sitagliptin",{"EARLY_PHASE1":8100,"PHASE1":8102,"PHASE2":8104,"PHASE3":8106,"PHASE4":8115,"NA":8117},{"trials":8101,"activeCount":102},[],{"trials":8103,"activeCount":102},[],{"trials":8105,"activeCount":102},[],{"trials":8107,"activeCount":102},[8108],{"nctId":8109,"briefTitle":8110,"status":112,"phases":8111,"primaryCompletion":8112,"completion":5201,"start":7800,"enrollment":7055,"conditions":8113,"interventions":8114},"NCT01600703","Sitagliptin Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production in Humans",[91,92],"2013-05",[7940],[8098],{"trials":8116,"activeCount":102},[],{"trials":8118,"activeCount":102},[],{"intervention":8120,"totalTrials":149,"cells":8121},"Diluent \u002F Insulin",{"EARLY_PHASE1":8122,"PHASE1":8124,"PHASE2":8126,"PHASE3":8128,"PHASE4":8137,"NA":8139},{"trials":8123,"activeCount":102},[],{"trials":8125,"activeCount":102},[],{"trials":8127,"activeCount":102},[],{"trials":8129,"activeCount":102},[8130],{"nctId":8131,"briefTitle":8132,"status":112,"phases":8133,"primaryCompletion":4157,"completion":4157,"start":1442,"enrollment":2357,"conditions":8134,"interventions":8135},"NCT00570050","Effect of Intranasal Insulin on Depressive Symptoms in Major Depressive Disorder",[92],[2307],[8120,8136],"Insulin \u002F Diluent",{"trials":8138,"activeCount":102},[],{"trials":8140,"activeCount":102},[],{"intervention":8136,"totalTrials":149,"cells":8142},{"EARLY_PHASE1":8143,"PHASE1":8145,"PHASE2":8147,"PHASE3":8149,"PHASE4":8155,"NA":8157},{"trials":8144,"activeCount":102},[],{"trials":8146,"activeCount":102},[],{"trials":8148,"activeCount":102},[],{"trials":8150,"activeCount":102},[8151],{"nctId":8131,"briefTitle":8132,"status":112,"phases":8152,"primaryCompletion":4157,"completion":4157,"start":1442,"enrollment":2357,"conditions":8153,"interventions":8154},[92],[2307],[8120,8136],{"trials":8156,"activeCount":102},[],{"trials":8158,"activeCount":102},[],{"intervention":8160,"totalTrials":149,"cells":8161},"Acetaminophen",{"EARLY_PHASE1":8162,"PHASE1":8164,"PHASE2":8166,"PHASE3":8168,"PHASE4":8177,"NA":8179},{"trials":8163,"activeCount":102},[],{"trials":8165,"activeCount":102},[],{"trials":8167,"activeCount":102},[],{"trials":8169,"activeCount":102},[8170],{"nctId":8171,"briefTitle":8172,"status":112,"phases":8173,"primaryCompletion":7961,"completion":7961,"start":7801,"enrollment":687,"conditions":8174,"interventions":8175},"NCT00152854","Acetaminophen for Cancer Pain",[92],[24,4785],[8160,8176],"acetaminophen",{"trials":8178,"activeCount":102},[],{"trials":8180,"activeCount":102},[],{"intervention":813,"totalTrials":149,"cells":8182},{"EARLY_PHASE1":8183,"PHASE1":8185,"PHASE2":8187,"PHASE3":8189,"PHASE4":8195,"NA":8197},{"trials":8184,"activeCount":102},[],{"trials":8186,"activeCount":102},[],{"trials":8188,"activeCount":102},[],{"trials":8190,"activeCount":102},[8191],{"nctId":805,"briefTitle":806,"status":112,"phases":8192,"primaryCompletion":808,"completion":808,"start":809,"enrollment":810,"conditions":8193,"interventions":8194},[91,92],[760],[813,576],{"trials":8196,"activeCount":102},[],{"trials":8198,"activeCount":102},[],{"intervention":8200,"totalTrials":149,"cells":8201},"Intravenous ImmuneGlobulin",{"EARLY_PHASE1":8202,"PHASE1":8204,"PHASE2":8206,"PHASE3":8208,"PHASE4":8219,"NA":8221},{"trials":8203,"activeCount":102},[],{"trials":8205,"activeCount":102},[],{"trials":8207,"activeCount":102},[],{"trials":8209,"activeCount":102},[8210],{"nctId":8211,"briefTitle":8212,"status":112,"phases":8213,"completion":8214,"start":8215,"enrollment":19,"conditions":8216,"interventions":8218},"NCT00306033","Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia Gravis",[92],"2005-05","2004-03",[8217],"Myasthenia Gravis",[8200],{"trials":8220,"activeCount":102},[],{"trials":8222,"activeCount":102},[],{"intervention":8224,"totalTrials":149,"cells":8225},"Ledipasvir\u002FSofosbuvir",{"EARLY_PHASE1":8226,"PHASE1":8228,"PHASE2":8230,"PHASE3":8232,"PHASE4":8242,"NA":8244},{"trials":8227,"activeCount":102},[],{"trials":8229,"activeCount":102},[],{"trials":8231,"activeCount":102},[],{"trials":8233,"activeCount":102},[8234],{"nctId":8235,"briefTitle":8236,"status":112,"phases":8237,"primaryCompletion":1955,"completion":1955,"start":5134,"enrollment":643,"conditions":8238,"interventions":8241},"NCT02597166","Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection",[92],[8239,8240],"Hepatitis C, Chronic","Cirrhosis, Decompensated",[8224],{"trials":8243,"activeCount":102},[],{"trials":8245,"activeCount":102},[],{"intervention":8247,"totalTrials":149,"cells":8248},"Sofosbuvir",{"EARLY_PHASE1":8249,"PHASE1":8251,"PHASE2":8253,"PHASE3":8255,"PHASE4":8264,"NA":8266},{"trials":8250,"activeCount":102},[],{"trials":8252,"activeCount":102},[],{"trials":8254,"activeCount":102},[],{"trials":8256,"activeCount":102},[8257],{"nctId":8258,"briefTitle":8259,"status":727,"phases":8260,"primaryCompletion":7164,"completion":5200,"start":552,"enrollment":149,"conditions":8261,"interventions":8263},"NCT02478229","Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)",[92],[8262],"Hepatitis C Viral Infection",[8247],{"trials":8265,"activeCount":102},[],{"trials":8267,"activeCount":102},[],{"intervention":775,"totalTrials":6986,"cells":8269},{"EARLY_PHASE1":8270,"PHASE1":8272,"PHASE2":8289,"PHASE3":8323,"PHASE4":8325,"NA":8327},{"trials":8271,"activeCount":102},[],{"trials":8273,"activeCount":102},[8274,8282],{"nctId":8275,"briefTitle":8276,"status":112,"phases":8277,"primaryCompletion":8278,"completion":8279,"start":743,"enrollment":3928,"conditions":8280,"interventions":8281},"NCT00892658","Sorafenib-RT in Treating Hepatocellular Carcinoma (SHEP)",[90],"2019-11","2020-12-16",[1714],[775],{"nctId":8283,"briefTitle":8284,"status":112,"phases":8285,"primaryCompletion":628,"completion":8286,"start":114,"enrollment":22,"conditions":8287,"interventions":8288},"NCT00610246","A Study of Radiation With Sorafenib in Advanced Cancer",[90],"2011-05",[24],[775],{"trials":8290,"activeCount":102},[8291,8300,8307,8311,8315],{"nctId":8292,"briefTitle":8293,"status":112,"phases":8294,"primaryCompletion":8295,"completion":8295,"start":8296,"enrollment":810,"conditions":8297,"interventions":8299},"NCT00892424","Sorafenib-RT Treatment for Liver Metastasis (SLIM)",[90,91],"2020-09-08","2008-11",[8298,24],"Liver Metastasis",[775],{"nctId":8301,"briefTitle":8302,"status":112,"phases":8303,"primaryCompletion":4347,"completion":4347,"start":8304,"enrollment":687,"conditions":8305,"interventions":8306},"NCT00609934","Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the Bone",[90,91],"2007-12",[1541],[775],{"nctId":765,"briefTitle":766,"status":112,"phases":8308,"primaryCompletion":768,"completion":769,"start":770,"enrollment":771,"conditions":8309,"interventions":8310},[90,91],[773],[775,576],{"nctId":1448,"briefTitle":1449,"status":112,"phases":8312,"primaryCompletion":685,"completion":685,"start":1451,"enrollment":1388,"conditions":8313,"interventions":8314},[91],[1453],[775,1335],{"nctId":8316,"briefTitle":8317,"status":112,"phases":8318,"primaryCompletion":742,"completion":8319,"start":114,"enrollment":1363,"conditions":8320,"interventions":8322},"NCT00480389","Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal",[91],"2013-03",[1541,8321],"Metastatic Disease",[775],{"trials":8324,"activeCount":102},[],{"trials":8326,"activeCount":102},[],{"trials":8328,"activeCount":102},[],{"intervention":8330,"totalTrials":479,"cells":8331},"Sunitinib",{"EARLY_PHASE1":8332,"PHASE1":8334,"PHASE2":8345,"PHASE3":8367,"PHASE4":8369,"NA":8371},{"trials":8333,"activeCount":102},[],{"trials":8335,"activeCount":102},[8336],{"nctId":8337,"briefTitle":8338,"status":112,"phases":8339,"primaryCompletion":8340,"completion":7288,"start":8341,"enrollment":1388,"conditions":8342,"interventions":8344},"NCT00981890","Stereotactic Radiosurgery With Sunitinib for Brain Metastases",[90],"2014-05","2009-07",[8343],"Brain Metastases",[8330],{"trials":8346,"activeCount":102},[8347,8356,8360],{"nctId":8348,"briefTitle":8349,"status":112,"phases":8350,"primaryCompletion":8351,"completion":8351,"start":674,"enrollment":1860,"conditions":8352,"interventions":8355},"NCT00843037","Study Of Sunitinib In Patients With Recurrent Paraganglioma\u002FPheochromocytoma",[91],"2022-03-14",[8353,8354],"Paraganglioma","Pheochromocytoma",[8330],{"nctId":753,"briefTitle":754,"status":112,"phases":8357,"primaryCompletion":756,"completion":756,"start":757,"enrollment":758,"conditions":8358,"interventions":8359},[91],[760],[762,576,763],{"nctId":8361,"briefTitle":8362,"status":112,"phases":8363,"primaryCompletion":7961,"completion":7961,"start":5734,"enrollment":643,"conditions":8364,"interventions":8366},"NCT00886132","A Study of Sunitinib in Recurrent and\u002For Metastatic Adenoid Cystic Carcinoma of the Salivary Glands",[91],[8365,3484],"Adenoid Cystic Carcinoma",[8330],{"trials":8368,"activeCount":102},[],{"trials":8370,"activeCount":102},[],{"trials":8372,"activeCount":102},[],{"intervention":8374,"totalTrials":479,"cells":8375},"Lenalidomide",{"EARLY_PHASE1":8376,"PHASE1":8378,"PHASE2":8380,"PHASE3":8417,"PHASE4":8419,"NA":8421},{"trials":8377,"activeCount":102},[],{"trials":8379,"activeCount":102},[],{"trials":8381,"activeCount":102},[8382,8392,8402,8410],{"nctId":8383,"briefTitle":8384,"status":112,"phases":8385,"primaryCompletion":7098,"completion":8386,"start":8387,"enrollment":511,"conditions":8388,"interventions":8390},"NCT03959358","A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders",[91],"2022-10-07","2020-07-03",[246,8389],"Amyloidosis",[8374,8391],"Pomalidomide",{"nctId":8393,"briefTitle":8394,"status":112,"phases":8395,"primaryCompletion":8396,"completion":8396,"start":8397,"enrollment":471,"conditions":8398,"interventions":8399},"NCT01702831","Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance",[91],"2022-07-31","2013-10-01",[246],[8400,8401,8374],"Busulfan","Melphalan",{"nctId":8403,"briefTitle":8404,"status":727,"phases":8405,"primaryCompletion":6760,"completion":6760,"start":8406,"enrollment":2202,"conditions":8407,"interventions":8409},"NCT00751296","Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)",[91],"2006-08",[8408],"Chronic Lymphocytic Leukaemia",[8374],{"nctId":8411,"briefTitle":8412,"status":112,"phases":8413,"primaryCompletion":3481,"completion":3481,"start":1794,"enrollment":607,"conditions":8414,"interventions":8416},"NCT00478959","Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma",[91],[8415],"Hodgkin Disease",[8374],{"trials":8418,"activeCount":102},[],{"trials":8420,"activeCount":102},[],{"trials":8422,"activeCount":102},[],{"intervention":8424,"totalTrials":98,"cells":8425},"bortezomib",{"EARLY_PHASE1":8426,"PHASE1":8428,"PHASE2":8430,"PHASE3":8456,"PHASE4":8458,"NA":8460},{"trials":8427,"activeCount":102},[],{"trials":8429,"activeCount":102},[],{"trials":8431,"activeCount":102},[8432,8441,8448],{"nctId":8433,"briefTitle":8434,"status":112,"phases":8435,"primaryCompletion":8436,"completion":8436,"start":8437,"enrollment":758,"conditions":8438,"interventions":8439},"NCT00570180","Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma",[91],"2015-09-15","2008-08-25",[246],[8440],"Bortezomib",{"nctId":8442,"briefTitle":8443,"status":112,"phases":8444,"primaryCompletion":7215,"start":8445,"conditions":8446,"interventions":8447},"NCT00052507","Bortezomib in Treating Patients With Metastatic or Recurrent Colorectal Cancer",[91],"2003-01",[32],[8424],{"nctId":8449,"briefTitle":8450,"status":112,"phases":8451,"primaryCompletion":8452,"start":8452,"conditions":8453,"interventions":8455},"NCT00066352","Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter",[91],"2003-09",[589,8454],"Transitional Cell Cancer of the Renal Pelvis and Ureter",[8424],{"trials":8457,"activeCount":102},[],{"trials":8459,"activeCount":102},[],{"trials":8461,"activeCount":102},[],{"intervention":6837,"totalTrials":98,"cells":8463},{"EARLY_PHASE1":8464,"PHASE1":8466,"PHASE2":8468,"PHASE3":8493,"PHASE4":8495,"NA":8497},{"trials":8465,"activeCount":102},[],{"trials":8467,"activeCount":102},[],{"trials":8469,"activeCount":102},[8470,8479,8483],{"nctId":8471,"briefTitle":8472,"status":727,"phases":8473,"primaryCompletion":8474,"completion":8474,"start":8475,"enrollment":1560,"conditions":8476,"interventions":8478},"NCT02245087","Eliminate Coronary Artery Disease",[91],"2019-09","2014-08",[8477],"Coronary Artery Disease",[6837],{"nctId":6830,"briefTitle":6831,"status":550,"phases":8480,"primaryCompletion":6833,"completion":6834,"start":6833,"enrollment":102,"conditions":8481,"interventions":8482},[91],[15],[792,6837],{"nctId":8484,"briefTitle":8485,"status":1723,"phases":8486,"primaryCompletion":8487,"completion":2047,"start":8488,"enrollment":8489,"conditions":8490,"interventions":8492},"NCT03186404","Statins for the Primary Prevention of Heart Failure in Patients Receiving Anthracycline Pilot Study",[91],"2021-12-21","2018-05-10",112,[24,27,8491],"Cardiotoxicity",[6837],{"trials":8494,"activeCount":102},[],{"trials":8496,"activeCount":102},[],{"trials":8498,"activeCount":102},[],{"intervention":8500,"totalTrials":98,"cells":8501},"7-hydroxystaurosporine",{"EARLY_PHASE1":8502,"PHASE1":8504,"PHASE2":8515,"PHASE3":8533,"PHASE4":8535,"NA":8537},{"trials":8503,"activeCount":102},[],{"trials":8505,"activeCount":102},[8506],{"nctId":8507,"briefTitle":8508,"status":112,"phases":8509,"primaryCompletion":1442,"start":8510,"enrollment":4142,"conditions":8511,"interventions":8513},"NCT00045175","UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer",[90],"2002-06",[734,732,8512],"Primary Peritoneal Cavity Cancer",[8500,8514],"topotecan hydrochloride",{"trials":8516,"activeCount":102},[8517,8524],{"nctId":8518,"briefTitle":8519,"status":112,"phases":8520,"primaryCompletion":8521,"start":5941,"conditions":8522,"interventions":8523},"NCT00072267","UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",[91],"2005-04",[734,732,8512],[8500,8514],{"nctId":8525,"briefTitle":8526,"status":112,"phases":8527,"primaryCompletion":8528,"start":8510,"conditions":8529,"interventions":8531},"NCT00045513","Combination Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma",[90,91],"2003-12",[8530,7711],"Leukemia",[8500,8532],"fludarabine phosphate",{"trials":8534,"activeCount":102},[],{"trials":8536,"activeCount":102},[],{"trials":8538,"activeCount":102},[],{"intervention":4221,"totalTrials":98,"cells":8540},{"EARLY_PHASE1":8541,"PHASE1":8543,"PHASE2":8545,"PHASE3":8567,"PHASE4":8569,"NA":8571},{"trials":8542,"activeCount":102},[],{"trials":8544,"activeCount":102},[],{"trials":8546,"activeCount":102},[8547,8555,8559],{"nctId":8548,"briefTitle":8549,"status":727,"phases":8550,"primaryCompletion":8551,"completion":6870,"start":7511,"enrollment":659,"conditions":8552,"interventions":8554},"NCT01201538","A Study of Nilotinib in Growing Vestibular Schwannomas",[91],"2011-10",[8553],"Growing Vestibular Schwannomas",[4221],{"nctId":4209,"briefTitle":4210,"status":112,"phases":8556,"primaryCompletion":4212,"completion":4212,"start":4213,"enrollment":479,"conditions":8557,"interventions":8558},[90,91],[4215,4216,4217,4218,4219],[4221,4200],{"nctId":8560,"briefTitle":8561,"status":727,"phases":8562,"primaryCompletion":8563,"completion":8563,"start":7511,"enrollment":687,"conditions":8564,"interventions":8565},"NCT01222143","Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia",[90,91],"2015-04",[2204],[8566,4221],"NOVE-HiDAC",{"trials":8568,"activeCount":102},[],{"trials":8570,"activeCount":102},[],{"trials":8572,"activeCount":102},[],{"intervention":8574,"totalTrials":98,"cells":8575},"Erlotinib",{"EARLY_PHASE1":8576,"PHASE1":8578,"PHASE2":8580,"PHASE3":8603,"PHASE4":8605,"NA":8607},{"trials":8577,"activeCount":102},[],{"trials":8579,"activeCount":102},[],{"trials":8581,"activeCount":102},[8582,8590,8599],{"nctId":8583,"briefTitle":8584,"status":112,"phases":8585,"primaryCompletion":8586,"completion":8587,"start":6996,"enrollment":1860,"conditions":8588,"interventions":8589},"NCT00462995","Surgery for Early Lung Cancer With Preoperative Erlotinib (Tarceva): A Clinical Phase II Trial (SELECT)",[91],"2012-01","2012-02",[570],[8574,8574],{"nctId":8591,"briefTitle":8592,"status":112,"phases":8593,"primaryCompletion":8594,"completion":1442,"start":8595,"enrollment":720,"conditions":8596,"interventions":8598},"NCT00497224","Phase II Trial of Erlotinib in Advanced Pancreatic Cancer",[91],"2008-12","2006-11",[24,8597],"Pancreas",[8574],{"nctId":625,"briefTitle":626,"status":112,"phases":8600,"primaryCompletion":628,"completion":629,"start":630,"enrollment":129,"conditions":8601,"interventions":8602},[91],[632],[72,634,635],{"trials":8604,"activeCount":102},[],{"trials":8606,"activeCount":102},[],{"trials":8608,"activeCount":102},[],{"intervention":8610,"totalTrials":98,"cells":8611},"Trametinib",{"EARLY_PHASE1":8612,"PHASE1":8614,"PHASE2":8616,"PHASE3":8646,"PHASE4":8648,"NA":8650},{"trials":8613,"activeCount":102},[],{"trials":8615,"activeCount":102},[],{"trials":8617,"activeCount":102},[8618,8630,8638],{"nctId":8619,"briefTitle":8620,"status":112,"phases":8621,"primaryCompletion":8622,"completion":8623,"start":552,"enrollment":643,"conditions":8624,"interventions":8628},"NCT02399943","A Trial of Trametinib and Panitumumab in RAS\u002FRAF Wild Type Advanced Colorectal Cancer",[91],"2019-04","2022-03-31",[32,8625,8626,8627],"KRAS Wildtype","NRAS Wildtype","BRAF Wildtype",[8610,8629],"Panitumumab",{"nctId":8631,"briefTitle":8632,"status":550,"phases":8633,"primaryCompletion":8634,"completion":8634,"start":5172,"enrollment":102,"conditions":8635,"interventions":8637},"NCT06098872","Pilot Study on Trametinib for Surgical Unruptured AVMs",[91],"2026-03-26",[8636],"Arteriovenous Malformations",[8610],{"nctId":8639,"briefTitle":8640,"status":112,"phases":8641,"primaryCompletion":7620,"completion":8642,"start":7164,"enrollment":36,"conditions":8643,"interventions":8644},"NCT02428270","A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer",[91],"2022-10-27",[609,789],[8645,8610],"GSK2256098",{"trials":8647,"activeCount":102},[],{"trials":8649,"activeCount":102},[],{"trials":8651,"activeCount":102},[],{"intervention":6976,"totalTrials":98,"cells":8653},{"EARLY_PHASE1":8654,"PHASE1":8656,"PHASE2":8669,"PHASE3":8675,"PHASE4":8677,"NA":8679},{"trials":8655,"activeCount":102},[],{"trials":8657,"activeCount":102},[8658,8662],{"nctId":6969,"briefTitle":6970,"status":112,"phases":8659,"primaryCompletion":6608,"completion":6608,"start":6972,"enrollment":1348,"conditions":8660,"interventions":8661},[90],[6974],[6962,6976],{"nctId":8663,"briefTitle":8664,"status":112,"phases":8665,"primaryCompletion":5134,"completion":2270,"start":5827,"enrollment":511,"conditions":8666,"interventions":8667},"NCT02740829","Assessment of Intranasal Glucagon on Endogenous Glucose Production",[90],[5110],[8668,6976],"Intranasal glucagon",{"trials":8670,"activeCount":102},[8671],{"nctId":6980,"briefTitle":6981,"status":112,"phases":8672,"primaryCompletion":6983,"completion":6984,"start":6985,"enrollment":6986,"conditions":8673,"interventions":8674},[90,91],[5470],[6962,6976],{"trials":8676,"activeCount":102},[],{"trials":8678,"activeCount":102},[],{"trials":8680,"activeCount":102},[],{"intervention":8682,"totalTrials":659,"cells":8683},"Celecoxib",{"EARLY_PHASE1":8684,"PHASE1":8686,"PHASE2":8688,"PHASE3":8705,"PHASE4":8707,"NA":8709},{"trials":8685,"activeCount":102},[],{"trials":8687,"activeCount":102},[],{"trials":8689,"activeCount":102},[8690,8697],{"nctId":8691,"briefTitle":8692,"status":112,"phases":8693,"primaryCompletion":6995,"completion":6995,"start":8215,"enrollment":1330,"conditions":8694,"interventions":8696},"NCT00188565","Celebrex With Preoperative Chemoradiation - Rectal Cancer",[90,91],[8695],"Colorectal Neoplasms",[8682],{"nctId":8698,"briefTitle":8699,"status":112,"phases":8700,"primaryCompletion":5916,"completion":5916,"start":8701,"enrollment":824,"conditions":8702,"interventions":8704},"NCT00152828","Celebrex - Cervix: Celecoxib in the Treatment of Patients With Locally Advanced Carcinoma of the Cervix",[90,91],"2001-02",[8703],"Cervix Neoplasms",[8682],{"trials":8706,"activeCount":102},[],{"trials":8708,"activeCount":102},[],{"trials":8710,"activeCount":102},[],{"intervention":8712,"totalTrials":659,"cells":8713},"Lenalidomide and Dexamethasone",{"EARLY_PHASE1":8714,"PHASE1":8716,"PHASE2":8718,"PHASE3":8737,"PHASE4":8739,"NA":8741},{"trials":8715,"activeCount":102},[],{"trials":8717,"activeCount":102},[],{"trials":8719,"activeCount":102},[8720,8729],{"nctId":8721,"briefTitle":8722,"status":112,"phases":8723,"primaryCompletion":8724,"completion":8724,"start":8725,"enrollment":1560,"conditions":8726,"interventions":8728},"NCT01270932","Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients",[91],"2017-12-18","2010-11",[8727,246],"Renal Failure",[8712],{"nctId":8730,"briefTitle":8731,"status":112,"phases":8732,"primaryCompletion":4140,"completion":4140,"start":8733,"enrollment":824,"conditions":8734,"interventions":8736},"NCT01133743","Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia",[91],"2010-05",[8735],"Chronic Lymphocytic Leukemia",[8712],{"trials":8738,"activeCount":102},[],{"trials":8740,"activeCount":102},[],{"trials":8742,"activeCount":102},[],{"intervention":8514,"totalTrials":659,"cells":8744},{"EARLY_PHASE1":8745,"PHASE1":8747,"PHASE2":8753,"PHASE3":8759,"PHASE4":8761,"NA":8763},{"trials":8746,"activeCount":102},[],{"trials":8748,"activeCount":102},[8749],{"nctId":8507,"briefTitle":8508,"status":112,"phases":8750,"primaryCompletion":1442,"start":8510,"enrollment":4142,"conditions":8751,"interventions":8752},[90],[734,732,8512],[8500,8514],{"trials":8754,"activeCount":102},[8755],{"nctId":8518,"briefTitle":8519,"status":112,"phases":8756,"primaryCompletion":8521,"start":5941,"conditions":8757,"interventions":8758},[91],[734,732,8512],[8500,8514],{"trials":8760,"activeCount":102},[],{"trials":8762,"activeCount":102},[],{"trials":8764,"activeCount":102},[],{"intervention":723,"totalTrials":659,"cells":8766},{"EARLY_PHASE1":8767,"PHASE1":8769,"PHASE2":8780,"PHASE3":8786,"PHASE4":8788,"NA":8790},{"trials":8768,"activeCount":102},[],{"trials":8770,"activeCount":102},[8771],{"nctId":8772,"briefTitle":8773,"status":112,"phases":8774,"primaryCompletion":8286,"start":8775,"enrollment":33,"conditions":8776,"interventions":8778},"NCT00126620","Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors",[90],"2005-09",[8777],"Unspecified Adult Solid Tumor, Protocol Specific",[723,8779],"sorafenib tosylate",{"trials":8781,"activeCount":102},[8782],{"nctId":715,"briefTitle":716,"status":112,"phases":8783,"primaryCompletion":718,"completion":718,"start":719,"enrollment":720,"conditions":8784,"interventions":8785},[90,91],[30],[678,723],{"trials":8787,"activeCount":102},[],{"trials":8789,"activeCount":102},[],{"trials":8791,"activeCount":102},[],{"intervention":679,"totalTrials":659,"cells":8793},{"EARLY_PHASE1":8794,"PHASE1":8796,"PHASE2":8802,"PHASE3":8810,"PHASE4":8812,"NA":8814},{"trials":8795,"activeCount":102},[],{"trials":8797,"activeCount":102},[8798],{"nctId":671,"briefTitle":672,"status":112,"phases":8799,"primaryCompletion":674,"start":675,"enrollment":541,"conditions":8800,"interventions":8801},[90],[21],[678,679,680],{"trials":8803,"activeCount":102},[8804],{"nctId":8805,"briefTitle":8806,"status":112,"phases":8807,"primaryCompletion":5941,"completion":6048,"start":1990,"enrollment":36,"conditions":8808,"interventions":8809},"NCT00045669","Imatinib Mesylate in Treating Patients With Salivary Gland Cancer",[91],[30],[679],{"trials":8811,"activeCount":102},[],{"trials":8813,"activeCount":102},[],{"trials":8815,"activeCount":102},[],{"intervention":8817,"totalTrials":659,"cells":8818},"doxorubicin hydrochloride",{"EARLY_PHASE1":8819,"PHASE1":8821,"PHASE2":8832,"PHASE3":8842,"PHASE4":8844,"NA":8846},{"trials":8820,"activeCount":102},[],{"trials":8822,"activeCount":102},[8823],{"nctId":8824,"briefTitle":8825,"status":112,"phases":8826,"primaryCompletion":8827,"completion":524,"start":6380,"enrollment":3928,"conditions":8828,"interventions":8830},"NCT01163903","Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours",[90],"2014-03",[8829],"Advanced Solid Tumours",[8831,8817],"pantoprazole sodium for",{"trials":8833,"activeCount":102},[8834],{"nctId":8835,"briefTitle":8836,"status":112,"phases":8837,"primaryCompletion":743,"completion":809,"start":8838,"enrollment":2202,"conditions":8839,"interventions":8840},"NCT00047229","Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)",[91],"2002-10",[1393],[8841,8817],"oblimersen sodium",{"trials":8843,"activeCount":102},[],{"trials":8845,"activeCount":102},[],{"trials":8847,"activeCount":102},[],{"intervention":8849,"totalTrials":659,"cells":8850},"perifosine",{"EARLY_PHASE1":8851,"PHASE1":8853,"PHASE2":8855,"PHASE3":8871,"PHASE4":8873,"NA":8875},{"trials":8852,"activeCount":102},[],{"trials":8854,"activeCount":102},[],{"trials":8856,"activeCount":102},[8857,8864],{"nctId":8858,"briefTitle":8859,"status":112,"phases":8860,"primaryCompletion":6996,"start":8861,"conditions":8862,"interventions":8863},"NCT00053924","Perifosine in Treating Patients With Advanced Pancreatic Cancer",[91],"2003-05",[609],[8849],{"nctId":8865,"briefTitle":8866,"status":112,"phases":8867,"primaryCompletion":8008,"start":8868,"conditions":8869,"interventions":8870},"NCT00054145","Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer",[91],"2003-06",[18],[8849],{"trials":8872,"activeCount":102},[],{"trials":8874,"activeCount":102},[],{"trials":8876,"activeCount":102},[],{"intervention":1354,"totalTrials":659,"cells":8878},{"EARLY_PHASE1":8879,"PHASE1":8881,"PHASE2":8887,"PHASE3":8893,"PHASE4":8895,"NA":8897},{"trials":8880,"activeCount":102},[],{"trials":8882,"activeCount":102},[8883],{"nctId":1343,"briefTitle":1344,"status":112,"phases":8884,"primaryCompletion":1346,"completion":1346,"start":1347,"enrollment":1348,"conditions":8885,"interventions":8886},[90],[1350,1351],[1335,1353,1354,1355],{"trials":8888,"activeCount":102},[8889],{"nctId":1438,"briefTitle":1439,"status":112,"phases":8890,"primaryCompletion":1441,"completion":1441,"start":1442,"enrollment":687,"conditions":8891,"interventions":8892},[91],[1444],[1335,1353,1354,1446],{"trials":8894,"activeCount":102},[],{"trials":8896,"activeCount":102},[],{"trials":8898,"activeCount":102},[],{"intervention":8900,"totalTrials":659,"cells":8901},"Rituximab",{"EARLY_PHASE1":8902,"PHASE1":8904,"PHASE2":8906,"PHASE3":8927,"PHASE4":8929,"NA":8931},{"trials":8903,"activeCount":102},[],{"trials":8905,"activeCount":102},[],{"trials":8907,"activeCount":102},[8908,8919],{"nctId":8909,"briefTitle":8910,"status":1723,"phases":8911,"primaryCompletion":8912,"completion":8913,"start":8914,"enrollment":511,"conditions":8915,"interventions":8918},"NCT04507477","Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial",[90,91],"2022-12-07","2023-02-07","2020-07-07",[8916,8917],"Epstein-Barr Virus Infections","Post-transplant Lymphoproliferative Disorder",[8900],{"nctId":8920,"briefTitle":8921,"status":727,"phases":8922,"primaryCompletion":8923,"completion":8923,"start":8733,"enrollment":149,"conditions":8924,"interventions":8926},"NCT01066598","A Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease (cGVHD)",[91],"2011-08",[8925],"Graft Versus Host Disease",[8900],{"trials":8928,"activeCount":102},[],{"trials":8930,"activeCount":102},[],{"trials":8932,"activeCount":102},[],{"intervention":1627,"totalTrials":659,"cells":8934},{"EARLY_PHASE1":8935,"PHASE1":8937,"PHASE2":8939,"PHASE3":8949,"PHASE4":8951,"NA":8953},{"trials":8936,"activeCount":102},[],{"trials":8938,"activeCount":102},[],{"trials":8940,"activeCount":102},[8941,8945],{"nctId":1941,"briefTitle":1942,"status":1723,"phases":8942,"primaryCompletion":1944,"completion":1944,"start":1945,"enrollment":1946,"conditions":8943,"interventions":8944},[91],[732,734,1948,1949],[87,1627],{"nctId":1620,"briefTitle":1621,"status":727,"phases":8946,"primaryCompletion":1623,"completion":1623,"start":1624,"enrollment":1574,"conditions":8947,"interventions":8948},[91],[570],[574,1599,1627],{"trials":8950,"activeCount":102},[],{"trials":8952,"activeCount":102},[],{"trials":8954,"activeCount":102},[],{"intervention":8956,"totalTrials":659,"cells":8957},"tipifarnib",{"EARLY_PHASE1":8958,"PHASE1":8960,"PHASE2":8970,"PHASE3":8980,"PHASE4":8982,"NA":8984},{"trials":8959,"activeCount":102},[],{"trials":8961,"activeCount":102},[8962],{"nctId":8963,"briefTitle":8964,"status":112,"phases":8965,"primaryCompletion":5468,"start":8008,"enrollment":3928,"conditions":8966,"interventions":8967},"NCT00101153","Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia",[90],[8530],[8968,8969,8956],"cytarabine","daunorubicin hydrochloride",{"trials":8971,"activeCount":102},[8972],{"nctId":8973,"briefTitle":8974,"status":112,"phases":8975,"primaryCompletion":8976,"start":8977,"conditions":8978,"interventions":8979},"NCT00047216","Tipifarnib in Treating Patients With Recurrent Bladder Cancer",[91],"2006-03","2002-11",[589],[8956],{"trials":8981,"activeCount":102},[],{"trials":8983,"activeCount":102},[],{"trials":8985,"activeCount":102},[],{"intervention":8987,"totalTrials":659,"cells":8988},"ENMD-2076",{"EARLY_PHASE1":8989,"PHASE1":8991,"PHASE2":8993,"PHASE3":9009,"PHASE4":9011,"NA":9013},{"trials":8990,"activeCount":102},[],{"trials":8992,"activeCount":102},[],{"trials":8994,"activeCount":102},[8995,9003],{"nctId":8996,"briefTitle":8997,"status":112,"phases":8998,"primaryCompletion":4266,"completion":4266,"start":8999,"enrollment":172,"conditions":9000,"interventions":9002},"NCT01914510","A Study of ENMD-2076 in Ovarian Clear Cell Cancers",[91],"2013-09",[9001],"Ovarian Clear Cell Carcinoma",[8987],{"nctId":9004,"briefTitle":9005,"status":112,"phases":9006,"primaryCompletion":4315,"completion":5134,"start":686,"enrollment":1860,"conditions":9007,"interventions":9008},"NCT01719744","Study of ENMD-2076 in Patients With Advanced\u002FMetastatic Soft Tissue Sarcoma",[91],[3486,3485,1862],[8987],{"trials":9010,"activeCount":102},[],{"trials":9012,"activeCount":102},[],{"trials":9014,"activeCount":102},[],{"intervention":9016,"totalTrials":659,"cells":9017},"Cytarabine",{"EARLY_PHASE1":9018,"PHASE1":9020,"PHASE2":9026,"PHASE3":9034,"PHASE4":9036,"NA":9038},{"trials":9019,"activeCount":102},[],{"trials":9021,"activeCount":102},[9022],{"nctId":8963,"briefTitle":8964,"status":112,"phases":9023,"primaryCompletion":5468,"start":8008,"enrollment":3928,"conditions":9024,"interventions":9025},[90],[8530],[8968,8969,8956],{"trials":9027,"activeCount":102},[9028],{"nctId":9029,"briefTitle":9030,"status":112,"phases":9031,"primaryCompletion":7511,"completion":1793,"start":8008,"enrollment":511,"conditions":9032,"interventions":9033},"NCT00480090","A Phase II Study of Ara-C (Cytarabine) in Men With Androgen Independent Prostate Cancer",[91],[15],[9016],{"trials":9035,"activeCount":102},[],{"trials":9037,"activeCount":102},[],{"trials":9039,"activeCount":102},[],{"intervention":1797,"totalTrials":659,"cells":9041},{"EARLY_PHASE1":9042,"PHASE1":9044,"PHASE2":9054,"PHASE3":9060,"PHASE4":9062,"NA":9064},{"trials":9043,"activeCount":102},[],{"trials":9045,"activeCount":102},[9046],{"nctId":9047,"briefTitle":9048,"status":112,"phases":9049,"primaryCompletion":6630,"start":8775,"enrollment":1560,"conditions":9050,"interventions":9051},"NCT00121277","Vorinostat and Capecitabine in Treating Patients With Metastatic or Unresectable Solid Tumors",[90],[8777],[9052,9053],"capecitabine","vorinostat",{"trials":9055,"activeCount":102},[9056],{"nctId":1790,"briefTitle":1791,"status":112,"phases":9057,"primaryCompletion":1793,"completion":1793,"start":1794,"enrollment":19,"conditions":9058,"interventions":9059},[91],[32],[1747,762,1797],{"trials":9061,"activeCount":102},[],{"trials":9063,"activeCount":102},[],{"trials":9065,"activeCount":102},[],{"intervention":9067,"totalTrials":659,"cells":9068},"Visbiome",{"EARLY_PHASE1":9069,"PHASE1":9071,"PHASE2":9073,"PHASE3":9091,"PHASE4":9093,"NA":9095},{"trials":9070,"activeCount":102},[],{"trials":9072,"activeCount":102},[],{"trials":9074,"activeCount":102},[9075,9083],{"nctId":9076,"briefTitle":9077,"status":1723,"phases":9078,"primaryCompletion":9079,"completion":9079,"start":2355,"enrollment":758,"conditions":9080,"interventions":9082},"NCT02441231","Probiotic Visbiome for Inflammation and Translocation in HIV II",[91],"2019-05",[9081],"HIV-1 Infection",[9067],{"nctId":9084,"briefTitle":9085,"status":727,"phases":9086,"primaryCompletion":9087,"completion":9087,"start":9088,"enrollment":149,"conditions":9089,"interventions":9090},"NCT02441244","Probiotic Visbiome for Inflammation and Translocation in HIV Ι",[91],"2016-12-19","2015-11-15",[9081],[9067],{"trials":9092,"activeCount":102},[],{"trials":9094,"activeCount":102},[],{"trials":9096,"activeCount":102},[],{"intervention":2176,"totalTrials":149,"cells":9098},{"EARLY_PHASE1":9099,"PHASE1":9101,"PHASE2":9103,"PHASE3":9109,"PHASE4":9111,"NA":9113},{"trials":9100,"activeCount":102},[],{"trials":9102,"activeCount":102},[],{"trials":9104,"activeCount":102},[9105],{"nctId":2168,"briefTitle":2169,"status":112,"phases":9106,"primaryCompletion":2171,"completion":2171,"start":2172,"enrollment":771,"conditions":9107,"interventions":9108},[90,91],[2174],[1774,2176],{"trials":9110,"activeCount":102},[],{"trials":9112,"activeCount":102},[],{"trials":9114,"activeCount":102},[],{"intervention":9116,"totalTrials":149,"cells":9117},"Cannabis Oil",{"EARLY_PHASE1":9118,"PHASE1":9120,"PHASE2":9122,"PHASE3":9131,"PHASE4":9133,"NA":9135},{"trials":9119,"activeCount":102},[],{"trials":9121,"activeCount":102},[],{"trials":9123,"activeCount":102},[9124],{"nctId":9125,"briefTitle":9126,"status":1723,"phases":9127,"primaryCompletion":6834,"completion":6834,"start":582,"enrollment":244,"conditions":9128,"interventions":9130},"NCT03639064","Cannabis Oil for Pain in Parkinson's Disease",[91],[9129],"Parkinson Disease",[9116],{"trials":9132,"activeCount":102},[],{"trials":9134,"activeCount":102},[],{"trials":9136,"activeCount":102},[],{"intervention":9138,"totalTrials":149,"cells":9139},"ASP7487, Velcade, Dexamethasone",{"EARLY_PHASE1":9140,"PHASE1":9142,"PHASE2":9144,"PHASE3":9155,"PHASE4":9157,"NA":9159},{"trials":9141,"activeCount":102},[],{"trials":9143,"activeCount":102},[],{"trials":9145,"activeCount":102},[9146],{"nctId":9147,"briefTitle":9148,"status":727,"phases":9149,"primaryCompletion":9150,"completion":9151,"start":9152,"enrollment":1363,"conditions":9153,"interventions":9154},"NCT01672736","A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma",[90,91],"2017-03-27","2017-12-27","2012-09",[246],[9138],{"trials":9156,"activeCount":102},[],{"trials":9158,"activeCount":102},[],{"trials":9160,"activeCount":102},[],{"intervention":9162,"totalTrials":149,"cells":9163},"MET-2",{"EARLY_PHASE1":9164,"PHASE1":9166,"PHASE2":9168,"PHASE3":9179,"PHASE4":9181,"NA":9183},{"trials":9165,"activeCount":102},[],{"trials":9167,"activeCount":102},[],{"trials":9169,"activeCount":102},[9170],{"nctId":9171,"briefTitle":9172,"status":550,"phases":9173,"primaryCompletion":4156,"completion":2996,"start":1917,"enrollment":102,"conditions":9174,"interventions":9178},"NCT06214403","Antimicrobial Resistant Organism Decolonization After Microbiome Perturbation",[91],[9175,9176,9177],"Gram-negative Bacteremia","Microbial Colonization","Antibiotic Resistant Infection",[9162],{"trials":9180,"activeCount":102},[],{"trials":9182,"activeCount":102},[],{"trials":9184,"activeCount":102},[],{"intervention":9186,"totalTrials":149,"cells":9187},"vitamin K1",{"EARLY_PHASE1":9188,"PHASE1":9190,"PHASE2":9192,"PHASE3":9203,"PHASE4":9205,"NA":9207},{"trials":9189,"activeCount":102},[],{"trials":9191,"activeCount":102},[],{"trials":9193,"activeCount":102},[9194],{"nctId":9195,"briefTitle":9196,"status":112,"phases":9197,"primaryCompletion":8724,"completion":8724,"start":9198,"enrollment":98,"conditions":9199,"interventions":9202},"NCT02324686","Vitamin K Supplementation in Patients on Hemodialysis",[91],"2014-01",[9200,9201],"End Stage Renal Failure on Dialysis","Atrial Fibrillation",[9186],{"trials":9204,"activeCount":102},[],{"trials":9206,"activeCount":102},[],{"trials":9208,"activeCount":102},[],{"intervention":9210,"totalTrials":149,"cells":9211},"Iron supplement 300-600 mg\u002Fday",{"EARLY_PHASE1":9212,"PHASE1":9214,"PHASE2":9216,"PHASE3":9228,"PHASE4":9230,"NA":9232},{"trials":9213,"activeCount":102},[],{"trials":9215,"activeCount":102},[],{"trials":9217,"activeCount":102},[9218],{"nctId":9219,"briefTitle":9220,"status":727,"phases":9221,"primaryCompletion":674,"start":8510,"enrollment":607,"conditions":9222,"interventions":9226},"NCT00152841","Effect of Iron and Vitamin E Supplementation on Disease Activity in Patients With Either Crohn's Disease or Ulcerative Colitis",[91],[9223,9224,9225],"Crohn's Disease","Ulcerative Colitis","Mild or Moderate Anaemia",[9210,9227],"Vitamin E 800IU",{"trials":9229,"activeCount":102},[],{"trials":9231,"activeCount":102},[],{"trials":9233,"activeCount":102},[],{"intervention":9227,"totalTrials":149,"cells":9235},{"EARLY_PHASE1":9236,"PHASE1":9238,"PHASE2":9240,"PHASE3":9246,"PHASE4":9248,"NA":9250},{"trials":9237,"activeCount":102},[],{"trials":9239,"activeCount":102},[],{"trials":9241,"activeCount":102},[9242],{"nctId":9219,"briefTitle":9220,"status":727,"phases":9243,"primaryCompletion":674,"start":8510,"enrollment":607,"conditions":9244,"interventions":9245},[91],[9223,9224,9225],[9210,9227],{"trials":9247,"activeCount":102},[],{"trials":9249,"activeCount":102},[],{"trials":9251,"activeCount":102},[],{"intervention":9253,"totalTrials":149,"cells":9254},"topiramate",{"EARLY_PHASE1":9255,"PHASE1":9257,"PHASE2":9259,"PHASE3":9268,"PHASE4":9270,"NA":9272},{"trials":9256,"activeCount":102},[],{"trials":9258,"activeCount":102},[],{"trials":9260,"activeCount":102},[9261],{"nctId":9262,"briefTitle":9263,"status":727,"phases":9264,"completion":6404,"start":9265,"enrollment":129,"conditions":9266,"interventions":9267},"NCT00296959","Topiramate as a Treatment for Levodopa-Induced Dyskinesia in Parkinson's Disease",[91],"2004-09",[6655],[9253],{"trials":9269,"activeCount":102},[],{"trials":9271,"activeCount":102},[],{"trials":9273,"activeCount":102},[],{"intervention":9275,"totalTrials":149,"cells":9276},"Sunitinib Malate",{"EARLY_PHASE1":9277,"PHASE1":9279,"PHASE2":9281,"PHASE3":9289,"PHASE4":9291,"NA":9293},{"trials":9278,"activeCount":102},[],{"trials":9280,"activeCount":102},[],{"trials":9282,"activeCount":102},[9283],{"nctId":9284,"briefTitle":9285,"status":727,"phases":9286,"primaryCompletion":8551,"completion":8551,"start":7824,"enrollment":98,"conditions":9287,"interventions":9288},"NCT00480935","A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma",[91],[1541],[9275],{"trials":9290,"activeCount":102},[],{"trials":9292,"activeCount":102},[],{"trials":9294,"activeCount":102},[],{"intervention":9296,"totalTrials":149,"cells":9297},"Amantadine",{"EARLY_PHASE1":9298,"PHASE1":9300,"PHASE2":9302,"PHASE3":9311,"PHASE4":9313,"NA":9315},{"trials":9299,"activeCount":102},[],{"trials":9301,"activeCount":102},[],{"trials":9303,"activeCount":102},[9304],{"nctId":9305,"briefTitle":9306,"status":1723,"phases":9307,"completion":1794,"start":5941,"enrollment":2261,"conditions":9308,"interventions":9310},"NCT00188383","Effects of N-Methyl-D-Aspartate (NMDA)-Receptor Antagonism on Hyperalgesia, Opioid Use, and Pain After Radical Prostatectomy",[90,91],[9309,4785,15],"Hyperalgesia",[9296],{"trials":9312,"activeCount":102},[],{"trials":9314,"activeCount":102},[],{"trials":9316,"activeCount":102},[],{"intervention":591,"totalTrials":149,"cells":9318},{"EARLY_PHASE1":9319,"PHASE1":9321,"PHASE2":9323,"PHASE3":9329,"PHASE4":9331,"NA":9333},{"trials":9320,"activeCount":102},[],{"trials":9322,"activeCount":102},[],{"trials":9324,"activeCount":102},[9325],{"nctId":579,"briefTitle":580,"status":112,"phases":9326,"primaryCompletion":582,"completion":582,"start":583,"enrollment":584,"conditions":9327,"interventions":9328},[91],[586,587,588,589],[591,72,577,576],{"trials":9330,"activeCount":102},[],{"trials":9332,"activeCount":102},[],{"trials":9334,"activeCount":102},[],{"intervention":1423,"totalTrials":149,"cells":9336},{"EARLY_PHASE1":9337,"PHASE1":9339,"PHASE2":9341,"PHASE3":9347,"PHASE4":9349,"NA":9351},{"trials":9338,"activeCount":102},[],{"trials":9340,"activeCount":102},[],{"trials":9342,"activeCount":102},[9343],{"nctId":1416,"briefTitle":1417,"status":112,"phases":9344,"primaryCompletion":1419,"completion":1419,"start":1420,"enrollment":541,"conditions":9345,"interventions":9346},[90,91],[746],[1335,1353,1423,1355],{"trials":9348,"activeCount":102},[],{"trials":9350,"activeCount":102},[],{"trials":9352,"activeCount":102},[],{"intervention":9354,"totalTrials":149,"cells":9355},"9-valent HPV vaccination",{"EARLY_PHASE1":9356,"PHASE1":9358,"PHASE2":9360,"PHASE3":9374,"PHASE4":9376,"NA":9378},{"trials":9357,"activeCount":102},[],{"trials":9359,"activeCount":102},[],{"trials":9361,"activeCount":102},[9362],{"nctId":9363,"briefTitle":9364,"status":1723,"phases":9365,"primaryCompletion":1229,"completion":9366,"start":9367,"enrollment":9368,"conditions":9369,"interventions":9373},"NCT03947775","HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL",[91],"2026-05-01","2022-09-01",228,[9370,9371,9372],"Anal Intraepithelial Neoplasia","Anal Cancer","Human Papilloma Virus",[9354],{"trials":9375,"activeCount":102},[],{"trials":9377,"activeCount":102},[],{"trials":9379,"activeCount":102},[],{"intervention":9381,"totalTrials":149,"cells":9382},"Anakinra",{"EARLY_PHASE1":9383,"PHASE1":9385,"PHASE2":9387,"PHASE3":9398,"PHASE4":9400,"NA":9402},{"trials":9384,"activeCount":102},[],{"trials":9386,"activeCount":102},[],{"trials":9388,"activeCount":102},[9389],{"nctId":9390,"briefTitle":9391,"status":550,"phases":9392,"primaryCompletion":9393,"completion":9393,"start":9394,"enrollment":102,"conditions":9395,"interventions":9397},"NCT06710197","IL-1 Inhibition in Early TNBC",[91],"2026-02-12","2025-03-05",[9396],"Early Stage Triple Negative ER Low Breast Cancer",[9381],{"trials":9399,"activeCount":102},[],{"trials":9401,"activeCount":102},[],{"trials":9403,"activeCount":102},[],{"intervention":9405,"totalTrials":149,"cells":9406},"Fluoxetine Hydrochloride",{"EARLY_PHASE1":9407,"PHASE1":9409,"PHASE2":9411,"PHASE3":9429,"PHASE4":9431,"NA":9433},{"trials":9408,"activeCount":102},[],{"trials":9410,"activeCount":102},[],{"trials":9412,"activeCount":102},[9413],{"nctId":9414,"briefTitle":9415,"status":112,"phases":9416,"primaryCompletion":9417,"completion":9417,"start":7354,"enrollment":2071,"conditions":9418,"interventions":9428},"NCT03448159","Fluoxetine Opens Window to Improve Motor Recovery After Stroke",[91],"2022-09-30",[958,9419,9420,9421,9422,9423,9424,9425,9426,9427],"Cerebrovascular Accident","Cerebral Infarction","Brain Infarction","Brain Ischemia","Cerebrovascular Disorders","Brain Diseases","Central Nervous System Diseases","Nervous System Diseases","Vascular Diseases",[9405],{"trials":9430,"activeCount":102},[],{"trials":9432,"activeCount":102},[],{"trials":9434,"activeCount":102},[],{"intervention":8391,"totalTrials":149,"cells":9436},{"EARLY_PHASE1":9437,"PHASE1":9439,"PHASE2":9441,"PHASE3":9447,"PHASE4":9449,"NA":9451},{"trials":9438,"activeCount":102},[],{"trials":9440,"activeCount":102},[],{"trials":9442,"activeCount":102},[9443],{"nctId":8383,"briefTitle":8384,"status":112,"phases":9444,"primaryCompletion":7098,"completion":8386,"start":8387,"enrollment":511,"conditions":9445,"interventions":9446},[91],[246,8389],[8374,8391],{"trials":9448,"activeCount":102},[],{"trials":9450,"activeCount":102},[],{"trials":9452,"activeCount":102},[],{"intervention":9454,"totalTrials":149,"cells":9455},"Axitinib",{"EARLY_PHASE1":9456,"PHASE1":9458,"PHASE2":9460,"PHASE3":9468,"PHASE4":9470,"NA":9472},{"trials":9457,"activeCount":102},[],{"trials":9459,"activeCount":102},[],{"trials":9461,"activeCount":102},[9462],{"nctId":9463,"briefTitle":9464,"status":112,"phases":9465,"primaryCompletion":4264,"completion":4264,"start":5916,"enrollment":607,"conditions":9466,"interventions":9467},"NCT01334112","Study of Axitinib in Patients With Unresectable Hepatocellular Carcinoma",[91],[1714],[9454],{"trials":9469,"activeCount":102},[],{"trials":9471,"activeCount":102},[],{"trials":9473,"activeCount":102},[],{"intervention":2207,"totalTrials":149,"cells":9475},{"EARLY_PHASE1":9476,"PHASE1":9478,"PHASE2":9480,"PHASE3":9486,"PHASE4":9488,"NA":9490},{"trials":9477,"activeCount":102},[],{"trials":9479,"activeCount":102},[],{"trials":9481,"activeCount":102},[9482],{"nctId":2197,"briefTitle":2198,"status":727,"phases":9483,"primaryCompletion":2200,"completion":2200,"start":2201,"enrollment":2202,"conditions":9484,"interventions":9485},[90,91],[2204,247,248,2205],[2207,2188],{"trials":9487,"activeCount":102},[],{"trials":9489,"activeCount":102},[],{"trials":9491,"activeCount":102},[],{"intervention":9493,"totalTrials":149,"cells":9494},"Ofatumumab with GSK2110183",{"EARLY_PHASE1":9495,"PHASE1":9497,"PHASE2":9499,"PHASE3":9509,"PHASE4":9511,"NA":9513},{"trials":9496,"activeCount":102},[],{"trials":9498,"activeCount":102},[],{"trials":9500,"activeCount":102},[9501],{"nctId":9502,"briefTitle":9503,"status":112,"phases":9504,"primaryCompletion":9505,"completion":9505,"start":8587,"enrollment":1560,"conditions":9506,"interventions":9508},"NCT01532700","An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)",[91],"2017-06-30",[9507],"Chronic Lymphocytic Leukemia (CLL)",[9493],{"trials":9510,"activeCount":102},[],{"trials":9512,"activeCount":102},[],{"trials":9514,"activeCount":102},[],{"intervention":9516,"totalTrials":149,"cells":9517},"Dasatinib",{"EARLY_PHASE1":9518,"PHASE1":9520,"PHASE2":9522,"PHASE3":9533,"PHASE4":9535,"NA":9537},{"trials":9519,"activeCount":102},[],{"trials":9521,"activeCount":102},[],{"trials":9523,"activeCount":102},[9524],{"nctId":9525,"briefTitle":9526,"status":1723,"phases":9527,"primaryCompletion":1419,"completion":9528,"start":4347,"enrollment":9529,"conditions":9530,"interventions":9532},"NCT02268370","Treatment-free Remission Accomplished With Dasatinib in Patients With CML",[91],"2021-10",131,[9531],"Chronic Myeloid Leukemia",[9516],{"trials":9534,"activeCount":102},[],{"trials":9536,"activeCount":102},[],{"trials":9538,"activeCount":102},[],{"intervention":9540,"totalTrials":149,"cells":9541},"Infliximab",{"EARLY_PHASE1":9542,"PHASE1":9544,"PHASE2":9546,"PHASE3":9555,"PHASE4":9557,"NA":9559},{"trials":9543,"activeCount":102},[],{"trials":9545,"activeCount":102},[],{"trials":9547,"activeCount":102},[9548],{"nctId":9549,"briefTitle":9550,"status":112,"phases":9551,"primaryCompletion":9552,"completion":9552,"start":698,"enrollment":2591,"conditions":9553,"interventions":9554},"NCT02363738","12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I\u002FII Depression",[91],"2017-04",[1648],[9540],{"trials":9556,"activeCount":102},[],{"trials":9558,"activeCount":102},[],{"trials":9560,"activeCount":102},[],{"intervention":1730,"totalTrials":149,"cells":9562},{"EARLY_PHASE1":9563,"PHASE1":9565,"PHASE2":9567,"PHASE3":9573,"PHASE4":9575,"NA":9577},{"trials":9564,"activeCount":102},[],{"trials":9566,"activeCount":102},[],{"trials":9568,"activeCount":102},[9569],{"nctId":1721,"briefTitle":1722,"status":1723,"phases":9570,"primaryCompletion":1314,"completion":1314,"start":1725,"enrollment":1726,"conditions":9571,"interventions":9572},[91],[1728,247,248],[1435,1730],{"trials":9574,"activeCount":102},[],{"trials":9576,"activeCount":102},[],{"trials":9578,"activeCount":102},[],{"intervention":9580,"totalTrials":149,"cells":9581},"glucose or normal saline",{"EARLY_PHASE1":9582,"PHASE1":9584,"PHASE2":9586,"PHASE3":9595,"PHASE4":9597,"NA":9599},{"trials":9583,"activeCount":102},[],{"trials":9585,"activeCount":102},[],{"trials":9587,"activeCount":102},[9588],{"nctId":9589,"briefTitle":9590,"status":112,"phases":9591,"primaryCompletion":8563,"completion":698,"start":9592,"enrollment":511,"conditions":9593,"interventions":9594},"NCT02607839","Regulation of Intestinal and Hepatic Lipoprotein Particle Production by Blood Glucose in Humans",[91],"2013-02",[7356],[9580],{"trials":9596,"activeCount":102},[],{"trials":9598,"activeCount":102},[],{"trials":9600,"activeCount":102},[],{"intervention":9602,"totalTrials":149,"cells":9603},"Inhaled Nitric Oxide",{"EARLY_PHASE1":9604,"PHASE1":9606,"PHASE2":9608,"PHASE3":9618,"PHASE4":9620,"NA":9622},{"trials":9605,"activeCount":102},[],{"trials":9607,"activeCount":102},[],{"trials":9609,"activeCount":102},[9610],{"nctId":9611,"briefTitle":9612,"status":112,"phases":9613,"primaryCompletion":5576,"completion":9198,"start":1793,"enrollment":9614,"conditions":9615,"interventions":9617},"NCT01255215","Inhaled Nitric Oxide for the Adjunctive Therapy of Severe Malaria: a Randomized Controlled Trial",[90,91],180,[9616],"Severe Malaria",[9602],{"trials":9619,"activeCount":102},[],{"trials":9621,"activeCount":102},[],{"trials":9623,"activeCount":102},[],{"intervention":8400,"totalTrials":149,"cells":9625},{"EARLY_PHASE1":9626,"PHASE1":9628,"PHASE2":9630,"PHASE3":9636,"PHASE4":9638,"NA":9640},{"trials":9627,"activeCount":102},[],{"trials":9629,"activeCount":102},[],{"trials":9631,"activeCount":102},[9632],{"nctId":8393,"briefTitle":8394,"status":112,"phases":9633,"primaryCompletion":8396,"completion":8396,"start":8397,"enrollment":471,"conditions":9634,"interventions":9635},[91],[246],[8400,8401,8374],{"trials":9637,"activeCount":102},[],{"trials":9639,"activeCount":102},[],{"trials":9641,"activeCount":102},[],{"intervention":8401,"totalTrials":149,"cells":9643},{"EARLY_PHASE1":9644,"PHASE1":9646,"PHASE2":9648,"PHASE3":9654,"PHASE4":9656,"NA":9658},{"trials":9645,"activeCount":102},[],{"trials":9647,"activeCount":102},[],{"trials":9649,"activeCount":102},[9650],{"nctId":8393,"briefTitle":8394,"status":112,"phases":9651,"primaryCompletion":8396,"completion":8396,"start":8397,"enrollment":471,"conditions":9652,"interventions":9653},[91],[246],[8400,8401,8374],{"trials":9655,"activeCount":102},[],{"trials":9657,"activeCount":102},[],{"trials":9659,"activeCount":102},[],{"intervention":9661,"totalTrials":149,"cells":9662},"Semaglutide",{"EARLY_PHASE1":9663,"PHASE1":9665,"PHASE2":9667,"PHASE3":9677,"PHASE4":9679,"NA":9681},{"trials":9664,"activeCount":102},[],{"trials":9666,"activeCount":102},[],{"trials":9668,"activeCount":102},[9669],{"nctId":9670,"briefTitle":9671,"status":112,"phases":9672,"primaryCompletion":9673,"completion":9673,"start":7185,"enrollment":9674,"conditions":9675,"interventions":9676},"NCT04466345","Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder",[91],"2024-12-27",72,[2307],[9661],{"trials":9678,"activeCount":102},[],{"trials":9680,"activeCount":102},[],{"trials":9682,"activeCount":102},[],{"intervention":9684,"totalTrials":149,"cells":9685},"Pantoprazole",{"EARLY_PHASE1":9686,"PHASE1":9688,"PHASE2":9690,"PHASE3":9699,"PHASE4":9701,"NA":9703},{"trials":9687,"activeCount":102},[],{"trials":9689,"activeCount":102},[],{"trials":9691,"activeCount":102},[9692],{"nctId":9693,"briefTitle":9694,"status":112,"phases":9695,"primaryCompletion":9696,"completion":9696,"start":686,"enrollment":7055,"conditions":9697,"interventions":9698},"NCT01748500","Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer",[91],"2021-03",[15],[9684],{"trials":9700,"activeCount":102},[],{"trials":9702,"activeCount":102},[],{"trials":9704,"activeCount":102},[],{"intervention":9706,"totalTrials":149,"cells":9707},"Afatinib",{"EARLY_PHASE1":9708,"PHASE1":9710,"PHASE2":9712,"PHASE3":9722,"PHASE4":9724,"NA":9726},{"trials":9709,"activeCount":102},[],{"trials":9711,"activeCount":102},[],{"trials":9713,"activeCount":102},[9714],{"nctId":9715,"briefTitle":9716,"status":112,"phases":9717,"primaryCompletion":9718,"completion":9718,"start":5873,"enrollment":687,"conditions":9719,"interventions":9721},"NCT02506517","A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene",[91],"2023-05-04",[9720],"Solid Tumors",[9706],{"trials":9723,"activeCount":102},[],{"trials":9725,"activeCount":102},[],{"trials":9727,"activeCount":102},[],{"intervention":9729,"totalTrials":149,"cells":9730},"Definity",{"EARLY_PHASE1":9731,"PHASE1":9733,"PHASE2":9735,"PHASE3":9744,"PHASE4":9746,"NA":9748},{"trials":9732,"activeCount":102},[],{"trials":9734,"activeCount":102},[],{"trials":9736,"activeCount":102},[9737],{"nctId":9738,"briefTitle":9739,"status":112,"phases":9740,"primaryCompletion":742,"completion":7961,"start":140,"enrollment":9741,"conditions":9742,"interventions":9743},"NCT01062178","Efficacy of Ultrasound Contrast Agent to Assess Renal Masses",[91],167,[1541],[9729],{"trials":9745,"activeCount":102},[],{"trials":9747,"activeCount":102},[],{"trials":9749,"activeCount":102},[],{"intervention":9751,"totalTrials":149,"cells":9752},"gemcitabine hydrochloride",{"EARLY_PHASE1":9753,"PHASE1":9755,"PHASE2":9757,"PHASE3":9768,"PHASE4":9770,"NA":9772},{"trials":9754,"activeCount":102},[],{"trials":9756,"activeCount":102},[],{"trials":9758,"activeCount":102},[9759],{"nctId":9760,"briefTitle":9761,"status":112,"phases":9762,"primaryCompletion":6909,"completion":9763,"start":9764,"enrollment":1836,"conditions":9765,"interventions":9766},"NCT00078975","3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer",[91],"2009-01-07","2004-04",[609],[9751,9767],"triapine",{"trials":9769,"activeCount":102},[],{"trials":9771,"activeCount":102},[],{"trials":9773,"activeCount":102},[],{"intervention":9767,"totalTrials":149,"cells":9775},{"EARLY_PHASE1":9776,"PHASE1":9778,"PHASE2":9780,"PHASE3":9786,"PHASE4":9788,"NA":9790},{"trials":9777,"activeCount":102},[],{"trials":9779,"activeCount":102},[],{"trials":9781,"activeCount":102},[9782],{"nctId":9760,"briefTitle":9761,"status":112,"phases":9783,"primaryCompletion":6909,"completion":9763,"start":9764,"enrollment":1836,"conditions":9784,"interventions":9785},[91],[609],[9751,9767],{"trials":9787,"activeCount":102},[],{"trials":9789,"activeCount":102},[],{"trials":9791,"activeCount":102},[],{"intervention":9793,"totalTrials":149,"cells":9794},"ipratropium bromide",{"EARLY_PHASE1":9795,"PHASE1":9797,"PHASE2":9799,"PHASE3":9807,"PHASE4":9809,"NA":9811},{"trials":9796,"activeCount":102},[],{"trials":9798,"activeCount":102},[],{"trials":9800,"activeCount":102},[9801],{"nctId":9802,"briefTitle":9803,"status":112,"phases":9804,"completion":630,"start":4669,"enrollment":129,"conditions":9805,"interventions":9806},"NCT00296946","Ipratropium Spray for Drooling Saliva in Parkinson's Disease",[91],[6655],[9793],{"trials":9808,"activeCount":102},[],{"trials":9810,"activeCount":102},[],{"trials":9812,"activeCount":102},[],{"intervention":8841,"totalTrials":149,"cells":9814},{"EARLY_PHASE1":9815,"PHASE1":9817,"PHASE2":9819,"PHASE3":9825,"PHASE4":9827,"NA":9829},{"trials":9816,"activeCount":102},[],{"trials":9818,"activeCount":102},[],{"trials":9820,"activeCount":102},[9821],{"nctId":8835,"briefTitle":8836,"status":112,"phases":9822,"primaryCompletion":743,"completion":809,"start":8838,"enrollment":2202,"conditions":9823,"interventions":9824},[91],[1393],[8841,8817],{"trials":9826,"activeCount":102},[],{"trials":9828,"activeCount":102},[],{"trials":9830,"activeCount":102},[],{"intervention":8629,"totalTrials":149,"cells":9832},{"EARLY_PHASE1":9833,"PHASE1":9835,"PHASE2":9837,"PHASE3":9843,"PHASE4":9845,"NA":9847},{"trials":9834,"activeCount":102},[],{"trials":9836,"activeCount":102},[],{"trials":9838,"activeCount":102},[9839],{"nctId":8619,"briefTitle":8620,"status":112,"phases":9840,"primaryCompletion":8622,"completion":8623,"start":552,"enrollment":643,"conditions":9841,"interventions":9842},[91],[32,8625,8626,8627],[8610,8629],{"trials":9844,"activeCount":102},[],{"trials":9846,"activeCount":102},[],{"trials":9848,"activeCount":102},[],{"intervention":9850,"totalTrials":149,"cells":9851},"Resveratrol",{"EARLY_PHASE1":9852,"PHASE1":9854,"PHASE2":9856,"PHASE3":9865,"PHASE4":9867,"NA":9869},{"trials":9853,"activeCount":102},[],{"trials":9855,"activeCount":102},[],{"trials":9857,"activeCount":102},[9858],{"nctId":9859,"briefTitle":9860,"status":112,"phases":9861,"primaryCompletion":8999,"completion":8999,"start":8551,"enrollment":1348,"conditions":9862,"interventions":9864},"NCT01451918","Regulation of Intestinal and Hepatic Lipoprotein Secretion by Resveratrol",[91],[9863,5470],"Dyslipidaemia",[9850],{"trials":9866,"activeCount":102},[],{"trials":9868,"activeCount":102},[],{"trials":9870,"activeCount":102},[],{"intervention":6940,"totalTrials":149,"cells":9872},{"EARLY_PHASE1":9873,"PHASE1":9875,"PHASE2":9877,"PHASE3":9883,"PHASE4":9885,"NA":9887},{"trials":9874,"activeCount":102},[],{"trials":9876,"activeCount":102},[],{"trials":9878,"activeCount":102},[9879],{"nctId":6934,"briefTitle":6935,"status":1723,"phases":9880,"primaryCompletion":4244,"completion":1834,"start":6937,"enrollment":720,"conditions":9881,"interventions":9882},[91],[537],[1787,6940],{"trials":9884,"activeCount":102},[],{"trials":9886,"activeCount":102},[],{"trials":9888,"activeCount":102},[],{"intervention":9890,"totalTrials":149,"cells":9891},"Interferon alfacon-1",{"EARLY_PHASE1":9892,"PHASE1":9894,"PHASE2":9896,"PHASE3":9905,"PHASE4":9907,"NA":9909},{"trials":9893,"activeCount":102},[],{"trials":9895,"activeCount":102},[],{"trials":9897,"activeCount":102},[9898],{"nctId":9899,"briefTitle":9900,"status":1723,"phases":9901,"primaryCompletion":9902,"completion":9902,"start":8725,"enrollment":607,"conditions":9903,"interventions":9904},"NCT01227798","Safety and Efficacy Study of Interferon to Treat Patients Hospitalized for Influenza",[90,91],"2011-11",[7623],[9890],{"trials":9906,"activeCount":102},[],{"trials":9908,"activeCount":102},[],{"trials":9910,"activeCount":102},[],{"intervention":9912,"totalTrials":149,"cells":9913},"Nabilone",{"EARLY_PHASE1":9914,"PHASE1":9916,"PHASE2":9918,"PHASE3":9927,"PHASE4":9929,"NA":9931},{"trials":9915,"activeCount":102},[],{"trials":9917,"activeCount":102},[],{"trials":9919,"activeCount":102},[9920],{"nctId":9921,"briefTitle":9922,"status":1723,"phases":9923,"start":6909,"enrollment":36,"conditions":9924,"interventions":9926},"NCT00384410","Use of the Cannabinoid Nabilone for the Promotion of Sleep in Chronic, Non-Malignant Pain Patients",[91],[4785,9925],"Insomnia",[9912],{"trials":9928,"activeCount":102},[],{"trials":9930,"activeCount":102},[],{"trials":9932,"activeCount":102},[],{"intervention":2360,"totalTrials":149,"cells":9934},{"EARLY_PHASE1":9935,"PHASE1":9937,"PHASE2":9939,"PHASE3":9945,"PHASE4":9947,"NA":9949},{"trials":9936,"activeCount":102},[],{"trials":9938,"activeCount":102},[],{"trials":9940,"activeCount":102},[9941],{"nctId":2351,"briefTitle":2352,"status":112,"phases":9942,"primaryCompletion":2354,"completion":2355,"start":2356,"enrollment":2357,"conditions":9943,"interventions":9944},[91],[15],[2342,2360,2361],{"trials":9946,"activeCount":102},[],{"trials":9948,"activeCount":102},[],{"trials":9950,"activeCount":102},[],{"intervention":2361,"totalTrials":149,"cells":9952},{"EARLY_PHASE1":9953,"PHASE1":9955,"PHASE2":9957,"PHASE3":9963,"PHASE4":9965,"NA":9967},{"trials":9954,"activeCount":102},[],{"trials":9956,"activeCount":102},[],{"trials":9958,"activeCount":102},[9959],{"nctId":2351,"briefTitle":2352,"status":112,"phases":9960,"primaryCompletion":2354,"completion":2355,"start":2356,"enrollment":2357,"conditions":9961,"interventions":9962},[91],[15],[2342,2360,2361],{"trials":9964,"activeCount":102},[],{"trials":9966,"activeCount":102},[],{"trials":9968,"activeCount":102},[],{"intervention":9970,"totalTrials":149,"cells":9971},"Dronabinol",{"EARLY_PHASE1":9972,"PHASE1":9974,"PHASE2":9976,"PHASE3":9986,"PHASE4":9988,"NA":9990},{"trials":9973,"activeCount":102},[],{"trials":9975,"activeCount":102},[],{"trials":9977,"activeCount":102},[9978],{"nctId":9979,"briefTitle":9980,"status":1723,"phases":9981,"primaryCompletion":141,"completion":718,"start":5802,"enrollment":9982,"conditions":9983,"interventions":9985},"NCT00418925","Efficacy of Dronabinol for the Treatment of Cervical Dystonia",[91],38,[9984],"Cervical Dystonia",[9970],{"trials":9987,"activeCount":102},[],{"trials":9989,"activeCount":102},[],{"trials":9991,"activeCount":102},[],{"intervention":9993,"totalTrials":149,"cells":9994},"AUY922",{"EARLY_PHASE1":9995,"PHASE1":9997,"PHASE2":9999,"PHASE3":10008,"PHASE4":10010,"NA":10012},{"trials":9996,"activeCount":102},[],{"trials":9998,"activeCount":102},[],{"trials":10000,"activeCount":102},[10001],{"nctId":10002,"briefTitle":10003,"status":727,"phases":10004,"primaryCompletion":5201,"completion":5201,"start":8586,"enrollment":244,"conditions":10005,"interventions":10007},"NCT01484860","Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy",[91],[10006,8321],"Adenocarcinoma of the Pancreas",[9993],{"trials":10009,"activeCount":102},[],{"trials":10011,"activeCount":102},[],{"trials":10013,"activeCount":102},[],{"intervention":1446,"totalTrials":149,"cells":10015},{"EARLY_PHASE1":10016,"PHASE1":10018,"PHASE2":10020,"PHASE3":10026,"PHASE4":10028,"NA":10030},{"trials":10017,"activeCount":102},[],{"trials":10019,"activeCount":102},[],{"trials":10021,"activeCount":102},[10022],{"nctId":1438,"briefTitle":1439,"status":112,"phases":10023,"primaryCompletion":1441,"completion":1441,"start":1442,"enrollment":687,"conditions":10024,"interventions":10025},[91],[1444],[1335,1353,1354,1446],{"trials":10027,"activeCount":102},[],{"trials":10029,"activeCount":102},[],{"trials":10031,"activeCount":102},[],{"intervention":10033,"totalTrials":149,"cells":10034},"Folfirinox",{"EARLY_PHASE1":10035,"PHASE1":10037,"PHASE2":10039,"PHASE3":10051,"PHASE4":10053,"NA":10055},{"trials":10036,"activeCount":102},[],{"trials":10038,"activeCount":102},[],{"trials":10040,"activeCount":102},[10041],{"nctId":10042,"briefTitle":10043,"status":112,"phases":10044,"primaryCompletion":9394,"completion":9394,"start":10045,"enrollment":2002,"conditions":10046,"interventions":10049},"NCT04469556","Pancreatic Adenocarcinoma Signature Stratification for Treatment",[91],"2020-10-14",[10047,1519,10048],"Pancreatic Cancer Metastatic","Advanced Pancreatic Cancer",[10033,10050],"Gemcitabine\u002Fnab-paclitaxel",{"trials":10052,"activeCount":102},[],{"trials":10054,"activeCount":102},[],{"trials":10056,"activeCount":102},[],{"intervention":10050,"totalTrials":149,"cells":10058},{"EARLY_PHASE1":10059,"PHASE1":10061,"PHASE2":10063,"PHASE3":10069,"PHASE4":10071,"NA":10073},{"trials":10060,"activeCount":102},[],{"trials":10062,"activeCount":102},[],{"trials":10064,"activeCount":102},[10065],{"nctId":10042,"briefTitle":10043,"status":112,"phases":10066,"primaryCompletion":9394,"completion":9394,"start":10045,"enrollment":2002,"conditions":10067,"interventions":10068},[91],[10047,1519,10048],[10033,10050],{"trials":10070,"activeCount":102},[],{"trials":10072,"activeCount":102},[],{"trials":10074,"activeCount":102},[],{"intervention":10076,"totalTrials":149,"cells":10077},"Ertugliflozin",{"EARLY_PHASE1":10078,"PHASE1":10080,"PHASE2":10082,"PHASE3":10093,"PHASE4":10095,"NA":10097},{"trials":10079,"activeCount":102},[],{"trials":10081,"activeCount":102},[],{"trials":10083,"activeCount":102},[10084],{"nctId":10085,"briefTitle":10086,"status":112,"phases":10087,"primaryCompletion":10088,"completion":10088,"start":10089,"enrollment":22,"conditions":10090,"interventions":10092},"NCT03416270","ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure",[91],"2021-04-14","2018-06-28",[10091,27],"Type 2 Diabetes Mellitus",[10076],{"trials":10094,"activeCount":102},[],{"trials":10096,"activeCount":102},[],{"trials":10098,"activeCount":102},[],{"intervention":4145,"totalTrials":149,"cells":10100},{"EARLY_PHASE1":10101,"PHASE1":10103,"PHASE2":10105,"PHASE3":10111,"PHASE4":10113,"NA":10115},{"trials":10102,"activeCount":102},[],{"trials":10104,"activeCount":102},[],{"trials":10106,"activeCount":102},[10107],{"nctId":4136,"briefTitle":4137,"status":112,"phases":10108,"primaryCompletion":4139,"completion":4140,"start":4141,"enrollment":4142,"conditions":10109,"interventions":10110},[91],[15],[4145,4127],{"trials":10112,"activeCount":102},[],{"trials":10114,"activeCount":102},[],{"trials":10116,"activeCount":102},[],{"intervention":10118,"totalTrials":149,"cells":10119},"Mirtazapine Treatment",{"EARLY_PHASE1":10120,"PHASE1":10122,"PHASE2":10124,"PHASE3":10134,"PHASE4":10136,"NA":10138},{"trials":10121,"activeCount":102},[],{"trials":10123,"activeCount":102},[],{"trials":10125,"activeCount":102},[10126],{"nctId":10127,"briefTitle":10128,"status":112,"phases":10129,"completion":10130,"start":675,"enrollment":36,"conditions":10131,"interventions":10133},"NCT00385437","Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder",[91],"2004-06",[2297,10132],"Excessive Daytime Sleepiness",[10118],{"trials":10135,"activeCount":102},[],{"trials":10137,"activeCount":102},[],{"trials":10139,"activeCount":102},[],{"intervention":10141,"totalTrials":149,"cells":10142},"Intraperitoneal (IP) Cisplatin",{"EARLY_PHASE1":10143,"PHASE1":10145,"PHASE2":10147,"PHASE3":10155,"PHASE4":10157,"NA":10159},{"trials":10144,"activeCount":102},[],{"trials":10146,"activeCount":102},[],{"trials":10148,"activeCount":102},[10149],{"nctId":10150,"briefTitle":10151,"status":727,"phases":10152,"primaryCompletion":8341,"completion":718,"start":6542,"enrollment":541,"conditions":10153,"interventions":10154},"NCT00889733","Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer",[90,91],[1704],[10141],{"trials":10156,"activeCount":102},[],{"trials":10158,"activeCount":102},[],{"trials":10160,"activeCount":102},[],{"intervention":10162,"totalTrials":149,"cells":10163},"Famotidine",{"EARLY_PHASE1":10164,"PHASE1":10166,"PHASE2":10168,"PHASE3":10177,"PHASE4":10179,"NA":10181},{"trials":10165,"activeCount":102},[],{"trials":10167,"activeCount":102},[],{"trials":10169,"activeCount":102},[10170],{"nctId":10171,"briefTitle":10172,"status":112,"phases":10173,"primaryCompletion":8827,"completion":8827,"start":629,"enrollment":6986,"conditions":10174,"interventions":10176},"NCT01937078","Famotidine for Levodopa-induced Dyskinesia in PD",[91],[10175],"Dyskinesia",[10162],{"trials":10178,"activeCount":102},[],{"trials":10180,"activeCount":102},[],{"trials":10182,"activeCount":102},[],{"intervention":1995,"totalTrials":149,"cells":10184},{"EARLY_PHASE1":10185,"PHASE1":10187,"PHASE2":10189,"PHASE3":10195,"PHASE4":10197,"NA":10199},{"trials":10186,"activeCount":102},[],{"trials":10188,"activeCount":102},[],{"trials":10190,"activeCount":102},[10191],{"nctId":1987,"briefTitle":1988,"status":727,"phases":10192,"start":1990,"enrollment":19,"conditions":10193,"interventions":10194},[91],[1992],[1994,1995],{"trials":10196,"activeCount":102},[],{"trials":10198,"activeCount":102},[],{"trials":10200,"activeCount":102},[],{"intervention":10202,"totalTrials":149,"cells":10203},"sodium selenite",{"EARLY_PHASE1":10204,"PHASE1":10206,"PHASE2":10208,"PHASE3":10217,"PHASE4":10219,"NA":10221},{"trials":10205,"activeCount":102},[],{"trials":10207,"activeCount":102},[],{"trials":10209,"activeCount":102},[10210],{"nctId":10211,"briefTitle":10212,"status":112,"phases":10213,"primaryCompletion":743,"completion":743,"start":5941,"enrollment":22,"conditions":10214,"interventions":10216},"NCT00188604","The Use of Selenium to Treat Secondary Lymphedema - Breast Cancer",[91],[2013,10215],"Lymphedema",[10202],{"trials":10218,"activeCount":102},[],{"trials":10220,"activeCount":102},[],{"trials":10222,"activeCount":102},[],{"intervention":10224,"totalTrials":149,"cells":10225},"Panitumumab, Oxaliplatin, 5-FU",{"EARLY_PHASE1":10226,"PHASE1":10228,"PHASE2":10230,"PHASE3":10239,"PHASE4":10241,"NA":10243},{"trials":10227,"activeCount":102},[],{"trials":10229,"activeCount":102},[],{"trials":10231,"activeCount":102},[10232],{"nctId":10233,"briefTitle":10234,"status":112,"phases":10235,"primaryCompletion":1442,"completion":1442,"start":10236,"enrollment":1336,"conditions":10237,"interventions":10238},"NCT01260415","A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases",[91],"2010-08",[32,1761],[10224],{"trials":10240,"activeCount":102},[],{"trials":10242,"activeCount":102},[],{"trials":10244,"activeCount":102},[],{"intervention":10246,"totalTrials":149,"cells":10247},"Empagliflozin 25 MG + Liraglutide 1.8 MG",{"EARLY_PHASE1":10248,"PHASE1":10250,"PHASE2":10252,"PHASE3":10263,"PHASE4":10265,"NA":10267},{"trials":10249,"activeCount":102},[],{"trials":10251,"activeCount":102},[],{"trials":10253,"activeCount":102},[10254],{"nctId":10255,"briefTitle":10256,"status":1723,"phases":10257,"primaryCompletion":10258,"completion":10258,"start":10259,"enrollment":758,"conditions":10260,"interventions":10261},"NCT04535960","Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: \"NATRIURETIC\" Trial",[91],"2023-10","2019-01-24",[10091],[10246,10262],"Liraglutide 1.8 MG + Empagliflozin 25 MG",{"trials":10264,"activeCount":102},[],{"trials":10266,"activeCount":102},[],{"trials":10268,"activeCount":102},[],{"intervention":10262,"totalTrials":149,"cells":10270},{"EARLY_PHASE1":10271,"PHASE1":10273,"PHASE2":10275,"PHASE3":10281,"PHASE4":10283,"NA":10285},{"trials":10272,"activeCount":102},[],{"trials":10274,"activeCount":102},[],{"trials":10276,"activeCount":102},[10277],{"nctId":10255,"briefTitle":10256,"status":1723,"phases":10278,"primaryCompletion":10258,"completion":10258,"start":10259,"enrollment":758,"conditions":10279,"interventions":10280},[91],[10091],[10246,10262],{"trials":10282,"activeCount":102},[],{"trials":10284,"activeCount":102},[],{"trials":10286,"activeCount":102},[],{"intervention":10288,"totalTrials":149,"cells":10289},"Ambisome ®",{"EARLY_PHASE1":10290,"PHASE1":10292,"PHASE2":10294,"PHASE3":10304,"PHASE4":10306,"NA":10308},{"trials":10291,"activeCount":102},[],{"trials":10293,"activeCount":102},[],{"trials":10295,"activeCount":102},[10296],{"nctId":10297,"briefTitle":10298,"status":10299,"phases":10300,"primaryCompletion":9198,"completion":9198,"start":8586,"enrollment":479,"conditions":10301,"interventions":10302},"NCT01254708","Safety and Efficacy Study of Inhaled AmBisome for Prevention of Aspergillus Colonization in Lung Transplant Recipients","SUSPENDED",[91],[175],[10288,10303],"Regular standard of care medication",{"trials":10305,"activeCount":102},[],{"trials":10307,"activeCount":102},[],{"trials":10309,"activeCount":102},[],{"intervention":10303,"totalTrials":149,"cells":10311},{"EARLY_PHASE1":10312,"PHASE1":10314,"PHASE2":10316,"PHASE3":10322,"PHASE4":10324,"NA":10326},{"trials":10313,"activeCount":102},[],{"trials":10315,"activeCount":102},[],{"trials":10317,"activeCount":102},[10318],{"nctId":10297,"briefTitle":10298,"status":10299,"phases":10319,"primaryCompletion":9198,"completion":9198,"start":8586,"enrollment":479,"conditions":10320,"interventions":10321},[91],[175],[10288,10303],{"trials":10323,"activeCount":102},[],{"trials":10325,"activeCount":102},[],{"trials":10327,"activeCount":102},[],{"intervention":622,"totalTrials":149,"cells":10329},{"EARLY_PHASE1":10330,"PHASE1":10332,"PHASE2":10334,"PHASE3":10340,"PHASE4":10342,"NA":10344},{"trials":10331,"activeCount":102},[],{"trials":10333,"activeCount":102},[],{"trials":10335,"activeCount":102},[10336],{"nctId":613,"briefTitle":614,"status":112,"phases":10337,"primaryCompletion":616,"completion":617,"start":618,"enrollment":607,"conditions":10338,"interventions":10339},[91],[620],[622,72,623,576],{"trials":10341,"activeCount":102},[],{"trials":10343,"activeCount":102},[],{"trials":10345,"activeCount":102},[],{"intervention":10347,"totalTrials":149,"cells":10348},"Methylphenidate Hydrochloride",{"EARLY_PHASE1":10349,"PHASE1":10351,"PHASE2":10353,"PHASE3":10362,"PHASE4":10364,"NA":10366},{"trials":10350,"activeCount":102},[],{"trials":10352,"activeCount":102},[],{"trials":10354,"activeCount":102},[10355],{"nctId":10356,"briefTitle":10357,"status":727,"phases":10358,"primaryCompletion":8286,"completion":8286,"start":1451,"enrollment":4142,"conditions":10359,"interventions":10360},"NCT00593853","Efficacy Study of Methylphenidate Hydrochloride to Reduce Fatigue in Prostate Cancer Patients Receiving Hormone Therapy",[91],[7242,959],[10347,10361],"Matched Placebo",{"trials":10363,"activeCount":102},[],{"trials":10365,"activeCount":102},[],{"trials":10367,"activeCount":102},[],{"intervention":10361,"totalTrials":149,"cells":10369},{"EARLY_PHASE1":10370,"PHASE1":10372,"PHASE2":10374,"PHASE3":10380,"PHASE4":10382,"NA":10384},{"trials":10371,"activeCount":102},[],{"trials":10373,"activeCount":102},[],{"trials":10375,"activeCount":102},[10376],{"nctId":10356,"briefTitle":10357,"status":727,"phases":10377,"primaryCompletion":8286,"completion":8286,"start":1451,"enrollment":4142,"conditions":10378,"interventions":10379},[91],[7242,959],[10347,10361],{"trials":10381,"activeCount":102},[],{"trials":10383,"activeCount":102},[],{"trials":10385,"activeCount":102},[],{"intervention":10387,"totalTrials":149,"cells":10388},"Varespladib",{"EARLY_PHASE1":10389,"PHASE1":10391,"PHASE2":10393,"PHASE3":10402,"PHASE4":10404,"NA":10406},{"trials":10390,"activeCount":102},[],{"trials":10392,"activeCount":102},[],{"trials":10394,"activeCount":102},[10395],{"nctId":10396,"briefTitle":10397,"status":112,"phases":10398,"primaryCompletion":5108,"completion":5108,"start":7824,"enrollment":10399,"conditions":10400,"interventions":10401},"NCT00533039","sPLA2 Inhibition to Decrease Enzyme Release After PCI Trial",[91],164,[8477],[10387],{"trials":10403,"activeCount":102},[],{"trials":10405,"activeCount":102},[],{"trials":10407,"activeCount":102},[],{"intervention":10409,"totalTrials":149,"cells":10410},"Triamcinolone Acetonide",{"EARLY_PHASE1":10411,"PHASE1":10413,"PHASE2":10415,"PHASE3":10425,"PHASE4":10427,"NA":10429},{"trials":10412,"activeCount":102},[],{"trials":10414,"activeCount":102},[],{"trials":10416,"activeCount":102},[10417],{"nctId":10418,"briefTitle":10419,"status":1723,"phases":10420,"primaryCompletion":1793,"completion":8551,"start":5916,"enrollment":607,"conditions":10421,"interventions":10423},"NCT01249937","Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab",[91],[10422],"Wet Macular Degeneration",[10424,10409],"Ranibizumab",{"trials":10426,"activeCount":102},[],{"trials":10428,"activeCount":102},[],{"trials":10430,"activeCount":102},[],{"intervention":7189,"totalTrials":149,"cells":10432},{"EARLY_PHASE1":10433,"PHASE1":10435,"PHASE2":10437,"PHASE3":10443,"PHASE4":10445,"NA":10447},{"trials":10434,"activeCount":102},[],{"trials":10436,"activeCount":102},[],{"trials":10438,"activeCount":102},[10439],{"nctId":7181,"briefTitle":7182,"status":1723,"phases":10440,"primaryCompletion":7184,"completion":7184,"start":7185,"enrollment":2002,"conditions":10441,"interventions":10442},[90,91],[2307,5737,7187,6999],[7189,7000],{"trials":10444,"activeCount":102},[],{"trials":10446,"activeCount":102},[],{"trials":10448,"activeCount":102},[],{"intervention":10450,"totalTrials":149,"cells":10451},"Abiraterone acetate with prednisone",{"EARLY_PHASE1":10452,"PHASE1":10454,"PHASE2":10456,"PHASE3":10468,"PHASE4":10470,"NA":10472},{"trials":10453,"activeCount":102},[],{"trials":10455,"activeCount":102},[],{"trials":10457,"activeCount":102},[10458],{"nctId":10459,"briefTitle":10460,"status":112,"phases":10461,"primaryCompletion":10462,"completion":10463,"start":1387,"enrollment":2802,"conditions":10464,"interventions":10465},"NCT02543255","Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)",[91],"2021-05-27","2021-07-20",[15],[10450,10466,10467],"Leuprolide","Cabazitaxel with peg-filgrastim",{"trials":10469,"activeCount":102},[],{"trials":10471,"activeCount":102},[],{"trials":10473,"activeCount":102},[],{"intervention":10466,"totalTrials":149,"cells":10475},{"EARLY_PHASE1":10476,"PHASE1":10478,"PHASE2":10480,"PHASE3":10486,"PHASE4":10488,"NA":10490},{"trials":10477,"activeCount":102},[],{"trials":10479,"activeCount":102},[],{"trials":10481,"activeCount":102},[10482],{"nctId":10459,"briefTitle":10460,"status":112,"phases":10483,"primaryCompletion":10462,"completion":10463,"start":1387,"enrollment":2802,"conditions":10484,"interventions":10485},[91],[15],[10450,10466,10467],{"trials":10487,"activeCount":102},[],{"trials":10489,"activeCount":102},[],{"trials":10491,"activeCount":102},[],{"intervention":10467,"totalTrials":149,"cells":10493},{"EARLY_PHASE1":10494,"PHASE1":10496,"PHASE2":10498,"PHASE3":10504,"PHASE4":10506,"NA":10508},{"trials":10495,"activeCount":102},[],{"trials":10497,"activeCount":102},[],{"trials":10499,"activeCount":102},[10500],{"nctId":10459,"briefTitle":10460,"status":112,"phases":10501,"primaryCompletion":10462,"completion":10463,"start":1387,"enrollment":2802,"conditions":10502,"interventions":10503},[91],[15],[10450,10466,10467],{"trials":10505,"activeCount":102},[],{"trials":10507,"activeCount":102},[],{"trials":10509,"activeCount":102},[],{"intervention":10511,"totalTrials":149,"cells":10512},"Imatinib",{"EARLY_PHASE1":10513,"PHASE1":10515,"PHASE2":10517,"PHASE3":10528,"PHASE4":10530,"NA":10532},{"trials":10514,"activeCount":102},[],{"trials":10516,"activeCount":102},[],{"trials":10518,"activeCount":102},[10519],{"nctId":10520,"briefTitle":10521,"status":112,"phases":10522,"primaryCompletion":10523,"completion":10524,"start":10525,"enrollment":2357,"conditions":10526,"interventions":10527},"NCT01126814","A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed\u002FRefractory C-kit Positive (AML) Acute Myeloid Leukemia",[90,91],"2009-09","2010-04","2004-07",[8530],[10511],{"trials":10529,"activeCount":102},[],{"trials":10531,"activeCount":102},[],{"trials":10533,"activeCount":102},[],{"intervention":10535,"totalTrials":149,"cells":10536},"Perampanel",{"EARLY_PHASE1":10537,"PHASE1":10539,"PHASE2":10541,"PHASE3":10551,"PHASE4":10553,"NA":10555},{"trials":10538,"activeCount":102},[],{"trials":10540,"activeCount":102},[],{"trials":10542,"activeCount":102},[10543],{"nctId":10544,"briefTitle":10545,"status":112,"phases":10546,"primaryCompletion":10547,"completion":10547,"start":10548,"enrollment":1860,"conditions":10549,"interventions":10550},"NCT02131467","Safety and Tolerability of Perampanel in Cervical Dystonia",[90,91],"2020-02-28","2017-09-01",[9984],[10535],{"trials":10552,"activeCount":102},[],{"trials":10554,"activeCount":102},[],{"trials":10556,"activeCount":102},[],{"intervention":10558,"totalTrials":149,"cells":10559},"Domperidone",{"EARLY_PHASE1":10560,"PHASE1":10562,"PHASE2":10564,"PHASE3":10575,"PHASE4":10577,"NA":10579},{"trials":10561,"activeCount":102},[],{"trials":10563,"activeCount":102},[],{"trials":10565,"activeCount":102},[10566],{"nctId":10567,"briefTitle":10568,"status":727,"phases":10569,"primaryCompletion":10570,"completion":10571,"start":8976,"enrollment":1860,"conditions":10572,"interventions":10574},"NCT00305331","Domperidone as a Treatment for Dopamine Agonist-induced Peripheral Edema in Patients With Parkinson's Disease",[91],"2008-07","2008-09",[6655,10573],"Peripheral Edema",[10558],{"trials":10576,"activeCount":102},[],{"trials":10578,"activeCount":102},[],{"trials":10580,"activeCount":102},[],{"intervention":10582,"totalTrials":149,"cells":10583},"Injection of autologous CD133+ stem cells at the time of coronary artery bypass grafting",{"EARLY_PHASE1":10584,"PHASE1":10586,"PHASE2":10588,"PHASE3":10599,"PHASE4":10601,"NA":10603},{"trials":10585,"activeCount":102},[],{"trials":10587,"activeCount":102},[],{"trials":10589,"activeCount":102},[10590],{"nctId":10591,"briefTitle":10592,"status":112,"phases":10593,"primaryCompletion":598,"completion":5425,"start":10594,"enrollment":129,"conditions":10595,"interventions":10598},"NCT01467232","IMPACT-CABG Trial: IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing Coronary Artery Bypass Grafting",[91],"2011-09",[27,10596,10597],"Heart Attack","Coronary Artery Bypass Surgery",[10582,10582],{"trials":10600,"activeCount":102},[],{"trials":10602,"activeCount":102},[],{"trials":10604,"activeCount":102},[],{"intervention":10606,"totalTrials":149,"cells":10607},"Alemtuzumab",{"EARLY_PHASE1":10608,"PHASE1":10610,"PHASE2":10612,"PHASE3":10622,"PHASE4":10624,"NA":10626},{"trials":10609,"activeCount":102},[],{"trials":10611,"activeCount":102},[],{"trials":10613,"activeCount":102},[10614],{"nctId":10615,"briefTitle":10616,"status":112,"phases":10617,"primaryCompletion":768,"completion":768,"start":5801,"enrollment":471,"conditions":10618,"interventions":10620},"NCT00775632","Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants",[91],[8925,10619],"Bone Marrow Transplantation",[10606,10621],"mycophenolate or cyclosporine and methotrexate",{"trials":10623,"activeCount":102},[],{"trials":10625,"activeCount":102},[],{"trials":10627,"activeCount":102},[],{"intervention":10621,"totalTrials":149,"cells":10629},{"EARLY_PHASE1":10630,"PHASE1":10632,"PHASE2":10634,"PHASE3":10640,"PHASE4":10642,"NA":10644},{"trials":10631,"activeCount":102},[],{"trials":10633,"activeCount":102},[],{"trials":10635,"activeCount":102},[10636],{"nctId":10615,"briefTitle":10616,"status":112,"phases":10637,"primaryCompletion":768,"completion":768,"start":5801,"enrollment":471,"conditions":10638,"interventions":10639},[91],[8925,10619],[10606,10621],{"trials":10641,"activeCount":102},[],{"trials":10643,"activeCount":102},[],{"trials":10645,"activeCount":102},[],{"intervention":5162,"totalTrials":149,"cells":10647},{"EARLY_PHASE1":10648,"PHASE1":10650,"PHASE2":10652,"PHASE3":10658,"PHASE4":10660,"NA":10662},{"trials":10649,"activeCount":102},[],{"trials":10651,"activeCount":102},[],{"trials":10653,"activeCount":102},[10654],{"nctId":5152,"briefTitle":5153,"status":1723,"phases":10655,"primaryCompletion":5155,"completion":5156,"start":5157,"enrollment":5158,"conditions":10656,"interventions":10657},[91],[5160],[5162,5143],{"trials":10659,"activeCount":102},[],{"trials":10661,"activeCount":102},[],{"trials":10663,"activeCount":102},[],{"intervention":10665,"totalTrials":149,"cells":10666},"Adrenocorticotrophic hormone ACTH",{"EARLY_PHASE1":10667,"PHASE1":10669,"PHASE2":10671,"PHASE3":10680,"PHASE4":10682,"NA":10684},{"trials":10668,"activeCount":102},[],{"trials":10670,"activeCount":102},[],{"trials":10672,"activeCount":102},[10673],{"nctId":10674,"briefTitle":10675,"status":112,"phases":10676,"primaryCompletion":686,"completion":9592,"start":730,"enrollment":511,"conditions":10677,"interventions":10679},"NCT01093157","A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy",[90,91],[10678],"Glomerulonephritis",[10665],{"trials":10681,"activeCount":102},[],{"trials":10683,"activeCount":102},[],{"trials":10685,"activeCount":102},[],{"intervention":10687,"totalTrials":149,"cells":10688},"Dexamethasone sodium phosphate",{"EARLY_PHASE1":10689,"PHASE1":10691,"PHASE2":10693,"PHASE3":10703,"PHASE4":10705,"NA":10707},{"trials":10690,"activeCount":102},[],{"trials":10692,"activeCount":102},[],{"trials":10694,"activeCount":102},[10695],{"nctId":10696,"briefTitle":10697,"status":112,"phases":10698,"primaryCompletion":5916,"completion":5916,"start":5107,"enrollment":2011,"conditions":10699,"interventions":10702},"NCT01030601","Analysis of the Effect of Intravitreal Dexamethasone Injection on Diabetic Macular Edema After Cataract Surgery (IDDMECS)",[91],[5110,10700,10701],"Macular Edema","Pseudophakia",[10687],{"trials":10704,"activeCount":102},[],{"trials":10706,"activeCount":102},[],{"trials":10708,"activeCount":102},[],{"intervention":2015,"totalTrials":149,"cells":10710},{"EARLY_PHASE1":10711,"PHASE1":10713,"PHASE2":10715,"PHASE3":10721,"PHASE4":10723,"NA":10725},{"trials":10712,"activeCount":102},[],{"trials":10714,"activeCount":102},[],{"trials":10716,"activeCount":102},[10717],{"nctId":2008,"briefTitle":2009,"status":727,"phases":10718,"start":1990,"enrollment":2011,"conditions":10719,"interventions":10720},[91],[2013],[1994,2015],{"trials":10722,"activeCount":102},[],{"trials":10724,"activeCount":102},[],{"trials":10726,"activeCount":102},[],{"intervention":10728,"totalTrials":149,"cells":10729},"GTI-2040",{"EARLY_PHASE1":10730,"PHASE1":10732,"PHASE2":10734,"PHASE3":10744,"PHASE4":10746,"NA":10748},{"trials":10731,"activeCount":102},[],{"trials":10733,"activeCount":102},[],{"trials":10735,"activeCount":102},[10736],{"nctId":10737,"briefTitle":10738,"status":112,"phases":10739,"primaryCompletion":5802,"completion":1794,"start":6048,"enrollment":1388,"conditions":10740,"interventions":10741},"NCT00087165","GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer",[91],[15],[10728,10742,10743],"docetaxel","prednisone",{"trials":10745,"activeCount":102},[],{"trials":10747,"activeCount":102},[],{"trials":10749,"activeCount":102},[],{"intervention":10742,"totalTrials":149,"cells":10751},{"EARLY_PHASE1":10752,"PHASE1":10754,"PHASE2":10756,"PHASE3":10762,"PHASE4":10764,"NA":10766},{"trials":10753,"activeCount":102},[],{"trials":10755,"activeCount":102},[],{"trials":10757,"activeCount":102},[10758],{"nctId":10737,"briefTitle":10738,"status":112,"phases":10759,"primaryCompletion":5802,"completion":1794,"start":6048,"enrollment":1388,"conditions":10760,"interventions":10761},[91],[15],[10728,10742,10743],{"trials":10763,"activeCount":102},[],{"trials":10765,"activeCount":102},[],{"trials":10767,"activeCount":102},[],{"intervention":10743,"totalTrials":149,"cells":10769},{"EARLY_PHASE1":10770,"PHASE1":10772,"PHASE2":10774,"PHASE3":10780,"PHASE4":10782,"NA":10784},{"trials":10771,"activeCount":102},[],{"trials":10773,"activeCount":102},[],{"trials":10775,"activeCount":102},[10776],{"nctId":10737,"briefTitle":10738,"status":112,"phases":10777,"primaryCompletion":5802,"completion":1794,"start":6048,"enrollment":1388,"conditions":10778,"interventions":10779},[91],[15],[10728,10742,10743],{"trials":10781,"activeCount":102},[],{"trials":10783,"activeCount":102},[],{"trials":10785,"activeCount":102},[],{"intervention":10787,"totalTrials":149,"cells":10788},"intravenous immunoglobulin + subcutaneous immunoglobulin",{"EARLY_PHASE1":10789,"PHASE1":10791,"PHASE2":10793,"PHASE3":10803,"PHASE4":10805,"NA":10807},{"trials":10790,"activeCount":102},[],{"trials":10792,"activeCount":102},[],{"trials":10794,"activeCount":102},[10795],{"nctId":10796,"briefTitle":10797,"status":112,"phases":10798,"primaryCompletion":1304,"completion":10799,"start":5058,"enrollment":607,"conditions":10800,"interventions":10801},"NCT04728425","Subcutaneous Immunoglobulin for Myasthenia Gravis",[91],"2023-12-30",[8217],[10802,10787],"subcutaneous immunoglobulin",{"trials":10804,"activeCount":102},[],{"trials":10806,"activeCount":102},[],{"trials":10808,"activeCount":102},[],{"intervention":10810,"totalTrials":149,"cells":10811},"Cannabis",{"EARLY_PHASE1":10812,"PHASE1":10814,"PHASE2":10816,"PHASE3":10828,"PHASE4":10830,"NA":10832},{"trials":10813,"activeCount":102},[],{"trials":10815,"activeCount":102},[],{"trials":10817,"activeCount":102},[10818],{"nctId":10819,"briefTitle":10820,"status":727,"phases":10821,"primaryCompletion":10822,"completion":10823,"start":10824,"enrollment":244,"conditions":10825,"interventions":10827},"NCT03247244","Safety and Efficacy of Cannabis in Tourette Syndrome",[91],"2019-06-06","2020-01-27","2018-01-15",[10826],"Tourette Syndrome",[10810,10810,10810],{"trials":10829,"activeCount":102},[],{"trials":10831,"activeCount":102},[],{"trials":10833,"activeCount":102},[],{"intervention":8566,"totalTrials":149,"cells":10835},{"EARLY_PHASE1":10836,"PHASE1":10838,"PHASE2":10840,"PHASE3":10846,"PHASE4":10848,"NA":10850},{"trials":10837,"activeCount":102},[],{"trials":10839,"activeCount":102},[],{"trials":10841,"activeCount":102},[10842],{"nctId":8560,"briefTitle":8561,"status":727,"phases":10843,"primaryCompletion":8563,"completion":8563,"start":7511,"enrollment":687,"conditions":10844,"interventions":10845},[90,91],[2204],[8566,4221],{"trials":10847,"activeCount":102},[],{"trials":10849,"activeCount":102},[],{"trials":10851,"activeCount":102},[],{"intervention":793,"totalTrials":149,"cells":10853},{"EARLY_PHASE1":10854,"PHASE1":10856,"PHASE2":10858,"PHASE3":10864,"PHASE4":10866,"NA":10868},{"trials":10855,"activeCount":102},[],{"trials":10857,"activeCount":102},[],{"trials":10859,"activeCount":102},[10860],{"nctId":781,"briefTitle":782,"status":112,"phases":10861,"primaryCompletion":784,"completion":784,"start":785,"enrollment":36,"conditions":10862,"interventions":10863},[91],[787,788,789,790],[792,576,793],{"trials":10865,"activeCount":102},[],{"trials":10867,"activeCount":102},[],{"trials":10869,"activeCount":102},[],{"intervention":10871,"totalTrials":149,"cells":10872},"Sodium Bicarbonate 8.4% Solution for",{"EARLY_PHASE1":10873,"PHASE1":10875,"PHASE2":10877,"PHASE3":10889,"PHASE4":10891,"NA":10893},{"trials":10874,"activeCount":102},[],{"trials":10876,"activeCount":102},[],{"trials":10878,"activeCount":102},[10879],{"nctId":10880,"briefTitle":10881,"status":550,"phases":10882,"primaryCompletion":10883,"completion":10884,"start":7353,"enrollment":102,"conditions":10885,"interventions":10887},"NCT03348826","Study of Sodium Bicarbonate in Restoring Blocked Catheters",[91],"2020-09-01","2021-09-02",[24,10886],"Central Venous Catheterization",[10871,10888],"Alteplase Injectable Solution",{"trials":10890,"activeCount":102},[],{"trials":10892,"activeCount":102},[],{"trials":10894,"activeCount":102},[],{"intervention":10888,"totalTrials":149,"cells":10896},{"EARLY_PHASE1":10897,"PHASE1":10899,"PHASE2":10901,"PHASE3":10907,"PHASE4":10909,"NA":10911},{"trials":10898,"activeCount":102},[],{"trials":10900,"activeCount":102},[],{"trials":10902,"activeCount":102},[10903],{"nctId":10880,"briefTitle":10881,"status":550,"phases":10904,"primaryCompletion":10883,"completion":10884,"start":7353,"enrollment":102,"conditions":10905,"interventions":10906},[91],[24,10886],[10871,10888],{"trials":10908,"activeCount":102},[],{"trials":10910,"activeCount":102},[],{"trials":10912,"activeCount":102},[],{"intervention":10914,"totalTrials":149,"cells":10915},"Revlimid",{"EARLY_PHASE1":10916,"PHASE1":10918,"PHASE2":10920,"PHASE3":10928,"PHASE4":10930,"NA":10932},{"trials":10917,"activeCount":102},[],{"trials":10919,"activeCount":102},[],{"trials":10921,"activeCount":102},[10922],{"nctId":10923,"briefTitle":10924,"status":112,"phases":10925,"primaryCompletion":8563,"completion":8563,"start":4600,"enrollment":3928,"conditions":10926,"interventions":10927},"NCT00957385","Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients",[91],[2204],[10914],{"trials":10929,"activeCount":102},[],{"trials":10931,"activeCount":102},[],{"trials":10933,"activeCount":102},[],{"intervention":8532,"totalTrials":149,"cells":10935},{"EARLY_PHASE1":10936,"PHASE1":10938,"PHASE2":10940,"PHASE3":10946,"PHASE4":10948,"NA":10950},{"trials":10937,"activeCount":102},[],{"trials":10939,"activeCount":102},[],{"trials":10941,"activeCount":102},[10942],{"nctId":8525,"briefTitle":8526,"status":112,"phases":10943,"primaryCompletion":8528,"start":8510,"conditions":10944,"interventions":10945},[90,91],[8530,7711],[8500,8532],{"trials":10947,"activeCount":102},[],{"trials":10949,"activeCount":102},[],{"trials":10951,"activeCount":102},[],{"intervention":634,"totalTrials":149,"cells":10953},{"EARLY_PHASE1":10954,"PHASE1":10956,"PHASE2":10958,"PHASE3":10964,"PHASE4":10966,"NA":10968},{"trials":10955,"activeCount":102},[],{"trials":10957,"activeCount":102},[],{"trials":10959,"activeCount":102},[10960],{"nctId":625,"briefTitle":626,"status":112,"phases":10961,"primaryCompletion":628,"completion":629,"start":630,"enrollment":129,"conditions":10962,"interventions":10963},[91],[632],[72,634,635],{"trials":10965,"activeCount":102},[],{"trials":10967,"activeCount":102},[],{"trials":10969,"activeCount":102},[],{"intervention":10971,"totalTrials":149,"cells":10972},"cisplatinum combined with infusional fluorouracil",{"EARLY_PHASE1":10973,"PHASE1":10975,"PHASE2":10977,"PHASE3":10989,"PHASE4":10991,"NA":10993},{"trials":10974,"activeCount":102},[],{"trials":10976,"activeCount":102},[],{"trials":10978,"activeCount":102},[10979],{"nctId":10980,"briefTitle":10981,"status":112,"phases":10982,"primaryCompletion":10983,"completion":10984,"start":10985,"enrollment":895,"conditions":10986,"interventions":10988},"NCT00188266","Study of Adjuvant Radiochemotherapy for Gastric Cancer",[90,91],"2013-12-19","2017-08-18","2002-08",[10987],"Stomach Neoplasms",[10971],{"trials":10990,"activeCount":102},[],{"trials":10992,"activeCount":102},[],{"trials":10994,"activeCount":102},[],{"intervention":2274,"totalTrials":149,"cells":10996},{"EARLY_PHASE1":10997,"PHASE1":10999,"PHASE2":11001,"PHASE3":11007,"PHASE4":11009,"NA":11011},{"trials":10998,"activeCount":102},[],{"trials":11000,"activeCount":102},[],{"trials":11002,"activeCount":102},[11003],{"nctId":2266,"briefTitle":2267,"status":112,"phases":11004,"primaryCompletion":2269,"completion":2269,"start":2270,"enrollment":36,"conditions":11005,"interventions":11006},[91],[2272],[2274,2248],{"trials":11008,"activeCount":102},[],{"trials":11010,"activeCount":102},[],{"trials":11012,"activeCount":102},[],{"intervention":11014,"totalTrials":149,"cells":11015},"GEFITINIB",{"EARLY_PHASE1":11016,"PHASE1":11018,"PHASE2":11020,"PHASE3":11029,"PHASE4":11031,"NA":11033},{"trials":11017,"activeCount":102},[],{"trials":11019,"activeCount":102},[],{"trials":11021,"activeCount":102},[11022],{"nctId":11023,"briefTitle":11024,"status":112,"phases":11025,"primaryCompletion":770,"completion":141,"start":6048,"enrollment":2357,"conditions":11026,"interventions":11028},"NCT00188617","Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC",[91],[11027],"LUNG CANCER",[11014],{"trials":11030,"activeCount":102},[],{"trials":11032,"activeCount":102},[],{"trials":11034,"activeCount":102},[],{"intervention":11036,"totalTrials":149,"cells":11037},"Aprepitant",{"EARLY_PHASE1":11038,"PHASE1":11040,"PHASE2":11042,"PHASE3":11052,"PHASE4":11054,"NA":11056},{"trials":11039,"activeCount":102},[],{"trials":11041,"activeCount":102},[],{"trials":11043,"activeCount":102},[11044],{"nctId":11045,"briefTitle":11046,"status":112,"phases":11047,"primaryCompletion":5201,"completion":11048,"start":10594,"enrollment":11049,"conditions":11050,"interventions":11051},"NCT01334086","Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy",[91],"2013-08-30",41,[2204],[11036],{"trials":11053,"activeCount":102},[],{"trials":11055,"activeCount":102},[],{"trials":11057,"activeCount":102},[],{"intervention":8645,"totalTrials":149,"cells":11059},{"EARLY_PHASE1":11060,"PHASE1":11062,"PHASE2":11064,"PHASE3":11070,"PHASE4":11072,"NA":11074},{"trials":11061,"activeCount":102},[],{"trials":11063,"activeCount":102},[],{"trials":11065,"activeCount":102},[11066],{"nctId":8639,"briefTitle":8640,"status":112,"phases":11067,"primaryCompletion":7620,"completion":8642,"start":7164,"enrollment":36,"conditions":11068,"interventions":11069},[91],[609,789],[8645,8610],{"trials":11071,"activeCount":102},[],{"trials":11073,"activeCount":102},[],{"trials":11075,"activeCount":102},[],{"intervention":11077,"totalTrials":149,"cells":11078},"JNJ-42756493",{"EARLY_PHASE1":11079,"PHASE1":11081,"PHASE2":11083,"PHASE3":11094,"PHASE4":11096,"NA":11098},{"trials":11080,"activeCount":102},[],{"trials":11082,"activeCount":102},[],{"trials":11084,"activeCount":102},[11085],{"nctId":11086,"briefTitle":11087,"status":727,"phases":11088,"primaryCompletion":11089,"completion":11089,"start":11090,"enrollment":129,"conditions":11091,"interventions":11093},"NCT02952573","Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement",[91],"2018-11-13","2017-06-13",[246,11092],"Relapsed\u002FRefractory",[11077,623],{"trials":11095,"activeCount":102},[],{"trials":11097,"activeCount":102},[],{"trials":11099,"activeCount":102},[],{"intervention":11101,"totalTrials":149,"cells":11102},"cisplatinium and fluorouracil - standard treatment",{"EARLY_PHASE1":11103,"PHASE1":11105,"PHASE2":11107,"PHASE3":11116,"PHASE4":11118,"NA":11120},{"trials":11104,"activeCount":102},[],{"trials":11106,"activeCount":102},[],{"trials":11108,"activeCount":102},[11109],{"nctId":11110,"briefTitle":11111,"status":112,"phases":11112,"primaryCompletion":4600,"completion":4265,"start":8868,"enrollment":3047,"conditions":11113,"interventions":11115},"NCT00188877","Intensity Modulated Radiation Therapy for Head and Neck Cancer",[91],[11114],"Nasopharyngeal Neoplasms",[11101],{"trials":11117,"activeCount":102},[],{"trials":11119,"activeCount":102},[],{"trials":11121,"activeCount":102},[],{"intervention":11123,"totalTrials":149,"cells":11124},"CFI-400945",{"EARLY_PHASE1":11125,"PHASE1":11127,"PHASE2":11138,"PHASE3":11140,"PHASE4":11142,"NA":11144},{"trials":11126,"activeCount":102},[],{"trials":11128,"activeCount":102},[11129],{"nctId":11130,"briefTitle":11131,"status":112,"phases":11132,"primaryCompletion":11133,"completion":11134,"start":8827,"enrollment":11135,"conditions":11136,"interventions":11137},"NCT01954316","A Study of CFI-400945 Fumarate in Patients With Advanced Cancer",[90],"2021-07","2021-07-22",46,[855],[11123],{"trials":11139,"activeCount":102},[],{"trials":11141,"activeCount":102},[],{"trials":11143,"activeCount":102},[],{"trials":11145,"activeCount":102},[],{"intervention":11147,"totalTrials":149,"cells":11148},"Clioquinol",{"EARLY_PHASE1":11149,"PHASE1":11151,"PHASE2":11163,"PHASE3":11165,"PHASE4":11167,"NA":11169},{"trials":11150,"activeCount":102},[],{"trials":11152,"activeCount":102},[11153],{"nctId":11154,"briefTitle":11155,"status":727,"phases":11156,"primaryCompletion":8999,"completion":8999,"start":6630,"enrollment":1336,"conditions":11157,"interventions":11162},"NCT00963495","Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy",[90],[2204,11158,8735,11159,11160,11161,246],"Acute Lymphocytic Leukemia","Myelodysplasia","Lymphoma, Non-Hodgkin","Hodgkin's Lymphoma",[11147],{"trials":11164,"activeCount":102},[],{"trials":11166,"activeCount":102},[],{"trials":11168,"activeCount":102},[],{"trials":11170,"activeCount":102},[],{"intervention":8779,"totalTrials":149,"cells":11172},{"EARLY_PHASE1":11173,"PHASE1":11175,"PHASE2":11181,"PHASE3":11183,"PHASE4":11185,"NA":11187},{"trials":11174,"activeCount":102},[],{"trials":11176,"activeCount":102},[11177],{"nctId":8772,"briefTitle":8773,"status":112,"phases":11178,"primaryCompletion":8286,"start":8775,"enrollment":33,"conditions":11179,"interventions":11180},[90],[8777],[723,8779],{"trials":11182,"activeCount":102},[],{"trials":11184,"activeCount":102},[],{"trials":11186,"activeCount":102},[],{"trials":11188,"activeCount":102},[],{"intervention":11190,"totalTrials":149,"cells":11191},"NK-92 cells",{"EARLY_PHASE1":11192,"PHASE1":11194,"PHASE2":11205,"PHASE3":11207,"PHASE4":11209,"NA":11211},{"trials":11193,"activeCount":102},[],{"trials":11195,"activeCount":102},[11196],{"nctId":11197,"briefTitle":11198,"status":112,"phases":11199,"primaryCompletion":7800,"completion":7800,"start":11200,"enrollment":1348,"conditions":11201,"interventions":11204},"NCT00990717","Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies",[90],"2005-03",[8530,7711,11202,11203],"Myeloma","Hodgkin's Disease",[11190],{"trials":11206,"activeCount":102},[],{"trials":11208,"activeCount":102},[],{"trials":11210,"activeCount":102},[],{"trials":11212,"activeCount":102},[],{"intervention":557,"totalTrials":149,"cells":11214},{"EARLY_PHASE1":11215,"PHASE1":11217,"PHASE2":11223,"PHASE3":11225,"PHASE4":11227,"NA":11229},{"trials":11216,"activeCount":102},[],{"trials":11218,"activeCount":102},[11219],{"nctId":548,"briefTitle":549,"status":550,"phases":11220,"primaryCompletion":552,"completion":552,"start":552,"enrollment":102,"conditions":11221,"interventions":11222},[90],[554,555],[557,72,558],{"trials":11224,"activeCount":102},[],{"trials":11226,"activeCount":102},[],{"trials":11228,"activeCount":102},[],{"trials":11230,"activeCount":102},[],{"intervention":11232,"totalTrials":149,"cells":11233},"Ciclopirox Olamine",{"EARLY_PHASE1":11234,"PHASE1":11236,"PHASE2":11246,"PHASE3":11248,"PHASE4":11250,"NA":11252},{"trials":11235,"activeCount":102},[],{"trials":11237,"activeCount":102},[11238],{"nctId":11239,"briefTitle":11240,"status":112,"phases":11241,"primaryCompletion":8112,"start":140,"enrollment":129,"conditions":11242,"interventions":11245},"NCT00990587","Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy",[90],[11243,11158,8735,11159,2204,11244,11203],"Hematologic Malignancy","Chronic Myelogenous Leukemia",[11232],{"trials":11247,"activeCount":102},[],{"trials":11249,"activeCount":102},[],{"trials":11251,"activeCount":102},[],{"trials":11253,"activeCount":102},[],{"intervention":8831,"totalTrials":149,"cells":11255},{"EARLY_PHASE1":11256,"PHASE1":11258,"PHASE2":11264,"PHASE3":11266,"PHASE4":11268,"NA":11270},{"trials":11257,"activeCount":102},[],{"trials":11259,"activeCount":102},[11260],{"nctId":8824,"briefTitle":8825,"status":112,"phases":11261,"primaryCompletion":8827,"completion":524,"start":6380,"enrollment":3928,"conditions":11262,"interventions":11263},[90],[8829],[8831,8817],{"trials":11265,"activeCount":102},[],{"trials":11267,"activeCount":102},[],{"trials":11269,"activeCount":102},[],{"trials":11271,"activeCount":102},[],{"intervention":680,"totalTrials":149,"cells":11273},{"EARLY_PHASE1":11274,"PHASE1":11276,"PHASE2":11282,"PHASE3":11284,"PHASE4":11286,"NA":11288},{"trials":11275,"activeCount":102},[],{"trials":11277,"activeCount":102},[11278],{"nctId":671,"briefTitle":672,"status":112,"phases":11279,"primaryCompletion":674,"start":675,"enrollment":541,"conditions":11280,"interventions":11281},[90],[21],[678,679,680],{"trials":11283,"activeCount":102},[],{"trials":11285,"activeCount":102},[],{"trials":11287,"activeCount":102},[],{"trials":11289,"activeCount":102},[],{"intervention":11291,"totalTrials":149,"cells":11292},"DNT cells",{"EARLY_PHASE1":11293,"PHASE1":11295,"PHASE2":11304,"PHASE3":11306,"PHASE4":11308,"NA":11310},{"trials":11294,"activeCount":102},[],{"trials":11296,"activeCount":102},[11297],{"nctId":11298,"briefTitle":11299,"status":112,"phases":11300,"primaryCompletion":71,"completion":71,"start":11301,"enrollment":6986,"conditions":11302,"interventions":11303},"NCT03027102","Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid Leukemia",[90],"2017-08-15",[2204],[11291],{"trials":11305,"activeCount":102},[],{"trials":11307,"activeCount":102},[],{"trials":11309,"activeCount":102},[],{"trials":11311,"activeCount":102},[],{"intervention":691,"totalTrials":149,"cells":11313},{"EARLY_PHASE1":11314,"PHASE1":11316,"PHASE2":11322,"PHASE3":11324,"PHASE4":11326,"NA":11328},{"trials":11315,"activeCount":102},[],{"trials":11317,"activeCount":102},[11318],{"nctId":682,"briefTitle":683,"status":112,"phases":11319,"primaryCompletion":685,"completion":524,"start":686,"enrollment":687,"conditions":11320,"interventions":11321},[90],[689],[691,576],{"trials":11323,"activeCount":102},[],{"trials":11325,"activeCount":102},[],{"trials":11327,"activeCount":102},[],{"trials":11329,"activeCount":102},[],{"intervention":1490,"totalTrials":149,"cells":11331},{"EARLY_PHASE1":11332,"PHASE1":11334,"PHASE2":11340,"PHASE3":11342,"PHASE4":11344,"NA":11346},{"trials":11333,"activeCount":102},[],{"trials":11335,"activeCount":102},[11336],{"nctId":1480,"briefTitle":1481,"status":550,"phases":11337,"primaryCompletion":1483,"completion":1483,"start":1484,"enrollment":102,"conditions":11338,"interventions":11339},[90],[1486,1487,1488],[1490,1466],{"trials":11341,"activeCount":102},[],{"trials":11343,"activeCount":102},[],{"trials":11345,"activeCount":102},[],{"trials":11347,"activeCount":102},[],{"intervention":11349,"totalTrials":149,"cells":11350},"CP-675,206",{"EARLY_PHASE1":11351,"PHASE1":11353,"PHASE2":11362,"PHASE3":11364,"PHASE4":11366,"NA":11368},{"trials":11352,"activeCount":102},[],{"trials":11354,"activeCount":102},[11355],{"nctId":11356,"briefTitle":11357,"status":727,"phases":11358,"primaryCompletion":8319,"start":6380,"enrollment":584,"conditions":11359,"interventions":11361},"NCT01334099","Safety Study of Radiation and CP-675,206 Infusion for Breast Cancer Patients",[90],[11360],"Metastatic Breast Cancer",[11349],{"trials":11363,"activeCount":102},[],{"trials":11365,"activeCount":102},[],{"trials":11367,"activeCount":102},[],{"trials":11369,"activeCount":102},[],{"intervention":11371,"totalTrials":149,"cells":11372},"EF5",{"EARLY_PHASE1":11373,"PHASE1":11375,"PHASE2":11384,"PHASE3":11386,"PHASE4":11388,"NA":11390},{"trials":11374,"activeCount":102},[],{"trials":11376,"activeCount":102},[11377],{"nctId":11378,"briefTitle":11379,"status":727,"phases":11380,"primaryCompletion":8510,"start":11381,"conditions":11382,"interventions":11383},"NCT00004261","EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma",[90],"1999-12",[18,826,30,15,3024],[11371],{"trials":11385,"activeCount":102},[],{"trials":11387,"activeCount":102},[],{"trials":11389,"activeCount":102},[],{"trials":11391,"activeCount":102},[],{"intervention":11393,"totalTrials":149,"cells":11394},"Mitotane",{"EARLY_PHASE1":11395,"PHASE1":11397,"PHASE2":11405,"PHASE3":11407,"PHASE4":11409,"NA":11411},{"trials":11396,"activeCount":102},[],{"trials":11398,"activeCount":102},[11399],{"nctId":11400,"briefTitle":11401,"status":112,"phases":11402,"primaryCompletion":8563,"completion":5425,"start":8999,"enrollment":149,"conditions":11403,"interventions":11404},"NCT02057237","A Safety and Feasibility Study of Mitotane in Prostate Cancer",[90],[15],[11393],{"trials":11406,"activeCount":102},[],{"trials":11408,"activeCount":102},[],{"trials":11410,"activeCount":102},[],{"trials":11412,"activeCount":102},[],{"intervention":11414,"totalTrials":149,"cells":11415},"ABI-007",{"EARLY_PHASE1":11416,"PHASE1":11418,"PHASE2":11426,"PHASE3":11428,"PHASE4":11430,"NA":11432},{"trials":11417,"activeCount":102},[],{"trials":11419,"activeCount":102},[11420],{"nctId":11421,"briefTitle":11422,"status":112,"phases":11423,"primaryCompletion":5826,"completion":5826,"start":10570,"enrollment":687,"conditions":11424,"interventions":11425},"NCT00731380","A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck Cancer",[90],[30],[11414],{"trials":11427,"activeCount":102},[],{"trials":11429,"activeCount":102},[],{"trials":11431,"activeCount":102},[],{"trials":11433,"activeCount":102},[],{"intervention":9053,"totalTrials":149,"cells":11435},{"EARLY_PHASE1":11436,"PHASE1":11438,"PHASE2":11444,"PHASE3":11446,"PHASE4":11448,"NA":11450},{"trials":11437,"activeCount":102},[],{"trials":11439,"activeCount":102},[11440],{"nctId":9047,"briefTitle":9048,"status":112,"phases":11441,"primaryCompletion":6630,"start":8775,"enrollment":1560,"conditions":11442,"interventions":11443},[90],[8777],[9052,9053],{"trials":11445,"activeCount":102},[],{"trials":11447,"activeCount":102},[],{"trials":11449,"activeCount":102},[],{"trials":11451,"activeCount":102},[],{"intervention":11453,"totalTrials":149,"cells":11454},"CFI-400945 Fumarate",{"EARLY_PHASE1":11455,"PHASE1":11457,"PHASE2":11466,"PHASE3":11468,"PHASE4":11470,"NA":11472},{"trials":11456,"activeCount":102},[],{"trials":11458,"activeCount":102},[11459],{"nctId":11460,"briefTitle":11461,"status":112,"phases":11462,"primaryCompletion":1858,"completion":1858,"start":7687,"enrollment":771,"conditions":11463,"interventions":11465},"NCT03187288","Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS",[90],[2204,11464,247,248],"Myelodysplastic Syndromes",[11453],{"trials":11467,"activeCount":102},[],{"trials":11469,"activeCount":102},[],{"trials":11471,"activeCount":102},[],{"trials":11473,"activeCount":102},[],{"intervention":8668,"totalTrials":149,"cells":11475},{"EARLY_PHASE1":11476,"PHASE1":11478,"PHASE2":11484,"PHASE3":11486,"PHASE4":11488,"NA":11490},{"trials":11477,"activeCount":102},[],{"trials":11479,"activeCount":102},[11480],{"nctId":8663,"briefTitle":8664,"status":112,"phases":11481,"primaryCompletion":5134,"completion":2270,"start":5827,"enrollment":511,"conditions":11482,"interventions":11483},[90],[5110],[8668,6976],{"trials":11485,"activeCount":102},[],{"trials":11487,"activeCount":102},[],{"trials":11489,"activeCount":102},[],{"trials":11491,"activeCount":102},[],{"intervention":703,"totalTrials":149,"cells":11493},{"EARLY_PHASE1":11494,"PHASE1":11496,"PHASE2":11502,"PHASE3":11504,"PHASE4":11506,"NA":11508},{"trials":11495,"activeCount":102},[],{"trials":11497,"activeCount":102},[11498],{"nctId":693,"briefTitle":694,"status":112,"phases":11499,"primaryCompletion":696,"completion":697,"start":698,"enrollment":541,"conditions":11500,"interventions":11501},[90],[700,701],[703,576],{"trials":11503,"activeCount":102},[],{"trials":11505,"activeCount":102},[],{"trials":11507,"activeCount":102},[],{"trials":11509,"activeCount":102},[],{"intervention":8969,"totalTrials":149,"cells":11511},{"EARLY_PHASE1":11512,"PHASE1":11514,"PHASE2":11520,"PHASE3":11522,"PHASE4":11524,"NA":11526},{"trials":11513,"activeCount":102},[],{"trials":11515,"activeCount":102},[11516],{"nctId":8963,"briefTitle":8964,"status":112,"phases":11517,"primaryCompletion":5468,"start":8008,"enrollment":3928,"conditions":11518,"interventions":11519},[90],[8530],[8968,8969,8956],{"trials":11521,"activeCount":102},[],{"trials":11523,"activeCount":102},[],{"trials":11525,"activeCount":102},[],{"trials":11527,"activeCount":102},[],{"intervention":11529,"totalTrials":149,"cells":11530},"EBV-Specific CTLs and CD45 Mab",{"EARLY_PHASE1":11531,"PHASE1":11533,"PHASE2":11542,"PHASE3":11544,"PHASE4":11546,"NA":11548},{"trials":11532,"activeCount":102},[],{"trials":11534,"activeCount":102},[11535],{"nctId":11536,"briefTitle":11537,"status":112,"phases":11538,"primaryCompletion":6630,"completion":11539,"start":8304,"enrollment":1574,"conditions":11540,"interventions":11541},"NCT00706316","Administration of Epstein Barr Virus - Specific Cytotoxic T-Lymphocytes to Metastatic EBV-Positive Nasopharygneal Cancer",[90],"2012-11",[632],[11529],{"trials":11543,"activeCount":102},[],{"trials":11545,"activeCount":102},[],{"trials":11547,"activeCount":102},[],{"trials":11549,"activeCount":102},[],{"intervention":11551,"totalTrials":149,"cells":11552},"Nitric Oxide",{"EARLY_PHASE1":11553,"PHASE1":11555,"PHASE2":11566,"PHASE3":11568,"PHASE4":11570,"NA":11572},{"trials":11554,"activeCount":102},[],{"trials":11556,"activeCount":102},[11557],{"nctId":11558,"briefTitle":11559,"status":112,"phases":11560,"primaryCompletion":11561,"completion":11562,"start":11563,"enrollment":7055,"conditions":11564,"interventions":11565},"NCT04383002","High Dose Inhaled Nitric Oxide for COVID-19 (ICU Patients)",[90],"2021-05-11","2021-06-11","2020-09-02",[3537],[11551],{"trials":11567,"activeCount":102},[],{"trials":11569,"activeCount":102},[],{"trials":11571,"activeCount":102},[],{"trials":11573,"activeCount":102},[],{"intervention":11575,"totalTrials":149,"cells":11576},"Lentivirus Alpha-gal A transduced stem cells",{"EARLY_PHASE1":11577,"PHASE1":11579,"PHASE2":11589,"PHASE3":11591,"PHASE4":11593,"NA":11595},{"trials":11578,"activeCount":102},[],{"trials":11580,"activeCount":102},[11581],{"nctId":11582,"briefTitle":11583,"status":112,"phases":11584,"primaryCompletion":11585,"completion":11585,"start":606,"enrollment":1574,"conditions":11586,"interventions":11588},"NCT02800070","Autologous Stem Cell Transplantation of Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease",[90],"2024-04",[11587],"Fabry Disease",[11575],{"trials":11590,"activeCount":102},[],{"trials":11592,"activeCount":102},[],{"trials":11594,"activeCount":102},[],{"trials":11596,"activeCount":102},[],{"intervention":11598,"totalTrials":149,"cells":11599},"Tigecycline",{"EARLY_PHASE1":11600,"PHASE1":11602,"PHASE2":11610,"PHASE3":11612,"PHASE4":11614,"NA":11616},{"trials":11601,"activeCount":102},[],{"trials":11603,"activeCount":102},[11604],{"nctId":11605,"briefTitle":11606,"status":112,"phases":11607,"primaryCompletion":4347,"completion":1374,"start":808,"enrollment":2202,"conditions":11608,"interventions":11609},"NCT01332786","Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia",[90],[2204],[11598],{"trials":11611,"activeCount":102},[],{"trials":11613,"activeCount":102},[],{"trials":11615,"activeCount":102},[],{"trials":11617,"activeCount":102},[],{"intervention":11619,"totalTrials":149,"cells":11620},"0.9% saline",{"EARLY_PHASE1":11621,"PHASE1":11632,"PHASE2":11634,"PHASE3":11636,"PHASE4":11638,"NA":11640},{"trials":11622,"activeCount":102},[11623],{"nctId":11624,"briefTitle":11625,"status":112,"phases":11626,"primaryCompletion":6155,"completion":6155,"start":2355,"enrollment":1348,"conditions":11627,"interventions":11629},"NCT02680548","Pilot RCT of Efficacy of Perineural Local Anesthetics and Steroids for Chronic Post-traumatic Ankle and Foot Pain",[89],[11628],"CHRONIC POST-TRAUMATIC NEUROPATHIC PAIN IN ANKLE AND FOOT",[11619,11630,11631],"0.25% bupivacaine hydrochloride injectable suspension USP","4mg\u002Fcc methylprednisolone acetate injectable suspension USP",{"trials":11633,"activeCount":102},[],{"trials":11635,"activeCount":102},[],{"trials":11637,"activeCount":102},[],{"trials":11639,"activeCount":102},[],{"trials":11641,"activeCount":102},[],{"intervention":11630,"totalTrials":149,"cells":11643},{"EARLY_PHASE1":11644,"PHASE1":11650,"PHASE2":11652,"PHASE3":11654,"PHASE4":11656,"NA":11658},{"trials":11645,"activeCount":102},[11646],{"nctId":11624,"briefTitle":11625,"status":112,"phases":11647,"primaryCompletion":6155,"completion":6155,"start":2355,"enrollment":1348,"conditions":11648,"interventions":11649},[89],[11628],[11619,11630,11631],{"trials":11651,"activeCount":102},[],{"trials":11653,"activeCount":102},[],{"trials":11655,"activeCount":102},[],{"trials":11657,"activeCount":102},[],{"trials":11659,"activeCount":102},[],{"intervention":11631,"totalTrials":149,"cells":11661},{"EARLY_PHASE1":11662,"PHASE1":11668,"PHASE2":11670,"PHASE3":11672,"PHASE4":11674,"NA":11676},{"trials":11663,"activeCount":102},[11664],{"nctId":11624,"briefTitle":11625,"status":112,"phases":11665,"primaryCompletion":6155,"completion":6155,"start":2355,"enrollment":1348,"conditions":11666,"interventions":11667},[89],[11628],[11619,11630,11631],{"trials":11669,"activeCount":102},[],{"trials":11671,"activeCount":102},[],{"trials":11673,"activeCount":102},[],{"trials":11675,"activeCount":102},[],{"trials":11677,"activeCount":102},[],{"intervention":1587,"totalTrials":149,"cells":11679},{"EARLY_PHASE1":11680,"PHASE1":11686,"PHASE2":11688,"PHASE3":11690,"PHASE4":11692,"NA":11694},{"trials":11681,"activeCount":102},[11682],{"nctId":1579,"briefTitle":1580,"status":112,"phases":11683,"primaryCompletion":1582,"completion":1582,"start":1583,"enrollment":511,"conditions":11684,"interventions":11685},[89],[1486,1487,1585],[1587,574],{"trials":11687,"activeCount":102},[],{"trials":11689,"activeCount":102},[],{"trials":11691,"activeCount":102},[],{"trials":11693,"activeCount":102},[],{"trials":11695,"activeCount":102},[],{"intervention":11697,"totalTrials":149,"cells":11698},"Pentoxifylline 400 MG",{"EARLY_PHASE1":11699,"PHASE1":11710,"PHASE2":11712,"PHASE3":11714,"PHASE4":11716,"NA":11718},{"trials":11700,"activeCount":102},[11701],{"nctId":11702,"briefTitle":11703,"status":112,"phases":11704,"primaryCompletion":11705,"completion":11706,"start":11707,"enrollment":584,"conditions":11708,"interventions":11709},"NCT04417049","Treatment of Bipolar Depression With Pentoxifylline",[89],"2021-11-03","2021-11-29","2021-07-12",[1648],[11697],{"trials":11711,"activeCount":102},[],{"trials":11713,"activeCount":102},[],{"trials":11715,"activeCount":102},[],{"trials":11717,"activeCount":102},[],{"trials":11719,"activeCount":102},[],{"intervention":11721,"totalTrials":149,"cells":11722},"6 weeks BCG instillation",{"EARLY_PHASE1":11723,"PHASE1":11733,"PHASE2":11735,"PHASE3":11737,"PHASE4":11739,"NA":11741},{"trials":11724,"activeCount":102},[11725],{"nctId":11726,"briefTitle":11727,"status":727,"phases":11728,"primaryCompletion":11729,"completion":11729,"start":11730,"enrollment":659,"conditions":11731,"interventions":11732},"NCT03266900","A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma to no Re-resection for Improving Progression Free Survival",[89],"2021-10-04","2017-11-16",[589,645],[11721],{"trials":11734,"activeCount":102},[],{"trials":11736,"activeCount":102},[],{"trials":11738,"activeCount":102},[],{"trials":11740,"activeCount":102},[],{"trials":11742,"activeCount":102},[],{"intervention":623,"totalTrials":6986,"cells":11744},{"EARLY_PHASE1":11745,"PHASE1":11747,"PHASE2":11749,"PHASE3":11769,"PHASE4":11782,"NA":11795},{"trials":11746,"activeCount":102},[],{"trials":11748,"activeCount":102},[],{"trials":11750,"activeCount":102},[11751,11755,11765],{"nctId":613,"briefTitle":614,"status":112,"phases":11752,"primaryCompletion":616,"completion":617,"start":618,"enrollment":607,"conditions":11753,"interventions":11754},[91],[620],[622,72,623,576],{"nctId":11756,"briefTitle":11757,"status":112,"phases":11758,"primaryCompletion":8595,"completion":11759,"start":11760,"enrollment":19,"conditions":11761,"interventions":11763},"NCT00188864","Dexamethasone for Palliation - Brain Metastases",[91],"2019-01-28","2003-11",[11762],"Neoplasm Metastasis",[11764],"dexamethasone",{"nctId":11086,"briefTitle":11087,"status":727,"phases":11766,"primaryCompletion":11089,"completion":11089,"start":11090,"enrollment":129,"conditions":11767,"interventions":11768},[91],[246,11092],[11077,623],{"trials":11770,"activeCount":102},[11771,11775],{"nctId":7260,"briefTitle":7261,"status":1723,"phases":11772,"primaryCompletion":7263,"completion":7263,"start":7164,"enrollment":7264,"conditions":11773,"interventions":11774},[91,92],[146,7266,7267],[623,7249],{"nctId":11776,"briefTitle":11777,"status":112,"phases":11778,"primaryCompletion":768,"completion":768,"start":6048,"enrollment":7464,"conditions":11779,"interventions":11781},"NCT00152867","Dexamethasone Study: Impact on Quality of Life of Continuing Dexamethasone Following Emetogenic Chemotherapy",[92],[24,11780,6115],"Emesis",[623],{"trials":11783,"activeCount":102},[11784],{"nctId":11785,"briefTitle":11786,"status":112,"phases":11787,"primaryCompletion":11788,"completion":6869,"start":11789,"enrollment":11790,"conditions":11791,"interventions":11794},"NCT03394820","The Optimal Time of IV Dexamethasone Administration for Prolongation of Peripheral Nerve Block",[93],"2023-11-23","2017-05-30",197,[11792,11793],"Peripheral Nerve Block Prolongation","Hand Injury Wrist",[623],{"trials":11796,"activeCount":102},[11797],{"nctId":11798,"briefTitle":11799,"status":112,"phases":11800,"primaryCompletion":140,"completion":141,"start":7239,"enrollment":3047,"conditions":11801,"interventions":11802},"NCT00802009","Dexamethasone and Analgesic Duration After Supraclavicular Brachial Plexus Blockade",[94],[4293],[623,11803],"Mepivicaine",{"intervention":10424,"totalTrials":479,"cells":11805},{"EARLY_PHASE1":11806,"PHASE1":11808,"PHASE2":11810,"PHASE3":11816,"PHASE4":11818,"NA":11827},{"trials":11807,"activeCount":102},[],{"trials":11809,"activeCount":102},[],{"trials":11811,"activeCount":102},[11812],{"nctId":10418,"briefTitle":10419,"status":1723,"phases":11813,"primaryCompletion":1793,"completion":8551,"start":5916,"enrollment":607,"conditions":11814,"interventions":11815},[91],[10422],[10424,10409],{"trials":11817,"activeCount":102},[],{"trials":11819,"activeCount":102},[11820],{"nctId":11821,"briefTitle":11822,"status":112,"phases":11823,"primaryCompletion":7800,"completion":7800,"start":9902,"enrollment":3047,"conditions":11824,"interventions":11826},"NCT01453920","Wet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab Dosing",[93],[11825],"Age Related Macular Degeneration",[10424,10424],{"trials":11828,"activeCount":102},[11829,11836],{"nctId":11830,"briefTitle":11831,"status":112,"phases":11832,"primaryCompletion":5200,"completion":4140,"start":8475,"enrollment":607,"conditions":11833,"interventions":11834},"NCT02218177","Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD",[],[11825],[11835,10424],"Aflibercept",{"nctId":11837,"briefTitle":11838,"status":1723,"phases":11839,"primaryCompletion":11840,"start":598,"enrollment":218,"conditions":11841,"interventions":11844},"NCT02372916","Geographic Atrophy and Intravitreal Ranibizumab Injections",[],"2016-11",[11842,11843],"Age-related Macular Degeneration","Geographic Atrophy",[10424],{"intervention":6321,"totalTrials":659,"cells":11846},{"EARLY_PHASE1":11847,"PHASE1":11849,"PHASE2":11851,"PHASE3":11853,"PHASE4":11855,"NA":11861},{"trials":11848,"activeCount":102},[],{"trials":11850,"activeCount":102},[],{"trials":11852,"activeCount":102},[],{"trials":11854,"activeCount":102},[],{"trials":11856,"activeCount":102},[11857],{"nctId":6313,"briefTitle":6314,"status":112,"phases":11858,"primaryCompletion":6316,"completion":4212,"start":2270,"enrollment":1348,"conditions":11859,"interventions":11860},[93],[6318],[6300,6320,6321],{"trials":11862,"activeCount":102},[11863],{"nctId":11864,"briefTitle":11865,"status":112,"phases":11866,"primaryCompletion":6608,"completion":8563,"start":629,"enrollment":11867,"conditions":11868,"interventions":11870},"NCT01378741","Reducing Delirium After Cardiac Surgery: A Multifaceted Approach Of Perioperative Care",[94],185,[11869,5694],"Delirium",[6321,11871],"Dexmedetomidine",{"intervention":11871,"totalTrials":659,"cells":11873},{"EARLY_PHASE1":11874,"PHASE1":11876,"PHASE2":11878,"PHASE3":11880,"PHASE4":11882,"NA":11884},{"trials":11875,"activeCount":102},[],{"trials":11877,"activeCount":102},[],{"trials":11879,"activeCount":102},[],{"trials":11881,"activeCount":102},[],{"trials":11883,"activeCount":102},[],{"trials":11885,"activeCount":102},[11886,11890],{"nctId":11864,"briefTitle":11865,"status":112,"phases":11887,"primaryCompletion":6608,"completion":8563,"start":629,"enrollment":11867,"conditions":11888,"interventions":11889},[94],[11869,5694],[6321,11871],{"nctId":11891,"briefTitle":11892,"status":727,"phases":11893,"primaryCompletion":11894,"completion":11894,"start":6760,"enrollment":687,"conditions":11895,"interventions":11896},"NCT02170948","The Effectiveness of the Addition of Dexmedetomidine to Analgesia for Ankle Surgery.",[94],"2019-01-04",[4293],[11871],{"intervention":11898,"totalTrials":659,"cells":11899},"Zoledronic acid",{"EARLY_PHASE1":11900,"PHASE1":11902,"PHASE2":11904,"PHASE3":11906,"PHASE4":11916,"NA":11918},{"trials":11901,"activeCount":102},[],{"trials":11903,"activeCount":102},[],{"trials":11905,"activeCount":102},[],{"trials":11907,"activeCount":102},[11908],{"nctId":11909,"briefTitle":11910,"status":112,"phases":11911,"primaryCompletion":8923,"completion":11912,"start":674,"enrollment":7055,"conditions":11913,"interventions":11915},"NCT01344967","Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Patients With Metastatic Breast Cancer: Duration of Effect",[91,92],"2011-12",[11914],"Metastatic Breast Cancer With Bone Involvement",[11898],{"trials":11917,"activeCount":102},[],{"trials":11919,"activeCount":102},[11920],{"nctId":11921,"briefTitle":11922,"status":112,"phases":11923,"primaryCompletion":3481,"completion":3481,"start":5107,"enrollment":2011,"conditions":11924,"interventions":11926},"NCT01062503","Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC",[],[2263,11925],"Bone Metastasis",[11898],{"intervention":11928,"totalTrials":659,"cells":11929},"exenatide",{"EARLY_PHASE1":11930,"PHASE1":11932,"PHASE2":11934,"PHASE3":11946,"PHASE4":11948,"NA":11950},{"trials":11931,"activeCount":102},[],{"trials":11933,"activeCount":102},[],{"trials":11935,"activeCount":102},[11936],{"nctId":11937,"briefTitle":11938,"status":1723,"phases":11939,"primaryCompletion":11940,"completion":5872,"start":4141,"enrollment":11941,"conditions":11942,"interventions":11944},"NCT01938235","Exenatide for Myocardial Protection During Reperfusion Study",[91],"2017-07",198,[11943],"Myocardial Infarction",[11945],"Exenatide",{"trials":11947,"activeCount":102},[],{"trials":11949,"activeCount":102},[],{"trials":11951,"activeCount":102},[11952],{"nctId":11953,"briefTitle":11954,"status":112,"phases":11955,"primaryCompletion":10594,"completion":10594,"start":5107,"enrollment":244,"conditions":11956,"interventions":11957},"NCT01056549","Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in Humans",[94],[7940],[11928],{"intervention":11959,"totalTrials":659,"cells":11960},"PF-00299804",{"EARLY_PHASE1":11961,"PHASE1":11963,"PHASE2":11965,"PHASE3":11974,"PHASE4":11976,"NA":11978},{"trials":11962,"activeCount":102},[],{"trials":11964,"activeCount":102},[],{"trials":11966,"activeCount":102},[11967],{"nctId":11968,"briefTitle":11969,"status":112,"phases":11970,"primaryCompletion":8587,"completion":4141,"start":8733,"enrollment":771,"conditions":11971,"interventions":11973},"NCT01116843","Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment",[90,91],[11972],"Oral Cavity Cancer",[11959],{"trials":11975,"activeCount":102},[],{"trials":11977,"activeCount":102},[],{"trials":11979,"activeCount":102},[11980],{"nctId":11981,"briefTitle":11982,"status":112,"phases":11983,"primaryCompletion":8319,"completion":769,"start":11912,"enrollment":584,"conditions":11984,"interventions":11985},"NCT01484847","A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell Carcinoma",[94],[910],[11959],{"intervention":10802,"totalTrials":659,"cells":11987},{"EARLY_PHASE1":11988,"PHASE1":11990,"PHASE2":11992,"PHASE3":11998,"PHASE4":12000,"NA":12002},{"trials":11989,"activeCount":102},[],{"trials":11991,"activeCount":102},[],{"trials":11993,"activeCount":102},[11994],{"nctId":10796,"briefTitle":10797,"status":112,"phases":11995,"primaryCompletion":1304,"completion":10799,"start":5058,"enrollment":607,"conditions":11996,"interventions":11997},[91],[8217],[10802,10787],{"trials":11999,"activeCount":102},[],{"trials":12001,"activeCount":102},[],{"trials":12003,"activeCount":102},[12004],{"nctId":12005,"briefTitle":12006,"status":112,"phases":12007,"primaryCompletion":5366,"completion":5366,"start":12008,"enrollment":129,"conditions":12009,"interventions":12011},"NCT03401268","Subcutaneous Ig in Allogeneic Stem Cell Transplant Recipients",[94],"2018-02-01",[12010],"Hypogammaglobulinemia",[10802],{"intervention":12013,"totalTrials":149,"cells":12014},"Dorzolamide 2% drops",{"EARLY_PHASE1":12015,"PHASE1":12017,"PHASE2":12019,"PHASE3":12021,"PHASE4":12023,"NA":12025},{"trials":12016,"activeCount":102},[],{"trials":12018,"activeCount":102},[],{"trials":12020,"activeCount":102},[],{"trials":12022,"activeCount":102},[],{"trials":12024,"activeCount":102},[],{"trials":12026,"activeCount":102},[12027],{"nctId":12028,"briefTitle":12029,"status":1723,"phases":12030,"completion":630,"start":8214,"enrollment":33,"conditions":12031,"interventions":12033},"NCT00152932","Ocular Blood Flow in Early Glaucoma Patients Before and After Treatment With Dorzolamide",[94],[12032],"Glaucoma",[12013],{"intervention":12035,"totalTrials":149,"cells":12036},"Bupivicaine, Hydromorphone",{"EARLY_PHASE1":12037,"PHASE1":12039,"PHASE2":12041,"PHASE3":12043,"PHASE4":12045,"NA":12047},{"trials":12038,"activeCount":102},[],{"trials":12040,"activeCount":102},[],{"trials":12042,"activeCount":102},[],{"trials":12044,"activeCount":102},[],{"trials":12046,"activeCount":102},[],{"trials":12048,"activeCount":102},[12049],{"nctId":12050,"briefTitle":12051,"status":112,"phases":12052,"primaryCompletion":1793,"completion":1793,"start":5618,"enrollment":25,"conditions":12053,"interventions":12055},"NCT00644111","Post-operative Epidural Analgesia After Minimally Invasive Lumbar Decompression and Fusion",[94],[12054],"Low Back Pain",[12035,12056],"Saline Placebo",{"intervention":12056,"totalTrials":149,"cells":12058},{"EARLY_PHASE1":12059,"PHASE1":12061,"PHASE2":12063,"PHASE3":12065,"PHASE4":12067,"NA":12069},{"trials":12060,"activeCount":102},[],{"trials":12062,"activeCount":102},[],{"trials":12064,"activeCount":102},[],{"trials":12066,"activeCount":102},[],{"trials":12068,"activeCount":102},[],{"trials":12070,"activeCount":102},[12071],{"nctId":12050,"briefTitle":12051,"status":112,"phases":12072,"primaryCompletion":1793,"completion":1793,"start":5618,"enrollment":25,"conditions":12073,"interventions":12074},[94],[12054],[12035,12056],{"intervention":12076,"totalTrials":149,"cells":12077},"Intrathecal Morphine",{"EARLY_PHASE1":12078,"PHASE1":12080,"PHASE2":12082,"PHASE3":12084,"PHASE4":12086,"NA":12088},{"trials":12079,"activeCount":102},[],{"trials":12081,"activeCount":102},[],{"trials":12083,"activeCount":102},[],{"trials":12085,"activeCount":102},[],{"trials":12087,"activeCount":102},[],{"trials":12089,"activeCount":102},[12090],{"nctId":12091,"briefTitle":12092,"status":10299,"phases":12093,"primaryCompletion":6843,"completion":6843,"start":12094,"enrollment":172,"conditions":12095,"interventions":12096},"NCT01790971","Spinal Morphine for Patients With Obstructive Sleep Apnea",[94],"2020-01",[5761],[12076,12097],"No Intrathecal Morphine",{"intervention":12097,"totalTrials":149,"cells":12099},{"EARLY_PHASE1":12100,"PHASE1":12102,"PHASE2":12104,"PHASE3":12106,"PHASE4":12108,"NA":12110},{"trials":12101,"activeCount":102},[],{"trials":12103,"activeCount":102},[],{"trials":12105,"activeCount":102},[],{"trials":12107,"activeCount":102},[],{"trials":12109,"activeCount":102},[],{"trials":12111,"activeCount":102},[12112],{"nctId":12091,"briefTitle":12092,"status":10299,"phases":12113,"primaryCompletion":6843,"completion":6843,"start":12094,"enrollment":172,"conditions":12114,"interventions":12115},[94],[5761],[12076,12097],{"intervention":12117,"totalTrials":149,"cells":12118},"Bolus of 0.2% ropivicaine 20 mls followed by 0.2% ropivicaine at an infusion rate of 5mls\u002Fhr until 0600 on postoperative day 2",{"EARLY_PHASE1":12119,"PHASE1":12121,"PHASE2":12123,"PHASE3":12125,"PHASE4":12127,"NA":12129},{"trials":12120,"activeCount":102},[],{"trials":12122,"activeCount":102},[],{"trials":12124,"activeCount":102},[],{"trials":12126,"activeCount":102},[],{"trials":12128,"activeCount":102},[],{"trials":12130,"activeCount":102},[12131],{"nctId":12132,"briefTitle":12133,"status":112,"phases":12134,"primaryCompletion":8551,"completion":8551,"start":7239,"enrollment":12135,"conditions":12136,"interventions":12138},"NCT00803348","Continuous Femoral Nerve Blockade and Readiness to Discharge Following Total Knee Arthroplasty",[94],99,[12137],"Knee Arthroplasty",[12117,12139,12140],"Bolus of 0.2% ropivicaine 20 mls followed by 0.1% ropivicaine at an infusion rate of 10mls\u002Fhr until 0600 on post-operative day 2","Saline control",{"intervention":12139,"totalTrials":149,"cells":12142},{"EARLY_PHASE1":12143,"PHASE1":12145,"PHASE2":12147,"PHASE3":12149,"PHASE4":12151,"NA":12153},{"trials":12144,"activeCount":102},[],{"trials":12146,"activeCount":102},[],{"trials":12148,"activeCount":102},[],{"trials":12150,"activeCount":102},[],{"trials":12152,"activeCount":102},[],{"trials":12154,"activeCount":102},[12155],{"nctId":12132,"briefTitle":12133,"status":112,"phases":12156,"primaryCompletion":8551,"completion":8551,"start":7239,"enrollment":12135,"conditions":12157,"interventions":12158},[94],[12137],[12117,12139,12140],{"intervention":12140,"totalTrials":149,"cells":12160},{"EARLY_PHASE1":12161,"PHASE1":12163,"PHASE2":12165,"PHASE3":12167,"PHASE4":12169,"NA":12171},{"trials":12162,"activeCount":102},[],{"trials":12164,"activeCount":102},[],{"trials":12166,"activeCount":102},[],{"trials":12168,"activeCount":102},[],{"trials":12170,"activeCount":102},[],{"trials":12172,"activeCount":102},[12173],{"nctId":12132,"briefTitle":12133,"status":112,"phases":12174,"primaryCompletion":8551,"completion":8551,"start":7239,"enrollment":12135,"conditions":12175,"interventions":12176},[94],[12137],[12117,12139,12140],{"intervention":12178,"totalTrials":149,"cells":12179},"Spinal hypobaric Mepivacaine Local Anesthetic",{"EARLY_PHASE1":12180,"PHASE1":12182,"PHASE2":12184,"PHASE3":12186,"PHASE4":12188,"NA":12190},{"trials":12181,"activeCount":102},[],{"trials":12183,"activeCount":102},[],{"trials":12185,"activeCount":102},[],{"trials":12187,"activeCount":102},[],{"trials":12189,"activeCount":102},[],{"trials":12191,"activeCount":102},[12192],{"nctId":12193,"briefTitle":12194,"status":112,"phases":12195,"primaryCompletion":12196,"completion":12197,"start":12198,"enrollment":2591,"conditions":12199,"interventions":12200},"NCT06166394","Spinal Hypobaric Local Anesthetic Study",[],"2023-10-17","2024-05-24","2023-06-09",[4294],[12178,12201],"Spinal hypobaric Bupivacaine Local Anesthetic",{"intervention":12201,"totalTrials":149,"cells":12203},{"EARLY_PHASE1":12204,"PHASE1":12206,"PHASE2":12208,"PHASE3":12210,"PHASE4":12212,"NA":12214},{"trials":12205,"activeCount":102},[],{"trials":12207,"activeCount":102},[],{"trials":12209,"activeCount":102},[],{"trials":12211,"activeCount":102},[],{"trials":12213,"activeCount":102},[],{"trials":12215,"activeCount":102},[12216],{"nctId":12193,"briefTitle":12194,"status":112,"phases":12217,"primaryCompletion":12196,"completion":12197,"start":12198,"enrollment":2591,"conditions":12218,"interventions":12219},[],[4294],[12178,12201],{"intervention":12221,"totalTrials":149,"cells":12222},"Barium concentration",{"EARLY_PHASE1":12223,"PHASE1":12225,"PHASE2":12227,"PHASE3":12229,"PHASE4":12231,"NA":12233},{"trials":12224,"activeCount":102},[],{"trials":12226,"activeCount":102},[],{"trials":12228,"activeCount":102},[],{"trials":12230,"activeCount":102},[],{"trials":12232,"activeCount":102},[],{"trials":12234,"activeCount":102},[12235],{"nctId":12236,"briefTitle":12237,"status":112,"phases":12238,"primaryCompletion":12239,"completion":5156,"start":12240,"enrollment":12241,"conditions":12242,"interventions":12246},"NCT04114617","Physiological Flow of Liquids in Healthy Swallowing",[],"2019-09-12","2016-01-01",80,[12243,12244,12245],"Deglutition","Healthy Swallowing","Aging",[12221],{"intervention":12248,"totalTrials":149,"cells":12249},"Erdafitinib",{"EARLY_PHASE1":12250,"PHASE1":12252,"PHASE2":12254,"PHASE3":12256,"PHASE4":12258,"NA":12260},{"trials":12251,"activeCount":102},[],{"trials":12253,"activeCount":102},[],{"trials":12255,"activeCount":102},[],{"trials":12257,"activeCount":102},[],{"trials":12259,"activeCount":102},[],{"trials":12261,"activeCount":102},[12262],{"nctId":12263,"briefTitle":12264,"status":112,"phases":12265,"primaryCompletion":12266,"completion":12266,"start":12267,"enrollment":149,"conditions":12268,"interventions":12270},"NCT06328491","Erdafitinib in Metastatic Steroid-cell Ovarian Cancer",[94],"2022-08-22","2022-05-30",[732,12269],"Steroid Cell Tumor, Malignant",[12248],{"intervention":12272,"totalTrials":149,"cells":12273},"therapeutic management strategy",{"EARLY_PHASE1":12274,"PHASE1":12276,"PHASE2":12278,"PHASE3":12280,"PHASE4":12282,"NA":12284},{"trials":12275,"activeCount":102},[],{"trials":12277,"activeCount":102},[],{"trials":12279,"activeCount":102},[],{"trials":12281,"activeCount":102},[],{"trials":12283,"activeCount":102},[],{"trials":12285,"activeCount":102},[12286],{"nctId":12287,"briefTitle":12288,"status":112,"phases":12289,"completion":12290,"start":12291,"enrollment":12292,"conditions":12293,"interventions":12294},"NCT00188851","Structured Treatment Interruption for HIV Patients With Virologic Failure",[94],"2005-11","2001-01",196,[5535],[12272],{"intervention":12296,"totalTrials":149,"cells":12297},"Pimonidazole hydrochloride",{"EARLY_PHASE1":12298,"PHASE1":12300,"PHASE2":12302,"PHASE3":12304,"PHASE4":12306,"NA":12308},{"trials":12299,"activeCount":102},[],{"trials":12301,"activeCount":102},[],{"trials":12303,"activeCount":102},[],{"trials":12305,"activeCount":102},[],{"trials":12307,"activeCount":102},[],{"trials":12309,"activeCount":102},[12310],{"nctId":12311,"briefTitle":12312,"status":112,"phases":12313,"primaryCompletion":6155,"completion":6155,"start":7511,"enrollment":6113,"conditions":12314,"interventions":12315},"NCT01248637","Study of Intratumoral Hypoxia Using Pre-operative Administration of Pimonidazole",[],[609],[12296],{"intervention":12317,"totalTrials":149,"cells":12318},"Valganciclovir or Ganciclovir",{"EARLY_PHASE1":12319,"PHASE1":12321,"PHASE2":12323,"PHASE3":12325,"PHASE4":12327,"NA":12329},{"trials":12320,"activeCount":102},[],{"trials":12322,"activeCount":102},[],{"trials":12324,"activeCount":102},[],{"trials":12326,"activeCount":102},[],{"trials":12328,"activeCount":102},[],{"trials":12330,"activeCount":102},[12331],{"nctId":12332,"briefTitle":12333,"status":112,"phases":12334,"primaryCompletion":1387,"completion":12335,"start":598,"enrollment":25,"conditions":12336,"interventions":12338},"NCT02370758","Cell Mediated Immunity for Secondary Prophylaxis in CMV SOT Patients",[94],"2017-06-16",[12337],"Cytomegalovirus Viraemia",[12317],{"intervention":11835,"totalTrials":149,"cells":12340},{"EARLY_PHASE1":12341,"PHASE1":12343,"PHASE2":12345,"PHASE3":12347,"PHASE4":12349,"NA":12351},{"trials":12342,"activeCount":102},[],{"trials":12344,"activeCount":102},[],{"trials":12346,"activeCount":102},[],{"trials":12348,"activeCount":102},[],{"trials":12350,"activeCount":102},[],{"trials":12352,"activeCount":102},[12353],{"nctId":11830,"briefTitle":11831,"status":112,"phases":12354,"primaryCompletion":5200,"completion":4140,"start":8475,"enrollment":607,"conditions":12355,"interventions":12356},[],[11825],[11835,10424],{"intervention":12358,"totalTrials":149,"cells":12359},"mRNA Vaccines or Viral vector-based vaccines for COVID",{"EARLY_PHASE1":12360,"PHASE1":12362,"PHASE2":12364,"PHASE3":12366,"PHASE4":12368,"NA":12370},{"trials":12361,"activeCount":102},[],{"trials":12363,"activeCount":102},[],{"trials":12365,"activeCount":102},[],{"trials":12367,"activeCount":102},[],{"trials":12369,"activeCount":102},[],{"trials":12371,"activeCount":102},[12372],{"nctId":12373,"briefTitle":12374,"status":1723,"phases":12375,"primaryCompletion":12376,"completion":11585,"start":12377,"enrollment":12378,"conditions":12379,"interventions":12382},"NCT05208983","SafeTy and Efficacy of Preventative CoVID Vaccines",[],"2024-03","2021-05-06",1286,[12380,12381],"COVID-19 Virus Infection","Vaccine Response",[12358],{"intervention":12384,"totalTrials":149,"cells":12385},"aspirin",{"EARLY_PHASE1":12386,"PHASE1":12388,"PHASE2":12390,"PHASE3":12392,"PHASE4":12394,"NA":12396},{"trials":12387,"activeCount":102},[],{"trials":12389,"activeCount":102},[],{"trials":12391,"activeCount":102},[],{"trials":12393,"activeCount":102},[],{"trials":12395,"activeCount":102},[],{"trials":12397,"activeCount":102},[12398],{"nctId":12399,"briefTitle":12400,"status":1723,"phases":12401,"completion":730,"start":5618,"enrollment":2305,"conditions":12402,"interventions":12405},"NCT00578760","Does Aspirin Have a Protective Role Against Chemotherapeutically Induced Ototoxicity?",[94],[12403,12404],"Hearing Loss","Ototoxicity",[12384],{"intervention":12407,"totalTrials":149,"cells":12408},"Isoflurane",{"EARLY_PHASE1":12409,"PHASE1":12411,"PHASE2":12413,"PHASE3":12415,"PHASE4":12417,"NA":12419},{"trials":12410,"activeCount":102},[],{"trials":12412,"activeCount":102},[],{"trials":12414,"activeCount":102},[],{"trials":12416,"activeCount":102},[],{"trials":12418,"activeCount":102},[],{"trials":12420,"activeCount":102},[12421],{"nctId":12422,"briefTitle":12423,"status":112,"phases":12424,"primaryCompletion":12425,"completion":12426,"start":5576,"enrollment":2591,"conditions":12427,"interventions":12429},"NCT01983800","AnaConDa Long Term Sedation Study",[94],"2018-02","2020-11",[12428],"Intubated Requiring Sedation for Greater Than 48 Hours",[12407,12430],"Propofol\u002Fmidazolam",{"intervention":12430,"totalTrials":149,"cells":12432},{"EARLY_PHASE1":12433,"PHASE1":12435,"PHASE2":12437,"PHASE3":12439,"PHASE4":12441,"NA":12443},{"trials":12434,"activeCount":102},[],{"trials":12436,"activeCount":102},[],{"trials":12438,"activeCount":102},[],{"trials":12440,"activeCount":102},[],{"trials":12442,"activeCount":102},[],{"trials":12444,"activeCount":102},[12445],{"nctId":12422,"briefTitle":12423,"status":112,"phases":12446,"primaryCompletion":12425,"completion":12426,"start":5576,"enrollment":2591,"conditions":12447,"interventions":12448},[94],[12428],[12407,12430],{"intervention":12450,"totalTrials":149,"cells":12451},"BRCA genetic data",{"EARLY_PHASE1":12452,"PHASE1":12454,"PHASE2":12456,"PHASE3":12458,"PHASE4":12460,"NA":12462},{"trials":12453,"activeCount":102},[],{"trials":12455,"activeCount":102},[],{"trials":12457,"activeCount":102},[],{"trials":12459,"activeCount":102},[],{"trials":12461,"activeCount":102},[],{"trials":12463,"activeCount":102},[12464],{"nctId":12465,"briefTitle":12466,"status":727,"phases":12467,"primaryCompletion":1441,"completion":12468,"start":8340,"enrollment":12469,"conditions":12470,"interventions":12471},"NCT02341118","Capturing BRCA1\u002F2 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome.",[],"2023-05-08",109,[732],[12450],{"intervention":12473,"totalTrials":149,"cells":12474},"Sumatriptan",{"EARLY_PHASE1":12475,"PHASE1":12477,"PHASE2":12479,"PHASE3":12481,"PHASE4":12483,"NA":12485},{"trials":12476,"activeCount":102},[],{"trials":12478,"activeCount":102},[],{"trials":12480,"activeCount":102},[],{"trials":12482,"activeCount":102},[],{"trials":12484,"activeCount":102},[],{"trials":12486,"activeCount":102},[12487],{"nctId":12488,"briefTitle":12489,"status":112,"phases":12490,"primaryCompletion":12491,"completion":12492,"start":729,"enrollment":172,"conditions":12493,"interventions":12496},"NCT01632657","Effect of Sumatriptan on the Postoperative Quality of Recovery After Elective Minimally Invasive Craniotomy",[94],"2019-10-15","2019-12-15",[12494,12495],"Postoperative Quality of Recovery","Postoperative Migrainous Headache",[12473],{"intervention":12498,"totalTrials":149,"cells":12499},"18-FDG PET\u002FCT, DWI, DCE-MRI",{"EARLY_PHASE1":12500,"PHASE1":12502,"PHASE2":12504,"PHASE3":12506,"PHASE4":12508,"NA":12510},{"trials":12501,"activeCount":102},[],{"trials":12503,"activeCount":102},[],{"trials":12505,"activeCount":102},[],{"trials":12507,"activeCount":102},[],{"trials":12509,"activeCount":102},[],{"trials":12511,"activeCount":102},[12512],{"nctId":12513,"briefTitle":12514,"status":112,"phases":12515,"primaryCompletion":4140,"completion":4140,"start":12516,"enrollment":1860,"conditions":12517,"interventions":12519},"NCT01899404","MRI FDG PET Imaging Cervix",[94],"2012-10-03",[12518],"Cervical Cancer Squamous Cell",[12498],{"intervention":12521,"totalTrials":149,"cells":12522},"Nasal steroid Beclomethasone",{"EARLY_PHASE1":12523,"PHASE1":12525,"PHASE2":12527,"PHASE3":12529,"PHASE4":12531,"NA":12533},{"trials":12524,"activeCount":102},[],{"trials":12526,"activeCount":102},[],{"trials":12528,"activeCount":102},[],{"trials":12530,"activeCount":102},[],{"trials":12532,"activeCount":102},[],{"trials":12534,"activeCount":102},[12535],{"nctId":12536,"briefTitle":12537,"status":112,"phases":12538,"primaryCompletion":6380,"completion":6380,"start":5107,"enrollment":1363,"conditions":12539,"interventions":12541},"NCT00775489","Nasal Steroids in Controlled Glaucoma",[94],[12540],"Intraocular Pressure",[12521,12542],"Saline",{"intervention":12542,"totalTrials":149,"cells":12544},{"EARLY_PHASE1":12545,"PHASE1":12547,"PHASE2":12549,"PHASE3":12551,"PHASE4":12553,"NA":12555},{"trials":12546,"activeCount":102},[],{"trials":12548,"activeCount":102},[],{"trials":12550,"activeCount":102},[],{"trials":12552,"activeCount":102},[],{"trials":12554,"activeCount":102},[],{"trials":12556,"activeCount":102},[12557],{"nctId":12536,"briefTitle":12537,"status":112,"phases":12558,"primaryCompletion":6380,"completion":6380,"start":5107,"enrollment":1363,"conditions":12559,"interventions":12560},[94],[12540],[12521,12542],{"intervention":12562,"totalTrials":149,"cells":12563},"Remifentanil",{"EARLY_PHASE1":12564,"PHASE1":12566,"PHASE2":12568,"PHASE3":12570,"PHASE4":12572,"NA":12574},{"trials":12565,"activeCount":102},[],{"trials":12567,"activeCount":102},[],{"trials":12569,"activeCount":102},[],{"trials":12571,"activeCount":102},[],{"trials":12573,"activeCount":102},[],{"trials":12575,"activeCount":102},[12576],{"nctId":12577,"briefTitle":12578,"status":112,"phases":12579,"primaryCompletion":5107,"completion":5107,"start":8214,"enrollment":9674,"conditions":12580,"interventions":12583},"NCT01056224","Effect of Remifentanil Boluses on Hemodynamics in Skull Pin Insertion",[94],[12581,12582],"Skull Pin Insertion","Short Duration Analgesia",[12562],{"intervention":12585,"totalTrials":149,"cells":12586},"BMS-833923",{"EARLY_PHASE1":12587,"PHASE1":12589,"PHASE2":12591,"PHASE3":12593,"PHASE4":12595,"NA":12597},{"trials":12588,"activeCount":102},[],{"trials":12590,"activeCount":102},[],{"trials":12592,"activeCount":102},[],{"trials":12594,"activeCount":102},[],{"trials":12596,"activeCount":102},[],{"trials":12598,"activeCount":102},[12599],{"nctId":12600,"briefTitle":12601,"status":112,"phases":12602,"primaryCompletion":12603,"completion":12603,"start":4141,"enrollment":659,"conditions":12604,"interventions":12606},"NCT02100371","Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome",[94],"2017-05",[12605],"Basal Cell Nevus Syndrome",[12585],{"intervention":12608,"totalTrials":149,"cells":12609},"Octreotide Acetate",{"EARLY_PHASE1":12610,"PHASE1":12612,"PHASE2":12614,"PHASE3":12616,"PHASE4":12618,"NA":12620},{"trials":12611,"activeCount":102},[],{"trials":12613,"activeCount":102},[],{"trials":12615,"activeCount":102},[],{"trials":12617,"activeCount":102},[],{"trials":12619,"activeCount":102},[],{"trials":12621,"activeCount":102},[12622],{"nctId":12623,"briefTitle":12624,"status":1723,"phases":12625,"primaryCompletion":12626,"start":4266,"enrollment":511,"conditions":12627,"interventions":12629},"NCT02977897","Fecal Calprotectin Levels in Mycophenolate Mofetil Induced Diarrhea and Treatment With Octreotide",[],"2017-11",[12628,7624],"Diarrhea",[12608],{"intervention":12631,"totalTrials":149,"cells":12632},"Rocuronium",{"EARLY_PHASE1":12633,"PHASE1":12635,"PHASE2":12637,"PHASE3":12639,"PHASE4":12641,"NA":12643},{"trials":12634,"activeCount":102},[],{"trials":12636,"activeCount":102},[],{"trials":12638,"activeCount":102},[],{"trials":12640,"activeCount":102},[],{"trials":12642,"activeCount":102},[],{"trials":12644,"activeCount":102},[12645],{"nctId":12646,"briefTitle":12647,"status":112,"phases":12648,"primaryCompletion":6760,"completion":8563,"start":10594,"enrollment":1560,"conditions":12649,"interventions":12651},"NCT01404793","SPME For Metabolomics And Concomitant Measurements Of Rocuronium Bromide Levels In Liver Transplantation",[],[12650],"Liver Failure",[12631],{"intervention":11803,"totalTrials":149,"cells":12653},{"EARLY_PHASE1":12654,"PHASE1":12656,"PHASE2":12658,"PHASE3":12660,"PHASE4":12662,"NA":12664},{"trials":12655,"activeCount":102},[],{"trials":12657,"activeCount":102},[],{"trials":12659,"activeCount":102},[],{"trials":12661,"activeCount":102},[],{"trials":12663,"activeCount":102},[],{"trials":12665,"activeCount":102},[12666],{"nctId":11798,"briefTitle":11799,"status":112,"phases":12667,"primaryCompletion":140,"completion":141,"start":7239,"enrollment":3047,"conditions":12668,"interventions":12669},[94],[4293],[623,11803],{"intervention":12671,"totalTrials":149,"cells":12672},"Ipilimumab at 3 mg\u002Fkg dose",{"EARLY_PHASE1":12673,"PHASE1":12675,"PHASE2":12677,"PHASE3":12679,"PHASE4":12681,"NA":12683},{"trials":12674,"activeCount":102},[],{"trials":12676,"activeCount":102},[],{"trials":12678,"activeCount":102},[],{"trials":12680,"activeCount":102},[],{"trials":12682,"activeCount":102},[],{"trials":12684,"activeCount":102},[12685],{"nctId":12686,"briefTitle":12687,"status":112,"phases":12688,"primaryCompletion":12689,"completion":12689,"start":742,"enrollment":479,"conditions":12690,"interventions":12692},"NCT01715077","Study of Ipilimumab in the Immune System",[94],"2017-10",[12691],"Previously Untreated and Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma",[12671],{"intervention":12694,"totalTrials":149,"cells":12695},"Usual hemodynamic management",{"EARLY_PHASE1":12696,"PHASE1":12698,"PHASE2":12700,"PHASE3":12702,"PHASE4":12704,"NA":12706},{"trials":12697,"activeCount":102},[],{"trials":12699,"activeCount":102},[],{"trials":12701,"activeCount":102},[],{"trials":12703,"activeCount":102},[],{"trials":12705,"activeCount":102},[],{"trials":12707,"activeCount":102},[12708],{"nctId":12709,"briefTitle":12710,"status":112,"phases":12711,"primaryCompletion":2269,"completion":2269,"start":12712,"enrollment":2591,"conditions":12713,"interventions":12715},"NCT03477617","Advanced Monitoring to Inform and Guide Perioperative Hemodynamic Optimization 1 (AMIGO-1) Study",[94],"2018-05-03",[12714],"Intraoperative Fluid Management",[12694],{"intervention":12717,"totalTrials":149,"cells":12718},"verapamil hyrochloride",{"EARLY_PHASE1":12719,"PHASE1":12721,"PHASE2":12723,"PHASE3":12725,"PHASE4":12727,"NA":12729},{"trials":12720,"activeCount":102},[],{"trials":12722,"activeCount":102},[],{"trials":12724,"activeCount":102},[],{"trials":12726,"activeCount":102},[],{"trials":12728,"activeCount":102},[],{"trials":12730,"activeCount":102},[12731],{"nctId":12732,"briefTitle":12733,"status":550,"phases":12734,"completion":628,"start":674,"enrollment":687,"conditions":12735,"interventions":12737},"NCT00559169","Verapamil and Catamenial Epilepsy",[94],[12736],"Catamenial Epilepsy",[12717],{"intervention":12739,"totalTrials":149,"cells":12740},"Ketorolac",{"EARLY_PHASE1":12741,"PHASE1":12743,"PHASE2":12745,"PHASE3":12747,"PHASE4":12749,"NA":12751},{"trials":12742,"activeCount":102},[],{"trials":12744,"activeCount":102},[],{"trials":12746,"activeCount":102},[],{"trials":12748,"activeCount":102},[],{"trials":12750,"activeCount":102},[],{"trials":12752,"activeCount":102},[12753],{"nctId":12754,"briefTitle":12755,"status":1723,"phases":12756,"primaryCompletion":718,"completion":6717,"start":6543,"enrollment":758,"conditions":12757,"interventions":12758},"NCT00956462","Steroids Versus Non-steroidal Anti-inflammatory Drugs Following Glaucoma Surgery",[94],[12032],[12739],{"intervention":12760,"totalTrials":149,"cells":12761},"Pegasys; Copegus.",{"EARLY_PHASE1":12762,"PHASE1":12764,"PHASE2":12766,"PHASE3":12768,"PHASE4":12770,"NA":12772},{"trials":12763,"activeCount":102},[],{"trials":12765,"activeCount":102},[],{"trials":12767,"activeCount":102},[],{"trials":12769,"activeCount":102},[],{"trials":12771,"activeCount":102},[],{"trials":12773,"activeCount":102},[12774],{"nctId":12775,"briefTitle":12776,"status":1723,"phases":12777,"start":12778,"enrollment":6113,"conditions":12779,"interventions":12780},"NCT00188240","Insulin Resistance Associated With Chronic Hepatitis C (CHC) and the Effect of Antiviral Therapy",[94],"2003-08",[4090,7736],[12760],{"intervention":12782,"totalTrials":149,"cells":12783},"Fluorocholine (18F-FCH)",{"EARLY_PHASE1":12784,"PHASE1":12786,"PHASE2":12788,"PHASE3":12790,"PHASE4":12792,"NA":12794},{"trials":12785,"activeCount":102},[],{"trials":12787,"activeCount":102},[],{"trials":12789,"activeCount":102},[],{"trials":12791,"activeCount":102},[],{"trials":12793,"activeCount":102},[],{"trials":12795,"activeCount":102},[12796],{"nctId":12797,"briefTitle":12798,"status":112,"phases":12799,"primaryCompletion":4140,"completion":4140,"start":5689,"enrollment":19,"conditions":12800,"interventions":12801},"NCT01993160","18F-FCH (Fluorocholine)-PET\u002FMR in Staging of High-Risk Prostate Cancer",[94],[15],[12782],{"intervention":12803,"totalTrials":149,"cells":12804},"Ropivacaine 0.5%",{"EARLY_PHASE1":12805,"PHASE1":12807,"PHASE2":12809,"PHASE3":12811,"PHASE4":12813,"NA":12815},{"trials":12806,"activeCount":102},[],{"trials":12808,"activeCount":102},[],{"trials":12810,"activeCount":102},[],{"trials":12812,"activeCount":102},[],{"trials":12814,"activeCount":102},[],{"trials":12816,"activeCount":102},[12817],{"nctId":12818,"briefTitle":12819,"status":112,"phases":12820,"primaryCompletion":12821,"completion":12821,"start":9152,"enrollment":2591,"conditions":12822,"interventions":12823},"NCT03427385","Minimum Local Anesthetic Dose for Adductor Canal Block",[94],"2014-08-05",[5016],[12803],{"intervention":12825,"totalTrials":149,"cells":12826},"Forearm Nerve Block",{"EARLY_PHASE1":12827,"PHASE1":12829,"PHASE2":12831,"PHASE3":12833,"PHASE4":12835,"NA":12837},{"trials":12828,"activeCount":102},[],{"trials":12830,"activeCount":102},[],{"trials":12832,"activeCount":102},[],{"trials":12834,"activeCount":102},[],{"trials":12836,"activeCount":102},[],{"trials":12838,"activeCount":102},[12839],{"nctId":12840,"briefTitle":12841,"status":1723,"phases":12842,"primaryCompletion":7353,"completion":12843,"start":12844,"enrollment":12845,"conditions":12846,"interventions":12848},"NCT03510559","Forearm vs Brachial Plexus Blockade for Routine Hand and Wrist Surgery",[94],"2020-08-01","2018-04-30",160,[12847],"Post-operative Pain Management",[12825,12849],"Brachial Plexus Block",{"intervention":12849,"totalTrials":149,"cells":12851},{"EARLY_PHASE1":12852,"PHASE1":12854,"PHASE2":12856,"PHASE3":12858,"PHASE4":12860,"NA":12862},{"trials":12853,"activeCount":102},[],{"trials":12855,"activeCount":102},[],{"trials":12857,"activeCount":102},[],{"trials":12859,"activeCount":102},[],{"trials":12861,"activeCount":102},[],{"trials":12863,"activeCount":102},[12864],{"nctId":12840,"briefTitle":12841,"status":1723,"phases":12865,"primaryCompletion":7353,"completion":12843,"start":12844,"enrollment":12845,"conditions":12866,"interventions":12867},[94],[12847],[12825,12849],{"intervention":12869,"totalTrials":149,"cells":12870},"Champix",{"EARLY_PHASE1":12871,"PHASE1":12873,"PHASE2":12875,"PHASE3":12877,"PHASE4":12879,"NA":12881},{"trials":12872,"activeCount":102},[],{"trials":12874,"activeCount":102},[],{"trials":12876,"activeCount":102},[],{"trials":12878,"activeCount":102},[],{"trials":12880,"activeCount":102},[],{"trials":12882,"activeCount":102},[12883],{"nctId":12884,"briefTitle":12885,"status":112,"phases":12886,"primaryCompletion":8725,"completion":9902,"start":12887,"enrollment":498,"conditions":12888,"interventions":12889},"NCT01243203","Smoking Cessation Program in the Preadmission Clinic: The Use of a Teachable Moment",[94],"2007-11",[6383],[12869],{"intervention":12891,"totalTrials":149,"cells":12892},"Smoking cessation counselling group",{"EARLY_PHASE1":12893,"PHASE1":12895,"PHASE2":12897,"PHASE3":12899,"PHASE4":12901,"NA":12903},{"trials":12894,"activeCount":102},[],{"trials":12896,"activeCount":102},[],{"trials":12898,"activeCount":102},[],{"trials":12900,"activeCount":102},[],{"trials":12902,"activeCount":102},[],{"trials":12904,"activeCount":102},[12905],{"nctId":12906,"briefTitle":6378,"status":112,"phases":12907,"primaryCompletion":9552,"completion":9552,"start":628,"enrollment":12908,"conditions":12909,"interventions":12910},"NCT01320462",[94],296,[6383],[12891],{"intervention":12912,"totalTrials":149,"cells":12913},"PET Scan",{"EARLY_PHASE1":12914,"PHASE1":12916,"PHASE2":12918,"PHASE3":12920,"PHASE4":12922,"NA":12924},{"trials":12915,"activeCount":102},[],{"trials":12917,"activeCount":102},[],{"trials":12919,"activeCount":102},[],{"trials":12921,"activeCount":102},[],{"trials":12923,"activeCount":102},[],{"trials":12925,"activeCount":102},[12926],{"nctId":12927,"briefTitle":12928,"status":112,"phases":12929,"primaryCompletion":5917,"completion":5917,"start":5940,"enrollment":5158,"conditions":12930,"interventions":12932},"NCT00887718","Positron Emission Tomography(PET) in Lymphoma Assessment",[94],[11161,12931],"Non Hodgkin's Lymphoma",[12912],{"intervention":12934,"totalTrials":149,"cells":12935},"Isoflurane\u002Fsevoflurane",{"EARLY_PHASE1":12936,"PHASE1":12938,"PHASE2":12940,"PHASE3":12942,"PHASE4":12944,"NA":12946},{"trials":12937,"activeCount":102},[],{"trials":12939,"activeCount":102},[],{"trials":12941,"activeCount":102},[],{"trials":12943,"activeCount":102},[],{"trials":12945,"activeCount":102},[],{"trials":12947,"activeCount":102},[12948],{"nctId":12949,"briefTitle":12950,"status":112,"phases":12951,"primaryCompletion":8586,"completion":5576,"start":10523,"enrollment":12952,"conditions":12953,"interventions":12954},"NCT01151254","Comparison of Propofol Based Versus Volatile Based Anesthesia and Postoperative Sedation",[94],146,[1263],[12934],{"intervention":12956,"totalTrials":149,"cells":12957},"Different dosages of Ketamine",{"EARLY_PHASE1":12958,"PHASE1":12960,"PHASE2":12962,"PHASE3":12964,"PHASE4":12966,"NA":12968},{"trials":12959,"activeCount":102},[],{"trials":12961,"activeCount":102},[],{"trials":12963,"activeCount":102},[],{"trials":12965,"activeCount":102},[],{"trials":12967,"activeCount":102},[],{"trials":12969,"activeCount":102},[12970],{"nctId":12971,"briefTitle":12972,"status":1723,"phases":12973,"completion":6048,"start":5941,"conditions":12974,"interventions":12976},"NCT00221871","Proper Dosage of Ketamine in Intravenous Regional Anesthesia",[94],[12975],"Pain.",[12956],{"intervention":12978,"totalTrials":149,"cells":12979},"standard of care influenza vaccine",{"EARLY_PHASE1":12980,"PHASE1":12982,"PHASE2":12984,"PHASE3":12986,"PHASE4":12988,"NA":12990},{"trials":12981,"activeCount":102},[],{"trials":12983,"activeCount":102},[],{"trials":12985,"activeCount":102},[],{"trials":12987,"activeCount":102},[],{"trials":12989,"activeCount":102},[],{"trials":12991,"activeCount":102},[12992],{"nctId":12993,"briefTitle":12994,"status":550,"phases":12995,"primaryCompletion":12996,"completion":12996,"start":12996,"enrollment":102,"conditions":12997,"interventions":12999},"NCT03327987","Early Flu Shots in SOT",[],"2019-05-07",[7623,12998],"Solid Organ Transplant",[12978],{"intervention":3488,"totalTrials":149,"cells":13001},{"EARLY_PHASE1":13002,"PHASE1":13004,"PHASE2":13006,"PHASE3":13008,"PHASE4":13010,"NA":13012},{"trials":13003,"activeCount":102},[],{"trials":13005,"activeCount":102},[],{"trials":13007,"activeCount":102},[],{"trials":13009,"activeCount":102},[],{"trials":13011,"activeCount":102},[],{"trials":13013,"activeCount":102},[13014],{"nctId":3477,"briefTitle":3478,"status":112,"phases":13015,"primaryCompletion":3480,"completion":3480,"start":3481,"enrollment":3482,"conditions":13016,"interventions":13017},[94],[3484,3485,3486,1376],[1864,3488,3489,3490,3491,3492,3493],{"intervention":3489,"totalTrials":149,"cells":13019},{"EARLY_PHASE1":13020,"PHASE1":13022,"PHASE2":13024,"PHASE3":13026,"PHASE4":13028,"NA":13030},{"trials":13021,"activeCount":102},[],{"trials":13023,"activeCount":102},[],{"trials":13025,"activeCount":102},[],{"trials":13027,"activeCount":102},[],{"trials":13029,"activeCount":102},[],{"trials":13031,"activeCount":102},[13032],{"nctId":3477,"briefTitle":3478,"status":112,"phases":13033,"primaryCompletion":3480,"completion":3480,"start":3481,"enrollment":3482,"conditions":13034,"interventions":13035},[94],[3484,3485,3486,1376],[1864,3488,3489,3490,3491,3492,3493],{"intervention":3490,"totalTrials":149,"cells":13037},{"EARLY_PHASE1":13038,"PHASE1":13040,"PHASE2":13042,"PHASE3":13044,"PHASE4":13046,"NA":13048},{"trials":13039,"activeCount":102},[],{"trials":13041,"activeCount":102},[],{"trials":13043,"activeCount":102},[],{"trials":13045,"activeCount":102},[],{"trials":13047,"activeCount":102},[],{"trials":13049,"activeCount":102},[13050],{"nctId":3477,"briefTitle":3478,"status":112,"phases":13051,"primaryCompletion":3480,"completion":3480,"start":3481,"enrollment":3482,"conditions":13052,"interventions":13053},[94],[3484,3485,3486,1376],[1864,3488,3489,3490,3491,3492,3493],{"intervention":3491,"totalTrials":149,"cells":13055},{"EARLY_PHASE1":13056,"PHASE1":13058,"PHASE2":13060,"PHASE3":13062,"PHASE4":13064,"NA":13066},{"trials":13057,"activeCount":102},[],{"trials":13059,"activeCount":102},[],{"trials":13061,"activeCount":102},[],{"trials":13063,"activeCount":102},[],{"trials":13065,"activeCount":102},[],{"trials":13067,"activeCount":102},[13068],{"nctId":3477,"briefTitle":3478,"status":112,"phases":13069,"primaryCompletion":3480,"completion":3480,"start":3481,"enrollment":3482,"conditions":13070,"interventions":13071},[94],[3484,3485,3486,1376],[1864,3488,3489,3490,3491,3492,3493],{"intervention":3492,"totalTrials":149,"cells":13073},{"EARLY_PHASE1":13074,"PHASE1":13076,"PHASE2":13078,"PHASE3":13080,"PHASE4":13082,"NA":13084},{"trials":13075,"activeCount":102},[],{"trials":13077,"activeCount":102},[],{"trials":13079,"activeCount":102},[],{"trials":13081,"activeCount":102},[],{"trials":13083,"activeCount":102},[],{"trials":13085,"activeCount":102},[13086],{"nctId":3477,"briefTitle":3478,"status":112,"phases":13087,"primaryCompletion":3480,"completion":3480,"start":3481,"enrollment":3482,"conditions":13088,"interventions":13089},[94],[3484,3485,3486,1376],[1864,3488,3489,3490,3491,3492,3493],{"intervention":3493,"totalTrials":149,"cells":13091},{"EARLY_PHASE1":13092,"PHASE1":13094,"PHASE2":13096,"PHASE3":13098,"PHASE4":13100,"NA":13102},{"trials":13093,"activeCount":102},[],{"trials":13095,"activeCount":102},[],{"trials":13097,"activeCount":102},[],{"trials":13099,"activeCount":102},[],{"trials":13101,"activeCount":102},[],{"trials":13103,"activeCount":102},[13104],{"nctId":3477,"briefTitle":3478,"status":112,"phases":13105,"primaryCompletion":3480,"completion":3480,"start":3481,"enrollment":3482,"conditions":13106,"interventions":13107},[94],[3484,3485,3486,1376],[1864,3488,3489,3490,3491,3492,3493],{"intervention":13109,"totalTrials":149,"cells":13110},"Plerixafor",{"EARLY_PHASE1":13111,"PHASE1":13113,"PHASE2":13115,"PHASE3":13117,"PHASE4":13119,"NA":13121},{"trials":13112,"activeCount":102},[],{"trials":13114,"activeCount":102},[],{"trials":13116,"activeCount":102},[],{"trials":13118,"activeCount":102},[],{"trials":13120,"activeCount":102},[],{"trials":13122,"activeCount":102},[13123],{"nctId":13124,"briefTitle":13125,"status":112,"phases":13126,"primaryCompletion":6760,"completion":8340,"start":8733,"enrollment":687,"conditions":13127,"interventions":13128},"NCT01141543","Feasibility and Efficiency Study of Leukemic Cell Mobilization With Plerixafor Injection",[],[2204],[13109],{"intervention":13130,"totalTrials":149,"cells":13131},"Luspatercept",{"EARLY_PHASE1":13132,"PHASE1":13134,"PHASE2":13136,"PHASE3":13138,"PHASE4":13140,"NA":13142},{"trials":13133,"activeCount":102},[],{"trials":13135,"activeCount":102},[],{"trials":13137,"activeCount":102},[],{"trials":13139,"activeCount":102},[],{"trials":13141,"activeCount":102},[],{"trials":13143,"activeCount":102},[13144],{"nctId":13145,"briefTitle":13146,"status":112,"phases":13147,"primaryCompletion":12266,"completion":13148,"start":12267,"enrollment":149,"conditions":13149,"interventions":13151},"NCT06254781","Luspatercept in Metastatic AGCT of the Ovary",[94],"2022-08-29",[13150],"Adult Granulosa Cell Tumor of the Ovary",[13130],{"intervention":13153,"totalTrials":149,"cells":13154},"Dexmedetomidine group",{"EARLY_PHASE1":13155,"PHASE1":13157,"PHASE2":13159,"PHASE3":13161,"PHASE4":13163,"NA":13165},{"trials":13156,"activeCount":102},[],{"trials":13158,"activeCount":102},[],{"trials":13160,"activeCount":102},[],{"trials":13162,"activeCount":102},[],{"trials":13164,"activeCount":102},[],{"trials":13166,"activeCount":102},[13167],{"nctId":13168,"briefTitle":13169,"status":727,"phases":13170,"primaryCompletion":13171,"completion":7121,"start":6984,"enrollment":584,"conditions":13172,"interventions":13174},"NCT03451227","Dexmedetomidine and Fentanyl Versus Midazolam and Remifentanil for Sedation in Patients Undergoing Ablation Procedures",[94],"2018-03-12",[13173],"Tachyarrhythmia",[13153,13175],"Remifentanil Group",{"intervention":13175,"totalTrials":149,"cells":13177},{"EARLY_PHASE1":13178,"PHASE1":13180,"PHASE2":13182,"PHASE3":13184,"PHASE4":13186,"NA":13188},{"trials":13179,"activeCount":102},[],{"trials":13181,"activeCount":102},[],{"trials":13183,"activeCount":102},[],{"trials":13185,"activeCount":102},[],{"trials":13187,"activeCount":102},[],{"trials":13189,"activeCount":102},[13190],{"nctId":13168,"briefTitle":13169,"status":727,"phases":13191,"primaryCompletion":13171,"completion":7121,"start":6984,"enrollment":584,"conditions":13192,"interventions":13193},[94],[13173],[13153,13175],{"intervention":13195,"totalTrials":149,"cells":13196},"CBD oil",{"EARLY_PHASE1":13197,"PHASE1":13199,"PHASE2":13201,"PHASE3":13203,"PHASE4":13205,"NA":13207},{"trials":13198,"activeCount":102},[],{"trials":13200,"activeCount":102},[],{"trials":13202,"activeCount":102},[],{"trials":13204,"activeCount":102},[],{"trials":13206,"activeCount":102},[],{"trials":13208,"activeCount":102},[13209],{"nctId":13210,"briefTitle":13211,"status":112,"phases":13212,"primaryCompletion":1944,"completion":13213,"start":13214,"enrollment":720,"conditions":13215,"interventions":13216},"NCT05351905","Improving Pain Disability With the Use of Oral Cannabinoids",[94],"2026-01-12","2022-11-22",[3073,4828,10810],[13195,13217],"CDB+THC oil",{"intervention":13217,"totalTrials":149,"cells":13219},{"EARLY_PHASE1":13220,"PHASE1":13222,"PHASE2":13224,"PHASE3":13226,"PHASE4":13228,"NA":13230},{"trials":13221,"activeCount":102},[],{"trials":13223,"activeCount":102},[],{"trials":13225,"activeCount":102},[],{"trials":13227,"activeCount":102},[],{"trials":13229,"activeCount":102},[],{"trials":13231,"activeCount":102},[13232],{"nctId":13210,"briefTitle":13211,"status":112,"phases":13233,"primaryCompletion":1944,"completion":13213,"start":13214,"enrollment":720,"conditions":13234,"interventions":13235},[94],[3073,4828,10810],[13195,13217],{"intervention":13237,"totalTrials":149,"cells":13238},"Spinal anesthesia group: bupivacaine 10-15mg",{"EARLY_PHASE1":13239,"PHASE1":13241,"PHASE2":13243,"PHASE3":13245,"PHASE4":13247,"NA":13249},{"trials":13240,"activeCount":102},[],{"trials":13242,"activeCount":102},[],{"trials":13244,"activeCount":102},[],{"trials":13246,"activeCount":102},[],{"trials":13248,"activeCount":102},[],{"trials":13250,"activeCount":102},[13251],{"nctId":13252,"briefTitle":13253,"status":1723,"phases":13254,"primaryCompletion":8278,"completion":13255,"start":8827,"enrollment":13256,"conditions":13257,"interventions":13260},"NCT01903421","Inhalational Anesthesia and Precipitation of Dementia: is There a Link?",[94],"2023-07",500,[13258,13259],"Alzheimer's Disease","Dementia",[13237,13261,13262],"General anesthesia group: induction propofol 1.5-2mg\u002Fkg and fentanyl 1-3g\u002Fkg, maintained with isoflurane or sevoflurane","Blood test",{"intervention":13261,"totalTrials":149,"cells":13264},{"EARLY_PHASE1":13265,"PHASE1":13267,"PHASE2":13269,"PHASE3":13271,"PHASE4":13273,"NA":13275},{"trials":13266,"activeCount":102},[],{"trials":13268,"activeCount":102},[],{"trials":13270,"activeCount":102},[],{"trials":13272,"activeCount":102},[],{"trials":13274,"activeCount":102},[],{"trials":13276,"activeCount":102},[13277],{"nctId":13252,"briefTitle":13253,"status":1723,"phases":13278,"primaryCompletion":8278,"completion":13255,"start":8827,"enrollment":13256,"conditions":13279,"interventions":13280},[94],[13258,13259],[13237,13261,13262],{"intervention":13262,"totalTrials":149,"cells":13282},{"EARLY_PHASE1":13283,"PHASE1":13285,"PHASE2":13287,"PHASE3":13289,"PHASE4":13291,"NA":13293},{"trials":13284,"activeCount":102},[],{"trials":13286,"activeCount":102},[],{"trials":13288,"activeCount":102},[],{"trials":13290,"activeCount":102},[],{"trials":13292,"activeCount":102},[],{"trials":13294,"activeCount":102},[13295],{"nctId":13252,"briefTitle":13253,"status":1723,"phases":13296,"primaryCompletion":8278,"completion":13255,"start":8827,"enrollment":13256,"conditions":13297,"interventions":13298},[94],[13258,13259],[13237,13261,13262],{"intervention":13300,"totalTrials":149,"cells":13301},"18F-Fluoroazomycin arabinoside",{"EARLY_PHASE1":13302,"PHASE1":13304,"PHASE2":13306,"PHASE3":13308,"PHASE4":13310,"NA":13312},{"trials":13303,"activeCount":102},[],{"trials":13305,"activeCount":102},[],{"trials":13307,"activeCount":102},[],{"trials":13309,"activeCount":102},[],{"trials":13311,"activeCount":102},[],{"trials":13313,"activeCount":102},[13314],{"nctId":13315,"briefTitle":13316,"status":550,"phases":13317,"primaryCompletion":598,"completion":598,"start":598,"enrollment":102,"conditions":13318,"interventions":13320},"NCT02496832","A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 or TH-302 Placebo",[94],[1551,13319,8321],"Advanced Disease",[13300],{"intervention":13322,"totalTrials":149,"cells":13323},"lisdexamfetamine dimesylate",{"EARLY_PHASE1":13324,"PHASE1":13326,"PHASE2":13328,"PHASE3":13330,"PHASE4":13332,"NA":13334},{"trials":13325,"activeCount":102},[],{"trials":13327,"activeCount":102},[],{"trials":13329,"activeCount":102},[],{"trials":13331,"activeCount":102},[],{"trials":13333,"activeCount":102},[],{"trials":13335,"activeCount":102},[13336],{"nctId":13337,"briefTitle":13338,"status":112,"phases":13339,"primaryCompletion":8586,"completion":8586,"start":7511,"enrollment":3205,"conditions":13340,"interventions":13342},"NCT01263548","To Evaluate the Safety and Metabolic Profile of Vyvanse for the Treatment of ADHD in Euthymic Adults With Bipolar I\u002FII Disorder",[],[13341,5737],"Attention Deficit\u002FHyperactivity Disorder",[13322],{"intervention":13344,"totalTrials":149,"cells":13345},"Citalopram",{"EARLY_PHASE1":13346,"PHASE1":13348,"PHASE2":13350,"PHASE3":13352,"PHASE4":13354,"NA":13356},{"trials":13347,"activeCount":102},[],{"trials":13349,"activeCount":102},[],{"trials":13351,"activeCount":102},[],{"trials":13353,"activeCount":102},[],{"trials":13355,"activeCount":102},[],{"trials":13357,"activeCount":102},[13358],{"nctId":13359,"briefTitle":13360,"status":112,"phases":13361,"primaryCompletion":5801,"completion":5801,"start":9764,"enrollment":3047,"conditions":13362,"interventions":13363},"NCT00188396","Effect of the Menstrual Cycle on the Symptoms of Depression and Treatment Response",[94],[2307,2297],[13344],{"intervention":13365,"totalTrials":149,"cells":13366},"Normothermic ex-vivo kidney perfusion Solution -Toronto",{"EARLY_PHASE1":13367,"PHASE1":13369,"PHASE2":13371,"PHASE3":13373,"PHASE4":13375,"NA":13377},{"trials":13368,"activeCount":102},[],{"trials":13370,"activeCount":102},[],{"trials":13372,"activeCount":102},[],{"trials":13374,"activeCount":102},[],{"trials":13376,"activeCount":102},[],{"trials":13378,"activeCount":102},[13379],{"nctId":13380,"briefTitle":13381,"status":112,"phases":13382,"primaryCompletion":13383,"completion":13383,"start":9087,"enrollment":771,"conditions":13384,"interventions":13386},"NCT03136848","The Feasibility and Safety of Normothermic ex Vivo Kidney Perfusion",[94],"2020-06",[13385],"Kidney Transplantation",[13365],{"intervention":13388,"totalTrials":149,"cells":13389},"Mepivacaine without fentanyl",{"EARLY_PHASE1":13390,"PHASE1":13392,"PHASE2":13394,"PHASE3":13396,"PHASE4":13398,"NA":13400},{"trials":13391,"activeCount":102},[],{"trials":13393,"activeCount":102},[],{"trials":13395,"activeCount":102},[],{"trials":13397,"activeCount":102},[],{"trials":13399,"activeCount":102},[],{"trials":13401,"activeCount":102},[13402],{"nctId":13403,"briefTitle":13404,"status":112,"phases":13405,"primaryCompletion":7239,"completion":7239,"start":13406,"enrollment":22,"conditions":13407,"interventions":13409},"NCT00803725","Spinal Mepivicaine With Fentanyl for Outpatient Knee Arthroscopy",[94],"2008-08",[13408],"Knee Arthroscopy",[13388,13410],"Mepivacaine with Fentanyl",{"intervention":13410,"totalTrials":149,"cells":13412},{"EARLY_PHASE1":13413,"PHASE1":13415,"PHASE2":13417,"PHASE3":13419,"PHASE4":13421,"NA":13423},{"trials":13414,"activeCount":102},[],{"trials":13416,"activeCount":102},[],{"trials":13418,"activeCount":102},[],{"trials":13420,"activeCount":102},[],{"trials":13422,"activeCount":102},[],{"trials":13424,"activeCount":102},[13425],{"nctId":13403,"briefTitle":13404,"status":112,"phases":13426,"primaryCompletion":7239,"completion":7239,"start":13406,"enrollment":22,"conditions":13427,"interventions":13428},[94],[13408],[13388,13410],{"intervention":13430,"totalTrials":149,"cells":13431},"Active treatment",{"EARLY_PHASE1":13432,"PHASE1":13434,"PHASE2":13436,"PHASE3":13438,"PHASE4":13440,"NA":13442},{"trials":13433,"activeCount":102},[],{"trials":13435,"activeCount":102},[],{"trials":13437,"activeCount":102},[],{"trials":13439,"activeCount":102},[],{"trials":13441,"activeCount":102},[],{"trials":13443,"activeCount":102},[13444],{"nctId":13445,"briefTitle":13446,"status":112,"phases":13447,"primaryCompletion":729,"completion":7961,"start":10236,"enrollment":1316,"conditions":13448,"interventions":13451},"NCT01133730","Transversalis Fascial Plane Nerve Block in Iliac Crest Bone Graft",[94],[13449,13450],"Upper Limb Surgery","Iliac Crest Bone Harvest",[13430],{"intervention":13453,"totalTrials":149,"cells":13454},"Verapamil",{"EARLY_PHASE1":13455,"PHASE1":13457,"PHASE2":13459,"PHASE3":13461,"PHASE4":13463,"NA":13465},{"trials":13456,"activeCount":102},[],{"trials":13458,"activeCount":102},[],{"trials":13460,"activeCount":102},[],{"trials":13462,"activeCount":102},[],{"trials":13464,"activeCount":102},[],{"trials":13466,"activeCount":102},[13467],{"nctId":13468,"briefTitle":13469,"status":1723,"phases":13470,"primaryCompletion":7961,"completion":7961,"start":6717,"enrollment":36,"conditions":13471,"interventions":13474},"NCT01126307","Study of Verapamil in Refractory Epilepsy",[94],[13472,13473],"Epilepsy","Seizures",[13453],{"intervention":13476,"totalTrials":149,"cells":13477},"Insulin Cardioplegia",{"EARLY_PHASE1":13478,"PHASE1":13480,"PHASE2":13482,"PHASE3":13484,"PHASE4":13486,"NA":13488},{"trials":13479,"activeCount":102},[],{"trials":13481,"activeCount":102},[],{"trials":13483,"activeCount":102},[],{"trials":13485,"activeCount":102},[],{"trials":13487,"activeCount":102},[],{"trials":13489,"activeCount":102},[13490],{"nctId":13491,"briefTitle":13492,"status":1723,"phases":13493,"start":13494,"enrollment":13495,"conditions":13496,"interventions":13498},"NCT00188994","Insulin Cardioplegia for Poor Left Ventricular Function",[94],"1999-08",800,[13497],"Left Ventricular Dysfunction",[13476],{"intervention":13500,"totalTrials":149,"cells":13501},"Intravenous Intralipid",{"EARLY_PHASE1":13502,"PHASE1":13504,"PHASE2":13506,"PHASE3":13508,"PHASE4":13510,"NA":13512},{"trials":13503,"activeCount":102},[],{"trials":13505,"activeCount":102},[],{"trials":13507,"activeCount":102},[],{"trials":13509,"activeCount":102},[],{"trials":13511,"activeCount":102},[],{"trials":13513,"activeCount":102},[13514],{"nctId":13515,"briefTitle":13516,"status":112,"phases":13517,"primaryCompletion":10570,"completion":5801,"start":8521,"enrollment":511,"conditions":13518,"interventions":13519},"NCT00152945","Determining the Responsiveness of Intestinal Lipoprotein Production to an Elevation of Plasma Free Fatty Acids",[94],[5470],[13500,13520],"Intravenous leucine, glycerol",{"intervention":13520,"totalTrials":149,"cells":13522},{"EARLY_PHASE1":13523,"PHASE1":13525,"PHASE2":13527,"PHASE3":13529,"PHASE4":13531,"NA":13533},{"trials":13524,"activeCount":102},[],{"trials":13526,"activeCount":102},[],{"trials":13528,"activeCount":102},[],{"trials":13530,"activeCount":102},[],{"trials":13532,"activeCount":102},[],{"trials":13534,"activeCount":102},[13535],{"nctId":13515,"briefTitle":13516,"status":112,"phases":13536,"primaryCompletion":10570,"completion":5801,"start":8521,"enrollment":511,"conditions":13537,"interventions":13538},[94],[5470],[13500,13520]]